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Summary 
 
The central dogma of molecular biology relies on the storage, transfer and propagation of genetic 
information from DNA to protein via RNA. Synthetic genes have been widely used to create 
genetically modified organisms, for a number of applications in therapeutics, agriculture, energy and 
environment related fields, material science and biotechnology. However, due to accidental or 
deliberate damage triggering from the exchange of genetic information with natural species via gene 
transfer, such artificial genetic constructs are generally considered as a potential threat to wild 
ecosystems.  
The development of orthogonal biological systems, through the chemical assembly of nucleic 
acids which do not occur in nature (Xeno Nucleic Acids, XNAs), has been conceived as a powerful 
genetic firewall to avoid genetic cross talk, thus addressing crucially related biosafety issues. Several 
XNA based-systems have been synthesized with this purpose, following modifications at the base, 
sugar and leaving group moieties along with the engineering of enzymes showing XNA associated 
catalytic activities. In order to reach their true evolutionary potential, however, reprogrammed 
organisms require the presence of XNA nucleotidic precursors of XNA polymers in sufficient amount 
inside the cell. The in vivo invasion of XNA replicons was envisioned to firstly materialize in 
bacteria, as anticipated by their relatively simple genetic architecture. Although most modified 
nucleosides could easily enter bacterial cells by passive diffusion, they are known to be poorly 
phosphorylated to their mono-phosphate forms by wild-type kinases. On the other hand, the delivery 
of nucleotides is restricted by hydrophobic interactions with the lipid bi-layer of the bacterial cell 
wall, as a result of their low pKa and high polarity. Bacteria nonetheless possess several 
transmembrane transport proteins that facilitate uptake, against a concentration gradient, of nutrients 
for their survival, such as peptides, sulfonates, sugars and vitamins etc., which otherwise would 
experience limited entry.  
On this basis, this doctoral thesis aims at exploring the viability of natural systems devoted to the 
transport of common metabolites as potential delivery tools for nucleotides in bacterial cells, by 
means of the systematic design and synthesis of different nucleotide-conjugates and their evaluation 
in a nutritional selection assay. Thymidine mono-phosphate (TMP) was chosen as exemplary 
nucleotide in a model study and the intracellular delivery of the corresponding TMP-conjugates could 
be established based on the growth of a suitable E. coli mutant auxotrophic for thymidine (thyA-, 
ΔphoA). 
In the first project (Chapter 2), a variety of di- to penta-peptides were chosen as delivery vehicles 
targeting different peptide permeases, thus a series of peptide-TMP conjugates (PNCs) were 
synthesized to be evaluated for their functional activity in E. coli. A number of linear and convergent 
synthetic strategies along with orthogonal protection-deprotection approaches are discussed for the 
synthesis of such conjugates, obtained by connecting the side chain functionalities of oligopeptides to 
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the 3’-hydroxyl group of TMP through bio-cleavable linkers such as carbamate (OCONH), ester 
(OCO), oxyamide (ONHCO), oxymethyleneoxyamide (OCH2ONHCO) and oxymethylene-oxyester 
(OCH2OCO).  
In chapter 3, design and synthesis of various PNCs of TMP are discussed, connected through 
various phosphoester linkers i.e. phosphate, phosphoramidate, phosphorothioate and thioethyl-
phosphate via the 5’-hydroxyl of thymidine and the α-carbon of the C-terminal glycine residue of L-
Ala-Gly. To gain a preliminary insight of potential in vivo metabolism, these conjugates were also 
evaluated as substrates in the template directed DNA-polymerization with different thermophilic and 
mesophylic DNA polymerases e.g. Therminator, Vent (exo-) and Klenow (exo-). A free carboxylic 
functionality is necessary for binding in the active site of the enzymes. The incorporation kinetic data 
(Vmax/KM) of the conjugate comprising a phosphoramidate linker and a free carboxylic group was 
found to be 994 fold lower than the natural substrate TTP, within the range of leaving groups mimics 
previously explored in our lab. 
In Chapter 4, novel sulfono-phosphoramidate conjugates exhibiting at 5′-phosphate position of 
deoxynucleotides, through a P-N bond, metabolites such as taurine or aliphatic sulfonates are 
described and evaluated, both as pyrophosphate mimics and substrates for sulfonate delivery systems. 
Taurine-N-acetic acid was identified as the best leaving group in polymerase catalyzed DNA synthesis 
with various thermophilic and mesophylic DNA polymerases e.g. Therminator, Vent (exo-) and 
Klenow (exo-), and base specificity followed the order G > A ≥ T > C. Compared to the natural 
substrate dGTP, the Vmax/KM value for taurine-N-acetic acid-dGMP reduces by 702 fold, comparable 
to other bioisosteric leaving groups such as IDA and IDP. 
In Chapter 5, the synthesis of various biotin-TMP and Kanamycin A-TMP conjugates, presenting 
some of the biocleavable linkers designed for PNCs, is described targeting biotin transport and 
aminoglycoside uptake systems, respectively. The biotin-TMP conjugates are linked through the 3’-
OH group of TMP to the carboxyl group of biotin comprising an oxymethyleneoxy ester, a carboxy 
ester, a carbamate and an oxymethyleneoxyamide linker, whilst kanamycin A-TMP conjugates with 
carbamate and thioehtyl cabamate linkers were obtained by exploiting the different chemical 
reactivity of polyamimo and polyhydroxyl functionalities of the aminoglycosidic moiety.  
In the last chapter (Chapter 6), the methods and results of biological evaluation of all conjugates 
of TMP with peptides, sulfonates, biotin and kanamycin using a thymidine auxotrophic E.coli mutant 
(thyA-, ΔphoA) is detailed. Unfortunately, none of those conjugates was found to be sustaining 
bacterial growth under the chosen experimental conditions. 
Several critical parameters influencing the outcome of the biological assay can be identified, for 
instance conjugate concentration and mode of addition, stability, phosphatase activity, recognition and 
binding, metabolism, and need to be addressed in the future along with the exploration of additional 
linkers and conjugates. 
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Samenvatting 
Het centrale dogma van moleculaire biologie steunt op de opslag, transfer en verbreiding 
van het genetische materiaal van DNA naar proteïnen via RNA. Synthetische genen kunnen 
worden gebruikt om genetisch gemodificeerde organismes te creëren. Deze organismes 
kunnen gebruikt worden voor verschillende toepassingen zoals therapeutics, landbouw, 
energie en milieu, materiaalkunde en biotechnologie. Maar dankzij het gevaar van al dan niet 
opzettelijk interacties van het gemodificieerd genetische materiaal met de genetische 
informatie van natuurlijke soorten via gene transfer, worden zulke artificiële genetische 
constructies gezien als een mogelijk gevaar voor natuurlijke ecosystemen. 
De ontwikkeling van orthogonale biologische systemen door de chemische synthese van 
niet natuurlijke nucleïnezuren (Xeno Nucleic Acids, XNA), wordt beschouwd als een goede 
genetische firewall om genetisch cross talk te voorkomen. XNA lossen op deze mannier de 
voornaamste problemen in verband met bioveiligheid op. Verschillende op XNA gebaseerde 
systemen zijn gesynthetiseerd om deze firewall op te bouwen. Dit start met modificaties aan 
de base, het suiker en de leaving group, gevolgd door het aanpassen van de enzymes die 
geassocieerd worden met de XNA catalystise werking. Om hun ultiem evolutionair potentieel 
vrij te maken, moeten gereprogrameerde organismes een voldoende grote concentratie van 
voorlopers van XNA nucleotides of hun polymeren in de cel hebben. De in vivo invasie van 
XNA replicons was origineel gericht naar bacteriën vanwege hun relatief eenvoudige 
genetische architectuur. Hoewel de meeste gemodificeerde nucleosiden gemakkelijk 
bacteriecellen kunnen binnendringen met behulp van passieve diffusie, worden ze moeilijk 
gephosphorolyseerd tot hun monofosfaat vorm door natuurlijke kinases. Aan de andere kant 
wordt de levering van nucleotiden binnen de bacteriecel gehinderd door hydrofobe interacties 
met de lipidelaag van de cel. Dit komt doordat nucleotiden een lage pKa en een hoge 
polariteit hebben. Bacteriën hebben niettemin verschillende transmembraan transport 
proteïnen die door middel van actief transport essentiële voedingstoffen zoals peptiden, 
sulfonaten, suikers en vitamen binnen de bacteriecel kunnen transporteren. 
Het doel van deze doctoraatsthesis is nagaan of deze natuurlijke systemen die gewijd zijn 
aan het transport van metabolieten, gebruikt kunnen worden als potentieel transportsysteem 
voor nucleotiden in bacteriecellen. Dit wordt onderzocht door het systematisch ontwerpen en 
synthetiseren van verschillende nucelotide-conjugaten, gevolgd door hun evaluatie in een 
voedingswaarde selectie assay. Thymidine mono-fosfaat (TMP) werd gekozen als voorbeeld 
nucleotide in een modelstudie waar de intracellulare levering van de corresponderende TMP-
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conjugaten kon worden geanalyseerd door de groei van geschikte E.coli mutanten, die 
auxotrofisch zijn voor thymidine (thyA-, ΔphoA), te bestuderen. 
Tijdens het eerste project (hoofdstuk twee) werd een varieteit van di- tot penta-peptides 
geselecteerd als transportmiddel, gericht naar verschillende peptide permeases, bijgevolg 
werd een serie van peptide-TMP conjugaten (PNCs) gesynthetiseerd. Deze werden 
geëvalueerd voor hun activiteit in E.coli. In dit hoofdstuk worden verschillende lineaire en 
convergente synthesemethoden in combinatie met een orthogonaal bescherming-
ontscherming strategie besproken, om de conjugaten te synthetiseren. Deze conjugaten 
werden bekomen door de koppeling van een zijketen functionele groep van de oligopeptiden 
met de 3’-hydroxyl groep van TMP door middel van biologische kliefbare linkers zoals 
carbamaat (OCONH), ester (OCO), oxyamide (ONHCO), oxymethyleneoxyamide 
(OCH2ONHCO) en oxymethylene-oxyester (OCH2OCO). 
In het derde hoofdstuk wordt het ontwerp en de synthese van verschillende PNCs of TMP 
bediscussieerd. Deze moleculen werden verbonden met behulp van verschillende fosfoester 
linkers zoals, fosfaat, fosforamidaat, fosforothioaat en thioethyl-fosfaat via de 5’hydroxyl van 
thymidine en de α-koolstof van de terminale C van glycine residue van L-Ala-Gly. Om een 
preliminair inzicht te krijgen in het potentieel van het in vivo metabolisme, werden deze 
conjugaten geëvalueerd als substraat in een templaat gerichte DNA polymerisatie reactie met 
verschillende thermofiele en mesofiele DNA polymerases zoals Therminator, Vent (exo-) en 
Klenow (exo-). Een vrije carboxyl groep is essentieel voor de binding van dit molecule in de 
actieve site van deze enzymes. De kinetische incorporatie data (Vmax/Km) van het conjugaat 
dat een fosforamidaatlinker en een vrije carboxyl groep bevat was 994 keer trager dan het 
natuurlijke substraat TTP. Dit resultaat is vergelijkbaar met eerder bekomen resultaten in ons 
labo. 
In hoofdstuk vier werd de synthese van  nieuwe sulfono-fosforamidaat conjugaten 
beschreven, waarbij de sulfono-fosforamidaat gekoppeld is aan de 5’-fosfaat postie van 
deoxynucleotiden door middel van een P-N binding. Metabolieten zoals taurine of alifatische 
sulfonaten zijn beschreven en geanalyseerd, zowel als pyrofosfaat mimics en als een substraat 
voor sulfonaat transportsystemen. Taurine-N-acetic acid was geïdentificeerd als de beste 
leaving group in een polymerase gecatalyseerde DNA synthese. Deze synthese werd 
uitgevoerd met verschillende termofiele en mesofiele Dna polymerases zoals Therminator, 
Vent (exo-) en Klenow (exo-). De base specifiteit had G > A ≥ T > C als volgorde. De 
Vmax/Km waarde voor taurine-N-acetic acid was 702 keer trager dan het natuurlijk substraat 
dGTP. Dit komt overeen met andere bioisosterische leaving groups zoals IDA en IDP. 
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In hoofdstuk vijf wordt de synthese van verschillende biotine-TMP en Kanamycin A-
TMP conjugaten voorgesteld. Deze zijn respectievelijk gericht naar het biotine transport en 
het aminoglycoside opnamesysteem. De gesynthetiseerde conjugaten bevatten één van de 
biologische kliefbare linkers die ontwikkeld waren voor PNCs. De biotin-TMP conjugaten 
zijn verbonden via de 3’-OH group van TMP met de carboxyl groep van biotine, bestaand uit 
een oxymethyleneoxy ester, een carboxyl ester, een carbamaat of een oxymethylenoxyamide 
linker. De kanamycin A-TMP conjugaten bevatten een carbamaat en een thioethyl carbamaat 
linker. Deze werden bekomen door gebruik te maken van de verschillende reactiviteit van de 
polyamino en polyhydroxyl functionele groepen van het aminoglycosidic deel van het 
molecule. 
In het laatste hoofdstuk (hoofdstuk zes) worden de verschillende methoden en de 
resultaten van de biologische evaluatie van alle TMP conjugaten met peptides, sulfonaten, 
biotin en kanamycin weergegeven, gebruik makend van het auxotrofisch E. coli mutant 
(thyA-, ΔphoA ). Spijtig genoeg kon geen van de conjugaten bactieriegroei stimuleren, onder 
de gekozen experimenteële omstandigheden. 
Verschillende cruciale parameters die het resultaat van de biologische assay kunnen 
beïnvloeden zijn geïdentificeerd: de conjugaat concentratie en de additie wijze, stabiliteit, 
phosphatase activiteit, herkenning en binding en metabolisme. Deze parameters moeten in de 
toekomst allemaal geanalyseerd en geverifieerd worden om mogelijke problemen uit te 
sluiten. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
 Abbreviations 
 
1D one dimensional 
2D two dimensional 
A adenine 
ACN Acetonitrile 
L-Ala L-alanine 
L-Asp 
Bn 
L-aspartic acid 
Benzyl 
Boc tert –butyloxycarbonyl 
(Boc)2O di-tert –butyl dicarbonate 
Bz Benzoyl 
C cytosine 
Cbz Carboxybenzyl 
COSY Correlation SpectroscopY 
DABCO 1,4-diazabicyclo[2.2.2]octane 
dAMP deoxyadenosine monophosphate 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCC dicyclohexylcarbodiimide 
DCM dichloromethane 
DMF N,N-dimethylformamide 
DMSO 
DPDS 
dimethyl sulfoxide 
2,2'-dipyridyldisulfide  
DPPA diphenylphosphoryl azide 
δ chemical shift 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleoside triphosphate 
D2O deuterium oxide (Heavy water) 
ds-DNA/RNA double-stranded DNA/RNA 
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EtOAc ethyl acetate 
Gly glycine 
L-Glu L-Glutamic acid 
HETCOR HETeronuclear CORrelation 
His histidine 
HIV Human immunodeficiency virus 
HMBC heteronuclear multiple bond correlation 
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HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
HSQC heteronuclear single quantum coherence 
Hz hertz 
IDA iminodiacetic acid 
L-Lys L-Lysine 
i-Pr isopropyl 
m-CPBA m-chloroperoxybenzoic acid 
Me methyl 
MHz megahertz 
MP monophosphate 
n-Bu n-butyl 
NDP nucleotide diphosphate 
NHS N-hydroxy succinimide 
NMI N-methylimidazole 
NMP nucleoside monophosphate 
NMR nuclear magnetic resonance 
n-Pr n-propyl 
NPs Nucleoside 5′-phosphoramidates 
NTP nucleoside triphosphate 
MMTr mono methoxy (4-) trityl chloride 
PCR Polymerase chain reaction 
Ph phenyl 
pTSA para-toluene sulfonyl chloride 
L-Phe L-Phenyl alanine 
Ppm 
Py 
parts per million 
pyridine 
RNA ribonucleic acid 
RT reverse transcriptase 
rt room temperature 
SATE S-acylthioethyl 
T thymine 
TBDMSCl tert-butyldimethylsilyl chloride 
TBDPSCl tert-butyldiphenylsilyl chloride 
TIBSCl 2,4,6-triisopropylbenzenesulfonyl chloride 
TEA triethylamine 
TEAB triethylammonium bicarbonate 
 x 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TK thymidine kinase 
TLC thin layer chromatography 
TMSCl Chlorotrimethylsilane 
(d)TMP Thymidine monophosphate 
TOCSY TOtal Correlation SpectroscopY 
TTP Thymidine triphosphate 
U uracil 
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Chapter 1 Introduction 
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Chapter I.        General Introduction 
1.1.  Nucleic acids: A brief history 
Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are the two essential biopolymers 
responsible for the storing and transmitting genetic information, from generation to generation in all 
living organisms. The Swiss scientist Friedrich Miescher was the first discoverer of DNA back in 
1869, but only in 1944 Avery and co-workers identified the important biological function of DNA as 
genetic material. Generally, in an eukaryotic cell, DNA is present inside the nucleus as a highly 
packed coiled structure, as complex with histone proteins. DNA is predominantly found in nature in a 
double-stranded anti-parallel helical form, while RNA is largely single-stranded. Francis Crick and 
James D. Watson first presented the double helical molecular structure of DNA in 1953[1] and they 
were awarded Nobel Prize together with Maurice Wilkins in 1962. Their findings ultimately led to the 
opening of the new field known as ‘Chemical Biology’, and building upon this idea scientist later 
discovered how DNA function as the storage of the genetic information, which then transfer the 
genetic information to RNA. RNA functions as an intermediate to transfer the genetic information 
from DNA to the protein level via a three-letter genetic code. Such information flow was first 
proposed (1956) by Francis Crick as the “central dogma” of molecular biology (Fig. 1-1), “DNA 
makes RNA makes protein”.   
 
Figure 1-1. Information flow in biological systems. 
1.1 .1.  Chemical structures of nucleosides and nucleotides 
DNA and RNA are both constructed from the four different nucleotide monomeric units by the 
repetition of phosphodiester linkages. Each nucleotide unit is comprised of a nucleobase (a 
heterocyclic nitrogenous base), a five-carbon sugar (either deoxy-ribose or ribose) and at least one 
phosphate group (Figure 1-2). Without the phosphate group, the nucleobase and sugar moiety together 
are denoted as a nucleoside and with respect to the attached phosphate group/s, the corresponding 
nucleotide can also be called a nucleoside monophosphate, diphosphate and triphosphate respectively. 
In the case of DNA, the sugar moiety is 2′-deoxy-D-ribose, which is connected to a nucleobase via a 
β-glycosidic C-N bond at the 1′-carbon position. Nucleobases are divided in two families, purines 
[adenine (A) or guanine (G)] or pyrimidines [cytosine (C) or thymine (T)]. The sugar found in RNA 
instead is D-ribose, and the same nucleobases can be attached to the ribose moiety as found in DNA, 
DNA
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with the exception of thymine, which is replaced by uracil (U). The nucleoside triphosphates 
[d(NTPs)] of the corresponding [deoxy-(nucleoside monophosphates)] act as substrates for 
polymerases and pyrophosphate as the metabolic active function necessary for nucleic acid 
biosynthesis in vivo.  
 
Figure 1-2. Chemical structures of natural nucleotides (left), and the five heterocyclic nucleobases 
(right) with the conventional atom numbering. 
 
1.1.2. Secondary structures of DNA and RNA 
Nucleic acids are built up via the formation of a repeating phosphodiester bond following the 
nucleophilic attack of the 3’-OH group of one nucleotide to the 5’-O-phosphate of another nucleotide 
with the aid of a suitable enzyme. Mostly, DNA occurs in nature as a double stranded helix, for at 
least some of their lifespans; whereas RNA as single stranded. The Watson-Crick type base pairing of 
the two strands fundamentally determines the secondary structure of DNA, where adenine is paired 
with thymine through two hydrogen bonds, and guanine is paired with cytosine through three 
hydrogen bonds (Fig. 1-4). Different conformations of a particular nucleotide, as represented by the 
backbone and glycosidic torsional angles, and the puckering mode of the sugar residues lead to 
different overall helical duplex conformations. 
The furanose sugar ring of DNA/RNA adopts a non-planar conformation that can be described as 
a twist of the C2’-C3’ bond with respect to the plane defined by C1’-O4’-C4’ atoms. When the 5’- 
and 2’-carbon share the same plane in the puckering orientation the resulting conformation is called 
C2’-endo, whilst when the 5’- and 3’-carbon share the same plane in the puckering orientation is 
called C3’-endo (Fig. 1-5).[2] Generally DNA-sugar adopts a South type puckering conformation, 
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while RNA-sugar prefers a north type puckering (Figure 1-5). Depending on the sequence context, 
ionic and hydration situations, the DNA-sugars can favor any of these puckering modes alone or in 
combination and thereby considerably influence the three-dimensional structure of DNA double 
helix.[3] 
 
Figure 1-3. Three-dimensional structure of a DNA-duplex (reproduced from 
http://academic.brooklyn.cuny .edu/biology/bio4f v/page/molecular%20biology/dna-structure.html) 
 
 
Figure 1-4. Classical Watson-Crick base pairing in DNA 
 
The nucleobases can also adopt two different orientations, syn- and anti- with respect to the 
sugar unit by rotation along the glycosidic bond. In the anti-conformation the bulk of base is away 
from the sugar ring and in the syn-conformation the bulk is closer to the sugar ring. Due to the steric 
crowd, generally the anti-conformation is more favored and abundant than the syn-form. 
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Figure 1-5. The different arrays of non-planar sugar conformation of the pentofuranosyl sugar ring of 
DNA (left) and RNA (right). 
 
1.2. Synthetic biology 
Synthetic biology is an emerging, interdisciplinary area of research in the field of biology, which 
bring together disciplines such as genetic engineering, molecular biology, systems 
biology, biotechnology, biophysics, and also evolutionary biology. The term "synthetic biology" dates 
back as early as the twentieth century, but it is only during 1970 that the polish geneticist Wacław 
Szybalski used it in a modern sense, writing: “Let me now comment on the question ‘what next’. Up to 
now we are working on the descriptive phase of molecular biology…. But the real challenge will start 
when we enter the synthetic phase of research in our field. We will then devise new control elements 
and add these new modules to the existing genomes or build up wholly new genomes. This would be a 
field with an unlimited expansion potential and hardly any limitations to building ‘new better control 
circuits’ or ..... Finally other ‘synthetic’ organisms, like a ‘new better mouse’. ... I am not concerned 
that we will run out of exciting and novel ideas, ... in the synthetic biology, in general.”[4] 
In 1978 Arber, Nathans and Smith won the Nobel Prize in Physiology and Medicine for the 
discovery of restriction enzymes, their work eventually leading to a boom in the construction of 
recombinant DNA molecules and analysis of individual genes. This represented a milestone in the 
field as not only existing genes could be defined and investigated but also new gene arrangements 
could be fabricated and evaluated. Although this field has been growing very rapidly over the last 15 
years, a broadly acknowledged single definition does not exist yet, but the main objective is 
"manipulating and fabricating biological devices, systems or pathways for our beneficial purposes, 
which do not exist in nature."  
1.2.1.  Applications of synthetic biology 
Synthetic biology is now no longer constrained to an abstract concept, but many challenges have 
started to be addressed and some significant progresses have been achieved by producing novel 
chemical entities, addressing environmental issues and thus improving overall human health. 
Probably, the first successful applicative example is the development of recombinant 
DNA technology which allowed to engineer E.coli bacteria for the large scale production of the 
human growth hormone to help under-growing individuals[5] and human insulin for diabetic 
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patients.[6] A similar principle was applied to engineer microbes for the production of most of the 
vitamins that are being consumed as supplements.  
Outstanding progress has been made in the cost effective production of synthetic biofuels from 
different cheap sources to address the global warming and energy self-reliance issues.[7] Different 
groups around the world also achieved ground breaking discoveries on the field of ‘biosensors’ by 
using engineered bioluminescent bacteria that can detect different environmental pollutant like 
mercury, arsenic, petroleum pollutant through quorum sensing.[8] As the world population is growing 
exponentially and so does the expected acute food shortage to feed the hungry world, remarkable 
efforts have been made through bio-engineered crops (green revolution) by joint efforts of different 
agro-biotech companies and academics from different universities. In the modern time the 
pharmaceutical industry has engineered proteins to be used as monoclonal antibodies and drug target 
mimics, required for high throughput screening. To tackle complex diseases like cancer or auto-
immune diseases, targeted complex engineered cells or proteins are required for screening purposes.[9] 
Besides, synthetic biology was successfully employed in material science for the production of 
reengineered curli nanofibers for substrate adhesion, protein immobilization and nanoparticle 
templating.[10] Along with the significant number of examples and on-going research projects, huge 
are the opportunities left for successful applications of synthetic biology that can be envisioned. With 
the advancements in this field, expectations are also increasing to engineer organisms with genuinely 
new features from what is already known, for example not just confining into the familiar 
recombinant technology, but also achieving the true evolution of synthetic organisms with alternative 
genetic systems. 
 
1.2.2.  Synthetic biology and biosafety 
As a consequence of the incorporation of synthetic DNA constructs together with synthetic 
enzymes in chromosomes and episomes of modified microorganisms for applications in agriculture, 
energetics and molecular biology, fundamental ethical questions and biosecurity issues due to the 
potential contamination of synthetic genetic sequence with natural system are raised. These artificial 
constructs are considered by some as a threat to the wild ecosystem and even alleged to manipulate 
the evolution of terrestrial life. These issues are not new, but were addressed by the regulation of 
companies producing synthetic DNA or enzymes,[11] during the early stages of development of the 
recombinant DNA technology and launching of genetically modified organisms (GMOs) in 
agriculture to improve crops yield and disease or insect resistant transgenic plants.[12] There are, 
however, also possible and perceived genetic pollution due to deliberate or unintended damage. There 
are already strict regulatory board for extensive guidelines for genetic engineering and synthetic 
biology in all over the world. SYNBIOSAFE and COSY are EU funded organizations which function 
in Europe to care for the safety related issues regarding synthetic biology.  
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1.3.  Xenobiology: The crucial biosafety tool 
“It is when we all play safe that we create a world of utmost insecurity.”- Dag HammerskjÖld. 
 To address the issue of biosafety, an important component in the development of technologies that 
must be emphasized is the avoidance of crosstalk between natural species and artificial biodiversity. 
Standardized DNA parts (BIOBRICKS), cost effective DNA synthesis, reliable DNA sequencing and 
molecular modeling prior to fabrication, are the key enabling technologies for advancement in this 
field. As it is now becoming easier to construct artificial genes, plasmids and chromosomes using 
standard protocols with the help of these technologies, the moon-shot goal of genetic reprogramming, 
directed mutagenesis and directed evolution could be anticipated. As an effort towards suitable 
biological systems devoid of cross contamination, it was proposed to design an orthogonal episome, 
i.e. a self-sustaining third type of information system different from DNA or RNA, which would not 
interfere (no vertical or horizontal gene transfer) with natural ecological system. 
  
1.3.1.  Xeno nucleic acids (XNAs) 
In order to create a parallel system in any discipline, it is necessary to start from the elementary 
building blocks. As the nucleic acids are the bio-systems carrying the natural genetic information, so 
to avoid cross talking interference, substitution of all of their fundamental units  must be substituted 
by modified or ‘xeno’ nucleic acids. Enormous efforts have been made to produce nucleic acids 
modifications, not only in this field but also in the medical one, for potential use as drugs especially in 
antiviral therapy, anti-gene, antisense and siRNA and also in other area like cellular probes, 
biosensors, aptamers and enzymes in biotechnology. Over the past few decades, chemistry based 
research has clearly established a third type of molecular system for storing genetic information other 
than DNA and RNA.[13] XNAs can different from natural nucleic acids from various aspects, as 
chemical modifications can be tailored either at the hetero-cyclic base moiety or at the sugar moiety 
or phosphodiester linkage or a combination. Recent progresses in the field of engineered polymerases 
to achieve enzymatic replication of unnatural nucleic acids paved the path to the synthesis and 
evolution of unique synthetic polymers with the desired properties and functions. Moreover, the base 
pairing ability of XNA with the desired oligonucleotide polymers, template based enzymatic 
incorporation fidelity of XNA, transcription and reverse-transcription of genetic message via XNA 
gene, are the key principles based on which natural nucleic acid mimics are recognized for the 
application in the synthetic biology field. 
 
1.3.2.  Base modifications 
There are numerous examples listed in the literature of modified nucleo-bases. While some of 
them have been designed for genetic and synthetic biology purposes (Fig. 1-6), others derive from 
therapeutic purposes. Different groups focused on the development of non-natural base-pairing 
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systems for incorporation into DNA and RNA, and in turn to expand the genetic alphabet. There are 
two main strategies to expand the genetic code, a) maintaining the Watson-Crick like hydrogen 
bonding mode in the modified base pairs, b) using hydrophobic groups that mimic the shape and 
polarity of natural bases through hydrophobic interactions (Fig. 1-6-1). Besides these, other strategies 
include size expansion, extra H-bond and metal mediated pairing (Fig. 1-6-1). In late 1980, the 
Benner group first introduced the several unnatural base pairs showing a Watson-Crick type hydrogen 
bonding pattern, such as isoguanine:isocytosine (isoC:isoG) (Fig. 1-6-2B), 6-amino-5-nitro-3-(1′-β-D-
2′-deoxyribofuranosyl)-2(1H)-pyridone:2-amino-8-(1′-β-D-2′-deoxyribofuranosyl)-imidazo[1,2-a]-
1,3,5-triazin-4(8H)-one (Z:P) (Fig. 1-6-2B) and 5-(2,4-diaminopyrimidine:xanthosine (dK:dX) for 
synthetic biology purposes based on AEGIS (artificially expanded genetic information systems).[14] 
The authors first successfully explored the isoC:isoG pair for its ability to be incorporated and 
replicated by the Klenow fragment of E.coli DNA polymerase. However, to maintain high isoC:isoG 
selectivity the simultaneous addition of 2-thiothymine (2-thioT) (Fig. 1-6-2A) was crucial to reduce 
isoG:dT base pairing, by forming strong 2-thioT:A pairing system.[15] They have also described that 
high fidelity and selectivity (97.5% retention) can be maintained with Z:P base pairs[16] both in DNA 
polymerization and PCR amplification.[17]  
Eric T Kool and co-workers first introduced the concept of xDNA with 8-component bases 
where the modifications were made for four natural nucleobases A, T, G, C to increase the molecular 
volume by introducing an extra phenyl ring in the bases: xA, xT, xG, xC or yA, yT, yG, yC (Fig. 1-6-
2A).[18] [19] The modified bases could also pair with the corresponding natural counterparts, and in a 
recent structural study it was shown that the greater the distance between the wider grooves and 
longer pitch of the double helix were responsible for the more stability of xDNA compared to natural 
DNA.[20] The same group also presented an analogous yDNA using the size expansion concept with a 
phenyl ring. Recently, the first living cell study in E.coli revealed that the two dXNA bases xA and 
Xc were recognized and replicated efficiently by E.coli polymerase to develop a normal message.[21]  
Apart from the hydrogen bonding modulation, efforts have also been made to mimic size, shape 
and polarity of a natural pairing system by a hydrophobic approach. Furthermore, Kool et al. 
developed an hydrophobic unnatural pair (Z:F) (Fig. 1-6-1), mimicking the canonical A:T base pair 
and found that the difluorotoluene which mimics thymine was also incorporated and replicated by 
DNA polymerase.  
Since Kool’s discovery of hydrophobic interactions for base modification, Hirao and co-workers 
produced the 7-(2-thienyl)-imidazo[4,5-b]pyridine (Ds):pyrrole-2-carbaldehyde (Pa) (Fig. 1-6-2C) 
and Ds:2-nitropyrrole (Pn) base pairs aiming at the expansion of the genetic alphabet, which retained 
high selectivity and fidelity per cycle (>99%) in PCR in the presence of a DNA polymerase with 
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3′→5′ exonuclease activity.[22] The simultaneous addition of γ-amido triphosphates was necessary to 
maintain high selectivity, but resulted in reduced fidelity. Building up on this idea to increase fidelity 
in PCR, they also developed a similar Ds: 2-nitro-4-propynylpyrrole (Px) base pair, with the aim of 
generating several functional assemblies of interest at the propargylic position of Px.[23] Site specific 
incorporations with high selectivity were observed for the Ds:Px pairing system,  in a PCR 
amplification of 107-fold by 30 cycles and with more than 99.9% fidelity per cycle, without the need 
of external addition of γ-amido triphosphates. 
 
Figure 1-6. Examples of unnatural base pairs with different types of bonding systems 
Romesberg’s group also independently studied the modification of hydrophobic base pairs in a 
systematic way aiming at the extension of genetic alphabet. Various hydrophobic bases were 
synthesized and screened for their pairing properties like d5SICS:dMMO2 (Fig. 1-6-2C), 7AI:7AI, 
PICS:PICS (Fig. 1-6-2D), d5SICS:dNaM and dTPT3:dNaM.[24] Notably, the d5SICS:dNaM pair has 
drawn lot of attention since it could be both replicated and transcribed in vitro as well as in vivo.[25, 26]  
(1) (2) 
xT 
F Z 
xA 
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1.3.3.  Sugar modifications 
A large number of studies have been devoted by different laboratories to develop xeno-nucleic 
acid systems by introducing sugar modifications mimicking the canonical ribose or deoxy-ribose 
sugar. Not only the sugar modification has potential applications in synthetic biology (summarized in 
fig. 1-7), but also in therapeutics, especially in antiviral therapy. 
Locked nucleic acids often abbreviated as LNA, were introduced independently by two groups, 
Imanishi and Wengel almost 15 years ago. Since then many laboratories have been working on those 
sugar modified nucleic acids for their potential applications as antisense oligonucleotides, molecular 
beacons, DNAzymes etc.[27] LNAs mimic the corresponding natural RNA moiety, where the 2’-O and 
C-4’ are bridged with an extra methylene group. This locking system allows the sugar ring to adopt a 
stable 3’-endo conformation which reproduces the natural RNA binding. Due to the reduction in 
conformation flexibility, LNA has an exceptional binding affinity for self-pairing and also towards 
natural DNA and RNA counterparts. Structural NMR spectroscopy studies revealed that a LNA-RNA 
duplex adopt an A-type double helical structure where a LNA-DNA duplex has a structural similarity 
to those of a natural RNA-DNA duplex.[28] The incorporation properties of LNA were studied using 
different DNA polymerases like Vent(exo-) and KOD(exo-) and also with T7 RNA polymerases, 
giving encouraging results.[29] Other variants of locked nucleic acid like xylo-LNA, 2’-thio LNA and 
2’-amino LNA are also being explored for various applications. 
Amongst the various nucleic acid mimetics developed by Eschenmoser et al., L-α-threofuranosyl 
nucleic acid (TNA) is of particular relevant to synthetic biology due to the inherent stability of this 
polymeric unit in the presence of nucleases.[30] Unlike DNA, phosphodiester bonds in TNA occur 
between the 2’- and 3’- position of the furanose ring (3’→2’) and no methylene group is present 
between the sugar rings. TNA polymers were found to be capable of exchanging information by 
forming intra-system duplexes with complementary TNA templates and also cross pairing with DNA 
and even more strongly with RNA. Structural studies by X-Ray crystallography revealed that a TNA-
TNA duplex prefers to adopt a structural similarity to the A-form of DNA or RNA, but with a 
relatively shorter distance between the repetitive units as anticipated.[31] Due to its structural 
simplicity and binding affinity, scientists have hypothesized that TNA could have served as an 
ancestral genetic system alternative to RNA in the prebiotic pool. The replication properties of TNA 
have been studied independently by Szostak and Herdewijn using different DNA polymerases and 
reverse transcriptases, but reported to be kinetically less efficient than natural analogues. Recently, 
TNA triphosphates were efficiently incorporated by an engineered reverse transcriptase (RT521) on a 
DNA template, and TNA sequences were generated up to 72 nt following canonical base-pairing 
selectivity and transcribed into DNA up to 93 nt based on a TNA template using the same 
polymerase.[32]  
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Figure 1-7. Examples of sugar and backbone modified nucleic acid analogues. 
 
Among the six-membered sugar mimics, Hexitol Nucleic Acid (HNA) and Cyclohexenyl 
Nucleic Acid (CeNA) are the two promising candidates introduced by Herdewijn and co-workers in 
the late 1990s. HNA is similar to DNA with a phosphorylated 1’, 5’-anhydrohexitol backbone bearing 
an extra methylene group present between C-1’ and O-4’ of the ß-D-2’-deoxyribose unit. HNA 
showed inter-system cross pairing with DNA, and its antisense properties are known due to its 
stronger binding with RNA,[33] furthermore HNA homo-duplexes are even more stable due to stronger 
intra-system cross pairing. Like LNA, it also forms A-type helices of HNA-HNA and HNA-RNA 
duplexes.[34] The other six-membered sugar mimic CeNA is characterized by a flexible cyclohexene 
ring with a ß-positioned nucleobase like in HNA.  Due to the intra- and inter-system pairings and its 
prolonged stability in serum, CeNA is also considered as a potential antisense candidate.[35] Both the 
triphosphates of HNA and CeNA showed moderate to good incorporation properties in the presence 
of different DNA-polymerases. Deep Vent (exo-) showed good incorporation efficiency and kinetics 
of incorporation were comparable to the natural analogues but with reduced fidelity. Cyclohexenyl 
nucleotides also showed good incorporation properties in the presence of Vent(exo-) DNA 
polymerase and HIV-reverse transcriptase, showing up to seven consecutive strand elongation based 
on a DNA template containing T and C.[36] Recently both HNA and CeNA triphosphates were 
efficiently incorporated up to 72 nt based on a DNA template by engineered DNA polymerase PolC7 
and Pol6G12 respectively.  Similarly, DNA sequences were also reverse-transcribed up to 72 nt on 
CeNA template and 73 nt  on a HNA template using engineered reverse transcriptases RT521K and 
RT521 respectively.[32]  
For their structural simplicity and conformational flexibility, acyclic nucleic acids were also 
explored early in the origin of life context, where they might have existed as precursors for non-
enzymatic oligomerization in the pre-RNA world.[37] [38] Some of these flexible nucleic acids still 
maintain canonical base pairing which is essential for polymerase-catalyzed incorporation studies. 
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FNA (flexible nucleic acid), based on formyl glycerol, is one of the initial acyclic nucleic acids that 
were thought to dominate in the prebiotic world, as hypothesized by Orgel.[37] Though FNA showed 
weak or no tendency to form stable duplexes with DNA, it was lately found by Switzer et al. that both 
the enantiomers of FNA can be incorporated by various DNA polymerases and with the higher 
efficiency for the (R)-isomer. Therminator DNA polymerase showed the highest fidelity, with 
incorporation up to 7 nt.[39] 
Like FNA, glycerol nucleic acid (GNA) is also highly flexible due to its propylene glycol 
phosphodiester backbone, although only particularly (S)-GNA has cross-pairing properties with RNA, 
whilst both the isomeric forms give relatively more stable self-paired homoduplexes.[40] Szostak was 
the first to examine the ability of GNA-triphosphates for their ability to be incorporated on a DNA 
template by different DNA polymerases, with therminator polymerase giving the best results with 
incorporation of 5 GNA unit.[41] Although GNA does not make stable strands with DNA, recently the 
formation of a full length DNA chain was established on a BstDNA polymerase catalyzed 
incorporation study based on a GNA template as reported by the same group.[42] 
One of the most promising examples of nucleic acid mimics is represented by peptide nucleic 
acid (PNA). Aminoethylglycine PNA (aegPNA) was first developed by Nielsen and Buchardt as a 
ligand to bind to double stranded DNA via Hoogsteen base pairing.[43] In aegPNA, the original sugar-
phosphate backbones were replaced by flexible achiral N-(2-aminoethyl) glycine pseudo-peptide 
polymeric units linked to nucleobases. Because of the formation of both homo-duplexes and hetero-
duplexes with DNA and RNA by Watson-Crick pairing with high thermal stability and sequence 
specificity, PNA has attracted researchers for its diverse applications in biomedical research, i.e. 
genome mapping, mutation detection, anti-sense and anti-gene therapy etc.[44] The enzymatic 
incorporation of PNA is not known, but non-enzymatic polymerization of PNA based on DNA or 
RNA or the vice-versa using pre-activated monomeric units, has been reported by Nielsen and 
Orgel[45] PNA has also been studied in the context of the pre-RNA world because of its simplicity, 
structural rigidity, robustness and probable spontaneous polymerization at the boiling point of 
water.[46] In the last few years lot of research efforts have been made to introduce other variants of 
PNA like thioester PNA (tPNA) and also to enhance the bioavailability and to increase the potency of 
PNA. tPNA[47] is constructed from a alternating sequence of cysteine and non-cysteine residues, 
preferably amino acids with polar, ionic side chains along a polypeptide backbone. The thioester 
linkage was chosen in view of the reversible tethering between nucleobase thioester monomers and 
cysteine residues in solution, via a chemoselective transesterification with fast reaction kinetics. Upon 
incubation, the tPNA enriched with the sequence of nucleobases complementary to the 
oligonucleotidic template is formed and this unique self-assembly process could shed light on 
replication mechanism in a synthetic biology construct. Although the choice of PNA is not a very 
popular one in synthetic biology, as a result of the higher fidelity and compatibility in the template 
based replication, PNA could be an important candidate.  
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1.3.4.  Leaving group modifications 
In order to design XNAs and corresponding artificial genes able to propagate in vivo, multiple 
chemical and biological properties for each structural component have to be kept in mind. For 
instance, nucleoside triphosphates (NTPs), endorsed by high energy phosphono-anhydride bonds, 
possess multiple biological roles such as information storage and transmission (ATP as a building 
block for RNA biosynthesis), energy transfer (ATP as an energy transporter), regulatory tuning (at the 
level of kinases and signal transduction) and proliferating metabolic corridors (ATP as an activated 
carrier molecule). So it was thought due to its multifunctional role, the triphosphate group might be a 
limiting factor for XNA-propagation in vivo using synthetic XNA-triphosphates. Additionally it was 
also proposed that the use of alternative leaving groups (ALGs) mimicking the function of 
pyrophosphate in NTPs could serve the purpose of an information system in vivo simultaneously 
eluding interference of other cellular function.[48] Ideally, XNA-based engineered polymerases could 
only recognize the modified nucleotides as building blocks for gene synthesis, not accepting natural 
NTPs as substrates and vice versa, ALGs should not be accepted by any natural enzymatic machinery. 
 
Figure 1-8: Chemical structures of modified nucleotide analogues with alternative leaving groups 
mimicking the pyrophosphate group. 
Prior to Herdewijn’s work, minor modifications like methylene phosphonates, phosphoramidates 
and halo-triphosphates were reported in the literature as triphosphate mimics, generally as substrate 
for HIV and AMV reverse transcriptases.[49] Herdewijn and co-workers made important contribution 
in this area by developing ALG-system which could mimic pyrophosphate in the enzyme-catalysed 
nucleic acid synthesis. As the nucleotide conjugates comprising ALGs do not occur in cellular media, 
to achieve in vivo XNA polymerisation, such synthetic precursors need to be supplied from outside 
the cell. For their successful application many prerequisites have been defined for substrates with an 
ALG, listed as follows: 
- Good water solubility and optimal chemical and enzymatic stability in extracellular media 
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- Should fit in the active site of the enzyme and exhibit good substrate property 
- The polymerase should mechanistically be able to release the leaving group 
- To ensure the irreversible polymerization process, any leaving group should be actively 
degraded or reused as common non-toxic cellular metabolites 
- Ability to be taken up actively inside the cell. 
Among the diverse range of leaving group modifications that were examined, some of the 
best illustrative examples are presented in Fig 1-8. The first ALGs that were recognized by 
polymerases were found to be two amino acid L-Asp and L-His, amongst the different amino acids 
screened. Whilst, L-Asp-dAMP and L-His-dAMP showed good substrate property mimicking natural 
dATP in DNA chain elongation studies catalyzed by HIV RT and Therminator DNA polymerase.[50] 
In case of HIV-RT, the efficiency of L-Asp-dAMP was higher than that of L-His-dAMP, but the 
fidelity of DNA synthesis slowed down after 2 nt. The L-Asp variant with all the nucleotides (L-Asp-
dAMP, L-Asp-dTMP, L-Asp-dGMP and L-Asp-dCMP) were also accepted for DNA incorporation by 
HIV-RT maintaining Watson-Crick base pairing.[51] From the steady state kinetics it was observed 
that despite the maximum initial rate (Vmax) of L-Asp-dAMP incorporation was comparable with the 
natural analogue dATP, the relatively high Km value of L-Asp-dAMP compared to dATP implies 
weak binding to the active site. Following these initial encouraging results, different leaving groups 
with phosphodiester linkages were also examined to compare the activity with phosphoramidate 
linkage containing ALGs. For example, the maximum velocity of ß-imidazole lactic acid-dAMP 
(ILA-dAMP) was higher by ten-fold than L-His-dAMP, while substrate affinity by two-fold.[52] [53] 
Likewise, nucleotide analogues of iminodiacetic acid (IDA), iminidipropionic acid (IDP) and 3-
phosphono-L-alanine were synthesized and evaluated as potential substrates for HIV-RT.[54]  
IDA and 3-phosphono-L-alanine conjugates with all four bases were synthesized to study the 
influence of the base moiety, and it was found that the incorporation efficiency decreases in the order 
A > T > G > C. Furthermore, the steady state kinetic analysis of phosphoramidate analogues of 
adenine IDA-dAMP, IDP-dAMP and 3-phosphono-L-Ala-dAMP indicated that catalytic efficiency 
(Vmax/ Km) with respect to the natural substrate dATP, is significantly declined by 940, 83 and 99 fold 
respectively. The lower specificity of the modified substrate may be due to lower binding affinity to 
the active site of commercially available polymerases. 
Along with the systematic investigation of the ALGs retaining the canonical base pairing, the 
directed XNA based evolution in the active site of nucleic acid polymerases was also explored for 
enhanced selectivity. The efficacy and fidelity of polymerase catalyzed synthesis of modified nucleic 
acid polymers from unnatural nucleoside triphosphates are generally low, due to proper selectivity of 
the polymerase towards the corresponding XNA precursor.  With the advent of directed polymerase 
evolution techniques (like phage display[55], CSR[56] and CST[32]), it now became relatively easy for 
fabricating engineered polymerases which can efficiently incorporate XNA precursors during the 
polymerization process. Considering the different enzymatic actions like copying, transcription, 
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translation and reverse-transcription, different DNA/RNA dependent XNA polymerases and XNA 
dependent DNA, RNA and XNA polymerases were also envisioned for the successful in vivo 
propagation and evolution of XNA.[57] Recently, Holliger and co-workers made fundamental progress 
in enzyme evolution by engineering polymerase mutants able to support in vitro assembling and 
replication of genetic messages for six types of sugar-modified XNAs (HNA, CeNA, ANA, FANA, 
TNA, and LNA). These engineered polymerase mutants are able to recognize and efficiently 
incorporate XNA building blocks from a DNA template. XNA sequences were generated up to 72 nt 
following canonical base-pairing selectivity and reverse-transcribed into DNA with 95% accuracy or 
more.[32]  
 
1.4. Orthogonal information system and importance of nucleotides 
uptake in bacteria 
To address the biosafety issues linked to synthetic biology, the construction of a third type of 
‘orthogonal’ nucleic acid system (episome) was postulated by Herdewijn and Marliere, with the 
foremost aim of preventing genetic cross talk with existing ecosystem, by acting as a genetic 
firewall.[57] In mathematics the term ‘orthogonal’ indicates two vectors that are perpendicular to each 
other or generally, things, which are non-related to each other. Applied to synthetic biology this 
concept implies in vivo propagation of modified nucleic acids (XNAs), which structurally differs from 
natural DNA or RNA, but can autonomously replicate and perform the necessary biological functions 
not interfering with natural biological pathways. For the long term goal of solving the ‘orthogonal 
episome’ puzzle, several significant correlated footsteps need to be examined independently and 
methodically which includes base, sugar and alternative leaving group modifications together with 
directed XNA based enzymes engineering. The proliferation of XNAs along with their well-tailored 
XNA based polymerases and XNA-zymes in an in vivo scenario is a truly multidisciplinary effort 
comprising chemistry and various fields of biology. 
Concerning the nucleobases, various single modifications have been carried out to mimic the 
natural canonical base pairing systems e.g. dP:dZ, isoC:isoG, ImNO:NaON, Ps:Dx and d5SICS:dNaM. 
Several alternative leaving groups e.g. L-Asp, IDA, IDP and 3-phosphono-L-Ala were examined 
which exhibit potential pyrophosphate mimicking properties.  Attempts towards the backbone 
modification e.g. HNA, CeNA, LNA, TNA have also been introduced different from DNA or RNA. It 
was also demonstrated by Holliger group, by fabricating engineered polymerases it was also possible 
in vitro efficient DNA based XNA incorporation and XNA based DNA reverse-transcription.[32] 
Recently, with the help of XNA replication technology, the same group has developed various 
XNAzymes based on four XNAs ANA, FANA, HNA and CeNA, that are able to mimic natural 
catalytic activities e.g. RNA endonuclease, RNA ligase and also XNA-XNA ligase activity on a 
FANA network. [58] 
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Fig 1-9: General outline of the probable propagation of XNA biosynthesis inside the bacterial cells. 
ALG = alternative leaving group. 
 
The first in vivo invasion of XNA replicons is more likely to take place in bacteria, in view of 
their relatively simple genetic architecture. However, XNAs synthesis is thought to entail high 
intracellular consumption (in vivo) of unnatural building blocks, which will thus need to be provided 
to the host cell, as XNA nucleotides do not occur in nature.  As those molecules are highly polar and 
remains charged at physiological pH, their passive diffusion in bacterial cells is restrained by 
hydrophobic lipid bi-layer.  On the other hand, most modified nucleosides can enter the bacterial cell 
easily but are poorly recognized and phosphorylated by host kinases. The bacterial cells will be 
equipped in turn with suitable enzymatic machinery for polymerization of the monomers. Thus far, 
efforts have focused on overexpression of endogenous kinases e.g. from Drosophila Melanogaster, to 
broad enzyme-substrate specificity to activate the modified nucleosides to their mono-phosphate form 
following nucleoside salvage pathways,[59] and more recently, on the transfection of E. coli with a 
plasmid encoding an algal nucleotide triphosphate transporter, which efficiently imports both the 
triphosphates of d5SICS and dNaM.[26] Despite the ground-breaking value of this last approach, which 
resulted in the first in vivo replication of an unnatural DNA base pair, its universal applicability to all 
unnatural bases and types of backbone modifications is yet to be validated. 
 
1.5.  Solid phase and liquid phase peptide synthesis 
Peptides are chemically synthesized by coupling the carboxylic acid group of one amino acid to 
the amine group of the next amino acid. Contrary to nature, for peptides are prepared beginning with a 
pre-activated C-terminus and terminates with a N-terminus, with suitable protections in between to 
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avoid undesired by-products, by using solid or solution phase methods. Solid phase peptide synthesis 
(SPPS) is nowadays a routine technique, developed by R.B. Merrifield almost 60 years ago on a 
polystyrene based solid phase.[60] SPPS provides a great advantage for the synthesis of large peptides 
giving overall high yields. In the last few decades the introduction of new polymer supports (binding 
both carboxyl and amine functions), coupling reagents, and improvements in the protection-
deprotection chemistry provided a new dimension to SPPS.[61] [62] The illustrative cycle for solid phase 
peptide synthesis is showed in Figure 1-10. Besides SPPS, liquid phase peptide synthesis (LPPS) is 
also sometimes helpful for small peptide up to five-mer. Scalability is an issue with SPPS in an 
inappropriately equipped laboratory, which can be solved using LPPS for short peptides. Sometimes, 
the harsh condition (e.g. conc. TFA) used for the final cleavage of peptides from the resin and 
withstanding of various sensitive orthogonal side chain protections for further functionalization, can 
be a concern, which also can be addressed by LPPS in a stepwise manner. 
 
 
Figure 1-10: Overview of solid phase peptide synthesis using Wang resin. 
 
1.6.  Synthesis of 5’-functionalized nucleotides 
In the past two decades, different strategies have been developed for the synthesis of nucleotide 
analogues and phosphoester derivatives as prodrugs for therapeutic purposes.  Originally, the 
synthesis of phosphotriester derivatives was proposed for masking the negative charges of 
monophosphates to improve lipophilicity and chemical stability.  Among the various strategies 
developed for the synthesis of symmetrical and mixed phosphoesters, the H-phosphonate approach, 
the phosphite triester method and the use of activated PV intermediates are the most important (fig. 1-
11). The H-phosphonate approach has been successfully used by the Kraszewski group for the 
synthesis of bis(aryl) nucleoside phosphotriesters.[63] The first step is the activation of an H-
phosphonate monoester by diphenyl chlorophosphate or pivaloyl chloride, then coupling with a 
hydroxyl functionality, followed by in situ oxidation with iodine or NCS, where a second hydroxyl 
functionality acts as nucleophile to form phosphoesters. The phosphoramidite approach is perhaps the 
most popular,[64] using a bis(alkyl)-N,N-diisopropylphosphoramidite and the corresponding alcohol to 
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access the pro-moiety. Then, acid catalysed phosphoramidite coupling with a nucleoside in the 
presence of a promoter like 1-H terazole followed by in situ oxidation (with proper choices among 
different activating agents or oxidation conditions) yields phosphotriesters. One-pot POCl3 mediated 
synthesis (PV chemistry) is one of the popular choices for preparing triphosphates and especially 
phosphotriesters which are sensitive to the final oxidation step.[65] 
 
 
Figure 1-11: Overview of different synthetic routes for the synthesis of phosphate derivatives. 
 
Similarly, phosphoramidates can also be accessed in different ways following diverse strategies 
that were used for the synthesis of phosphotriesters (fig. 1-12). DCC mediated coupling of a 
phosphate group of a dNMP with the corresponding amine is still one of the more convenient ways 
for phosphoramidate synthesis, as reported by Khorana for triphosphate synthesis in 1958.[66] DCC 
mediated coupling was also used by Abraham et al. to synthesize amino acid-containing 
phosphoramidates.[67] Using of this method allows the synthesis of pre-activated species for 
nucleophilic coupling, e.g. imidazolide-dNMP or morpholine-dNMP, that are stable and storable for 
convenient usage. An alternative to the synthesis of these intermediates is the Mukayiama oxidation-
reduction condensation by using dipyridinium disulfide and triphenylphosphine.[68] H-phosphonates, 
phosphoramidite approach or POCl3 chemistry (described earlier for phosphotriester synthesis) are the 
other alternatives for the phosphoramidates synthesis using corresponding amine instead of alcohol. 
Phosphorothiate and thiophosphoramidate (fig. 1-13) derivatives can be synthesized by using 
thiophosphoryl chloride or commercially available O/N-alkylthionophosphodichloridates and 
coupling the corresponding alcohol / amine in a sequential addition in the presence of a base at low 
Chapter 1 Introduction 
 18 
temperature.[69] Alternatively, such analogues have been also synthesized via the 1,3,2-
oxathiaphospholane chemistry introduced by Stec.[70] 
 
 
Figure 1-12: Overview of different synthetic routes for the synthesis of phosphoramidate derivatives. 
 
 
Figure 1-13: Synthesis of phosphorothioate derivatives using thiophosphoryl chloride or via 1,3,2-
oxathiaphospholane. 
 
1.7.  Conjugation chemistry 
Selection of a suitable linkage is an important measure for the successful delivery of any 
conjugate in cellulo. Firstly, the linker should be stable in the extracellular medium and secondly, 
once the conjugate enters the targeted cells, it should release the attached cargo, after either chemical 
or enzymatic cleavage. Different types of bio-cleavable linkers have been designed e.g. thioether, 
disulfide, oxime, carbamate, ester, amide, oxyamide, thiazolidine, hydrazone, urea, phosphate and 
triazole etc. to enhance cellular uptake and target oligonucleotide delivery.[71] Various chemical 
strategies for the synthesis of linkers for conjugation to a cargo are described in fig. 1-14. The 
thioether linkage is one of the most commonly used linkages for conjugation because of its higher 
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stability. Formation of such linkage occurs either by nucleophilic substitution[72] or by Michael 
addition[73] of thiols. A disulfide linkage was also utilized for conjugation of nucleotides at the 5’- or 
3’- positions, either by direct oxidation of the two reacting thiols[74] or by activating one of the thiol 
group with 2-2’-dipyridyldithiol followed by nucleophilic substitution by the other thiol group.[75] 
Along with the numerous reports on the use of amide linkages, research efforts have been also put to 
develop covalent conjugates with oxime, hydrazone, thiazolidine, by ligation of amino-oxy, hydrazine 
and cysteine containing peptide respectively with a suitable aldehyde derivative.[76] By utilizing ‘click 
chemistry’ between an alkyne and an azide in presence of a Cu (I) catalyst for the formation of 1,2,3-
triazoles can also been included in the list of ‘linkage’ modification.[77] The formation of urea, 
carbamate or carbonate linkages was also realized by activating amino or hydroxyl functionalities 
with an activator  like carbonyl diimidazole, and then reacting with another fragment bearing an 
amine or a hydroxyl group.[78] 
 
 
Figure 1-14: Overview of the synthesis of different conjugates with various linkages. 
 
1.8. Microbial transport systems-a potential tool for nucleotides 
delivery 
Both Gram-negative and Gram-positive bacteria possess a rigid cell structure, where the cell 
membrane is the most dynamic element in the cell. The discovery of novel antibacterial drugs for 
combating resistance issues is a very hard challenge due to the limited permeability of many drugs or 
to the efflux systems of bacteria which can expel the drug outside the cell. The cell wall of both 
Gram-negative and Gram-positive bacteria is composed of a multilayered rigid structure to shield the 
cell from osmotic shock and physical damage. In most Gram-positive bacteria, the cell wall consists 
Chapter 1 Introduction 
 20 
of thick multilayered peptidoglycans and thin lipids linked with teichoic acid. On the contrary, the cell 
walls of Gram negative bacteria are thinner, composed of a thin peptidoglycan layer and an outer 
membrane comprising lipopolysaccharides (LPS), lipoproteins and phospholipids. This is the key 
barrier for transport of charged polar molecules and many antibiotics. Gram negative bacteria also 
possess a periplasmic space which contains many enzymes for transport, degradation and synthesis. 
Generally, water and few small uncharged molecules (Mol. Wt.< 100 Daltons) can enter the bacterial 
cell through membrane porins, but the bacterial membrane does not allow the passage of large 
substances and charged molecules, whilst charged nutrients (e.g. Na+, K+) are transported by transport 
proteins present in the membrane via specific transport systems.  
Mostly the membrane proteins which are involved in transport processes are designated broadly 
as porters, transport systems, carrier proteins and permeases. Mainly three types of transport processes 
are involved which are known as uniport, symport and antiport. Uniporters allow a solute to pass 
through in one direction, symporters allow the passage of two solutes in the same direction and time, 
and finally antiporters allow two solutes to pass in opposite directions at the same time. Bacteria have 
evolved a compact transport system utilizing various transport proteins, due to their urge to 
concentrate essential nutrients inside the cytoplasm against the concentration gradient of the 
environment, in different extreme conditions. There are mainly four well-accepted categories of 
transporters, a) channels, b) porters, c) primary active transporters and d) group translocators. 
Generally the facilitated diffusion system and passive transport of molecules or ions across the 
membranes are aided by channels, which are less common in bacteria. Accumulation of solutes inside 
bacterial cells needs active transport systems, which can be of two types, ion driven transport systems 
(IDT) and binding-protein dependent transport systems (BPDT). Through IDT, many amino acids and 
ions are accumulated via symport or antiport processes utilizing energy from proton motive force 
(pmf) or chemiosmotic potential. As the bacterial active transport machinery accumulates solutes 
inside the cytoplasm at higher concentrations than that of the environment, which requires energy 
according to law of chemical kinetics. Generally the primary active transporters use a ‘primary’ 
source of energy either from chemical, electrical or solar sources. There are various types of active 
transporter systems differing by the way of utilizing sources of energy e.g. P-P bond hydrolysis-
driven transporters (ATP hydrolysis), decarboxylation driven transporters, methyl transfer-driven 
transporters, oxidoreduction-driven transporters and light absorption-driven transporters. On the other 
hand, binding-protein dependent transport systems (BPDT) are far more complex than the facilitated 
transport, as they comprise four proteins. Out of these four proteins, two forms a channel in the 
transmembrane domain that allows passage of the solute, the third protein is located in the periplasmic 
space and has a very strong binding affinity for the specific solute, translocating the solute to a fourth 
protein which acknowledges the solute into the membrane channel. A conformational change allows 
the solutes through the channel by using of energy generally provided by the hydrolysis of ATP to 
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ADP. One of such subfamily of active transporter is the ABC (ATP Binding Cassette) transporter, 
where the fourth protein is the nucleotide binding domain (NBD) and ATP hydrolysis is linked to the 
active transport. 
 
Figure 1-15: Proposed mechanism of transport of ABC transporters (reproduced from 
https://www.boundless.com/microbiology/textbooks/boundless-microbiology-textbook/bacteria-
archaea-and-eukaryote-cell-structure-4/transport-across-the-cell-membrane-33/abc-transporters-256-
1009/) 
 
In bacteria, ABC transporters[79] transport a broad range of substrates including peptides, sugars, 
ions, amino acids, vitamins like biotin and thiamine, sulfonates and sulfates and other molecules that 
are mostly hydrophilic, which otherwise would have a restricted entry from the lipid bi-layer of the 
membrane. However for the nucleotides there is no such specific transporter in bacteria, and as 
nucleotides are also charged hydrophilic compounds at physiological pH their entry is also restricted 
by lipid bi-layers. The exploitation of one of these transporters by constructing nucleotide conjugates 
with suitable solutes could make it possible to deliver these molecules in the bacterial cell. The 
systematic exploration of these transporter systems, may pave the way for nucleotide delivery. Due to 
the wide range of possibilities to assemble nucleotide conjugates, only some of them were explored in 
the limit of this thesis, which are described in the following paragraphs. 
 
1.8.1.  Peptide transporters in microorganisms 
Extensive research has been performed by various groups on the structure, physiological role and 
molecular mechanism of different peptide permeases from E. coli and S. typhimurium.[80] Three types 
of peptide permeases are mainly found in bacteria: the dipeptide (Dpp), tripeptide (Tpp) and 
oligopeptide permease (Opp). Recent research[81] based on molecular recognition, unveiled that they 
are complementary in many ways; a) for a particular peptide each recognizes different conformational 
forms, b) capable to transport all small peptides from the peptide pool by operating simultaneously. 
Specificity and selectivity of substrate transport via Dpp has been determined by several techniques 
like radio- or fluorescent-labelled peptides utilizing Opp and Tpp auxotrophic E.coli strain[80], which 
revealed that although Dpp can transport both di- and tri-peptides, the rate is much higher for di-
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peptides. Like Dpp, Tpp can also transport both di- and tri-peptides, but with a different substrate 
specificity. Amongst the three peptide permeases, generally Opp is the most abundant periplasmic 
protein (7-10% of total periplasmic proteins) and structurally well-studied.[82] It was crystallized in its 
free form and also with ligated peptides, its three dimensional structure by X-ray analysis revealed 
three-domains and the existence of large hydrated cavities for accommodating the lateral chains of 
amino acids in order to cope with the various peptide structures that the transport system can be 
confronted with during the natural life of E. coli. Remarkably, upon binding to diverse ligands and 
chemical groups, the structure of the protein is not affected. 
 
Table 1-1: Optimal features for molecular recognition of peptides by peptide permeases Dpp, Tpp and 
Opp. 
Feature Dpp-Type Tpp-Type Opp-Type 
Number of residues 2 (3) 2 (3) (2) 3-6 
N-terminal 
α-amino group 
Positively charged amino group optimal; substitution with charge retention 
acceptable 
C-terminal 
α-carboxyl group 
Negatively charged carboxylate optimal charged carboxylate not 
essential 
Peptide bonds All trans (± 180º ) highly preferred 
Residue chirality All L-stereo chemistry optional 
N-C distance (distance 
betwwen N- and C- 
terminus) 
5.1-6.4 Å 4.5-5.6 Å > 6.5 Å 
Side chains  All natural and some larger, unnatural side chains recognized 
Isopotential field There should be symmetric about the N- and C- termini 
Stabilization by 
backbone atoms 
Unmodified peptide bond NH and CO groups are ideal to  H-bond with 
suitable groups on transporter proteins 
 
Different features of the each permease are summarized in Table 1-1, which have been 
established using a range of biological and biophysical assays. In vitro binding studies on peptide 
complexes of E.coli OppA revealed high affinity and broad substrate specificity for small peptides 
comprising two up to five/six L-amino acids, regardless of their sequence. It was also revealed that 
OPP has a preference for peptides containing Ala, Gly, Phe[83] and basic residues[84], specifically 
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lysine, which may result from a negatively charged surface in proximity of the initial binding site. 
From different investigations it has been established that the presence of free α-amino and carboxyl 
groups at the N- and C-terminal respectively was important for binding to E.coli OppA, but it 
remained impossible to explain why other protected peptides were also translocated, though less 
effectively.[83] By exploiting peptide-delivery systems different therapeutic[85] and antimicrobial 
[86]compounds were also transported inside the bacterial cell, which can be challenging to be delivered 
by direct means. To the best of our knowledge, peptide delivery system has never been exploited for 
nucleotide delivery in bacterial cell. Although there are reports on the use of cell penetrating peptides 
(CPP) as a vehicle for cargo delivery in mostly mammalian cells, these CPPs also exhibit 
antimicrobial properties limiting their use in bacterial cells for cargo delivery.[87] 
 
1.8.2.  Biotin transporter in microorganism 
Biotin is an important nutrient for many bacteria and most of them are capable of de novo 
biosynthesis of biotin. Several of them are also able to transport exogenous biotin for their growth 
when biotin is present in the medium[88] and even concentrations of 5 ng/mL are sufficient for 
bacterial growth as first reported by Pai and Lichstein using a biotin auxotrophic E. coli strain.[89] 
After this, several groups have tried to identify gene coding for biotin transporters both for gram 
negative and gram positive bacteria.[90] It is well accepted that energy-coupling factor (ECF) 
transporters, a special type of ABC transporters, are responsible for biotin transport.[91] In most 
bacteria the BioMNY module is found, but in E. coli an analogous biotin transporter YigM was 
identified. Moreover, biotin transporter systems were also exploited for cargo delivery in bacterial 
cells. Walter and Altmen reported that biotinylated peptide conjugates can be delivered up to 31-mer 
peptide sequence in E. coli cells, which is otherwise limited to a maximum of five to six-mer for non-
biotinylated peptides.[92] Although not reported for uptake studies, a variety of chemically conjugated 
biotinylated nucleotides are known for labeling, incorporation, PCR and quantification studies.[93] 
 
1.8.3.  Sulfonate transporters in microorganisms 
Sulfur is an essential nutrient in all microorganisms for the biosynthesis of crucial building 
blocks, such as sulfur containing amino acids cysteine and methionine, and cofactors like biotin, 
thiamine, lipoic acid, molybdoptrein, glutathione, coenzyme A and M. The source of sulphur in 
bacterial cells is either in inorganic form like sulfates and sulfides or an external organically bound 
sulfur like sulfonates (R-SO3−) and sulfate esters (ROSO3−). Under sulfur starvation conditions 
bacteria express different proteins for transport of external sulfonates and sulfates, which are 
metabolized through a series of enzymatic steps, giving sulfide as degradative intermediate[94]	   and 
eventually sulfur as nutrient, through the sulphur assimilation cycle.[95] As sulfates, sulfonates and 
sulfonate esters are charged polar molecules with low pKa values at physiological pH, their passive 
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diffusion is hindered by the lipid bi-layer, and rather involves an active uptake system for cellular 
accumulation.[96] In bacteria, the role of active transport for sulfonates and sulfates accumulation has 
been extensively studied. It was revealed that the tauABC protein, encoded by the tauABCD gene 
cluster and ssuABC, encoded by the ssuEADCB gene cluster, are responsible for taurine and 
alkanesulfonates uptake respectively.  
 
 
Figure 1-16: Substrate specificities of E.coli TauABC and SsuABC transporters (partly adapted from 
Ref:[95]) 
 
The TauD gene expresses for the protein alpha-ketoglutarate-dependent dioxygenase, whilst the 
SsuD gene expresses a flavin mononucleotide dependent monooxygenase, both promoting the 
desulfonation process from taurine and a wide range of other sulfonates respectively.[95] TauABC and 
ssuABC also belong to the ABC type transport systems and like other ABC transporters they also 
consist of specific periplasmic binding proteins and consume energy from ATP hydrolysis. A series of 
sulfonate compounds were evaluated as a source of sulphur, as summarized in fig. 1-16, and the 
specificity of the transporters was also determined by growing phenotypes of different E.coli mutants 
devoid of one or more genes for the putative TauABC and SsuABC transporters. It was observed that 
few particular sulfonates entered the cell exclusively via a specific transporter whilst few others were 
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taken up by both the transporters.[95] Although there are no reports of indicating that sulfonate 
transporters could be used for cargo delivery inside bacterial cells, their potential use for cellular 
delivery within a sulfur-based nutritional selection system cannot be excluded. 
 
1.8.4.  Aminoglycosides uptake in bacteria 
Aminoglycosides (AGs) are clinically important drugs, showing broad-spectrum antibacterial 
activity against both gram-negative and gram-positive bacteria, binding to the bacterial ribosomal 30S 
and 50S subunits and inhibiting protein synthesis. The uptake of aminoglycosides inside the bacterial 
cells is an energy requiring process and can be accumulated against a concentration gradient. The 
detailed mechanism by which AGs penetrate into the bacterial cytoplasm remains obscure but based 
on available models (streptomycin and gentamicin) it has been postulated that cellular uptake of AGs 
comprised of three different stages.[97] The first step is the non-specific electrostatic interaction 
between positively charged aminoglycosides and negatively charged lipopolysaccharide (LPS) or 
phospholipids of the bacterial outer membrane followed by two energy dependent stages named 
energy-dependent phase I (EDPI) and energy-dependent phase II (EDPII). The first step is reversible, 
concentration dependent and unaffected by the inhibitors of the subsequent energized steps. In case of 
EDPI, the rate of uptake is dependent on the external concentration of AGs and also prone to 
inhibitors of oxidative phosphorylation and electron transporter. Although the exact mechanism in 
EDPII remains elusive, it is thought to include an accelerated energy-dependent transport of AGs 
across the cytoplasmic membrane following EDPI, through a process that uses energy from electron 
transport and ATP hydrolysis and which can be inhibited by some inhibitors of protein synthesis. For 
their cationic nature and strong binding properties with negatively-charged species, AGs were used in 
micelle formation and as cationic lipids for gene transfection, amongst others.[98] Although several 
modes of bacterial resistance to AGs have been described, enzymatic modification is the most 
common cause of resistance,[99] which occurs intra-cellularly. In most cases AGs penetrate bacterial 
cell membrane effectively, leaving the option of utilizing AGs in bacterial cargo delivery, especially 
in resistant mutants. Due to the lipophilic nature of polyamines, several AGs[100] and 
guanidinoglycosides[101] based conjugates have been introduced to enhance cellular uptake and 
transfection for poly-nucleic acid drugs (siRNA or gene delivery), mainly in mammalian cells. 
 
1.9. Thymineless death (TLD) 
Nucleotides are constructed from small natural fragments that go through a sequence of 
biochemical transformations promoted by specific enzymes mainly following de novo pathways in 
bacterial cells (Fig. 6-1). In de novo biosynthesis of dTTP, the enzyme thymidylate synthase plays a 
crucial role, catalysing the methyl group transfer from 5,10-methylenetetrahydrofolate to the 5-
position of the uridine ring in dUMP leading to the formation of dTMP. The salvage pathway for 
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deoxyribinucleotides involves conversion of nucleosides to their monophosphate derivatives that are 
recovered during the degradation of DNA and RNA or supplied externally. In E. coli, thymidine 
kinase converts thymidine to its mono-phosphate form (Fig. 1-17). 
 
 
Figure 1-17: Thymidine triphosphate metabolism in E. coli. 
 
Under thymine starvation conditions microorganisms suffer from cell death a phenomenon 
known for many years as thymineless death (TLD), on the contrary other nutritional requirements 
having a biostatic rather than deadly consequences. Thymine starvation has both direct and indirect 
effects, which encompasses both single- and double-stranded DNA breaks respectively. Although 
recombinational DNA repair processes could restore the single-stranded DNA damage, the double-
stranded DNA breaks ultimately leading to cell death. The deletion of the thyA gene in E. coli strains 
which encodes for thymidylate synthase causes thymine starvation and ultimately leads to TLD, as 
first observed by Cohen and Barner using a thymine auxotrophic mutant (thyA-).[102] No active 
thymidylate synthetase is functional in thymine auxotrophic E.coli (thyA-) cells; thus as a result no 
dTMP, dTDP or dTTP are produced endogenously. Unlike wild type cells, thyA mutants can utilize 
exogenous thymine for the production of dTTP via a salvage pathway. The salvage pathway involves 
deoxyribose-1-phosphate (dRib-1-P) and thymine, which are converted first to thymidine and 
subsequently to dTMP by the action of thymidine kinase. The lack of dRib-1-P pool in wild type 
strain generally explains the reason of their inability to use exogenous thymine. Because of the 
absence of thymidylate synthetase, the conversion of dUMP to dTMP is prevented. The cumulated 
dUMP then degrades to uracil and dRib-1-P thus acting as the source of dRib-1-P pool in thyA 
mutants. Apart from gene deletion, research efforts have been focused on developing other 
approaches to achieve thymine starvation e.g. (a) Inhibiting folate metabolism by using either 
sulphonamides,[103] cytosine arabinoside,[104] showdomycin[105]  or methotrexate / aminopterin / 
trimethoprim (dihydrofolate reductase inhibitor),[106] and thereby interfering with thymidylate 
synthesis (b) Using FUdR a direct inhibitor of thymidylate synthase (c) Inhibiting thymidine 
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phosphorylase that converts thymine to thymidine with addition of a ribonucleoside in the growth 
medium.[107]  
 
1.10.  Objectives of the research 
In view of nucleotides low cell-penetrating ability and inclination to undergo fast enzymatic 
dephosphorylation before being taken up, we wished to develop a delivery tool for their active uptake, 
based on a nutritional selection system. Each organism needs to take up extracellular nutrients in 
order to ensure the necessary supply of materials and energy for cellular functioning. Various 
transport systems are known to carry out the transfer of organic and inorganic molecules from outside 
the cell into the cytoplasm.  
 
 
Figure 1-17. Concept for the rational design of peptide-nucleotide conjugates as delivery systems of 
natural and modified nucleotides in prokaryotic cells.  
 
The general concept of our proposed approach consists in linking the information system to a 
nutrient essential for the cell, thus taking advantage of natural transport pathways or uptake systems 
occurring in bacterial cells, to eventually facilitate nucleotide delivery across the cytoplasmic 
membrane. A bio-cleavable covalent bond is designed to maintain the conjugate intact during cellular 
uptake, but allow facile release of the nucleotide intracellularly (either chemically or enzymatically). 
Building on previous studies, 2’-deoxythymidine monophosphate (dTMP) is selected as archetypal 
nucleotide system. The relevant dTMP conjugate is supplied within the nutrient medium to a 
thymidine auxotrophic E.coli strain deleted for the ThyA gene encoding for thymidylate synthase, 
which is known to unconditionally require thymine or thymidine for growth. So in principle the 
engineered auxotrophic strains can only survive only if dTMP is transported and released inside the 
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bacterial cells. Based on this model study and upon successful delivery of dTMP inside the bacterial 
cells, the vectors for the active uptake system can be fabricated for XNA delivery mimicking similar 
transport mechanisms. 
 
It is the aim of this thesis to create a variety of biocarrier-nucleotide conjugates for uptake 
evaluation in auxotrophic bacterial cells. We plan to perform the initial work in E. coli, since, it 
represents an ideal model organism for studying cellular processes, as its biology is well known. With 
this background, we set our objectives to synthesize and evaluate a diverse set of biocarrier-nucleotide 
conjugates, linked with a labile linker, and conjugated either at the 3’-hydroxyl or at the 5’- phosphate 
position of dTMP. Upon successful foundation of the auxotrophic model, particular delivery vehicle 
can also be attached to nucleotides containing fluorescent bases, which can be visualized under 
confocal microscopy as an additional evidence of this hypothesis.  
 
Di- to hexapeptides containing L-amino acids are easily taken up by bacterial cells 
irrespective of their sequences. The structural basis for molecular recognition of such substrates 
by peptide transporters has been extensively studied (see section 1.8.1). Few examples of the 
successful exploitation of peptide transporter systems for delivery of different antimicrobial and 
therapeutic agents are also reported, but this concept has never been expanded to bacterial uptake 
of nucleotide analogues. A series of oligopeptides coupled via a bio-labile linker to either in the 
3’- or 5’-position of TMP has been developed aiming at nucleotides delivery in bacterial cells. 
The efficient synthesis and purification of different macromolecules of peptide-nucleotide 
conjugates (PNCs), and biocarrier-conjugates in general are a very challenging task in view of the 
introduction of highly polar phosphate groups concurrently with a bio-labile linker possessing a 
modest stability. The development of new robust and improved synthetic methods has been 
planned to obtain different biocarrier-nucleotide conjugates in high purity and yield. In the first 
project (Chapter 2) we aimed at the synthesis and evaluation of new PNCs linked at the 3’-
hydroxyl group of dTMP for nucleotides delivery in bacterial cells exploiting naturally occurring 
peptide permeases. Five different linkers were chosen for conjugation of PNCs which are 
assumed to be liable to cleavage inside the bacterial cell i.e. carbamate (OCONH), ester (OCO), 
oxyamide (ONHCO), oxymethyleneoxyamide (OCH2ONHCO), oxymethylene-oxyester 
(OCH2OCO). Different α-substituted glycine containing di- and tri-peptides were described for 
delivering and releasing the attached cargo inside the bacterial cells, as first reported by Gilvarg 
et al. In the second project (Chapter 3), synthesis and evaluation of diverse novel 5’-phospho-
linked peptide nucleotide conjugates (PNCs) assembled from α-substituted glycine dipeptides, 
were planned for nucleotides delivery studies in bacterial cells. Different synthetic routes and 
metabolic stability studies were designed for these PNCs with the two assembling units, linked by 
various phosphoesters linkers such as phosphate, phosphoramidate, phosphorothioate and 
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thioethyl-phosphate between the α-carbon of a C-terminal glycine residue and the 5’-hydroxyl 
group of thymidine. Many bacteria are also capable of transporting extracellular sulfonates (R-
SO3−) and sulfate esters (ROSO3−) inside the cells as a source of sulfur under sulphur-starvation 
conditions. In the third project (Chapter 4) a series of sulfonate derived phosphoramidate 
conjugates of dTMP, connected through 5’-hydroxyl group of dTMP, were designed and 
synthesized, and studied both as active intermediates in the enzymatic primer-extension of DNA 
and for nucleotide delivery in bacteria targeting sulfonate transporters (see section 1.8.3). 
Generally bacteria are able to transport peptides up to six-mers, but biotinylation of peptides 
facilitates transportation of peptide sequences up to 31-mer in bacterial cells targeting biotin 
transport systems (see section 1.8.2). Due to the lipophilic nature of polyamines, aminoglycosides 
are well known for their bacterial cell-penetrating ability (see section 1.8.4).  In the fourth project 
(Chapter 5) different biotin-nucleotide and aminoglycoside-nucleotide systems (linked at 3’-
hydroxyl of dTMP) were designed, synthesized and evaluated for cellular delivery in E.coli 
auxotrophic strains, targetting the corresponding biotin transporters or aminoglycoside uptake 
systems. 
 
1.11.  References 
 
[1] J. D. Watson, F. H. C. Crick, Nature 1953, 171, 737-738. 
[2] M. Sundaralingam, Journal of the American Chemical Society 1965, 87, 599-606. 
[3] B. Basham, G. P. Schroth, P. S. Ho, Proceedings of the National Academy of Sciences 1995, 92, 6464-
6468. 
[4] W. Szybalski, Adv Exp Med Biol 1974, 44, 23-24. 
[5] M. Rezaei, S. H. Zarkesh-Esfahani, Journal of Research in Medical Sciences 2012, 17, 681-685. 
[6] L. Villakomaroff, A. Efstratiadis, S. Broome, P. Lomedico, R. Tizard, S. P. Naber, W. L. Chick, W. 
Gilbert, Proceedings of the National Academy of Sciences of the United States of America 1978, 75, 
3727-3731. 
[7] Y. Kung, W. Runguphan, J. D. Keasling, Acs Synthetic Biology 2012, 1, 498-513. 
[8] A. Prindle, P. Samayoa, I. Razinkov, T. Danino, L. S. Tsimring, J. Hasty, Nature 2012, 481, 39-44. 
[9] D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, C. H. June, New England Journal of Medicine 2011, 
365, 725-733. 
[10] P. Q. Nguyen, Z. Botyanszki, P. K. R. Tay, N. S. Joshi, Nature Communications 2014, 5. 
[11] H. Bugl, J. P. Danner, R. J. Molinari, J. T. Mulligan, H.-O. Park, B. Reichert, D. A. Roth, R. Wagner, 
B. Budowle, R. M. Scripp, J. A. L. Smith, S. J. Steele, G. Church, D. Endy, Nature Biotechnology 
2007, 25, 627-629. 
[12] P. Ronald, Genetics 2011, 188, 11-20. 
[13] A. Eschenmoser, Science 1999, 284, 2118-2124. 
[14] S. A. Benner, Accounts of Chemical Research 2004, 37, 784-797. 
[15] A. M. Sismour, S. A. Benner, Nucleic Acids Research 2005, 33, 5640-5646. 
[16] Z. Yang, D. Hutter, P. Sheng, A. M. Sismour, S. A. Benner, Nucleic Acids Research 2006, 34, 6095-
6101. 
[17] Z. Yang, A. M. Sismour, P. Sheng, N. L. Puskar, S. A. Benner, Nucleic Acids Research 2007, 35, 
4238-4249. 
[18] A. T. Krueger, E. T. Kool, in Chem Biol, Vol. 16, United States, 2009, pp. 242-248. 
[19] M. Winnacker, E. T. Kool, Angewandte Chemie International Edition 2013, 52, 12498-12508. 
Chapter 1 Introduction 
 30 
[20] S. R. Lynch, H. Liu, J. Gao, E. T. Kool, Journal of the American Chemical Society 2006, 128, 14704-
14711. 
[21] J. C. Delaney, J. Gao, H. Liu, N. Shrivastav, J. M. Essigmann, E. T. Kool, Angewandte Chemie 
International Edition 2009, 48, 4524-4527. 
[22] I. Hirao, M. Kimoto, T. Mitsui, T. Fujiwara, R. Kawai, A. Sato, Y. Harada, S. Yokoyama, Nat Meth 
2006, 3, 729-735; I. Hirao, T. Mitsui, M. Kimoto, S. Yokoyama, Journal of the American Chemical 
Society 2007, 129, 15549-15555. 
[23] M. Kimoto, R. Kawai, T. Mitsui, S. Yokoyama, I. Hirao, Nucleic Acids Research 2009, 37. 
[24] K. Dhami, D. A. Malyshev, P. Ordoukhanian, T. Kubelka, M. Hocek, F. E. Romesberg, Nucleic Acids 
Research 2014, 42, 10235-10244. 
[25] L. Li, M. Degardin, T. Lavergne, D. A. Malyshev, K. Dhami, P. Ordoukhanian, F. E. Romesberg, 
Journal of the American Chemical Society 2014, 136, 826-829. 
[26] D. A. Malyshev, K. Dhami, T. Lavergne, T. Chen, N. Dai, J. M. Foster, I. R. Correa, F. E. Romesberg, 
Nature 2014, 509, 385-388. 
[27] M. Petersen, J. Wengel, Trends in Biotechnology 2003, 21, 74-81. 
[28] K. E. Nielsen, J. Rasmussen, R. Kumar, J. Wengel, J. P. Jacobsen, M. Petersen, Bioconjugate 
Chemistry 2004, 15, 449-457. 
[29] R. N. Veedu, J. Wengel, Molecular Biosystems 2009, 5, 787-792; R. N. Veedu, B. Vester, J. Wengel, 
Journal of the American Chemical Society 2008, 130, 8124-+. 
[30] K. U. Schöning, P. Scholz, S. Guntha, X. Wu, R. Krishnamurthy, A. Eschenmoser, Science 2000, 290, 
1347-1351. 
[31] M. O. Ebert, C. Mang, R. Krishnamurthy, A. Eschenmoser, B. Jaun, Journal of the American Chemical 
Society 2008, 130, 15105-15115. 
[32] V. B. Pinheiro, A. I. Taylor, C. Cozens, M. Abramov, M. Renders, S. Zhang, J. C. Chaput, J. Wengel, 
S. Y. Peak-Chew, S. H. McLaughlin, P. Herdewijn, P. Holliger, Science 2012, 336, 341-344. 
[33] E. Lescrinier, R. Esnouf, J. Schraml, R. Busson, H. A. Heus, C. W. Hilbers, P. Herdewijn, Chemistry & 
Biology 2000, 7, 719-731. 
[34] C. Hendrix, H. Rosemeyer, I. Verheggen, A. Van Aerschot, F. Seela, P. Herdewijn, Chemistry – A 
European Journal 1997, 3, 110-120. 
[35] J. Wang, B. Verbeure, I. Luyten, E. Lescrinier, M. Froeyen, C. Hendrix, H. Rosemeyer, F. Seela, A. 
Van Aerschot, P. Herdewijn, Journal of the American Chemical Society 2000, 122, 8595-8602. 
[36] V. Kempeneers, M. Renders, M. Froeyen, P. Herdewijn, Nucleic Acids Research 2005, 33, 3828-3836. 
[37] G. F. Joyce, A. W. Schwartz, S. L. Miller, L. E. Orgel, Proceedings of the National Academy of 
Sciences of the United States of America 1987, 84, 4398-4402. 
[38] S. Zhang, C. Switzer, J. C. Chaput, Chemistry & Biodiversity 2010, 7, 245-258. 
[39] B. D. Heuberger, C. Switzer, Journal of the American Chemical Society 2008, 130, 412-413. 
[40] M. K. Schlegel, A. E. Peritz, K. Kittigowittana, L. L. Zhang, E. Meggers, Chembiochem 2007, 8, 927-
932. 
[41] J. J. Chen, C. H. Tsai, X. Cai, A. T. Horhota, L. W. McLaughlin, J. W. Szostak, Plos One 2009, 4. 
[42] C. H. Tsai, J. Y. Chen, J. W. Szostak, Proceedings of the National Academy of Sciences of the United 
States of America 2007, 104, 14598-14603. 
[43] P. E. Nielsen, M. Egholm, R. H. Berg, O. Buchardt, Science 1991, 254, 1497-1500. 
[44] R. Gambari, Expert Opin Ther Pat 2014, 24, 267-294. 
[45] C. Bohler, P. E. Nielsen, L. E. Orgel, Nature 1995, 376, 578-581. 
[46] P. Wittung, P. E. Nielsen, O. Buchardt, M. Egholm, B. Norden, Nature 1994, 368, 561-563; K. E. 
Nelson, M. Levy, S. L. Miller, Proceedings of the National Academy of Sciences 2000, 97, 3868-3871. 
[47] Y. Ura, J. M. Beierle, L. J. Leman, L. E. Orgel, M. R. Ghadiri, Science 2009, 325, 73-77. 
[48] P. Herdewijn, P. Marlière, FEBS Letters 2012, 586, 2049-2056. 
[49] L. A. Alexandrova, A. Y. Skoblov, M. V. Jasko, L. S. Victorova, A. A. Krayevsky, Nucleic Acids 
Research 1998, 26, 778-786; R. G. Yount, D. Babcock, W. Ballantyne, D. Ojala, Biochemistry 1971, 
10, 2484-2489; R. S. Goody, F. Eckstein, Journal of the American Chemical Society 1971, 93, 6252-
6257. 
Chapter 1 Introduction 
 31 
[50] O. Adelfinskaya, P. Herdewijn, Angewandte Chemie International Edition 2007, 46, 4356-4358. 
[51] O. Adelfinskaya, M. Terrazas, M. Froeyen, P. Marliere, K. Nauwelaerts, P. Herdewijn, Nucleic Acids 
Research 2007, 35, 5060-5072. 
[52] A. Giraut, N. Dyubankova, X. P. Song, P. Herdewijn, Chembiochem 2009, 10, 2246-2252. 
[53] A. Giraut, P. Herdewijn, ChemBioChem 2010, 11, 1399-1403. 
[54] S. Yang, M. Froeyen, E. Lescrinier, P. Marliere, P. Herdewijn, Organic & Biomolecular Chemistry 
2011, 9, 111-119; X. P. Song, C. Bouillon, E. Lescrinier, P. Herdewijn, Chembiochem 2011, 12, 1868-
1880; A. Giraut, X. P. Song, M. Froeyen, P. Marliere, P. Herdewijn, in Nucleic Acids Res, Vol. 38, 
England, 2010, pp. 2541-2550. 
[55] H. Pedersen, S. Holder, D. P. Sutherlin, U. Schwitter, D. S. King, P. G. Schultz, Proceedings of the 
National Academy of Sciences of the United States of America 1998, 95, 10523-10528. 
[56] F. J. Ghadessy, J. L. Ong, P. Holliger, Proceedings of the National Academy of Sciences of the United 
States of America 2001, 98, 4552-4557. 
[57] P. Herdewijn, P. Marliere, Chemistry & Biodiversity 2009, 6, 791-808. 
[58] A. I. Taylor, V. B. Pinheiro, M. J. Smola, A. S. Morgunov, S. Peak-Chew, C. Cozens, K. M. Weeks, P. 
Herdewijn, P. Holliger, Nature 2015, 518, 427-430. 
[59] Y. Wu, M. Fa, E. L. Tae, P. G. Schultz, F. E. Romesberg, Journal of the American Chemical Society 
2002, 124, 14626-14630; S. K. Jarchow-Choy, E. Sjuvarsson, H. O. Sintim, S. Eriksson, E. T. Kool, 
Journal of the American Chemical Society 2009, 131, 5488-5494. 
[60] R. B. Merrifield, Journal of the American Chemical Society 1963, 85, 2149-2154. 
[61] M. Amblard, J.-A. Fehrentz, J. Martinez, G. Subra, Molecular Biotechnology 2006, 33, 239-254. 
[62] M. Amblard, J.-A. Fehrentz, J. Martinez, G. Subra, in Peptide Synthesis and Applications, Vol. 298 
(Ed.: J. Howl), Humana Press, 2005, pp. 3-24. 
[63] J. Romanowska, A. Szymańska-Michalak, J. Boryski, J. Stawiński, A. Kraszewski, R. Loddo, G. 
Sanna, G. Collu, B. Secci, P. La Colla, Bioorganic & medicinal chemistry 2009, 17, 3489-3498. 
[64] I. Lefebvre, C. Perigaud, A. Pompon, A.-M. Aubertin, J.-L. Girardet, A. Kirn, G. Gosselin, J.-L. 
Imbach, Journal of Medicinal Chemistry 1995, 38, 3941-3950; T. P. Prakash, M. Prhavc, A. B. Eldrup, 
P. D. Cook, S. S. Carroll, D. B. Olsen, M. W. Stahlhut, J. E. Tomassini, M. MacCoss, S. M. Galloway, 
C. Hilliard, B. Bhat, Journal of Medicinal Chemistry 2005, 48, 1199-1210; N. Schlienger, C. Périgaud, 
G. Gosselin, J.-L. Imbach, The Journal of Organic Chemistry 1997, 62, 7216-7221. 
[65] A.-L. Villard, G. Coussot, I. Lefebvre, P. Augustijns, A.-M. Aubertin, G. Gosselin, S. Peyrottes, C. 
Périgaud, Bioorganic & Medicinal Chemistry 2008, 16, 7321-7329; N. Schlienger, T. Beltran, C. 
Perigaud, I. Lefebvre, A. Pompon, A. M. Aubertin, G. Gosselin, J. L. Imbach, Bioorganic & Medicinal 
Chemistry Letters 1998, 8, 3003-3006. 
[66] M. Smith, H. G. Khorana, Journal of the American Chemical Society 1958, 80, 1141-1145. 
[67] T. W. Abraham, T. I. Kalman, E. J. McIntee, C. R. Wagner, Journal of Medicinal Chemistry 1996, 39, 
4569-4575. 
[68] Mukaiyam.T, Hashimot.M, Bulletin of the Chemical Society of Japan 1971, 44, 2284-+. 
[69] Z. W. Miao, H. Fu, B. Han, Y. Chen, Y. F. Zhao, Synthetic Communications 2002, 32, 1159-1167; Z.-
W. Miao, H. Fu, G.-Z. Tu, Y.-F. Zhao, Synthetic Communications 2002, 32, 3301-3309. 
[70] W. J. Stec, A. Grajkowski, A. Kobylanska, B. Karwowski, M. Koziolkiewicz, K. Misiura, A. 
Okruszek, A. Wilk, P. Guga, M. Boczkowska, Journal of the American Chemical Society 1995, 117, 
12019-12029. 
[71] K. Lu, Q.-P. Duan, L. Ma, D.-X. Zhao, Bioconjugate Chemistry 2010, 21, 187-202. 
[72] N. J. Ede, G. W. Tregear, J. Haralambidis, Bioconjugate Chemistry 1994, 5, 373-378. 
[73] R. Eritja, A. Pons, M. Escarcellar, E. Giralt, F. Albericio, Tetrahedron 1991, 47, 4113-4120. 
[74] L. Chaloin, P. Vidal, P. Lory, J. Méry, N. Lautredou, G. Divita, F. Heitz, Biochemical and Biophysical 
Research Communications 1998, 243, 601-608. 
[75] J.-P. Bongartz, A.-M. Aubertain, P. G. Milhaud, B. Lebleu, Nucleic Acids Research 1994, 22, 4681-
4688. 
Chapter 1 Introduction 
 32 
[76] N. Venkatesan, B. H. Kim, Chemical Reviews 2006, 106, 3712-3761; T. S. Zatsepin, D. A. Stetsenko, 
M. J. Gait, T. S. Oretskaya, Bioconjugate Chemistry 2005, 16, 471-489; Y. Singh, N. Spinelli, E. 
Defrancq, Current Organic Chemistry 2008, 12, 263-290. 
[77] P. M. Gramlich, C. T. Wirges, A. Manetto, T. Carell, Angew Chem Int Ed Engl 2008, 47, 8350-8358. 
[78] T. Kubo, Z. Zhelev, B. Rumiana, H. Ohba, K. Doi, M. Fujii, Organic & Biomolecular Chemistry 2005, 
3, 3257-3259. 
[79] A. L. Davidson, E. Dassa, C. Orelle, J. Chen, Microbiology and Molecular Biology Reviews 2008, 72, 
317-364. 
[80] J. W. Payne, M. W. Smith, Adv Microb Physiol 1994, 36, 1-80. 
[81] M. K. Doeven, J. Kok, B. Poolman, in Mol Microbiol, Vol. 57, England, 2005, pp. 640-649. 
[82] J. R. H. Tame, G. N. Murshudov, E. J. Dodson, T. K. Neil, G. G. Dodson, C. F. Higgins, A. J. 
Wilkinson, Science 1994, 264, 1578-1581. 
[83] C. A. Guyer, D. G. Morgan, J. V. Staros, J Bacteriol 1986, 168, 775-779. 
[84] M. M. Klepsch, M. Kovermann, C. Low, J. Balbach, H. P. Permentier, F. Fusetti, J. W. de Gier, D. J. 
Slotboom, R. P. Berntsson, in J Mol Biol, Vol. 414, 2011 Elsevier Ltd, England, 2011, pp. 75-85. 
[85] T. E. Fickel, C. Gilvarg, Nat New Biol 1973, 241, 161-163. 
[86] S. M. Hammond, A. Claesson, A. M. Jansson, L. G. Larsson, B. G. Pring, C. M. Town, B. Ekstrom, 
Nature 1987, 327, 730-732. 
[87] M. Benincasa, S. Pacor, R. Gennaro, M. Scocchi, Antimicrobial Agents and Chemotherapy 2009, 53, 
3501-3504. 
[88] A. Piffeteau, M. Zamboni, M. Gaudry, Biochimica Et Biophysica Acta 1982, 688, 29-36. 
[89] C. H. Pai, H. C. Lichstein, Biochim Biophys Acta 1965, 100, 36-42. 
[90] P. Hebbeln, D. A. Rodionov, A. Alfandega, T. Eitinger, Proceedings of the National Academy of 
Sciences of the United States of America 2007, 104, 2909-2914; O. Prakash, Eisenber.Ma, Journal of 
Bacteriology 1974, 120, 785-791. 
[91] F. Finkenwirth, F. Kirsch, T. Eitinger, Bioengineered 2014, 5, 129-132. 
[92] J. R. Walker, E. Altman, Applied and Environmental Microbiology 2005, 71, 1850-1855. 
[93] G. Gebeyehu, P. Y. Rao, P. SooChan, D. A. Simms, L. Klevan, Nucleic Acids Research 1987, 15, 
4513-4534. 
[94] M. A. Kertesz, Fems Microbiology Reviews 2000, 24, 135-175. 
[95] E. Eichhorn, J. R. Van der Ploeg, T. Leisinger, Journal of Bacteriology 2000, 182, 2687-2695. 
[96] M. A. Kertesz, Research in Microbiology 2001, 152, 279-290. 
[97] B. Becker, M. A. Cooper, Acs Chemical Biology 2013, 8, 105-115. 
[98] M. F. Gouzy, M. Lauer, F. Gonzaga, A. Schulz, J. H. Fuhrhop, Langmuir 2002, 18, 10091-10094; Y. 
Zhang, J. M. Pelet, D. A. Heller, Y. Dong, D. Chen, Z. Gu, B. J. Joseph, J. Wallas, D. G. Anderson, 
Advanced materials (Deerfield Beach, Fla.) 2013, 25, 4641-4645; P. Belmont, A. Aissaoui, M. 
Hauchecorne, N. Oudrhiri, L. Petit, J.-P. Vigneron, J.-M. Lehn, P. Lehn, The Journal of Gene Medicine 
2002, 4, 517-526. 
[99]  
[100] A. Ghilardi, D. Pezzoli, M. C. Bellucci, C. Malloggi, A. Negri, A. Sganappa, G. Tedeschi, G. Candiani, 
A. Volonterio, Bioconjug Chem 2013, 24, 1928-1936. 
[101] N. W. Luedtke, P. Carmichael, Y. Tor, Journal of the American Chemical Society 2003, 125, 12374-
12375. 
[102] S. S. Cohen, H. D. Barner, Proc Natl Acad Sci U S A 1954, 40, 885-893. 
[103] R. Then, P. Angehrn, J Gen Microbiol 1973, 76, 255-263. 
[104] C. Atkinson, K. A. Stacey, Biochim. Biophys. Acta 1968, 166, 705-707. 
[105] T. I. Kalman, Biochem. Biophys. Res. Commun. 1972, 49, 1007-1013. 
[106] Freifeld.D, J. Bacteriol. 1965, 90, 1153-1154; S. I. Ahmad, S. H. Kirk, A. Eisenstark, Annu Rev 
Microbiol 1998, 52, 591-625. 
[107] J. V. Boyle, M. E. Jones, J. Bacteriol. 1970, 104, 264-271. 
 
Chapter 2 3’-Peptide Nucleotide Conjugates 
 33 
 
Chapter 2 
 
Tailoring new peptide-nucleotide conjugates (PNCs) for nucleotides 
delivery in bacterial cells 
 
 
 
This chapter is based on an article published by S. De, E. Groaz and P. Herdewijn, Eur. J. 
Org. Chem., 2014, 11, 2322-2348  
 
 
 
ABSTRACT 
The design and synthesis of peptide-2’-deoxythymidine-5'-O-monophosphate conjugates as potential 
active delivery systems of nucleotides in auxotrophic E. coli strains is presented. A series of 
oligopeptides were allowed to react with 5’-O-(dibenzylphosphate)-2’-deoxythymidine or its suitably 
3’- derivatized analogues to provide the relevant peptide-nucleotide adducts, owing to the formation 
of a biolabile chemical connection. Employing strategies based on principles of orthogonal protection 
and activation, rational variations were made to the linker as well as the peptide moiety in order to 
tune metabolic stability.  
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2.1. INTRODUCTION 
The ability to encode uncharted heritable information in polymers that are different from DNA 
and RNA relies upon chemical diversification and enzymatic proliferation of artificial nucleic acids 
(XNAs).[1, 2] With the aim of controlling and preventing cross contamination, new synthetic genetic 
sequences will have to be conceived to satisfy a principle of orthogonality with respect to wild 
biodiversity, leading to the establishment of self-reliant genetic enclaves.[3] Fundamental progress in 
enzyme evolution has recently been achieved with the discovery of engineered polymerase mutants 
able to recognize and efficiently incorporate backbone modified nucleotide building blocks (HNA, 
CeNA, ANA, FANA, TNA, and LNA) from a DNA template. XNA sequences were generated up to 
72 nt following canonical base-pairing selectivity and reverse-transcribed into DNA.[4] Nonetheless, 
major challenges remain to be addressed if XNAs are to reach their true evolutionary potential as 
genetic reprogramming tools in vivo.[5] The molecular assembly of xenopolymers within the host cell 
requires the intracellular availability of preactivated unnatural precursors, since most modified 
nucleoside substrates are poorly phosphorylated by host kinases. However, negatively charged 
nucleotides suffer from low cell-penetrating ability and a known instability as a result of their 
propensity to undergo hydrolysis to the phosphate-free state of nucleosides by exocytoplasmic 
phosphatases before being taken up.  
Given that, we envisaged that specifically tailored nucleotide conjugates might act as active 
delivery systems, exploiting membrane uptake systems naturally occurring in bacterial cells for 
internalization of essential nutrients, to eventually facilitate nucleotide delivery across the 
cytoplasmatic membrane. In particular, the rationale for our study hinges on the significance of 
internalization of essential nutrients, to eventually facilitate nucleotide delivery across the 
cytoplasmatic membrane. In particular, the rationale for our study hinges on the significance of 
peptide transporters in prokaryotic microorganisms, best represented by the vast family of binding-
protein-dependent permeases.[6] The derivatization of ligands with peptides is an attractive concept in 
medicinal chemistry as it provides cellular access of synthetic antimicrobial compounds, which might 
be difficult or impossible to be delivered by direct means.[7, 8] Microbial permeases are 
multicomponent ATP-binding cassette (ABC) proteins mediating active transport of peptides, as 
source of amino acids, carbon, nitrogen and energy.[9, 10] In Gram-negative species, three classes of 
peptide permeases (Dpp, Tpp and Opp) have been found, which display a complementary selectivity 
for different conformations, size and composition of oligopeptide sequences, thus ensuring complete 
uptake from the peptide pool. Amid the range of periplasmic proteins required for initial molecular 
recognition and binding by permeases, the oligopeptide binding protein OppA is the most abundant 
(7-10%) and structurally well-defined.[11, 12] In vitro binding studies on peptide complexes of E. coli 
OppA highlighted high affinity and broad substrate specificity for small peptides comprising two up 
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to five/six L-amino acids, regardless of their sequence.[13, 14] Further investigations have suggested a 
preference for peptides containing Ala, Gly, Phe[13] and basic residues,[15] in particular lysines, which 
may result from a negatively charged surface in proximity of the initial binding site.  
It has been suggested that the presence of free α-amino and carboxyl groups at the N- and C-
terminal respectively were necessary for binding to E. coli OppA and subsequent transmembrane 
translocation into the cell, but protected peptides were also transported although less effectively.[13] 
However, the presence of a free amino group might trigger extracellular metabolism of the peptide 
conjugate by peptidases or degradation by chemical means owing to its high reactivity  
 
Figure 2-1. Chemical diversity in the design of novel peptide-nucleotide conjugates (PNCs) as 
delivery system of natural and modified nucleotides in prokaryotic cells. 
With this knowledge in mind, an approach, which consists of conjugating oligopeptides through 
a bioreversible linkage to nucleotides, appeared to be logical in attempt to elaborate a new cellular 
uptake system. It is however anticipated that the success of this proposal would strongly depend on 
the metabolic stability of the relevant adducts, which ought to be sufficiently stable to be able to cross 
the cell wall without undergoing premature degradation, while being cleaved at the linker site once in 
the presence of intracellular enzymes. To assess the viability of our model, we selected 5’-thymidylate 
(dTMP) nucleotide conjugates as initial synthetic targets, for which reliable nutritional selections are 
well-established using E. coli mutants lacking thymidylate synthase. A conjugate derived from a 
pyridoxal-pyroglutamyl-tripeptido-nucleotide, which could release the dTMP synthon through an 
autocatalytic elimination process, was prepared, but purification and scaling-up of this adduct was not 
straightforward.[16] We describe here a further elaboration of this concept with the synthesis of a large 
Linker Peptide
OCONH
For-M-K-OMe,
For-G-K-F-OMe,
For-G-βA-F-OMe,
For-M-K-F-OMe,
For-M-K-A-OMe,
For-M-K-K-OMe,
For-M-K-A-F-OMe,
For-M-K-A-A-F-OMe,
A-K-A-OMe,
A-K-A
ONHCO For-M-E-OMe
OCH2ONHCO
For-M-E-OMe,
For-M-E-NH2
OCH2OCO For-G-E-A-OMe
OCO For-M-K-K,
For-G-E-F
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diversity of peptide-nucleoside conjugate (PNCs) analogues, prepared by covalently linking di- to 
pentapeptidic linear chain, through various spacers, to the 3’-position on the ribose moiety. Amino 
acidic residues as well as chemical connections between dTMP and peptides were systematically 
examined, as summarized in Figure 2-1. The α-amino group at the N-terminus was either unmodified 
or protected as a formylamide, which can be hydrolytically cleaved by E. coli peptide deformylase. 
This enzyme is known to exhibit a preference for substrates containing N-formyl methionine, 
followed by N-formyl glycine.[17] The α- or β-carboxyl groups featuring in the second or third residue 
together with the amino functionality in side chain of Lys were utilized to form the connecting bond. 
Following internalization of the conjugate in the cell, the peptide might be hydrolysed by E. coli 
PepN, the principal cytosolic aminopeptidase enzyme responsible for the hydrolysis of peptides, 
whose activity varies in the following order Arg>Ala>Lys>Gly.[18]  
2.2. RESULTS AND DISCUSSION 
Several strategies have been described in the literature to prepare peptide-oligonucleotide 
conjugates connected through variously functionalized linkers, such as a thioether, a disulfide, an 
amide and an oxime moiety etc.[19] For our study, we selected five different linkers (Figure 2-1), 
which were assumed liable to cleavage inside the bacterial cell, either by a chemical or an enzymatic 
mechanism, i.e. carbamate (OCONH), ester (OCO), oxyamide (ONHCO), oxymethyleneoxyamide 
(OCH2ONHCO), oxymethylene-oxyester (OCH2OCO). The corresponding peptide-nucleotide 
conjugates (PNCs) were synthesized by reacting the 3’-hydroxyl group of dTMP with the side chain 
functionalities of an oligopeptide, for example an amino or a carboxylic acid group.  
Firstly, di-, tri-, tetra-, and pentapeptides were conveniently prepared according to the NHS-
activated ester method[20] starting from commercially available N-Boc protected/formylated amino 
acids, as shown in Scheme 2-1. In the first step, NHS-activated carboxyester derivatives were formed 
and subsequently coupled with an incoming amino acid without need of protection at the C-terminal. 
The side chain functionalities were orthogonally protected as Boc, Fmoc, Cbz, OBn or tBu during 
peptide synthesis and were removed prior to coupling to the free 3’-OH group of thymidine. For the 
acidic deprotection of the N-Boc group, thioanisole was used as radical scavenger,[21] while an excess 
of Pd/C was used in order to avoid catalyst poisoning during removal of the benzyl group of 
methionine-containing peptides. In the case of peptide 2.4c, the Fmoc group was removed using Et3N 
in dichloromethane. Ethanol was employed as solvent[22] for N-Cbz deprotection of 2.12 to obtain 
2.13, since in the presence of methanol a N-methylated side product was formed instead.  
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Scheme 2-1. Preparation of dipeptides 2.2a, 2.2b and 2.8, tripeptides 2.4h, 2.5a-g and 2.13, 
tetrapeptide 2.9 and pentapeptide 2.10. Reagents and conditions: (a) (i) NHS, DCC, THF, 0 °C to r.t., 
2-12 h, (ii) Amino acid, NaHCO3, THF/H2O, 0 °C to r.t., 16 h; (b) 10% Pd/C (Degussa), H2, EtOH or 
MeOH, r.t., 6-24 h; (c) TFA, DCM, 0 °C to r.t., 2 h; (d) Et3N:DCM (2:1), r.t., 72 h; (e) TFA, 
Thioanisole, DCM, r.t., 4 h. 
 The construction of PNCs can be accomplished by either linking the peptide at the 3’-position of 
thymidine followed by 5’-O-phosphorylation, or by reversing the order of the reactions sequence. For 
the synthesis of our first PNC analogue 2.19 featuring a carbamoyl linker (OCONH), it was decided 
to apply the first proposed protocol, as described in Scheme 2-2. In the first step the 5’-hydroxyl 
group of 2’-deoxythymidine was selectively protected with a MMTr group[23] leading to 5’-O-MMTr-
2’-deoxythymidine 2.14, which was activated at the 3’-OH using carbonyldiimidazole (CDI)[24, 25] or 
4-nitrophenyl chloroformate[26] (via intermediate 2.15) and then reacted with the ε-amino group of the  
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Figure 2-2. Proposed reaction pathway for peptide synthesis without protection of the incoming 
amino acid. 
 
Scheme 2-2. Synthesis of 3'-O-carbamoyl peptide conjugate of dTMP 2.19. Reagents and conditions: 
(a) MMTrCl, Et3N, DMAP, DMF, r.t., 4 h; (b) 4-nitro phenyl chloroformate, Py, DCM, 0 °C to r.t., 24 
h; (c) Peptide 2.5d, Et3N, DCM, r.t.; (d) 80% AcOH, r.t., 3.5 h; (e) (i) Dibenzyl N,N-
diisopropylphosphoramidite, 0.45M tetrazole in ACN, DCM, r.t., 12 h, (ii) H2O2, -40 °C to r.t., 2 h; (f) 
10% Pd/C (Degussa), H2, Et3N, MeOH. 
lysine residue of peptide 2.5d to afford compound 2.16. After detritylation, the phosphate group was 
introduced at the 5’-position using dibenzyl-N,N-diisopropyl phosphoramidite and hydrogen peroxide 
as oxidizing agent. The resulting thymidine-5' dibenzyl phosphate product 2.18 was subjected to 
hydrogenation in the presence of Pd/C to produce the free phosphate functionality. However, this 
strategy was not applicable to the synthesis of N-formyl-L-methionine-containing analogues 
presumably due to the instability of the thiomethyl group in the course of the oxidation of P(III) to P(V), 
even when milder oxidizing reagents, such as a diluted solution of I2 in pyridine-THF-H2O, were 
used.[27, 28] Therefore, the route towards compound 2.19 was repeated using as starting material 3’-
benzoyl thymidine 2.21, as described in Scheme 2-3. The dibenzylphosphate group at the 5’-position 
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of 2.21 was introduced first, followed by peptide conjugation. The same synthetic method was 
extended to afford nine different PNCs 2.18 and 2.25-2.32 built upon a carbamoyl linker. 
 
Scheme 2-3. Synthesis of 3'-carbamoyl peptide conjugates of dTMP 2.19 and 2.33-2.42. Reagents and 
conditions: (a) BzCl, Py, 0 °C, 3 h; (b) 80% AcOH, r.t., 3.5 h; (c) (i) Dibenzyl N,N-
diisopropylphosphoramidite, 0.45M tetrazole in ACN, DCM, r.t., 12 h, (ii) H2O2, -40 °C to r.t., 2 h; 
(d) 7N NH3 in MeOH, 0 °C to r.t., 24 h; (e) 4-nitro phenyl chloroformate, Py, DCM, 0 °C to r.t., 24 h; 
(f) Peptide-NH2 (2.5c-2.5g, 2.8-2.10 or 2.13), Et3N, DCM, r.t.; (g) 10% Pd/C (Degussa), H2, MeOH or 
EtOH, r.t., 24 h; (h) TFA, Thioanisole, H2O, r.t., 3 h; (i) LiOH, THF:MeOH:H2O (1:1:1), r.t., 3 h.  
With regard to this second route, protection of the secondary OH group was necessary to obtain 
the corresponding phosphorylated nucleoside 2.23 in good yield.[29, 30, 31] Thus, we elected to protect 
the free hydroxyl functionality of compound 2.14 using benzoyl chloride[32]. Standard MMTr 
deprotection proceeded as expected using 80% AcOH to give 3’-O-benzoyl-2’-deoxythymidine 2.21 
which was in turn phosphorylated with dibenzyl N,N-diisopropyl-phosphoramidite and 1H-
tetrazole[33] at the 5’-position and then oxidized in the presence of hydrogen peroxide to furnish 5’-
dibenzylphosphate-3’-O-benzoyl-2’-deoxythymidine 2.22 in 92% yield over two-steps. 
Debenzoylation was affected by treatment of 2.22 with saturated methanolic ammonia to provide key 
intermediate 2.23 in 95% yield, which served as a common substrate for the subsequent coupling step 
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exploring various 3’-O linkers. In Scheme 2-3, the 3’-OH was derivatized with 4-nitrophenyl 
chloroformate in pyridine to furnish 4-nitrophenyl carbonate 2.24 in moderate yield.[34] The activated 
carbonate was then treated with amino- peptides 2.5c-2.5g, 2.8-2.10 and 2.13 to generate carbamates 
2.18 and 2.25-2.32 with yields ranging from 64 to 88%, depending on the peptide used. Finally, 
hydrogenolysis of the benzyl groups was carried out under mild conditions, in order to prevent 
reduction of the double bond of the thymine ring, using 10% palladium on carbon (Degussa) or 20% 
Pd(OH)2/C at atmospheric pressure, smoothly affording phosphate derivatives 2.19 and 2.33-2.40 in 
58-83% yields. 
Notably, debenzylation by hydrogenation was successful for conjugates containing methionine in 
the peptide chain. A larger excess of Pd/C was employed during the reaction to avoid catalyst 
poisoning deriving from the thiomethyl group. In most of the cases, except for compounds 2.36 where 
a free amino group is present in the peptidic side chain, 2 equivalents of Et3N were employed to 
neutralize the strong acidity of the phosphoric acid group during O-dibenzyl deprotection. The 
terminal amino group of 2.37 was deprotected with TFA affording conjugate 2.41, which was then 
treated with LiOH to liberate the terminal carboxyl group leading to compound 2.42. 
 
Scheme 2-4. Synthesis of 3'-oxyamide peptide conjugate of dTMP 2.48. Reagents and conditions: (a) 
(i) MMTrCl, Et3N, Py, r.t., 16 h, (ii) MsCl, Et3N, r.t., 2 h, (iii) NaOH, EtOH, reflux, 1.5 h; (b) (i) N-
hydroxy phthalimide, PPh3, DIAD, Toluene, 0 °C to r.t., 2 h, (ii) 80% AcOH, r.t., 3 h; (c) (i) Dibenzyl 
N,N-diisopropylphosphoramidite, 0.45M tetrazole in ACN, DCM, r.t., 12 h, (ii) H2O2, -40 °C to r.t., 2 
h; (d) 4% MeNH2, EtOH, r.t., 0.5 h; (e) Dipeptide 2.2a, DCC, DMAP, DCM/DMF, r.t., 24 h; (f) 10% 
Pd/C (Degussa), H2, MeOH, Et3N, r.t., 24 h. 
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Fig 2-3: Proposed reaction mechanism for the formation of 2.43 from thymidine via 2-3’-anhydro 
intermediate formation. 
The synthesis of the 3’-oxyamide linked PNC 2.48 is described in Scheme 2-4. The 3’-oxyamine 
intermediate 2.46 was synthesized starting from 2’-deoxythymidine according to modified literature 
procedures.[35, 36, 37] 5’-O-MMTr-2’-deoxy-xylo-thymidine 2.43 was obtained from 2’-deoxythymidine 
in 48% yield over three steps.[38]  
The protected hydroxylamine functionality was formed via Mitsunobu inversion using N-
hydroxyphthalimide. Removal of MMTr and phosphorylation at the 5’-position, as previously 
described, yielded the protected hydroxylamine 2.45, which was then treated with 4% methylamine to 
restore the 3’-ONH2 group. Although stronger nucleophilic reagents like hydrazine hydrate or 
hydroxylamine are more efficient for phthalimide deprotection, our reagent of choice was diluted 
methylamine, to minimize rate of side reactions at the protected 5’-phosphate moiety.  
Coupling between the 3’-oxyamino group of compound 2.46 with the free carboxylic acid group 
of dipeptide 2.2a in the presence of DCC, led to benzyl-protected oxyamide 2.47, which was 
subjected to catalytic hydrogenation using Pd/C and Et3N at atmospheric pressure. Final purification 
by RP-HPLC yielded 2.48 as a triethylammonium salt. The common key intermediate towards 3’-
oxymethyleneoxyamide PNCs 2.57 and 2.58 is compound 2.54 (Scheme 2-5), which can be coupled 
with different peptides exhibiting a free carboxylic acid group in their side chain residue.[39, 40] Product 
2.54 was obtained starting from 5’-O-protected-3’-O-methylenethiomethyl-2’-deoxythymidine 2.50, 
which was synthesized modifying a procedure from the literature.[41] The acid stable TBDPS group 
was selected to mask the 5’-position in view of potential complications in a later stage of the synthetic 
scheme. The 3’-thioacetal group of 2.50 (obtained via Pummerer rearrangement from 2.49, fig. 2-4) 
was converted by treatment with sulfuryl chloride into its chloromethylether derivative, which, 
without further purification, was reacted with N-hydroxyphthalimide to obtain 3’-O-
aminooxymetylene derivative 2.51. The 5’-TBDPS protection was removed by action of Et3N·3HF 
and the free 5’-hydroxyl group was phosphorylated using our general protocol. Phthalimide 
deprotection followed by DCC coupling with dipeptides 2.2a and 2.2b yielded the conjugates 2.55 
and 2.56 respectively. Benzyl deprotection and HPLC purification as previously described, yielded 
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the 5’-O-monophosphate of 2’-deoxythymidine-3’-oxymethyleneoxyamide peptide conjugates 2.57 
and 2.58 as triethylammonium salts. 
 
Scheme 2-5. Synthesis of 3'-oxymethyleneoxyamide peptide conjugates of dTMP 2.57 and 2.58. 
Reagents and conditions: (a) (i) TBDPS-Cl, Imidazole, DMF, r.t., 4 h; (b) DMSO, Ac2O, AcOH, r.t., 
48 h; (c) (i) SO2Cl2, DCM, 0 °C to r.t., 2 h, (ii) N-Hydroxy phthalimide, DBU, DCM, r.t., 24 h; (d) 
Et3NH·3HF, THF, r.t., 36 h; (e) (i) Dibenzyl N,N-diisopropylphosphoramidite, 0.45M tetrazole in 
ACN, DCM, r.t., 12 h, (ii) H2O2, -40 °C to r.t., 2 h; (f) 4% MeNH2, EtOH, r.t., 0.5 h; (g) Dipeptide 
2.2a or 2.2b, DCC, DMAP, DCM/DMF, r.t., 24h; (h)10% Pd/C (Degussa), H2, Et3N, MeOH, r.t., 24 
h. 
Due to its propensity to undergo cleavage by cellular carboxyesterase, the oxymethylene ester 
moiety has been described in the literature in the generation of bioavailable antiretroviral prodrugs 
based on acyclic nucleosides,[42, 43] and as biolabile 2’-O-protecting group for the development of 
short synthetic double-stranded RNA sequences with therapeutic applications in vivo.[44, 45, 46] The 
formation of 3’-O-methylacyloxy PNC 2.62 essentially followed known procedures for similar 
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transformations, by activating previously synthesized intermediate 2.50 and using the β-carboxyl 
group of tripeptide 2.5a as a nucleophile (Scheme 2-6).  
 
 
 
Fig 2-4: Proposed reaction mechanism for the formation of 2.50 from 2.49 via Pummerer 
rearrangement. 
A first attempt using NIS/NCS as activating agent[47] did not give satisfactory yields of 
compound 2.59, therefore we switched more successfully to the sulfuryl chloride method.[48, 49] 
TBDPS deprotection using Et3N·3HF and phosphorylation at the 5’-position was carried out as 
described in Scheme 2-5, yielding compound 2.61. Finally, Pd(OH)2-mediated hydrogenolysis in the 
presence of Et3N furnished triethylammonium salt 2.62 in moderate yield, due to undesirable side 
reactions involving cleavage of the linker, giving rise to dTMP and peptide as by-products.  
 
Scheme 2-6. Synthesis of 3'-oxymethyleneoxyester peptide conjugate of dTMP 2.62. Reagents and 
conditions: (a) (i) SO2Cl2, DCM, 0 °C to r.t., 2 h, (ii) Peptide-CO2H 2.5a, DBU, DCM, r.t., 24 h; (b) 
Et3NH·3HF, THF, r.t., 36 h; (c) (i) Dibenzyl N,N-diisopropylphosphoramidite, 0.45M tetrazole in 
ACN, DCM, r.t., 12 h, (ii) H2O2, -40 °C to r.t., 2 h; (e) 20% Pd(OH)2/C, H2, NaHCO3, EtOH/H2O, r.t., 
1.5 h. 
The synthesis of PNCs with an ester linker was thought to be particularly promising in view of 
the known susceptibility of such functional group to intracellular hydrolysis by bacterial esterases. 
Analogue 2.65 was obtained from previously prepared protected-2’-deoxythymidine-5’-O-
monophosphate 2.23 by standard coupling to the free terminal carboxylate of tripeptide 2.4h in the 
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presence of DCC and DMAP as catalyst,[50] in good yield. Deprotection of the dibenzyl phosphate via 
catalytic hydrogenation led to 2.64, which, without further purification, underwent removal of the 
NH-Boc protecting groups in the presence of TFA to furnish final compound 2.65 as a TFA salt in 
62% yield over two steps (Scheme 2-7). When Cbz was used in place of Boc, attempts to remove all 
protecting groups in one step using catalytic hydrogenation resulted in a complex mixture of 
degradation products. 
 
Scheme 2-7. Synthesis of 3'-carboxyester peptide conjugate of dTMP 2.65. Reagents and conditions: 
(a) Peptide-CO2H 2.4h, DCC, DMAP, DCM:DMF (5:1), r.t., 24 h; (b) 10% Pd/C (Degussa), H2, 
MeOH, r.t., 24 h; (c) TFA, Thioanisole, H2O, r.t., 5 h.  
 
Scheme 2-8. Synthesis of 3'-carboxyester peptide conjugate of dTMP 2.70. Reagents and conditions: 
(a) TBDMSCl, Im, dry DMF; (b) TFA:H2O (10:1), DCM; (c) (i) Dibenzyl N,N-
diisopropylphosphoramidite, 0.45M tetrazole in ACN, DCM, 0 °C to r.t., 12 h, (ii) H2O2, -25 °C to 
r.t., 2 h; (d) Et3N·3HF, THF, 24 h; (e) Peptide-CO2H 2.5b, DCC, DMAP, DMF, DCM, r.t., 24 h; (b) 
10% Pd/C (Degussa), H2, THF, r.t., 24 h. 
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The key intermediate 5’-O-(dibenzylphosphate)-2’-deoxythymidine 2.23 could also be prepared 
through an alternative sequence of protection/deprotection steps. Hence, the synthesis, illustrated in 
Scheme 2-8, started with the bis-silylation of thymidine to form intermediate 2.66, which was 
selectively deprotected at the 5’-position using a 10:1 ratio of TFA in H2O in good yield (59%).[51] 
Compound 2.67 was then subjected to standard phosphorylation, followed by TBDMS cleavage, 
providing the required substrate 2.23 with which to carry out peptide coupling. In this step the use of a 
milder reagent such as Et3N·HF was found to afford higher chemical yields than TBAF. In the 
presence of the free β-carboxyl group of tripeptide 2.5b, DCC and DMAP, 2.23 was cleanly converted 
into conjugate 2.69 and eventually its triethylammonium salt 2.70. 
2.3. CONCLUSION 
The derivatization of ligands with peptides can be used to achieve a large improvement in the 
cellular uptake of hydrophilic structures. We have reported the application of this methodology to 
nucleotides, which has led to the development of a broad variety of peptide-5'-thymidylate conjugates 
featuring linker moieties such as carbamate, ester, oxyamide, oxymethyleneoxyamide and 
oxymethyleneoxyester, all potentially liable to enzymatic or chemical cleavage inside the bacterial 
cell. Final deprotection of all structures was achieved in high yield by palladium-catalyzed 
hydrogenolysis. Of particular note is the unexpected tolerance of the thiomethyl functionality present 
in methionine-containing PNCs to the debenzylation conditions. 
2.4. EXPERIMENTAL SECTION 
General information 
For all reactions, analytical grade solvents were used. All moisture-sensitive reactions were 
carried out under an argon or nitrogen atmosphere in oven-dried glassware (135 ºC). Reaction 
temperatures are reported as bath temperatures. Precoated aluminum sheets (254 nm) were used for 
TLC. Compounds were visualized with UV light (λ = 254 nm). Products were purified by flash 
chromatography on ICN silica gel 63-200, 60 Å. 1H, 13C and 31P NMR spectra were recorded on 
Bruker Avance 300 MHz, 500 MHz or 600 MHz spectrometers. For final compounds, 1H and 13C 
resonance assignments were made using 2D NMR correlation experiments (COSY, gHSQC and 
gHMBC). For sake of clarity, NMR signals of protons and carbons for sugar and base moieties are 
indicated with and without a prime, respectively. Chemical shifts were referenced to residual solvent 
signals at δ H/C 7.26/77.00 (CDCl3), 3.31/49.10 (MeOD) and 2.50/39.50 (DMSO-d6) relative to TMS 
as internal standard. Coupling constants are expressed in hertz (Hz). Splitting patterns are reported as 
s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad). High resolution mass 
spectra were acquired on a quadrupole orthogonal acceleration time-of-flight mass spectrometer 
(Synapt G2 HDMS, Waters, Milford, MA). Samples were infused at 3 µL/min and spectra were 
obtained in positive or negative ionization mode with a resolution of 15000 (FWHM), using leucine 
enkephalin as lock mass. All the methods use MeCN/H2O gradients. Water contains either 0.1 % TFA 
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or 0.1 % NH3. All final compounds were purified by preparative RP-HPLC (XbridgeTM Prep C18 5µm 
OBD 19 x 150 mm column). 
General procedures for oligopeptides synthesis. Method (a). DCC (1.3 eq.) was added to a 
solution of N-Boc- or N-formyl-amino acid (1 eq.) and N-hydroxysuccinimide (1.2 eq.) in dry THF 
(~4 mL/mmol) at 0 °C, and the mixture was stirred for an additional 0.5 h at 0 °C, then for 2-6 h 
(monitoring by TLC) at r.t. under an argon atmosphere. The resulting DCU was filtered off, and the 
filtrate was concentrated in vacuo to obtain the corresponding activated ester. This compound was 
then dissolved in dry THF (2 mL/mmol), and to this solution was then added a suspension of a second 
amino acid (1.2 eq.) and NaHCO3 (4 eq.) in water (2 mL/mmol) at 0 °C under an argon atmosphere. 
The reaction mixture was then stirred at r.t. for 16 h, cooled and neutralized by addition of 1N HCl. 
The aqueous layer was extracted 3 times with ethyl acetate, the combined organic fractions were 
dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting crude residue 
was purified by column chromatography on silica gel (gradient: CH2Cl2/MeOH 98:2, v/v; 96:4, 
v/v; 94:6, v/v) to obtain the desired compound. Method (b). A minor modification of Method (a) 
was applied during the work-up stage when the carboxyl group at the C-terminal in the peptides was 
protected as ester or amide. Thus, after amide coupling with the activated ester, the reaction mixture 
was diluted with 10% NaHCO3 and extracted with ethyl acetate to ease the purification step by 
removing the acidic by-products. 
N-For-L-Met-L-Glu(OBn)OMe (2.1a): Following Method (b), dipeptide 2.1a was obtained as a 
white solid (1.01 g, 87%), in two steps, starting from N-For-L-Met-OH (0.5 g, 2.82 mmol), N-
hydroxysuccinimide (0.39 g, 3.38 mmol) and DCC (0.76 g, 3.67 mmol) in THF (20 mL), and H-L-
Glu(OBn)OMe·TFA salt (1.18 g, 3.24 mmol, prepared from Boc-L-Glu(OBn)OMe and TFA in DCM 
with 1 eq. of thioanisole), NaHCO3 (0.95 g, 11.3 mmol) in 1:1 THF/H2O (30 mL) 1H NMR (300 
MHz, CDCl3) δ = 8.16 (s, 1H, CHO), 7.35-7.32 (m, 5H, Ar-H), 7.03 (d, J = 7.7 Hz, 1H, NH-Glu), 
6.47 (d, J = 7.5 Hz, 1H, NH-Met), 5.12 (s, 2H, OCH2Ph), 4.77-4.70 (m, 1H, αCH-Met), 4.64-4.59 (m, 
1H, αCH-Glu), 3.74 (s, 3H, OCH3), 2.64-2.55 (m, 2H, γCH2-Met), 2.52-2.43 (m, 2H, γCH2-Glu), 
2.29-1.96 (m unresolved, 7H, βCH2-Glu, SCH3 and βCH2-Met); 13C NMR (75 MHz, CDCl3) δ = 172.7 
(δCO-Glu), 171.8 (αCO-Glu), 170.7 (CO-Met), 160.9 (CHO), 135.8 (1C-Ph), 128.7 (Ar-C), 128.5 
(Ar-C), 128.4 (Ar-C), 66.8 (OCH2Ph), 52.7 (OCH3), 52.0 (αC-Glu), 50.7 (αC-Met), 31.8 (βC-Met), 
30.4 (γC-Glu), 29.9 (γC-Met), 27.0 (βC-Glu), 15.2 (SCH3); HRMS for C19H26N2O6S [M-H]- calcd.: 
411.1584, found: 411.1584. 
N-For-L-Met-L-Glu(OBn)-NH2 (2.1b): Following Method (b), dipeptide 2.1b was obtained as a 
white solid (0.76 g, 68%), in two steps, starting from N-For-L-Met-OH (0.5 g, 2.82 mmol), N-
hydroxysuccinimide (0.39 g, 3.38 mmol) and DCC (0.76 g, 3.67 mmol) in THF (20 mL), and H-L-
Glu(OBn)-NH2·TFA salt (1.09 g, 3.24 mmol, prepared from Boc-L-Glu(OBn)-NH2 and TFA in DCM 
with 1 eq. of thioanisole), NaHCO3 (0.95 g, 11.3 mmol) in 1:1 THF/H2O (30 mL). 1H NMR (300 
MHz, DMSO-d6) δ = 8.32 (d, J = 8.2 Hz, 1H, NH-Met), 8.05 (d, J = 8.0 Hz, 1H, NH-Glu), 8.02 (s, 
1H, CHO), 7.38-7.34 (m, 5H, Ar-H), 7.30 (br s, 1H, NH-CONH2), 7.09 (br s, 1H, NH-CONH2), 5.08 
(s, 2H, OCH2Ph), 4.43-4.36 (m, 1H, αCH-Met), 4.24-4.16 (m, 1H, αCH-Glu), 2.44 (t, J = 7.9 Hz, 2H, 
γCH2-Met), 2.36 (t, J = 7.8 Hz, 2H, γCH2-Glu), 2.02 (s, 3H, SCH3), 1.98-1.86 (m, 2H, βCH2-Glu), 
1.81-1.71 (m, 2H, βCH2-Met); 13C NMR (75 MHz, DMSO-d6) δ = 172.7 (αCO-Glu), 172.1 (δCO-
Glu), 170.7 (CO-Met), 161.1 (CHO), 136.2 (1C-Ph), 128.4 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 65.5 
(OCH2Ph), 51.6 (αC-Glu), 50.6 (αC-Met), 31.9 (βC-Met), 30.1 (γC-Glu), 29.3 (γC-Met), 27.1 (βC-
Glu), 14.6 (SCH3); HRMS for C18H25N3O5S [M+Na]+ calcd.: 418.1407, found: 418.1407. 
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N-For-Gly-L-Glu(OBn)OH (2.3a): Following Method (a), dipeptide 2.3a was obtained as a 
white solid (2.47 g, 79%) in two steps, starting from N-For-Gly-OH (1.0 g, 9.70 mmol), N-
hydroxysuccinimide (1.34 g, 11.6 mmol), DCC (2.6 g, 12.6 mmol) in THF (30 mL) and H-L-
Glu(OBn)-OH·TFA salt (3.92 g, 11.2 mmol, prepared from Boc-L-Glu(OBn)-OH and TFA in DCM 
with 1 eq. of thioanisole), NaHCO3 (3.26 g, 38.8 mmol) in 1:1 THF/H2O (60 mL). 1H NMR (300 
MHz, DMSO-d6) δ = 12.73 (br s, 1H, CO2H), 8.23-8.21 (m, 2H, 2 x NH), 8.07 (s, 1H, CHO), 
7.37-7.34 (m, 5H, Ar-H), 5.09 (s, 2H, OCH2Ph), 4.30-4.23 (m, 1H, αCH-Glu), 3.78 (app t, J = 5.3 
Hz, 2H, αCH2-Gly), 2.43 (t, J = 7.7 Hz, 2H, γCH2-Glu), 2.10-1.78 (m, 2H, βCH2-Glu), 1.81-1.71 
(m, 2H, βCH2-Met); 13C NMR (75 MHz, DMSO-d6) δ = 173.0 (αCO-Glu), 172.1 (δCO-Glu), 
168.5 (CO-Gly), 161.4 (CHO), 136.2 (1C-Ph), 128.4 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 65.5 
(OCH2Ph), 51.1 (αC-Glu), 40.3 (αC-Gly), 30.0 (γC-Glu), 26.3 (βC-Glu); HRMS for C15H18N2O6 
[M-H]- calcd.: 321.1092, found: 321.1090. 
N-For-Gly-L-Glu(OtBu)OH (2.3b): Following Method (a), dipeptide 2.3b was obtained as a 
white solid (2.79 g, 84%), in two steps, starting from N-For-L-Gly-OH (1.00 g, 9.70 mmol), N-
hydroxysuccinimide (1.34 g, 11.6 mmol) and DCC (2.60 g, 12.6 mmol) in THF (16 mL), and H-L-
Glu(OtBu)-OH (2.46 g, 12.1 mmol), NaHCO3 (2.24 g, 26.7 mmol, 2.2 eq.) in 1:1 THF/H2O (30 mL). 
1H NMR (300 MHz, MeOD) δ = 8.18 (s, 1H, CHO), 4.49-4.45 (m, 1H, αCH-Glu), 3.99 (br s, 2H, 
αCH2-Gly), 2.34 (t, J = 7.5 Hz, 2H, γCH2-Glu), 2.21-2.09 (m, 1H, βCH2-Glu), 1.98-1.88 (m, 1H, 
βCH2-Glu), 1.43 (s, 9H, C(CH3)3); 13C NMR (75 MHz, MeOD) δ = 173.0 (CO-Glu), 172.1 (CO-
Glu), 169.3 (CO-Gly), 162.6 (CHO), 80.2 (1C-tBu), 51.2 (αC-Glu), 40.2 (αC-Gly), 30.8 (γC-Glu), 
26.7 (tBu), 26.2 (βC-Glu); HRMS for C12H19N2O6 [M-H]- calcd.: 287.1248, found: 287.1245. 
N-For-Gly-L-β-amino-Ala(Fmoc)OH (2.3c): Following Method (a), dipeptide 2.3c was obtained 
as a white solid (1.54 g, 70.3%) in two steps, starting from N-For-Gly-OH (0.55 g, 5.33 mmol), N-
hydroxysuccinimide (0.74 g, 6.40 mmol), DCC (1.43 g, 6.93 mmol) in THF (20 mL) and H-L-β-
amino-Ala(Fmoc)-OH·TFA salt (2.70 g, 6.13 mmol, prepared from Boc-L-β-amino-Ala(Fmoc)-OH 
and TFA in DCM with 1 eq. of thioanisole), NaHCO3 (1.79 g, 21.4 mmol) in 1:1 THF/H2O (50 mL). 
1H NMR (300 MHz, DMSO-d6) δ = 12.19 (br s, 1H, CO2H), 8.24 (t, J = 5.0 Hz, 1H, NH), 8.17 (d, J = 
7.9 Hz, 1H, NH), 8.08 (s, 1H, CHO), 7.89 (d, J = 7.4 Hz, 2H, ArH-Fmoc), 7.69 (d, J = 7.3 Hz, 2H, 
ArH-Fmoc), 7.44-7.31 (m, 4H, ArH-Fmoc), 4.35-4.22 (unresolved m, 4H, αH-β-amino-Ala, OCH2-
Fmoc and CH-Fmoc), 3.80 (d, J = 5.8 Hz, 2H, αCH2-Gly), 3.50-3.30 (m, 2H, βCH2-β-amino-Ala 
merged with DMSO); 13C NMR (75 MHz, DMSO-d6) δ = 171.5 (CO-β-amino-Ala), 168.5 (CO-Gly), 
161.4 (CHO), 156.3 (OCONH), 143.8 (Ar-C), 140.7 (Ar-C), 127.6 (Ar-C), 127.1 (Ar-C), 125.2 (Ar-
C), 120.1 (Ar-C), 65.6 (OCH2-Fmoc), 52.3 (αC-β-amino-Ala), 46.6 (CH-Fmoc), 41.5 (αC-Gly), 30.7 
(βC-β-amino-Ala); HRMS for C21H21N3O6 [M-H]- calcd.: 410.1357, found: 410.1357. 
N-For-Gly-Lys(Boc)OH (2.3d): Following Method (a), dipeptide 2.3d was obtained as a white 
solid (2.60 g, 81%) in two steps, starting from N-For-Gly-OH (1.0 g, 9.70 mmol), N-
hydroxysuccinimide (1.34 g, 11.6 mmol), DCC (2.60 g, 12.6 mmol) in THF (35 mL) and H-L-
Lys(Boc)OH (2.87 g, 11.6 mmol), NaHCO3 (2.44 g, 29.1 mmol) in 1:1 THF/H2O (40 mL). 1H NMR 
(300 MHz, DMSO-d6) δ = 12.16 (br s, 1H, CO2H), 8.20-8.14 (m, 2H, 2 x NH), 8.06 (s, 1H, CHO), 
6.76 (t, J = 4.9 Hz, 1H, εNH-Lys), 4.19-4.12 (m, 1H, αH-Lys), 3.79 (d, J = 7.5 Hz, 2H, αH-Gly), 
2.91-2.85 (m, 2H, εCH2-Lys), 1.71-1.52 (m, 2H, βCH2-Lys), 1.39-1.33 (m, 11H, tBu and δCH2-Lys), 
1.31-1.22 (m, 2H, γCH2-Lys); HRMS for C14H25N3O6 [M+Na]+ calcd.: 354.1636, found: 354.1635. 
N-For-L-Met-L-Lys(Boc)OH (2.3e): Following Method (a), dipeptide 2.3e was obtained as a 
white solid (1.25 g, 84%), in two steps, starting from N-For-L-Met-OH (0.65 g, 3.67 mmol), N-
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hydroxysuccinimide (0.51 g, 4.40 mmol), DCC (0.98 g, 4.77 mmol) in THF (20 mL) and H-L-
Lys(Boc)-OH (0.99 g, 4.03 mmol), NaHCO3 (1.23 g, 14.7 mmol) in 1:1 THF/H2O (40 mL). 1H NMR 
(300 MHz, DMSO-d6) δ = 12.56 (br s, 1H, CO2H), 8.28 (d, J = 8.3 Hz, 1H, NH-Met), 8.24 (d, J = 7.6 
Hz, 1H, αNH-Lys), 8.00 (s, 1H, CHO), 6.76 (t, J = 5.3 Hz, 1H, εNH-Lys), 4.50-4.43 (m, 1H, αH-
Met), 4.15-4.08 (m, 1H, αH-Lys), 2.91-2.85 (m, 2H, εCH2-Lys), 2.44 (t, J = 8.0 Hz, 2H, γCH2-Met), 
2.03 (s, 3H, -SCH3), 1.95-1.77 (m, 2H, βCH2-Met), 1.75-1.56 (m, 2H, βCH2-Lys), 1.36-1.21 (m, 13H, 
tBu, δCH2-Lys and γCH2-Lys); 13C NMR (75 MHz, DMSO-d6) δ = 173.4 (CO-Lys), 170.7 (CO-Met), 
160.8 (CHO), 155.5 (OCONH), 77.2 (1C of tBu), 51.9 (αC-Lys), 50.1 (αC-Met), 39.6 (εC-Lys), 32.4 
(βC-Met), 30.4 (βC-Lys), 29.2 (γC-Met), 29.1 (δC-Lys), 28.2 (CH3-tBu), 22.8 (γC-Lys), 14.6 (SCH3); 
HRMS for C17H31N3O6S [M-H]- calcd.: 404.1861, found: 404.1861. 
N-For-L-Met-L-Lys(Boc)OMe (2.3f): Following Method (b), dipeptide 2.3f was obtained as a 
white solid (1.02 g, 86%), in two steps, starting from N-For-L-Met-OH (0.5 g, 2.82 mmol), N-
hydroxysuccinimide (0.39 g, 3.39 mmol), DCC (0.76 g, 3.67 mmol) in THF (18 mL) and H-L-
Lys(Boc)OMe·HCl salt (0.92 g, 3.10 mmol), NaHCO3 (0.83 g, 9.87 mmol) in 1:1 THF/H2O (30 mL). 
1H NMR (300 MHz, DMSO-d6) δ = 8.39 (d, J = 7.2 Hz, 1H, αNH-Lys), 8.29 (d, J = 8.2 Hz, 1H, NH-
Met), 8.01 (s, 1H, CHO), 6.76 (t, J = 5.4 Hz, 1H, εNH-Lys), 4.51-4.44 (m, 1H, αH-Met), 4.22-4.16 
(m, 1H, αH-Lys), 3.62 (s, 3H, OCH3), 2.91-2.85 (m, 2H, εCH2-Lys), 2.44 (t, J = 7.9 Hz, 2H, γCH2-
Met), 2.04 (s, 3H, SCH3), 1.93-1.77 (m, 2H, βCH2-Met), 1.75-1.58 (m, 2H, βCH2-Lys), 1.37 (s, 9H, 
tBu), 1.35-1.21 (m, 4H, δCH2-Lys and γCH2-Lys); 13C NMR (75 MHz, DMSO-d6) δ = 172.4 (CO-
Lys), 170.9 (CO-Met), 160.8 (CHO), 155.5 (OCONH), 77.3 (1C of tBu), 52.0 (αC-Lys), 51.8 (OCH3), 
50.0 (αC-Met), 39.6 (εC-Lys), 32.3 (βC-Met), 30.3 (βC-Lys), 29.2 (γC-Met), 29.0 (δC-Lys), 28.2 
(CH3-tBu), 22.7 (γC-Lys), 14.6 (SCH3); HRMS for C18H33N3O6S [M-H]- calcd.: 418.2017, found: 
418.2022. 
Boc-L-Ala-L-Lys(Cbz)OH (2.11): Following Method (a), dipeptide 2.11 was obtained as a white 
solid (1.63 g, 68%), in two steps, starting from Boc-L-Ala-OH (1.0 g, 5.29 mmol), N-
hydroxysuccinimide (0.73 g, 6.35 mmol), DCC (1.42 g, 6.88 mmol) in THF (25 mL) and H-L-
Lys(Cbz)OH (1.70 g, 6.08 mmol), NaHCO3 (1.78 g, 21.2 mmol) in 1:1 THF/H2O (50 mL). 1H NMR 
(300 MHz, DMSO-d6) δ = 10.49 (br s, 1H, CO2H), 7.80 (d, J = 7.6 Hz, 1H, αNH-Lys), 7.29-7.23 (m, 
5H, Ar-H), 7.10 (t, J = 5.9 Hz, 1H, εNH-Lys), 6.77 (d, J = 7.5 Hz, 1H, NH-Ala), 4.91 (s, 2H, 
OCH2Ph), 4.10-4.03 (m, 1H, αH-Lys), 3.93-3.86 (m, 1H, αH-Ala), 2.90-2.85 (m, 2H, εCH2-Lys), 
1.64-1.41 (m, 2H, βCH2-Lys), 1.35-1.20 (m, 11H, CH3-tBu and δCH2-Lys), 1.16-0.93 (m, 5H, CH3-
Ala and  γCH2-Lys); 13C NMR (75 MHz, DMSO-d6) δ = 173.6 (CO-Lys), 172.9 (CO-Ala), 156.2 
(OCONH), 155.1 (OCONH), 137.4 (1C-Ph), 128.5 (Ar-C), 127.8 (Ar-C), 78.2 (1C of tBu), 65.2 (-
OCH2Ph), 51.7 (αC-Lys), 49.6 (αC-Ala), 40.2 (εC-Lys), 30.9 (βC-Lys), 29.1 (δC-Lys), 28.3 (CH3-
tBu), 22.6 (γC-Lys), 18.2 (CH3-Ala); HRMS for C22H33N3O7 [M-H]- calcd.: 450.2245, found: 
450.2236. 
N-For-Met-L-Glu-OMe (2.2a): To a stirring solution of 2.1a (1.00 g, 2.44 mmol) in EtOH was 
added 10% Pd/C Degussa (0.5 g, 50% w/w) and the mixture was hydrogenated at atmospheric 
pressure using a balloon filled with H2 for 16 h. The catalyst was removed by filtration and the filtrate 
was concentrated under reduced pressure. The resulting crude residue was purified by column 
chromatography on silica gel (gradient CH2Cl2/MeOH 99:1, v/v; 97:3, v/v; 94:6, v/v) to give 
compound 2.2a (0.75 g, 96%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ = 12.15 (br s, 1H, 
CO2H), 8.43 (t, J = 7.4 Hz, 1H, NH-Glu), 8.30 (d, J = 7.9 Hz, 1H, NH-Met), 8.01 (s, 1H, CHO), 4.89-
4.41 (m, 1H, αH-Met), 4.31-4.23 (m, 1H, αH-Glu), 3.62 (s, 3H, OCH3), 2.44 (t, J = 7.9 Hz, 2H, γCH2-
Met), 2.29 (t, J = 7.5 Hz, 2H, γCH2-Glu), 2.04 (s, 3H, -SCH3), 2.01-1.72 (unresolved m, 4H, βCH2-
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Glu and βCH2-Met); 13C NMR (75 MHz, DMSO-d6) δ = 173.6 (δCO-Glu), 172.0 (αCO-Glu), 171.0 
(CO-Met), 160.9 (CHO), 51.9 (OCH3), 51.2 (αC-Glu), 50.1 (αC-Met), 32.1 (βC-Met), 29.8 (γC-Glu), 
29.2 (γC-Met), 25.9 (βC-Glu), 14.6 (SCH3); HRMS for C11H20N2O6S [M-H]- calcd.: 319.0969, found: 
319.0975. 
N-For-Met-L-Glu-NH2 (2.2b): Following a similar procedure as used for the synthesis of 
compound 2.2a, 2.1b (0.76 g, 2.44 mmol) was hydrogenated in the presence of 10% Pd/C Degussa 
(0.38 g, 50% w/w) in EtOH and the resulting product was purified by column chromatography on 
silica gel (gradient CH2Cl2/MeOH 99:2, v/v; 97:4, v/v; 94:8, v/v) to give 2.2b (0.51 g, 86%) as a 
white solid. 1H NMR (300 MHz, DMSO-d6) δ = 12.09 (br s, 1H, CO2H), 8.33 (d, J = 7.9 Hz, 1H, NH-
Met), 8.04-8.01 (m, NH-Glu and CHO), 7.29 (br s, 1H, NH-CONH2), 7.07 (br s, 1H, NH-CONH2), 
4.44-4.37 (m, 1H, αH-Met), 4.21-4.14 (m, 1H, αH-Glu), 2.44 (t, J = 7.9 Hz, 2H, γCH2-Met), 2.29 (t, J 
= 7.6 Hz, 2H, γCH2-Glu), 2.03 (s, 3H, SCH3), 1.97-1.85 (m, 2H, βCH2-Glu), 1.81-1.71 (m, 2H, βCH2-
Met); 13C NMR (75 MHz, DMSO-d6) δ = 174.0 (δCO-Glu), 172.9 (αCO-Glu), 170.6 (CO-Met), 161.2 
(CHO), 51.8 (αC-Glu), 50.6 (αC-Met), 31.9 (βC-Met), 30.3 (γC-Glu), 29.3 (γC-Met), 27.2 (βC-Glu), 
14.6 (SCH3); HRMS for C11H19N3O5S [M-H]- calcd.: 304.0972, found: 304.0975. 
N-For-L-Met-L-Lys(NH2·TFA)-OMe (2.8): To a stirring solution of 2.3f 162.9 mg, 0.388 
mmol), thioanisole (0.046 mL, 0.388 mmol) in CH2Cl2 (4 mL) was slowly added trifluoroacetic acid 
(1 mL) at 0 °C. The mixture was then slowly warmed to r.t. and stirred for 4 h. After removal of all 
the volatiles under reduced pressure, the resulting residue was co-evaporated with toluene (3 times) to 
afford compound 2.8 as a colorless foam (168.3 mg, quantitative), which was used directly in the 
next step without any further purification.  
N-For-Gly-L-Glu(OBn)-L-Ala-OMe (2.4a): Following Method (b), tripeptide 2.4a was 
obtained as a white solid (2.04 g, 79%), in two steps, starting from 2.3a (2.04 g, 6.33 mmol), N-
hydroxysuccinimide (0.87 g, 7.59 mmol), DCC (1.70 g, 8.23 mmol) in THF (36 mL) and H-L-Ala-
OMe·HCl salt (1.02 g, 7.28 mmol), NaHCO3 (2.13 g, 25.32 mmol) in 1:1 THF/H2O (40 mL). 1H 
NMR (300 MHz, DMSO-d6) δ = 8.43 (d, J = 6.8 Hz, 1H, NH-Ala), 8.21 (t, J = 5.2 Hz, 1H, NH-
Gly), 8.10 (d, J = 8.1 Hz, 1H, NH-Glu), 8.06 (s, 1H, CHO), 7.38-7.32 (m, 5H, Ar-H), 5.09 (s, 2H, 
OCH2Ph), 4.40-4.33 (m, 1H, αCH-Glu), 4.30-4.21 (m, 1H, αCH-Ala), 3.77 (d, J = 7.3 Hz, 2H, 
αCH2-Gly), 3.59 (s, 3H, OCH3), 2.41 (t, J = 8.1 Hz, 2H, γCH2-Glu), 2.02-1.75 (m, 2H, βCH2-
Glu), 1.29 (d, J = 7.3 Hz, 3H, CH3-Ala); 13C NMR (75 MHz, DMSO-d6) δ = 172.8 (δCO-Glu), 
172.2 (CO-Ala), 170.8 (αCO-Glu), 168.3 (CO-Gly), 161.4 (CHO), 136.2 (1C Ph), 128.4 (Ar-C), 
128.0 (Ar-C), 127.9 (Ar-C), 65.5 (OCH2Ph), 51.8 (OCH3), 51.2 (αC-Glu), 47.6 (αC-Ala), 40.5 
(αC-Gly), 29.8 (γC-Glu), 27.5 (βC-Glu), 16.6 (CH3-Ala); HRMS for C19H25N3O7 [M+H]+ calcd.: 
408.1765, found: 408.1765. 
N-For-Gly-L-Glu(OtBu)-L-Phe-OMe (2.4b): Following Method (a), tripeptide 2.4b was 
obtained as a white solid (2.29 g, 69%), in two steps, starting from 2.3b (2.11 g, 7.32 mmol), N-
hydroxysuccinimide (1.01 g, 8.78 mmol), DCC (1.96 g, 9.51 mmol) in THF (14 mL) and H-L-Phe-
OMe·HCl salt (2.00 g, 9.27 mmol), NaHCO3 (1.72 g, 20.5 mmol, 2.2 eq.) in 1:1 THF/H2O (40 mL). 
1H NMR (300 MHz, MeOD) δ = 8.18 (s, 1H, CHO), 7.29-7.20 (m, 5H, Ar-H), 4.67 (dd, J = 8.5, 
5.6 Hz, 1H, αCH-Phe), 4.40 (dd, J = 8.3, 5.3 Hz, 1H, αCH-Glu), 3.92 (br s, 2H, αCH2-Gly), 3.70 
(s, 3H, OCH3), 3.21-3.15 (m, 1H, βCH2-Phe), 3.06-2.98 (m, 1H, βCH2-Phe), 2.31-2.26 (m, 2H, 
γCH2-Glu), 2.04-2.00 (m, 1H, βCH2-Glu), 1.88-1.85 (m, 1H, βCH2-Glu), 1.46 (s, 9H, C(CH3)3); 
13C NMR (75 MHz, MeOD) δ = 172.2 (δCO-Glu), 171.6 (CO), 171.4 (CO), 169.1 (CO), 162.5 
(CHO), 136.3 (1C-Ph), 128.5 (Ar-C), 127.8 (Ar-C), 126.2 (Ar-C), 53.5, 52.0, 51.0, 40.3, 36.5, 
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30.7 (γC-Glu), 26.6 (βC-Glu), 26.5 (tBu); HRMS for C22H32N3O7 [M+H]+ calcd.: 450.2234, 
found: 450.2233. 
N-For-Gly-L-β-amino-Ala(Fmoc)-L-Phe-OMe (2.4c): Following Method (b), tripeptide 2.4c was 
obtained as a white solid (1.42 g, 72.8%), in two steps, starting from 2.3c (1.4 g, 3.40 mmol), N-
hydroxysuccinimide (0.47 g, 4.09 mmol), DCC (0.91 g, 4.42 mmol) in THF (25 mL) and H-L-Phe-
OMe·HCl salt (0.84 g, 3.91 mmol), NaHCO3 (1.14 g, 13.6 mmol) in 1:1 THF/H2O (50 mL). 1H NMR 
(500 MHz, DMSO-d6) δ = 8.41 (d, J = 7.6 Hz, 1H, NH-Phe), 8.24 (t, J = 4.9 Hz, 1H, NH-Gly), 8.09 
(s, 1H, CHO), 8.02 (d, J = 8.1 Hz, 1H, NH-β-amino-Ala), 7.88 (d, J = 7.6 Hz, 2H, ArH-Fmoc), 7.69 
(d, J = 7.5 Hz, 2H, ArH-Fmoc), 7.43-7.15 (m, 9H, ArH-Fmoc and ArH-Phe), 7.17 (t, J = 5.0 Hz, 1H, 
βNH-β-amino-Ala), 4.51-4.47 (m, 1H, αH-Phe), 4.55-4.42 (m, 1H, αH-β-amino-Ala), 4.30-4.28 (m, 
1H, OCH2-Fmoc), 4.24-4.21 (m, 1H, CH-Fmoc), 3.79 (d, J = 5.7 Hz, 2H, αCH2-Gly), 3.56 (s, 3H, 
OCH3), 3.35-3.15 (m, 2H, βCH2-β-amino-Ala), 3.06-2.93 (m, 2H, βCH2-Phe); 13C NMR (125 MHz, 
DMSO-d6) δ = 171.7 (CO-Phe), 169.7 (CO-β-amino-Ala), 168.5 (CO-Gly), 161.6 (CHO), 156.3 
(OCONH), 143.9 (1C Fmoc), 140.8 (1C Fmoc), 137.1 (1C Ph), 129.2 (Ar-C), 129.1 (Ar-C), 128.3 
(Ar-C), 127.7 (Ar-C), 127.4 (Ar-C), 127.2 (Ar-C), 126.7 (Ar-C), 125.3 (Ar-C), 121.5 (Ar-C), 120.1 
(Ar-C), 65.7 (OCH2-Fmoc), 53.8 (αC-Phe), 52.7 (αC-β-amino-Ala), 52.0 (OCH3), 46.7 (CH-Fmoc), 
42.3 (βC-Phe), 40.7 (αC-Gly), 36.6 (βC-β-amino-Ala); HRMS for C31H32N4O7 [M+H]+ calcd.: 
573.2343, found: 573.2346. 
N-For-Gly-L-Lys(Boc)-L-Phe-OMe (2.4d): Following Method (b), tripeptide 2.4d was obtained 
as a white solid (1.82 g, 72%), in two steps, starting from 2.3d (1.7 g, 5.13 mmol), N-
hydroxysuccinimide (0.71 g, 6.16 mmol), DCC (1.38 g, 6.67 mmol) in THF (35 mL) and H-L-Phe-
OMe·HCl salt (1.33 g, 6.16 mmol), NaHCO3 (1.72 g, 20.52 mmol) in 1:1 THF/H2O (50 mL). 1H 
NMR (500 MHz, DMSO-d6) δ = 8.37 (d, J = 7.4 Hz, 1H, NH-Phe), 8.19 (t, J = 5.2 Hz, 1H, NH-Gly), 
8.06 (s, 1H, CHO), 7.97 (d, J = 8.1 Hz, 1H, NH-Lys), 7.30-7.19 (m, 5H, Ar-H), 6.73 (t, J = 5.1 Hz, 
1H, εNH-Lys), 4.49-4.41 (m, 1H, αH-Phe), 4.31-4.24 (m, 1H, αH-Lys), 3.76 (d, J = 5.7 Hz, 2H, αH-
Gly), 3.57 (s, 3H, OCH3), 3.06-2.92 (m, 2H, βCH2-Phe), 2.89-2.83 (m, 2H, εCH2-Lys), 1.61-1.43 (m, 
2H, βCH2-Lys), 1.37-1.29 (m, 11H, tBu and δCH2-Lys), 1.26-1.13 (m, 2H, γCH2-Lys); 13C NMR (125 
MHz, DMSO-d6) δ = 171.7 (CO-Phe), 171.6 (CO-Lys), 168.0 (CO-Gly), 161.4 (CHO), 155.5 
(OCONH), 137.1 (1C-Ph), 129.0 (Ar-C), 128.2 (Ar-C), 126.5 (Ar-C), 77.3 (1C of tBu), 53.6 (αC-
Phe), 52.1 (αC-Lys), 51.8 (OCH3), 40.4 (αC-Gly), 39.6 (εC-Lys), 36.5 (βC-Phe), 31.9 (βC-Lys), 29.3 
(δC-Lys), 28.3 (CH3-tBu), 22.4 (γC-Lys); HRMS for C24H36N4O7 [M+H]+ calcd.: 493.2656, found: 
493.2659. 
N-For-L-Met-L-Lys(Boc)-L-Ala-OMe (2.4e): Following Method (b), tripeptide 2.4e was obtained 
as a white solid (1.50 g, 88.5%), in two steps, starting from 2.3e (1.4 g, 3.45 mmol), N-
hydroxysuccinimide (0.48 g, 4.14 mmol), DCC (0.93 g, 4.49 mmol) in THF (30 mL) and H-L-Ala-
OMe·HCl salt (0.53 g, 3.80 mmol), NaHCO3 (0.87 g, 10.36 mmol) in 1:1 THF/H2O (40 mL). 1H 
NMR (300 MHz, DMSO-d6) δ = 8.30 (t, J = 6.9 Hz, 1H, NH), 8.27 (d, J = 9.4 Hz, 1H, NH), 8.02-8.00 
(m, 2H, CHO and NH), 6.73 (t, J = 5.3 Hz, 1H, εNH-Lys), 4.47-4.40 (m, 1H, αH-Met), 4.29-4.20 (m, 
2H, αH-Lys and αH-Ala), 3.61 (s, 3H, OCH3), 2.91-2.84 (m, 2H, εCH2-Lys), 2.42 (t, J = 7.9 Hz, 2H, 
γCH2-Met), 2.02 (s, 3H, SCH3), 1.94-1.72 (m, 2H, βCH2-Met), 1.69-1.49 (m, 2H, βCH2-Lys), 1.40-
1.31 (m, 11H, CH3-tBu and δCH2-Lys), 1.29-1.20 (m, 5H, CH3-Ala and γCH2-Lys); 13C NMR (75 
MHz, DMSO-d6) δ = 172.9 (CO-Ala), 171.4 (CO-Lys), 170.5 (CO-Met), 160.9 (CHO), 155.5 
(OCONH), 77.3 (1C of tBu), 52.2 (αC-Lys), 51.8 (OCH3), 50.3 (αC-Met), 47.5 (αC-Ala), 39.8 (εC-
Lys), 32.2 (βC-Met), 31.7 (βC-Lys), 29.3 (γC-Met), 29.2 (δC-Lys), 28.2 (CH3-tBu), 22.5 (γC-Lys), 
16.8 (CH3-Ala), 14.6 (SCH3); HRMS for C21H38N4O7S [M+Na]+ calcd.: 513.2353, found: 513.2352. 
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N-For-L-Met-L-Lys(Boc)-L-Lys(Cbz)-OMe (2.4f): Following Method (b), tripeptide 2.4f was 
obtained as a white solid (1.07 g, 67%), in two steps, starting from 3e (0.92 g, 2.27 mmol), N-
hydroxysuccinimide (0.31 g, 2.72 mmol), DCC (0.61 g, 2.95 mmol) in THF (20 mL) and H-L-
Lys(Cbz)-OMe·HCl salt (0.86 g, 2.61 mmol), NaHCO3 (0.76 g, 9.08 mmol) in 1:1 THF/H2O (30 mL). 
1H NMR (300 MHz, DMSO-d6) δ = 8.31-8.25 (m, 2H, 2 x NH), 8.02-8.00 (m, 2H, CHO and NH), 
7.36-7.30 (m, 5H, Ar-H), 7.22 (t, J = 5.1 Hz, 1H, εNH-LysC-ter), 6.73 (t, J = 5.0 Hz, 1H, εNH-LysN-ter), 
5.00 (s, 2H, OCH2Ph), 4.47-4.40 (m, 1H, αH-Met), 4.32-4.25 (m, 1H, αH-LysN-ter), 4.22-4.15 (m, 1H, 
αH-LysC-ter), 3.61 (s, 3H, OCH3), 2.99-2.93 (m, 2H, εCH2-Lys), 2.89-2.83 (m, 2H, εCH2-Lys), 2.41 (t, 
J = 7.9 Hz, 2H, γCH2-Met), 2.02 (s, 3H, SCH3), 1.94-1.70 (m, 2H, βCH2-Met), 1.69-1.44 (m, 4H, 2 x 
βCH2-Lys), 1.40-1.17 (m, 17H, CH3-tBu, 2 x δCH2-Lys and 2 x γCH2-Lys); 13C NMR (75 MHz, 
DMSO-d6) δ = 172.4 (CO-LysC-ter), 171.6 (CO-Met), 170.4 (CO-LysN-ter), 161.0 (CHO), 156.0 
(OCONH), 155.5 (OCONH), 137.3 (1C-Ph), 128.3 (Ar-C), 127.7 (Ar-C), 77.3 (1C of tBu), 65.1 
(OCH2Ph), 52.3 (αC-LysN-ter), 51.7 (OCH3 and αC-LysC-ter), 50.4 (αC-Met), 40.0 (εC-Lys), 32.1 (βC-
Met), 31.9 (βC-Lys), 30.5 (βC-Lys), 29.3 (γC-Met), 29.2 (δC-Lys), 28.8 (δC-Lys), 28.2 (CH3-tBu), 
22.6 (γC-Lys), 22.5 (γC-Lys), 14.5 (SCH3); HRMS for C32H51N5O9S [M-H]- calcd.: 680.3334, found: 
680.3336. 
N-For-L-Met-L-Lys(Boc)-L-Phe-OMe (2.4g): Following Method (b), tripeptide 2.4g was obtained 
as a white solid (1.02 g, 86%), in two steps, starting from 2.3e (0.5 g, 1.23 mmol), N-
hydroxysuccinimide (0.17 g, 1.48 mmol), DCC (0.33 g, 1.60 mmol) in THF (18 mL) and H-L-Phe-
OMe·HCl salt (0.29 g, 1.36 mmol), NaHCO3 (0.41 g, 4.93 mmol) in 1:1 THF/H2O (30 mL). 1H NMR 
(300 MHz, CDCl3) δ = 8.14 (s, 1H, CHO), 7.69 (d, J = 8.1 Hz, 1H, αNH-Lys), 7.60-7.57 (m, 2H, NH-
Met and NH-Phe), 7.27-7.11 (m, 5H, Ar-H Phe), 5.03-4.98 (m, 1H, εNH-Lys), 4.96-4.88 (m, 1H, αH-
Met), 4.84-4.77 (m, 1H, αH-Phe), 4.74-4.69 (m, 1H, αH-Lys), 3.69 (s, 3H, OCH3), 3.11-3.01 (m, 4H, 
εCH2-Lys and βCH2-Phe), 2.47 (t, J = 6.8 Hz, 2H, γCH2-Met), 2.04 (s, 3H, SCH3), 2.00-1.90 (m, 2H, 
βCH2-Met), 1.79-1.63 (m, 2H, βCH2-Lys), 1.47-1.40 (m, 11H, tBu and δCH2-Lys), 1.35-1.28 (m, 2H, 
γCH2-Lys); 13C NMR (75 MHz, CDCl3) δ = 172.0 (CO-Phe), 171.5 (CO-Lys), 171.1 (CO-Met), 161.4 
(CHO), 156.2 (OCONH),  136.0 (1C of Phe), 129.2 (Ar-C), 128.6 (Ar-C), 127.2 (Ar-C), 79.1 (1C of 
tBu), 53.7 (αC-Phe), 52.9 (αC-Lys), 52.4 (OCH3), 50.6 (αC-Met), 40.2 (εC-Lys), 37.9 (βC-Phe), 32.8 
(βC-Met and βC-Lys), 30.0 (γC-Met), 29.6 (δC-Lys), 28.5 (CH3-tBu), 22.6 (γC-Lys), 15.4 (SCH3); 
HRMS for C27H42N4O7S [M-H]- calcd.: 565.2701, found: 565.2700. 
N-For-L-Met-L-Lys(Boc)-L-Lys(Boc)-OH (2.4h): Following Method (a), tripeptide 2.4h was 
obtained as a white solid (0.54 g, 62%), in two steps, starting from 2.3e (0.56 g, 1.38 mmol), N-
hydroxysuccinimide (0.19 g, 1.66 mmol), DCC (0.37 g, 1.79 mmol) in THF (15 mL) and H-L-
Lys(Boc)-OH (0.39 g, 1.59 mmol), NaHCO3 (0.46 g, 5.52 mmol) in 1:1 THF/H2O (20 mL). 1H NMR 
(300 MHz, DMSO-d6) δ = 12.51 (s, 1H, CO2H), 8.28 (d, J = 8.0 Hz, 1H, NH-Met), 8.04-8.02 (m, 3H, 
2 x NH-Lys and CHO), 6.77-6.71 (m, 2H, 2 x εNH-Lys), 4.47-4.40 (m, 1H, αH-Met), 4.28-4.24 (m, 
1H, αH-LysN-ter), 4.23-4.21 (m, 1H, αH-LysC-ter), 2.91-2.83 (m, 4H, 2 x εCH2-Lys), 2.42 (t, J = 7.8 Hz, 
2H, γCH2-Met), 2.02 (s, 3H, SCH3), 1.90-1.70 (m, 2H, βCH2-Met), 1.69-1.48 (m, 4H, 2 x βCH2-Lys), 
1.40-1.15 (m, 26H, 2 x CH3-tBu, 2 x δCH2-Lys and 2 x γCH2-Lys); 13C NMR (75 MHz, DMSO-d6) δ 
= 173.4 (CO-LysC-ter), 171.5 (CO-Met), 170.5 (CO-LysN-ter), 160.9 (CHO), 155.5 (2 x OCONH), 77.3 
(1C of tBu), 52.3 (αC-LysN-ter), 51.8 (αC-LysC-ter), 50.3 (αC-Met), 39.6 (2 x εC-Lys), 32.2 (βC-Met), 
31.6 (βC-Lys), 30.6 (βC-Lys), 29.3 (γC-Met), 29.1 (2 x δC-Lys), 28.2 (CH3-tBu), 22.6 (2 x γC-Lys), 
14.6 (SCH3); HRMS for C28H51N5O9S [M-H]- calcd.: 632.3334, found: 632.3334. 
N-For-L-Met-L-Lys(Boc)-L-Ala-OH (2.4i): Following Method (a), tripeptide 2.4i was obtained as 
a white solid (2.04 g, 85%), in two steps, starting from 2.3e (2.04 g, 5.03 mmol), N-
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hydroxysuccinimide (0.70 g, 6.04 mmol), DCC (1.35 g, 6.54 mmol) in THF (40 mL) and H-L-Ala-
OH (0.49 g, 5.53 mmol), NaHCO3 (1.69 g, 20.12 mmol) in 1:1 THF/H2O (50 mL). 1H NMR (300 
MHz, DMSO-d6) δ = 12.52 (br s, 1H, CO2H), 8.28 (d, J = 8.0 Hz, 1H, αNH-Met), 8.13 (d, J = 7.1 Hz, 
1H, αNH-Ala), 8.03-8.01 (m, 2H, CHO and αNH-Lys), 6.73 (t, J = 4.4 Hz, 1H, εNH-Lys), 4.47-4.40 
(m, 1H, αH-Met), 4.26-4.15 (m, 2H, αH-Ala and αH-Lys), 2.89-2.84 (m, 2H, εCH2-Lys), 2.43 (t, J = 
7.8 Hz, 2H, γCH2-Met), 2.03 (s, 3H, -SCH3), 1.93-1.70 (m, 2H, βCH2-Met), 1.63-1.48 (m, 2H, βCH2-
Lys), 1.40-1.33 (m, 11H, tBu and δCH2-Lys), 1.30-1.19 (m, 5H, CH3-Ala and γCH2-Lys); 13C NMR 
(75 MHz, DMSO-d6) δ = 172.0 (CO2H), 171.2 (CO-Lys), 170.5 (CO-Met), 161.0 (CHO), 155.5 
(OCONH), 77.3 (1C of tBu), 52.2 (αC-Lys), 50.4 (αC-Met), 47.4 (αC-Ala), 40.2 (εC-Lys), 32.2 (βC-
Met), 31.7 (βC-Lys), 29.3 (γC-Met), 29.2 (δC-Lys), 28.3 (CH3-tBu), 22.6 (γC-Lys), 17.1 (CH3-Ala), 
14.6 (SCH3); HRMS for C20H36N4O7S [M-H]- calcd.: 475.2232, found: 475.2231. 
Boc-L-Ala-L-Lys(Cbz)-L-Ala-OMe (2.12): Following Method (b), tripeptide 2.12 was obtained as 
a white solid (1.10 g, 75%), in two steps, starting from 2.11 (1.23 g, 2.72 mmol), N-
hydroxysuccinimide (0.38 g, 3.27 mmol), DCC (0.73 g, 3.54 mmol) in THF (20 mL) and H-L-Ala-
OMe·HCl (0.44 g, 3.13 mmol), NaHCO3 (0.92 g, 10.92 mmol) in 1:1 THF/H2O (30 mL). 1H NMR 
(300 MHz, CDCl3) δ = 7.33-7.29 (m, 5H, Ar-H), 6.99-6.94 (m, 2H, 2 x NH), 5.28-5.22 (m, 2H, 2 x 
NH), 5.08 (s, 2H, OCH2Ph), 4.57-4.44 (m, 2H, αH-Lys and αH-AlaC-ter), 4.20-4.16 (m, 1H, αH-AlaN-
ter), 3.69 (s, 3H, OCH3), 3.21-3.14 (m, 2H, εCH2-Lys), 1.89-1.61 (m, 2H, βCH2-Lys), 1.55-1.47 (m, 
2H, δCH2-Lys), 1.42 (s, 9H, CH3-tBu), 1.39-1.36 (m, 5H, CH3-AlaC-ter and γCH2-Lys), 1.32 (d, J = 7.0 
Hz, 3H, CH3-AlaN-ter); 13C NMR (75 MHz, CDCl3) δ = 173.3 (CO-AlaC-ter), 172.9 (CO-AlaN-ter), 173.3 
(CO-Lys), 156.8 (OCONH), 155.7 (OCONH), 136.7 (1C-Ph), 128.6 (Ar-C), 128.3 (Ar-C), 128.2 (Ar-
C), 80.3 (1C of tBu), 66.7 (OCH2Ph), 52.8 (αC-Lys), 52.5 (OCH3), 50.3 (αC-AlaN-ter), 48.2 (αC-AlaC-
ter), 40.4 (εC-Lys), 31.9 (βC-Lys), 29.3 (δC-Lys), 28.4 (CH3-tBu), 22.2 (γC-Lys), 18.4 (CH3-AlaN-ter), 
18.0 (CH3-AlaC-ter); HRMS for C26H40N4O8 [M+H]+ calcd.: 537.2919, found: 537.2916. 
N-For-Gly-L-Glu-L-Ala-OMe (2.5a): Following a similar procedure as used for the synthesis of 
2.2a, compound 2.4a (2.00 g, 4.91 mmol) was hydrogenated in the presence of 10% Pd/C Degussa 
(0.20 g, 10% w/w) in MeOH (60 mL) to give 2.5a (1.42 g, 91%) as a white solid after purification. 1H 
NMR (300 MHz, DMSO-d6) δ = 12.09 (br s, 1H, γCO2H-Glu), 8.41 (d, J = 6.8 Hz, 1H, NH-Ala), 8.21 
(t, J = 5.2 Hz, 1H, NH-Gly), 8.09-8.06 (m, 2H, NH-Glu and CHO), 4.36-4.29 (m, 1H, αCH-Glu), 
4.27-4.20 (m, 1H, αCH-Ala), 3.77 (d, J = 5.8 Hz, 2H, αCH2-Gly), 3.61 (s, 3H, OCH3), 2.25 (t, J = 8.1 
Hz, 2H, γCH2-Glu), 1.95-1.67 (m, 2H, βCH2-Glu), 1.28 (d, J = 7.0 Hz, 3H, CH3-Ala); 13C NMR (75 
MHz, DMSO-d6) δ = 174.0 (δCO-Glu), 172.9 (CO-Ala), 171.0 (αCO-Glu), 168.3 (CO-Gly), 161.5 
(CHO), 51.9 (OCH3), 51.4 (αC-Glu), 47.6 (αC-Ala), 40.5 (αC-Gly), 29.9 (γC-Glu), 27.6 (βC-Glu), 
16.7 (CH3-Ala); HRMS for C12H19N3O7 [M-H]- calcd.: 316.1150, found: 316.1152. 
N-For-Gly-L-Glu-L-Phe-OMe (2.5b): A solution of 2.4b (0.13 g, 0.29 mmol) in CH2Cl2 (4 mL) 
was cooled to 0 °C and trifluoroacetic acid was then added. The reaction mixture was then stirred for 
15 min at 0 °C and subsequently for 2 h at r.t. To this solution was then added toluene (6 mL), after 
which the volatiles were removed in vacuo. The remaining crude residue was purified by column 
chromatography on silica gel (gradient CH2Cl2/MeOH 98:1, v/v; 96:5, v/v; 94:7, v/v, 94:10, v/v) to 
afford 2.5b as a white foam (0.11 g, quant.). 1H NMR (300 MHz, MeOD) δ = 8.08 (s, 1H, CHO), 
7.21-7.10 (m, 5H, Ar-H), 4.61-4.56 (m, 1H, αCH-Phe) 4.35 (dd, J = 8.3, 5.6 Hz, 1H, αCH-Glu), 3.83 
(br s, 2H, αCH2-Gly), 3.59 (s, 3H, OCH3), 3.11-3.04 (m, 1H, βCH2-Phe), 2.96-2.88 (m, 1H, βCH2-
Phe), 2.26 (t, J = 8.0 Hz, 2H, γCH2-Glu), 1.97-1.93 (m, 1H, βCH2-Glu), 1.83-1.79 (m, 1H, βCH2-
Glu); 13C NMR (75 MHz, MeOD) δ = 173.5 (δCO-Glu), 170.2 (CO), 169.9 (CO), 167.6 (CO), 161.1 
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(CHO), 134.8 (1C-Ph), 127.0 (Ar-C), 126.3 (Ar-C), 124.6 (Ar-C), 50.6, 49.5, 46.6, 38.8, 34.9, 27.8 
(γC-Glu), 25.1 (βC-Glu); HRMS for C18H22N3O7 [M-H]- calcd.: 392.1463, found: 392.1462. 
N-For-Gly-L-β-amino-Ala-L-Phe-OMe (2.5c): A solution of 2.4c (0.92 g, 10.92 mmol) in a 2:1 
mixture of Et3N:CH2Cl2 (21 mL) was stirred at r.t. for 72 h. After reaction completion, the mixture 
was concentrated under reduced pressure and the crude residue was purified by column 
chromatography on silica gel (gradient CH2Cl2/MeOH 98:2, v/v; 96:4, v/v; 94:6, v/v) to afford 2.5c as 
a colorless foam (0.57 g, 68%). 1H NMR (300 MHz, DMSO-d6) δ = 8.45-8.43 (m, 1H, NH-Phe), 8.20-
8.19 (m, 1H, NH-Gly), 8.07-7.99 (m, 2H, CHO and NH-β-amino-Ala), 7.29-7.15 (m, 5H, ArH-Phe), 
4.50-4.42 (m, 1H, αH-Phe), 4.31-4.29 (m, 1H, αH-β-amino-Ala), 3.69 (d, J = 5.7 Hz, 2H, αCH2-Gly), 
3.58 (s, 3H, OCH3), 3.41 (br s, 2H, βNH2-β-amino-Ala), 3.33-3.08 (m, 2H, βCH2-β-amino-Ala), 3.03-
2.88 (m, 2H, βCH2-Phe); HRMS for C16H22N4O5 [M+H]+ calcd.: 351.1663, found: 351.1667. 
N-For-Gly-L-Lys(NH2·TFA)-L-Phe-OMe (2.5d): Following a similar procedure as used for the 
synthesis of 2.8, compound 2.4d (265.6 mg, 0.539 mmol), thioanisole (0.063 mL, 0.539 mmol) and 
trifluoroacetic acid (3 mL) in CH2Cl2 (9 mL) afforded 2.5d as a colorless foam (272.9 mg, 
quantitative), which was used directly in the next step without any further purification.  
N-For-L-Met-L-Lys(NH2·TFA)-L-Ala-OMe (2.5e): Following a similar procedure as used for the 
synthesis of 2.8, compound 2.4e (200 mg, 0.407 mmol), thioanisole (0.048 mL, 0.407 mmol) and 
trifluoroacetic acid (2 mL) in CH2Cl2 (6 mL) afforded 2.5e as a colorless foam (205.5 mg, 
quantitative), which was used directly in the next step without any further purification.  
N-For-L-Met-L-Lys(NH2·TFA)-L-Lys(Cbz)-OMe (2.5f): Following a similar procedure as used 
for the synthesis of 2.8, compound 2.4f (400 mg, 0.587 mmol), thioanisole (0.07 mL, 0.587 mmol) 
and trifluoroacetic acid (3 mL) in CH2Cl2 (9 mL) afforded 2.5f as a colorless foam (408.1 mg, 
quantitative), which was used directly in the next step without any further purification.  
N-For-L-Met-L-Lys(NH2·TFA)-L-Phe-OMe (2.5g): Following a similar procedure as used for the 
synthesis of 2.8, compound 2.4g (220 mg, 0.388 mmol), thioanisole (0.046 mL, 0.388 mmol) and 
trifluoroacetic acid (1 mL) in CH2Cl2 (4 mL) afforded 2.5g as a colorless foam (225.4 mg, 
quantitative), which was used directly in the next step without any further purification. 
Boc-L-Ala-L-Lys-L-Ala-OMe (2.13): Following a similar procedure as used for the synthesis of 
2.2a, compound 2.12 (1.10 g, 2.05 mmol) was hydrogenated in the presence of 10% Pd/C Degussa 
(0.11 g, 10% w/w) in EtOH (40 mL) to give 2.13 as a colorless foam (0.82 g, quantitative), which was 
used directly in the next step without any further purification. 1H NMR (500 MHz, DMSO-d6) δ = 
8.39 (d, J = 6.4 Hz, 1H, NH-AlaC-ter), 7.73 (d, J = 8.0 Hz, 1H, NH-Lys), 6.96 (d, J = 7.4 Hz, 1H, NH-
AlaN-ter), 4.44 (br s, 2H, εNH2-Lys), 4.29-4.204 (m, 2H, αH-Lys and αH-AlaC-ter), 4.00-3.92 (m, 1H, 
αH-AlaN-ter), 3.60 (s, 3H, OCH3), 2.57 (t, J = 6.9 Hz, 2H, εCH2-Lys), 1.69-1.45 (m, 2H, βCH2-Lys), 
1.45-1.36 (m, 11H, δCH2-Lys and CH3-tBu), 1.28-1.21 (m, 5H, CH3-AlaC-ter and  γCH2-Lys), 1.15 (d, J 
= 7.1 Hz, 3H, CH3-AlaN-ter); 13C NMR (125 MHz, CDCl3) δ = 172.9 (CO-AlaC-ter), 172.4 (CO-AlaN-ter), 
171.4 (CO-Lys), 155.0 (OCONH), 78.1 (1C of tBu), 51.8 (αC-Lys and OCH3), 49.7 (αC-AlaN-ter), 47.5 
(αC-AlaC-ter), 40.4 (εC-Lys), 32.1 (βC-Lys), 30.7 (δC-Lys), 28.1 (CH3-tBu), 22.1 (γC-Lys), 18.0 (CH3-
AlaN-ter), 16.8 (CH3-AlaC-ter); HRMS for C18H34N4O6 [M+H]+ calcd.: 403.2551, found: 403.2543. 
N-For-L-Met-L-Lys(Boc)-L-Ala-L-Ala-OH (2.6a): Following Method (a), tetrapeptide 2.6a was 
obtained as a white solid (0.99 g, 86%), in one-pot without filtration of DCU, starting from 2.4i (1.0 g, 
2.10 mmol), N-hydroxysuccinimide (0.29 g, 2.52 mmol), DCC (0.56 g, 2.73 mmol) in THF (18 mL) 
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and H-L-Ala-OH (0.21 g, 2.31 mmol), NaHCO3 (0.70 g, 8.39 mmol) in 1:1 THF/H2O (40 mL). 1H 
NMR (300 MHz, DMSO-d6) δ = 12.55 (br s, 1H, CO2H), 8.28 (d, 1H, J = 8.0 Hz, αNH-Met), 8.10-
8.03 (m, 2H, αNH-Lys and αNH-AlaN-ter), 8.02 (s, 1H, CHO), 7.94 (d, 1H, J = 7.3 Hz, αNH- AlaC-ter), 
6.73 (t, J = 5.3 Hz, 1H, εNH-Lys), 4.47-4.40 (m, 1H, αH-Met), 4.31-4.27 (m, 1H, αH- AlaC-ter), 4.24-
4.16 (m, 2H, αH-Lys and αH- AlaN-ter), 2.89-2.84 (m, 2H, εCH2-Lys), 2.43 (t, J = 7.8 Hz, 2H, γCH2-
Met), 2.03 (s, 3H, SCH3), 1.95-1.73 (m, 2H, βCH2-Met), 1.68-1.44 (m, 2H, βCH2-Lys), 1.40-1.33 (m, 
11H, tBu and δCH2-Lys), 1.32-1.17 (m, 8H, 2 x CH3-Ala and γCH2-Lys); 13C NMR (75 MHz, DMSO-
d6) δ = 173.9 (CO-AlaC-ter), 171.8 (CO-Lys), 171.0 (CO-AlaN-ter), 170.6 (CO-Met), 160.9 (CHO), 
155.5 (OCONH), 77.3 (1C of tBu), 52.5 (αC-Lys), 50.4 (αC-Met), 47.7 (αC-AlaC-ter), 47.4 (αC-AlaN-
ter), 40.2 (εC-Lys), 32.2 (βC-Met), 31.5 (βC-Lys), 29.3 (γC-Met), 29.2 (δC-Lys), 28.3 (CH3-tBu), 22.7 
(γC-Lys), 18.1 (CH3-AlaC-ter), 17.2 (CH3-AlaN-ter), 14.6 (SCH3); HRMS for C23H41N5O8S [M+Na]+ 
calcd.: 570.2568, found: 570.2571. 
N-For-L-Met-L-Lys(Boc)-L-Ala-L-Phe-OMe (2.6b): Following Method (b), tetrapeptide 2.6b 
was obtained as a white solid (0.55 g, 82%), in one-pot without filtration of DCU, starting from 2.4i 
(0.5 g, 1.05 mmol), N-hydroxysuccinimide (0.15 g, 1.26 mmol), DCC (0.28 g, 1.36 mmol) in THF (10 
mL) and H-L-Phe-OMe.HCl (0.25 g, 1.15 mmol), NaHCO3 (0.26 g, 3.15 mmol) in 1:1 THF/H2O (30 
mL). 1H NMR (300 MHz, DMSO-d6) δ = 8.29-8,24 (m, 2H, αNH-Met and αNH-Phe), 8.05-8.02 (m, 
2H, CHO and αNH-Lys), 7.90 (d, J = 7.4 Hz, 1H, αNH-Ala), 7.30-7.19 (m, 5H, Ar-H Phe),  6.73 (t, J 
= 5.7 Hz, 1H, εNH-Lys), 4.49-4.44 (m, 1H, αH-Met), 4.32-4.27 (m, 1H, αH-Ala), 4.25-4.19 (m, 1H, 
αH-Lys), 3.57 (s, 3H, OCH3), 3.05-2.94 (m, 2H, βCH2-Phe), 2.92-2.82 (m, 2H, εCH2-Lys), 2.43 (t, J = 
7.8 Hz, 2H, γCH2-Met), 2.02 (s, 3H, -SCH3), 1.95-1.73 (m, 2H, βCH2-Met), 1.65-1.44 (m, 2H, βCH2-
Lys), 1.40-1.24 (m, 11H, tBu and δCH2-Lys), 1.24-1.13 (m, 5H, CH3-Ala and γCH2-Lys); 13C NMR 
(75 MHz, DMSO-d6) δ = 172.2 (CO-Ala), 171.7 (CO-Phe), 171.0 (CO-Lys), 170.6 (CO-Met), 160.9 
(CHO), 155.5 (OCONH), 136.9 (1C of Phe), 129.0 (Ar-C), 128.2 (Ar-C), 126.5 (Ar-C), 77.3 (1C of 
tBu), 53.5 (αC-Phe), 52.4 (αC-Lys), 51.8 (OCH3), 50.4 (αC-Met), 47.8 (αC-Ala), 40.2 (εC-Lys), 36.6 
(βC-Phe), 32.2 (βC-Met), 31.5 (βC-Lys), 29.3 (γC-Met), 29.2 (δC-Lys), 28.2 (CH3-tBu), 22.7 (γC-
Lys), 18.2 (CH3-Ala), 14.6 (SCH3); HRMS for C30H47N5O8S [M+Na]+ calcd.: 660.3038, found: 
660.3049. 
N-For-L-Met-L-Lys(NH2·TFA)-L-Ala-L-Phe-OMe (2.9): Following a similar procedure as used 
for the synthesis of 2.8, compound 2.6b (248 mg, 0.388 mmol), thioanisole (0.046 mL, 0.388 mmol) 
and trifluoroacetic acid (1 mL) in CH2Cl2 (4 mL) afforded 2.9 as a colorless foam (253 mg, 
quantitative), which was used directly in the next step without any further purification.  
N-For-L-Met-L-Lys(Boc)-L-Ala-L-Ala-L-Phe-OMe (2.7): Following Method (b), pentapeptide 
2.7 was obtained as a white solid (0.87 g, 81%), in two steps, starting from 2.6a (0.83 g, 1.51 mmol), 
N-hydroxysuccinimide (0.21 g, 1.82 mmol), DCC (0.41 g, 1.97 mmol) in THF (20 mL) and H-L-Phe-
OMe.HCl (0.36 g, 1.67 mmol), NaHCO3 (0.38 g, 4.54 mmol) in 1:1 THF/H2O (38 mL). 1H NMR (300 
MHz, DMSO-d6) δ = 8.28 (d, J = 8.3 Hz, 1H, αNH-Met),  8.23 (d, J = 7.6 Hz, 1H, αNH-Phe), 8.06 (d, 
J = 7.7 Hz, 1H, αNH-Lys), 8.02 (s, 1H, CHO), 7.96 (d, J = 7.2 Hz, 1H, αNH-Ala), 7.85 (d, J = 7.7 Hz, 
1H, αNH-Ala), 7.30-7.19 (m, 5H, Ar-H Phe),  6.73 (t, J = 5.4 Hz, 1H, εNH-Lys), 4.49-4.40 (m, 2H, 
αH-Met and αH-Phe), 4.30-4.20 (unresolved m, 3H, 2 x αH-Ala and αH-Lys), 3.58 (s, 3H, OCH3), 
3.06-2.93 (m, 2H, βCH2-Phe), 2.90-2.84 (m, 2H, εCH2-Lys), 2.43 (t, J = 7.7 Hz, 2H, γCH2-Met), 2.03 
(s, 3H, -SCH3), 1.95-1.73 (m, 2H, βCH2-Met), 1.72-1.47 (m, 2H, βCH2-Lys), 1.40-1.31 (m, 11H, tBu 
and δCH2-Lys), 1.24-1.12 (m, 8H, 2 x CH3-Ala and γCH2-Lys); 13C NMR (75 MHz, DMSO-d6) δ = 
172.2 (CO-AlaC-ter), 171.7 (CO-Phe), 171.5 (CO-AlaN-ter), 171.2 (CO-Lys), 170.6 (CO-Met), 161.0 
(CHO), 155.5 (OCONH), 137.0 (1C of Phe), 129.0 (Ar-C), 128.2 (Ar-C), 126.5 (Ar-C), 77.3 (1C of 
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tBu), 53.5 (αC-Phe), 52.5 (αC-Lys), 51.8 (OCH3), 50.4 (αC-Met), 47.9 (αC-Ala), 47.9 (αC- AlaC-ter), 
47.7 (αC- AlaN-ter), 40.2 (εC-Lys), 36.6 (βC-Phe), 32.2 (βC-Met), 31.5 (βC-Lys), 29.3 (γC-Met), 29.2 
(δC-Lys), 28.3 (CH3-tBu), 22.7 (γC-Lys), 18.2 (CH3-Ala), 17.9 (CH3-Ala), 14.6 (SCH3); HRMS for 
C33H52N6O9S [M-H]- calcd.: 707.3443, found: 707.3451. 
N-For-L-Met-L-Lys(NH2·TFA)-L-Ala-L-Ala-L-Phe-OMe (2.10): Following a similar procedure 
as used for the synthesis of 2.8, compound 2.7 (275 mg, 0.388 mmol), thioanisole (0.046 mL, 0.388 
mmol) and trifluoroacetic acid (1 mL) in CH2Cl2 (4 mL) afforded 2.10 as a colorless foam (281 mg, 
quantitative), which was used directly in the next step without any further purification. 
5’-O-(4-Monomethoxytrityl)-2’-deoxythymidine (2.14):[23] To a stirring solution of thymidine 
(2.50 g, 10.32 mmol) in dry DMF (26 mL) was added triethylamine (3.61 mL, 25.8 mmol), followed 
by DMAP (0.10 g, 0.825 mmol) and 4-monomethoxytrityl chloride (6.37 g, 20.64 mmol) and the 
resulting mixture was stirred at r.t. for 4 h. The reaction mixture was quenched with water (260 mL) 
and the aqueous layer was extracted with ethyl acetate (3 x 150 mL). The collected organic fractions 
were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was 
purified by column chromatography on silica gel (gradient Hexane/Ethyl acetate 2:1, v/v; 1:1, v/v; 
1:2, v/v) to give 2.14 (5.14 g, 97%) as a colorless foam. 1H NMR (300 MHz, CDCl3) δ = 8.79 (br s, 
1H, NH), 7.57 (d, J = 1.1 Hz, 1H, H-6), 7.42-7.39 (m, 4H, Ar-H), 7.33-7.22 (m, 8H, Ar-H), 6.86-6.83 
(m, 2H, Ar-H), 6.42 (dd, J = 7.6, 6.1 Hz, 1H, H-1’), 4.59-4.57 (m, 1H, H-3’), 4.08-4.05 (m, 1H, H-4’), 
3.79 (s, 3H, OCH3), 3.49-3.35 (m, 2H, H-5’ and H-5’’), 2.44-2.29 (m, 2H, H-2’ and H-2’’), 1.47 (d, J 
= 1.1 Hz, 3H, CH3); HRMS for C30H30N2O6 [M+Na]+calcd.: 537.1996, found: 537.1998. 
5’-O-(4-Monomethoxytrityl)-3’-O-(4-nitrophenyl carbonate)-2’-deoxythymidine (2.15): 
Compound 2.14 (1.00 g, 1.95 mmol) was coevaporated with dry pyridine (2 x 5 mL), redissolved in 
dry pyridine (5 ml) and to this solution was slowly added a suspension of 4-nitrophenyl chloroformate 
(0.432 g, 2.14 mmol) in a mixture of CH2Cl2/Pyridine (70:1, 5 mL) at 0 °C. The reaction mixture was 
then stirred overnight at r.t. After removal of all the volatiles under reduced pressure, the resulting 
residue was redissolved in CH2Cl2 (4 mL) and this solution was slowly added into 30 mL of 
vigorously stirring diethyl ether. The resulting precipitate was filtered off and the filtrate was poured 
into stirring hexane (100 mL) to give a white precipitate, which was filtered and dried to afford 2.15 
(0.87 g, 66%) as a white solid. 1H NMR (300 MHz, CDCl3) δ = 8.81 (br s, 1H, NH), 8.31-8.27 (m, 
2H, Ar-H), 7.61 (s, 1H, H-6), 7.39- 7.26 (m, 14H, Ar-H), 6.87-6.84 (m, 2H, Ar-H), 6.39 (dd, J = 8.8, 
5.6 Hz, 1H, H-1’), 5.51-5.45 (m, 1H, H-3’), 4.32 (br s, 1H, H-4’), 3.79 ( s, 3H, OCH3), 3.60-3.47 (m, 
2H, H-5’ and H-5’’), 2.79-2.47 (m, 2H, H-2’ and H-2’’), 1.43 (s, 3H, CH3); 13C NMR (75 MHz, 
CDCl3) δ = 163.6, 159.1, 155.2, 152.0, 150.5, 145.7, 143.7, 135.2, 134.6, 130.5, 128.5, 128.4, 128.3, 
127.6, 125.5, 122.2, 121.8, 113.5 112.0, 84.4, 83.6, 80.5, 63.9, 55.4, 38.0, 11.8; HRMS for 
C37H33N3O10 [M+Na]+calcd.: 702.2058, found: 702.2081. 
5’-O-(4-Monomethoxytrityl)-3’-O-[N-For-Gly-L-Lys(ε-carbamate)-L-Phe-OMe]-2’-
deoxythymidine (2.16): To a stirring solution of tripeptide 2.5d (110 mg, 0.217 mmol) and Et3N 
(0.105 mL, 0.868 mmol) in dry CH2Cl2 (5 mL) was added 2.15 (132 mg, 0.195 mmol) in dry CH2Cl2 
at 0 °C and the stirring was continued at r.t. for 16 h. The reaction mixture was then diluted with 
CH2Cl2 and washed twice with 10% aq. NaHCO3. The organic layer was dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude residue was purified by column chromatography 
on silica gel (gradient CH2Cl2/EtOH 99:1, v/v; 97:3, v/v; 94:6, v/v) to afford 2.16 as a white solid 
(160 mg, 79%). 1H NMR (300 MHz, DMSO-d6) δ = 11.39 (br s,1H, NH), 8.40 (d, J = 7.4 Hz, 1H, 
NH-Phe), 8.22 (t, J = 5.4 Hz, 1H, NH-Gly), 8.06 (s, 1H, CHO), 7.99 (d, J = 8.2 Hz, 1H, NH-Lys), 
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7.53 (s, 1H, H-6), 7.53-7.19 (m, 18H, Ar-H and εNH-Lys), 6.23 (dd, J = 7.8, 6.5 Hz, 1H, H-1’), 5.24-
5.23 (m, 1H, H-3’), 4.48-4.41 (m, 1H, αH-Phe), 4.31-4.25 (m, 1H, αH-Lys), 4.05 (br s, 1H, H-4’), 
3.75 (s, 2H, CH2-Gly), 3.56 (s, 3H, OCH3), 3.39-3.20 (m, 2H, H-5’ and H-5’’), 2.99-2.94 (m, 4H, 
εCH2-Lys and βCH2-Phe), 2.47-2.25 (m, 1H, H-2’and H-2’’), 1.77 (s, 3H, CH3-Thy), 1.62-1.55 (m, 
2H, βCH2-Lys), 1.54-1.45 (m, 5H, δCH2-Lys and CH3-Thy), 1.37-1.24 (m, 2H, γCH2-Lys); 13C NMR 
(75 MHz, DMSO-d6) δ = 171.7, 171.6, 168.1, 163.6, 161.4, 158.3, 155.2, 150.4, 144.1, 143.8, 137.1, 
135.4, 134.6, 130.1, 129.0, 128.2, 127.9, 127.1, 126.5, 113.3, 109.9, 83.6, 83.2, 74.2, 63.9, 55.1, 63.6, 
52.1, 51.7, 40.4, 36.8, 36.5, 31.9, 29.1, 22.4, 11.6; HRMS for C50H56N6O12 [M+Na]+calcd.: 955.3848, 
found: 955.3813. 
5’-Hydroxy-3’-O-[N-For-Gly-L-Lys(ε-carbamate)-L-Phe-OMe]-2’-deoxythymidine (2.17): A 
solution of 2.16 (147 mg, 0.157 mmol) in 80% AcOH (2 mL) was stirred at r.t. for 3.5 h. The volatiles 
were then removed under reduced pressure and coevaporated twice with toluene. The crude residue 
was purified by column chromatography on silica gel (gradient CH2Cl2/MeOH 100:0, v/v; 98:2, v/v; 
96:5, v/v) to give 2.17 (85 mg, 82%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ = 11.32 (br 
s,1H, NH), 8.38 (d, J = 7.3 Hz, 1H, NH-Phe), 8.19 (t, J = 5.1 Hz, 1H, NH-Gly), 8.06 (s, 1H, CHO), 
7.96 (d, J = 7.9 Hz, 1H, NH-Lys), 7.73 (s, 1H, H-6), 7.31-7.19 (m, 5H, Ar-H), 6.17 (dd, J = 8.5, 5.9 
Hz, 1H, H-1’), 5.19 (t, J = 4.7 Hz, 1H, εNH-Lys), 5.11-5.09 (m, 1H, H-3’), 4.48-4.40 (m, 1H, αH-
Phe), 4.31-4.23 (m, 1H, αH-Lys), 3.93 (br s, 1H, H-4’), 3.75 (d, J = 5.6 Hz, 2H, αCH2-Gly), 3.63-3.60 
(m, 2H, H-5’ and H-5’’), 3.57 (s, 3H, OCH3), 3.05-2.89 (m, 4H, εCH2-Lys and βCH2-Phe), 2.33-2.17 
(m, 2H, H-2’ and H-2’’), 1.78 (s, 3H, CH3-Thy), 1.59-1.47 (m, 2H, βCH2-Lys), 1.46-1.34 (m, 2H, 
δCH2-Lys), 1.28-1.15 (m, 2H, γCH2-Lys); 13C NMR (75 MHz, DMSO-d6) δ = 171.8, 171.6, 168.1, 
163.7, 161.4, 155.4, 150.5, 137.1, 135.8, 129.1, 128.3, 126.6, 109.7, 85.5, 83.7, 74.6, 61.5, 40.4, 36.8, 
36.5, 31.9, 30.7, 29.1, 22.4, 12.3; HRMS for C30H40N6O11 [M+H]+calcd.: 661.2827, found: 661.2828. 
5’-O-(Dibenzylphosphate)-3’-O-[N-For-Gly-L-Lys(ε-carbamate)-L-Phe-OMe]-2’-
deoxythymidine (2.18): To a stirred suspension of 2.17 (210 mg, 0.317 mmol) in dry CH2Cl2 (5 mL) 
was added 0.45M tetrazole in ACN (3.53 mL, 1.59 mmol) followed by dibenzyldiisopropyl 
phosphoramidite (0.24 mL, 0.697 mmol) at 0 ºC and the reaction mixture was stirred at r.t. for 12 h. 
After cooling to -40 ºC, 35% H2O2 (0.14 mL, 1.59 mmol) was slowly added and the resulting mixture 
was stirred first at 0 ºC for 1 h and then at r.t. for 1 h. The mixture was cooled and quenched with 10% 
(w/v) aq. NaHSO3 (6 mL). Athe aqueous layer was extracted with CH2Cl2 (3 x 30 mL), the combined 
organic fractions were dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude residue was purified by column chromatography on silica gel (gradient CH2Cl2/MeOH 99:1, 
v/v; 98:2, v/v; 96:4, v/v) to give 2.18 (230 mg, 79%) as a colorless foam. 
5’-O-(4-Monomethoxytrityl)-3’-O-benzoyl-2’-deoxythymidine (2.20): To a stirring solution of 
2.14 (3.09 g, 6.01 mmol) in pyridine (25 mL), benzoyl chloride (0.80 mL, 6.91 mmol) was slowly 
added at 0 ºC and resulting mixture was stirred for 3 h at 0 ºC. The reaction mixture was then diluted 
with CH2Cl2 (200 mL) and washed with saturated aq. NaHCO3 and brine. The organic layer was dried 
over Na2SO4, filtered, evaporated and coevaporated with toluene. The cude residue was purified by 
column chromatography on silica gel (gradient Hexane/Ethyl acetate 3:1, v/v; 2:1, v/v; 1:1, v/v) to 
give 2.20 (3.53 g, 95%) as a colorless foam. 1H NMR (300 MHz, CDCl3) δ = 9.56 (br s,1H, NH), 
8.06-8.03 (m, 2H, Ar-H), 7.66 (s, 1H, H-6), 7.60-7.25 (m, 15H, Ar-H), 6.87-6.84 (m, 2H, Ar-H), 6.56 
(dd, J = 8.7, 5.7 Hz, 1H, H-1’), 5.74-5.72 (m, 1H, H-3’), 4.30-4.29 (m, 1H, H-4’), 3.78 (s, 3H, OCH3), 
3.61-3.51 (m, 2H, H-5’ and H-5’’), 2.69-2.51 (m, 2H, H-2’ and H-2’’), 1.43 (s, 3H, CH3); 13C NMR 
(75 MHz, CDCl3) δ = 166.0, 164.0, 158.9, 150.8, 143.9, 143.8, 135.4, 134.8, 133.6, 130.5, 129.8, 
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129.4, 128.6, 128.5, 128.4, 128.1, 127.4, 113.4, 111.8, 87.5, 84.5, 84.2, 75.9, 63.9, 55.3, 38.2, 11.8; 
HRMS for C37H34N2O7 [M+Na]+calcd.: 641.2258, found: 641.2257. 
5’-Hydroxy-3’-O-benzoyl-2’-deoxythymidine (2.21):[52] A solution of 2.20 (3.35 g, 5.41 mmol) in 
80% AcOH (40 mL) was stirred at r.t. for 3.5 h. The volatiles were then removed under reduced 
pressure and twice coevaporated with toluene. The residue was purified by column chromatography 
on silica gel (gradient CH2Cl2/MeOH 100:0, v/v; 98:2, v/v; 96:4, v/v) to give 2.21 (1.7 g, 91%) as a 
white solid. 1H NMR (300 MHz, DMSO-d6) δ = 11.35 (br s,1H, NH), 8.03-8.00 (m, 2H, o-H of Ph), 
7.79 (d, J = 1.1 Hz, 1H, H-6), 7.71-7.66 (m, 1H, p-H of Ph), 7.58-7.53 (m, 2H, m-H of Ph), 6.30 (app 
t, J = 7.1 Hz, 1H, H-1’), 5.49-5.48 (m, 1H, H-3’), 5.26 (br s, 1H, OH), 4.18-4.15 (m, 1H, H-4’), 3.71 
(br s, 2H, H-5’ and H-5’’), 2.43-2.39 (m, 2H, H-2’ and H-2’’), 1.80 (d, J = 1.0 Hz, 3H, CH3); 13C 
NMR (75 MHz, DMSO-d6) δ = 165.2 (COPh), 163.7 (C-4), 150.5 (C-2), 135.9 (C-6), 133.6 (p-C of 
Ph), 129.4 (1C of Ph), 129.3 (o-C of Ph), 128.8 (m-C of Ph), 109.8 (C-5), 84.6 (C-1’), 83.8 (C-4’), 
75.7 (C-3’), 61.4 (C-5’), 36.7 (C-2’), 12.3 (CH3); HRMS for C37H34N2O7 [M+H]+calcd.: 347.1237, 
found: 347.1238. 
5’-O-(Dibenzylphosphate)-3’-O-benzoyl-2’-deoxythymidine (2.22): To a stirring suspension of 
2.21 (1.6 g, 4.62 mmol) in dry CH2Cl2 (20 mL), 0.45M tetrazole in ACN (51.33 mL, 23.10 mmol) 
was added followed by dibenzyldiisopropyl phosphoramidite (3.47 mL, 10.16 mmol) at 0 ºC and the 
reaction mixture was stirred at r.t. for 12 h. After cooling to -40 ºC, 35% H2O2 (1.97 mL, 23.10 mmol) 
was slowly added and the resulting mixture was stirred at 0 ºC for 1 h and an additional 1 h at r.t. 
Then the reaction mixture was again cooled and finally quenched with 10% (w/v) aq. NaHSO3 (30 
mL). The aqueous layer was extracted with CH2Cl2 (3 x 100 mL), collected organic fractions were 
dried over Na2SO4, concentrated under reduced pressure and crude residue was purified by column 
chromatography on silica gel (gradient Hexane/Ethyl acetate 3:1, v/v; 2:1, v/v; 1:1, v/v) to give 2.22 
(2.59 g, 92%) as a colorless foam. 1H NMR (300 MHz, CDCl3) δ = 9.38 (br s,1H, NH), 8.05-8.02 (m, 
2H, Ar-H), 7.63-7.58 (m, 1H, Ar-H), 7.49-7.44 (m, 3H, H-6 and Ar-H), 7.35 (br s, 10H, Ar-H), 6.46 
(dd, J = 9.0, 5.4 Hz, 1H, H-1’), 5.37-5.35 (m, 1H, H-3’), 5.15-5.03 (m, 4H, OCH2Ph), 4.38-4.34 (m, 
1H, H-4’), 4.25 (br s, 2H, H-5’ and H-5’’), 2.48-2.42 (m, 2H, H-2’ and H-2’’), 1.86 (s, 3H, CH3); 13C 
NMR (75 MHz, CDCl3) δ = 166.0 (COPh), 163.8 (C-4), 150.7 (C-2), 135.5 (d, 3JC,P = 6.0 Hz, 1C of 
OCH2Ph),135.0 (C-6), 133.7 (Ar-C), 129.8 (Ar-C), 129.1 (Ar-C), 129.0 (Ar-C), 128.8 (Ar-C), 128.6 
(Ar-C), 128.2 (Ar-C), 111.9 (C-5), 84.6 (C-1’), 83.0 (d, 3JC,P = 8.3 Hz, C-4’), 75.3 (C-3’), 69.9 (app t, 
2JC,P = 5.3 Hz, OCH2), 67.3 (d, 2JC,P =5.7 Hz, C-5’), 37.3 (C-2’), 12.4 (CH3); 31P NMR (121 MHz, 
CDCl3) δ = -0.6; HRMS for C37H34N2O7 [M+H]+calcd.: 607.1840, found: 607.1840. 
5’-O-(Dibenzylphosphate)-2’-deoxythymidine (2.23): A solution of 2.22 (2.52 g, 4.15 mmol) in 
7N NH3 in MeOH (30 mL) was stirred at 0 ºC for 3 h and then at r.t. for 24 h. The volatiles were 
removed under reduced pressure and the crude residue was purified by column chromatography on 
silica gel (gradient CH2Cl2/MeOH 99:1, v/v; 98:2, v/v; 97:3, v/v) to give 2.23 (1.98 g, 95%) as a 
colorless foam. 1H NMR (300 MHz, CDCl3) δ = 9.41 (br s,1H, NH), 7.34- 7.33 (m, 11H, H-6 and Ar-
H), 6.29 (app t, J = 6.7 Hz, 1H, H-1’), 5.11-4.99 (m, 4H, OCH2Ph), 4.37-4.33 (m, 1H, H-3’), 4.22-
4.14 (m, 2H, H-5’ and H-5’’), 4.04-4.00 (m, 2H, H-4’), 2.35-2.27 (m, 1H, H-2’), 2.03-1.96 (m, 1H, H-
2’’), 1.81 (d, J = 1.0 Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ = 164.0 (C-4), 150.7 (C-2), 149.8 
(C1 of PhNO2), 145.36 (p-C of PhNO2), 135.7 (C-6), 135.4 (d, 3JC,P = 7.3 Hz, 1C of OCH2Ph), 129.1 
(Ar-C), 128.9 (Ar-C), 128.2 (Ar-C), 111.5 (C-5), 85.0 (C-1’), 84.8 (d, 3JC,P = 7.5 Hz, C-4’), 71.1 (C-
3’), 70.1-70.0 (2d, 2JC,P = 5.6 Hz, 2 x OCH2Ph), 66.9 (d, 2JC,P = 5.7 Hz, C-5’), 40.2 (C-2’), 12.5 (CH3); 
31P NMR (121 MHz, CDCl3) δ = -0.5; HRMS for C24H27N2O8P [M+H]+calcd.: 503.1578, found: 
503.1580. 
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5’-O-(Dibenzylphosphate)-3’-O-(4-nitrophenyl carbonate)-2’-deoxythymidine (2.24): 
Compound 2.23 (1.12 g, 2.23 mmol) was coevaporated with dry pyridine (2 x 5 mL), redissolved in 
dry pyridine (7 ml) and then a suspension of 4-nitrophenyl chloroformate (0.539 g, 2.67 mmol) in a 
mixture of CH2Cl2/Pyridine (70:1, 7.1 mL) was slowly added at 0 ºC . The reaction mixture was then 
stirred at 0 ºC for 2 h and at r.t. for 24 h. The volatiles were removed under reduced pressure and the 
residue was redissolved in CH2Cl2 (150 mL) and washed with saturated aq. NaHCO3 (2 x 70 mL). 
The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The crude 
residue was purified by column chromatography on silica gel (gradient Hexane/Ethyl acetate 2:1, v/v; 
1:1, v/v; 1:3, v/v) to afford 2.24 (0.99 g, 67%) as a colorless foam. 1H NMR (300 MHz, CDCl3) δ = 
8.43 (br s,1H, NH), 8.32-8.29 (m, 2H, Ar-H), 7.41- 7.26 (m, 13H, H-6 and Ar-H), 6.39 (dd, J = 9.3, 
5.3 Hz, 1H, H-1’), 5.17-5.15 (m, 1H, H-3’), 5.12-5.00 (m, 4H, OCH2Ph), 4.28-4.27 (m, 1H, H-4’), 
4.26-4.20 (m, 2H, H-5’ and H-5’’), 2.48-2.41 (m, 1H, H-2’), 2.04-1.93 (m, 1H, H-2’’), 1.86 (d, J = 1.0 
Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ = 162.9 (C-4), 154.7 (COPhNO2), 151.5 (C-2), 149.8 
(C1 of PhNO2), 145.36 (p-C of PhNO2), 135.0 (d, 3JC,P = 5.8 Hz, 1C of OCH2Ph), 134.4 (C-6), 128.7 
(Ar-C), 128.6 (Ar-C), 128.5 (Ar-C), 128.4 (Ar-C), 127.8 (Ar-C), 125.1 (Ar-C), 121.3 (Ar-C), 111.6 
(C-5), 84.1 (C-1’), 81.9 (d, 3JC,P = 8.2 Hz, C-4’), 79.1 (C-3’), 69.6 (app t, 2JC,P = 4.9 Hz, OCH2Ph), 
66.6 (d, 2JC,P =5.5 Hz, C-5’), 36.7 (C-2’), 12.0 (CH3); 31P NMR (121 MHz, CDCl3) δ = -0.5; HRMS 
for C31H30N3O12P [M+H]+calcd.: 668.1640, found: 668.1638. 
General procedure for the synthesis of 3’-carbamoyl peptide conjugates of dTMP (2.18 and 
2.25-2.32): To a stirring solution of peptide-NH2·TFA salt (1 eq.) and Et3N (4 eq.) in dry CH2Cl2 was 
added a solution of compound 2.24 in dry CH2Cl2 at 0 ºC and the stirring was continued at r.t. for 24 
h. The reaction mixture was then diluted with CH2Cl2 and washed twice with 20% aq. NaHCO3. The 
organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The crude 
residue was purified by column chromatography on silica gel (gradient CH2Cl2/MeOH 99:1, v/v; 98:2, 
v/v; 96:4, v/v) to afford the desired 3’-carbamoyl PNCs. 
5’-O-(Dibenzylphosphate)-3’-O-[N-For-Gly-L-β-amino-Ala-(β-carbamate)-L-Phe-OMe]-2’-
deoxythymidine (2.25): Compound 2.25 was prepared according to the general procedure starting 
from 2.24 (240 mg , 0.365 mmol), tripeptide 2.5c (179 mg, 0.510 mmol) and Et3N (0.05 mL, 0.539 
mmol) in dry CH2Cl2 (15 ml). The crude residue was purified by column chromatography on silica gel 
(gradient CH2Cl2/MeOH 99:1, v/v; 97:3, v/v; 92:5, v/v) to give conjugate 2.25 (259 mg, 82%) as a 
colorless foam. 1H NMR (300 MHz, CDCl3) δ = 9.93 (br s, 1H, NH-Thy), 8.18 (s, 1H, CHO), 7.65 (d, 
J = 7.2 Hz, 1H, NH-Phe), 7.65 (d, J = 7.2 Hz, 1H, NH-β-amino-Ala), 7.39 (s, 1H, H-6), 7.32 (br s, 
10H, Ar-H of OBn), 7.26-7.09 (m, 5H, Ar-H of Phe), 6.39 (t, J = 6.3 Hz, 1H, NH-Gly), 6.25 (dd, J = 
8.3, 5.2 Hz, 1H, H-1’), 5.07-4.98 (m, 5H, H-3’ and 2 x OCH2Ph), 4.83-4.76 (m, 1H, αH-Phe), 4.75-
4.68 (m, 1H, αH-β-amino-Ala), 4.28-4.17 (m, 2H, H-5’ and H-5’’), 4.14 (br s, 1H, H-4’), 4.04-3.88 
(m, 2H, CH2-Gly), 3.67 (s, 3H, OCH3), 3.58-3.33 (m, 2H, βCH2-β-amino-Ala), 3.16-2.99 (m, 2H, 
βCH2-Phe), 2.38-2.14 (m, 2H, H-2’ and H-2’’), 1.80 (s, 3H, CH3-Thy); 13C NMR (75 MHz, CDCl3) δ 
= 172.0 (CO-Phe), 169.7 (CO-β-amino-Ala), 169.4 (CO-Gly), 164.0 (C-4), 162.4 (CHO), 156.5 
(OCONH), 151.1 (C-2), 136.1 (C-6), 135.5 (d, 3JC,P = 5.5 Hz, 1C of OCH2Ph), 135.1 (1C Ph-Phe), 
129.3 (Ar-C), 129.0 (Ar-C), 128.9 (Ar-C), 128.6 (Ar-C), 128.2 (Ar-C), 127.2 (Ar-C), 112.0 (C-5), 
84.6 (C-1’), 82.8 (d, 3JC,P = 7.7 Hz, C-4’), 75.5 (C-3’), 69.9 (app t, 2JC,P = 5.0 Hz, 2 x OCH2Ph), 67.4 
(d, 2JC,P = 4.9 Hz, C-5’), 53.9 (αC-Phe), 53.6 (αC-β-amino-Ala), 52.6 (OCH3), 43.3 (βC-β-amino-Ala), 
41.7 (αC-Gly), 37.8 (C-2’), 37.2 (βC-Phe), 12.5 (CH3); 31P NMR (121 MHz, CDCl3) δ = -0.7; HRMS 
for C41H47N6O14P [M+H]+calcd.: 879.2960, found: 879.2966. 
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5’-O-(Dibenzylphosphate)-3’-O-[N-For-Gly-L-Lys(ε-carbamate)-L-Phe-OMe]-2’-
deoxythymidine (2.18): Compound 2.18 was prepared according to the general procedure starting 
from 2.24 (300 mg , 0.449 mmol), tripeptide 2.5d (273 mg, 0.539 mmol) and Et3N (0.25 mL, 1.80 
mmol) in dry CH2Cl2 (15 ml). The crude residue was purified by column chromatography on silica gel 
(gradient CH2Cl2/MeOH 99:1, v/v; 97:2, v/v; 92:4, v/v) to give conjugate 2.18 (322 mg, 78%) as a 
colorless foam. 1H NMR (300 MHz, CD3OD) δ = 8.15 (s, 1H, CHO), 7.46 (s, 1H, H-6), 7.36 (br s, 
10H, Ar-H of OBn), 7.29-7.17 (m, 5H, Ar-H of Phe), 6.23 (dd, J = 8.6, 5.8 Hz, 1H, H-1’), 5.12-5.08 
(m, 5H, H-3’ and 2 x OCH2Ph), 4.67-4.63 (m, 1H, αH-Phe), 4.38-4.33 (m, 1H, αH-Lys), 4.30-4.26 
(m, 2H, H-5’ and H-5’’), 4.17-4.16 (m, 1H, H-4’), 3.90 (s, 2H, CH2-Gly), 3.67 (s, 3H, OCH3), 3.16-
2.96 (m, 4H, εCH2-Lys and βCH2-Phe), 2.33-2.27 (m, 1H, H-2’), 2.12-2.02 (m, 1H, H-2’’), 1.77 (s, 
3H, CH3-Thy), 1.71-1.58 (m, 2H, βCH2-Lys), 1.51-1.47 (m, 2H, δCH2-Lys), 1.33-1.29 (m, 2H, γCH2-
Lys); 13C NMR (75 MHz, CD3OD) δ = 173.9 (CO-Phe), 173.3 (CO-Lys), 170.7 (CO-Gly), 166.1 (C-
4), 164.2 (CHO), 157.8 (OCONH), 152.2 (C-2), 138.1 (1C Ph-Phe), 137.1 (C-6), 137.0 (d, 3JC,P = 6.1 
Hz, 1C of OCH2Ph), 130.3 (Ar-C), 129.9 (Ar-C), 129.8 (Ar-C), 129.5 (Ar-C), 129.2 (Ar-C), 127.9 
(Ar-C), 112.1 (C-5), 86.2 (C-1’), 84.4 (d, 3JC,P = 7.7 Hz, C-4’), 75.7 (C-3’), 71.2-71.1 (2d, 2JC,P = 5.7 
Hz, 2 x OCH2Ph), 68.7 (d, 2JC,P = 5.8 Hz, C-5’), 55.2 (αC-Phe), 54.4 (αC-Lys), 52.7 (OCH3), 42.0 
(αC-Gly), 41.5 (εC-Lys), 38.3 (C-2’), 38.1 (βC-Phe), 32.8 (βC-Lys), 30.3 (δC-Lys), 23.8 (γC-Lys), 
12.5 (CH3); 31P NMR (121 MHz, CD3OD) δ = -1.2; HRMS for C44H53N6O14P [M-H]-calcd.: 919.3284, 
found: 919.3287. 
5’-O-(Dibenzylphosphate)-3’-O-[N-For-L-Met-L-Lys(ε-carbamate)-L-Phe- OMe]-2’-
deoxythymidine (2.26): Compound 2.26 was prepared according to the general procedure starting 
from 2.24 (246.2 mg, 0.367 mmol), tripeptide 2.5g (225.4 mg, 0.3882 mmol) and Et3N (0.22 mL, 1.55 
mmol) in dry CH2Cl2 (20 ml). The crude residue was purified by column chromatography on silica gel 
(gradient CH2Cl2/MeOH 99:1, v/v; 97:3, v/v; 92:5, v/v) to give conjugate 2.26 (330 mg, 85%) as a 
colorless foam. 1H NMR (300 MHz, DMSO-d6) δ = 11.36 (br s, 1H, NH-Thy), 8.33 (d, J = 7.5 Hz, 
1H, NH-Phe), 8.27 (d, J = 8.4 Hz, 1H, NH-Met), 8.01-8.00 (m, 2H, CHO and αNH-Lys), 7.50 (s, 1H, 
H-6), 7.36-7.34 (m, 11H, Ar-H of OBn and εNH-Lys), 7.26-7.19 (m, 5H, Ar-H of Phe), 6.19 (app t, J 
= 7.3 Hz, 1H, H-1’), 5.07-5.04 (m, 5H, H-3’ and 2 x OCH2Ph), 4.50-4.39 (m, 2H, αH-Met and αH-
Phe), 4.26-4.20 (unresolved m, 3H, αH-Lys, H-5’ and H-5’’), 4.10 (br s, 1H, H-4’) 3.56 (s, 3H, 
OCH3), 3.05-2.89 (m, 4H, εCH2-Lys and βCH2-Phe), 2.39 (t, J = 7.8 Hz, 2H, γCH2-Met), 2.23-2.18 
(m, 2H, H-2’ and H-2’’), 2.00 (s, 3H, SCH3), 1.91-1.72 (m, 2H, βCH2-Met), 1.69 (s, 3H, CH3-Thy), 
1.63-1.45 (m, 2H, βCH2-Lys), 1.40-1.36 (m, 2H, δCH2-Lys), 1.28-1.19 (m, 2H, γCH2-Lys); 13C NMR 
(75 MHz, DMSO-d6) δ = 171.7 (CO-Phe), 171.5 (CO-Lys), 170.4 (CO-Met), 163.5 (C-4), 160.9 
(CHO), 155.2 (OCONH), 150.4 (C-2), 137.0 (1C of Phe), 135.9 (d, 3JC,P = 6.8 Hz, 1C of OCH2Ph), 
135.4 (C-6), 129.0 (Ar-C), 128.5 (Ar-C), 128.4 (Ar-C), 128.2 (Ar-C), 127.8 (Ar-C), 126.5 (Ar-C),  
110.0 (C-5), 83.9 (C-1’), 82.2 (d, 3JC,P = 7.4 Hz, C-4’), 73.6 (C-3’), 68.7 (2d, 2JC,P = 5.5 Hz, 2 x 
OCH2Ph), 67.0 (d, 2JC,P = 5.7 Hz, C-5’), 53.4 (αC-Phe), 52.2 (αC-Lys), 51.8 (OCH3), 50.3 (αC-Met), 
40.2 (εC-Lys), 36.5 (βC-Phe), 36.0 (C-2’), 32.2 (βC-Met), 31.7 (βC-Lys), 29.3 (γC-Met), 29.0 (δC-
Lys), 22.5 (γC-Lys), 14.6 (-SCH3), 12.0 (CH3-Thy); 31P NMR (121 MHz, DMSO-d6) δ = -0.9; HRMS 
for C47H59N6O14PS [M-H]-calcd.: 993.3474, found: 993.3478. 
5’-O-(Dibenzylphosphate)-3’-O-[N-For-L-Met-L-Lys(ε-carbamate)-L-Ala-OMe]-2’-
deoxythymidine (2.27): Compound 2.27 was prepared according to the general procedure starting 
from 2.24 (226.6 mg, 0.339 mmol), tripeptide 2.5e (205.5 mg, 0.407 mmol) and Et3N (0.19 mL, 1.36 
mmol) in dry CH2Cl2 (15 ml). The crude residue was purified by column chromatography on silica gel 
(gradient CH2Cl2/MeOH 99:1, v/v; 97:3, v/v; 92:5, v/v) to give conjugate 2.27 (224.5 mg, 72%) as a 
colorless foam. 1H NMR (500 MHz, DMSO-d6) δ = 11.3 (br s, 1H, NH-Thy), 8.31 (d, J = 6.8 Hz, 1H, 
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NH-Ala), 8.27 (d, J = 8.1 Hz, 1H, NH-Met), 8.03-8.01 (m, 2H, CHO and αNH-Lys), 7.50 (s, 1H, H-
6), 7.8a-7.35 (m, 11H, Ar-H of OBn and εNH-Lys), 6.19 (app t, J = 7.3 Hz, 1H, H-1’), 5.08-5.05 (m, 
5H, H-3’ and 2 x OCH2Ph), 4.46-4.41 (m, 1H, αH-Met), 4.27-4.22 (unresolved m, 4H, αH-Lys, αH-
Ala, H-5’ and H-5’’), 4.11 (br s, 1H, H-4’), 3.61 (s, 3H, OCH3), 2.99-2.95 (m, 2H, εCH2-Lys), 2.42 (t, 
J = 7.9 Hz, 2H, γCH2-Met), 2.22-2.19 (m, 2H, H-2’ and H-2’’), 2.02 (s, 3H, SCH3), 1.91-1.72 (m, 2H, 
βCH2-Met), 1.69 (s, 3H, CH3-Thy), 1.67-1.48 (m, 2H, βCH2-Lys), 1.43-1.37 (m, 2H, δCH2-Lys), 
1.33-1.22 (m, 5H, γCH2-Lys and CH3-Ala ); 13C NMR (125 MHz, DMSO-d6) δ = 172.9 (CO-Ala), 
171.4 (CO-Lys), 170.5 (CO-Met), 163.6 (C-4), 161.0 (CHO), 155.2 (OCONH), 150.4 (C-2), 135.9 (d, 
3JC,P = 6.9 Hz, 1C of OCH2Ph), 135.4 (C-6), 128.5 (Ar-C), 128.4 (Ar-C), 127.8 (Ar-C), 110.0 (C-5), 
83.9 (C-1’), 82.2 (d, 3JC,P = 7.2 Hz, C-4’), 73.6 (C-3’), 68.7 (d, 2JC,P = 5.4 Hz, 2 x OCH2Ph), 67.1 (d, 
2JC,P = 5.9 Hz, C-5’), 52.1 (αC-Lys), 51.8 (OCH3), 50.4 (αC-Met), 47.5 (αC-Ala), 40.2 (εC-Lys), 36.0 
(C-2’), 32.2 (βC-Met), 31.6 (βC-Lys), 29.3 (γC-Met), 29.1 (δC-Lys), 22.5 (γC-Lys), 16.8 (CH3-Ala), 
14.6 (-SCH3), 12.0 (CH3-Thy); 31P NMR (202 MHz, DMSO-d6) δ = -0.9; HRMS for C41H55N6O14PS 
[M-H]-calcd.: 917.3161, found: 917.3145. 
5’-O-(Dibenzylphosphate)-3’-O-[N-For-L-Met-L-Lys(ε-carbamate)-L-Lys(Cbz)-OMe]-2’-
deoxythymidine (2.28): Compound 2.28 was prepared according to the general procedure starting 
from 2.24 (326.3 mg, 0.489 mmol), tripeptide 2.5f (408.1 mg, 0.587 mmol) and Et3N (0.33 mL, 2.35 
mmol) in dry CH2Cl2 (15 ml). The crude residue was purified by column chromatography on silica gel 
(gradient CH2Cl2/MeOH 99:1, v/v; 97:2, v/v; 92:4, v/v) to give conjugate 2.28 (347 mg, 64%) as a 
colorless foam. 1H NMR (300 MHz, DMSO-d6) δ = 11.53 (br s, 1H, NH-Thy), 8.31-8.25 (m, 2H, 2 x 
NH),  8.03-8.01 (m, 2H, CHO and NH), 7.50 (s, 1H, H-6), 7.36-7.19 (m, 15H, Ar-H of OBn), 7.23-
7.19 (m, 1H, NH), 6.18 (app t, J = 7.2 Hz, 1H, H-1’), 5.07-5.04 (m, 5H, H-3’ and 2 x POCH2Ph-
OBn), 4.99 (s, 2H, OCH2-Cbz), 4.47-4.39 (m, 1H, αH-Met), 4.30-4.15 (m, 4H, 2 x αH-Lys, H-5’ and 
H-5’’), 4.09 (br s, 1H, H-4’), 3.61 (s, 3H, OCH3), 2.99-2.92 (m, 4H, 2 x εCH2-Lys), 2.41 (t, J = 7.8 
Hz, 2H, γCH2-Met), 2.22-2.16 (m, 2H, H-2’ and H-2’’), 2.01 (s, 3H, SCH3), 1.90-1.76 (m, 2H, βCH2-
Met), 1.69 (s, 3H, CH3-Thy), 1.67-1.49 (m, 4H, 2 x βCH2-Lys), 1.42-1.35 (m, 4H, 2 x δCH2-Lys), 
1.33-1.17 (m, 4H, 2 x γCH2-Lys); 13C NMR (75 MHz, DMSO-d6) δ = 172.4 (CO-LysC-Ter), 171.6 (CO-
Met), 170.4 (CO-LysN-Ter), 163.5 (C-4), 161.0 (CHO), 155.2 (2 x OCONH), 150.4 (C-2), 137.2 (C-6), 
135.9 (d, 3JC,P = 6.7 Hz, 1C of OCH2Ph), 135.4 (1C of Ph-Cbz), 128.5 (Ar-C), 128.4 (Ar-C), 128.3 
(Ar-C), 127.8 (Ar-C), 127.7 (Ar-C), 127.6 (Ar-C), 110.0 (C-5), 83.9 (C-1’), 82.2 (d, 3JC,P = 8.2 Hz, C-
4’), 73.6 (C-3’), 68.8-68.7 (3 x OCH2Ph), 65.1 (d, 2JC,P = 3.7 Hz, C-5’), 52.3 (αC-Lys), 52.6 (αC-Lys 
and OCH3), 50.4 (αC-Met), 39.5 (2 x εC-Lys merged with DMSO-d6), 36.0 (C-2’), 32.1 (βC-Met), 
31.8 (2 x βC-Lys), 30.5 (γC-Met), 29.3 (δC-Lys), 28.9 (δC-Lys), 22.5 (2 x γC-Lys), 14.5 (SCH3), 12.0 
(CH3-Thy); 31P NMR (121 MHz, DMSO-d6) δ = -0.9; HRMS for C52H68N7O16PS [M-H]-calcd.: 
1108.4108, found: 1108.4100. 
5’-O-(Dibenzylphosphate)-3’-O-[N-Boc-L-Ala-L-Lys(ε-carbamate)-L-Ala-OMe]-2’-
deoxythymidine (2.29): Compound 2.29 was prepared according to the general procedure starting 
from 2.24 (505 mg, 0.756 mmol), tripeptide 2.13 (350 mg, 0.89 mmol) and Et3N (0.16 mL, 1.13 
mmol) in dry CH2Cl2 (20 ml). The crude residue was purified by column chromatography on silica gel 
(gradient CH2Cl2/MeOH 99:1, v/v; 97:2, v/v; 92:4, v/v) to give conjugate 2.29 (619 mg, 88%) as a 
colorless foam. 1H NMR (500 MHz, CDCl3) δ = 9.41 (br s, 1H, NH-Thy), 7.44 (s, 1H, H-6), 7.33 (br 
s, 10H, Ar-H of OBn), 7.06 (br s, 2H, NH-AlaC-Ter and NH-Lys), 6.29 (dd, J = 9.1, 5.3 Hz, 1H, H-1’), 
5.62 (br s, 1H, ε-NH-Lys), 5.39 (br s, 1H, NH-AlaN-Ter), 5.10-5.01 (m, 5H, H-3’ and 2 x OCH2Ph), 
4.55-4.48 (m, 2H, αH-AlaC-Ter and αH-Lys), 4.29-4.26 (m, 2H, H-5’), 4.21-4.19 (m, 2H, αH-AlaN-Ter 
and H-5’’), 4.16 (br s, 1H, H-4’), 3.74 (s, 3H, OCH3), 3.58-3.33 (m, 2H, εCH2-Lys), 2.31-2.25 (m, 
2H, H-2’), 1.93-1.86 (m, 2H, H-2’’ and βCH2’-Lys), 1.84 (s, 3H, CH3-Thy), 1.71-1.63 (m, 1H, βCH2’’-
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Lys), 1.57-1.48 (m, 1H, δCH2-Lys), 1.42 (s, 9H, tBu), 1.40-1.34 (m, 8H, γCH2-Lys, 2 x CH3-Ala); 13C 
NMR (125 MHz, CDCl3) δ = 173.4 (CO-AlaC-Ter), 173.2 (CO-AlaN-Ter), 171.3 (CO-Lys), 163.9 (C-4), 
155.7 (2 x OCONH), 150.8 (C-2), 135.5 (d, 3JC,P = 5.6 Hz, 1C of OCH2Ph), 135.2 (C-6), 129.0 (Ar-
C), 128.8 (Ar-C), 128.2 (Ar-C), 111.9 (C-5), 84.6 (C-1’), 83.1 (d, 3JC,P = 8.0 Hz, C-4’), 80.2 (1C tBu), 
75.0 (C-3’), 69.9-69.8 (2d, 2JC,P = 5.4 Hz, 2 x OCH2Ph), 67.4 (d, 2JC,P = 5.8 Hz, C-5’), 52.8 (αC- AlaC-
Ter), 52.6 (OCH3), 48.2 (αC-Lys and αC-AlaN-Ter), 40.6 (εC-Lys), 37.4 (C-2’), 29.1 (βC-Lys), 28.4 
(δC-Lys and CH3-tBu), 22.4 (γC-Lys), 18.0 (2 x CH3-Ala), 12.4 (CH3-Thy); 31P NMR (202 MHz, 
CDCl3) δ = -0.7; HRMS for C43H59N6O15P [M-H]-calcd.: 929.3703, found: 929.3715. 
5’-O-(Dibenzylphosphate)-3’-O-[N-For-L-Met-L-Lys(ε-carbamate)OMe]-2’-deoxythymidine 
(2.30): Compound 2.30 was prepared according to the general procedure starting from 2.24 (246.2 
mg, 0.367 mmol), dipeptide 2.8 (168.3 mg, 0.3882 mmol) and Et3N (0.22 mL, 1.55 mmol) in dry 
CH2Cl2 (15 ml). The crude residue was purified by column chromatography on silica gel (gradient 
CH2Cl2/MeOH 99:1, v/v; 97:3, v/v; 92:4, v/v) to give conjugate 2.30 (276.5 mg, 84%) as a colorless 
foam. 1H NMR (300 MHz, CDCl3) δ = 10.30 (br s, 1H, NH-Thy), 8.20 (s, 1H, CHO), 7.56 (d, J = 7.9 
Hz, 1H, NH-Met), 7.46 (s, 1H, H-6), 7.37-7.34 (m, 11H, Ar-H of OBn and αNH-Lys), 6.30 (dd, J = 
9.0, 5.3 Hz, 1H, H-1’), 5.95 (t, J = 5.5 Hz, εNH-Lys), 5.12-5.04 (m, 5H, H-3’ and 2 x OCH2Ph), 4.76-
4.69 (m, 1H, αH-Met), 4.61-4.54 (m, 1H, αH-Lys), 4.27-4.22 (unresolved m, 3H, H-4’, H-5’ and H-
5’’), 3.73 (s, 3H, OCH3), 3.18-3.11 (m, 2H, εCH2-Lys), 2.57 (t, J = 7.2 Hz, 2H, γCH2-Met), 2.30-2.24 
(m, 1H, H-2’), 2.17-1.98 (m, 5H, SCH3 and βCH2-Met), 1.92-1.65 (m, 6H, CH3-Thy, H-2’’ and βCH2-
Lys), 1.58-1.48 (m, 2H, δCH2-Lys), 1.42-1.32 (m, 2H, γCH2-Lys); 13C NMR (75 MHz, CDCl3) δ = 
172.5 (CO-Lys), 171.2 (CO-Met), 164.1 (C-4), 161.7 (CHO), 155.6 (OCONH), 151.1 (C-2), 135.4 (d, 
3JC,P = 6.2 Hz, 1C of OCH2Ph), 135.1 (C-6), 128.8 (Ar-C), 128.7 (Ar-C), 128.0 (Ar-C), 111.9 (C-5), 
84.4 (C-1’), 83.0 (d, 3JC,P = 8.0 Hz, C-4’), 74.7 (C-3’), 69.7 (2d, 2JC,P = 5.5 Hz, 2 x OCH2Ph), 67.3 (d, 
2JC,P = 5.4 Hz, C-5’), 52.4 (OCH3), 52.0 (αC-Lys), 51.0 (αC-Met), 40.4 (εC-Lys), 37.3 (C-2’), 31.5 
(βC-Met), 29.9 (βC-Lys and γC-Met), 28.8 (δC-Lys), 22.4 (γC-Lys), 15.2 (-SCH3), 12.3 (CH3-Thy); 
31P NMR (121 MHz, CDCl3) δ = -0.8; HRMS for C31H44N5O13PS [M-H]-calcd.: 756.2320, found: 
756.2347. 
5’-O-(Dibenzylphosphate)-3’-O-[N-For-L-Met-L-Lys(ε-carbamate)-L-Ala-L-Phe-OMe]-2’-
deoxythymidine (2.31): Compound 2.31 was prepared according to the general procedure starting 
from 2.24 (246.2 mg, 0.367 mmol), tetrapeptide 2.9 (253 mg, 0.3882 mmol) and Et3N (0.22 mL, 1.55 
mmol) in dry CH2Cl2 (20 ml). The crude residue was purified by column chromatography on silica gel 
(gradient CH2Cl2/MeOH 99:1, v/v; 97:3, v/v; 92:5, v/v) to give conjugate 2.31 (339 mg, 82%) as a 
colorless foam. 1H NMR (300 MHz, DMSO-d6) δ = 11.36 (br s, 1H, NH-Thy), 8.30-8.25 (m, 2H, NH-
Phe and NH-Met), 8.05 (d, J = 8.0 Hz, 1H, αNH-Lys), 8.02 (s, 1H, CHO), 7.91 (d, J = 7.5 Hz, 1H, 
αNH-Ala), 7.50 (s, 1H, H-6), 7.36-7.32 (m, 11H, Ar-H of OBn and εNH-Lys), 7.29-7.19 (m, 5H, Ar-
H of Phe), 6.19 (app t, J = 7.3 Hz, 1H, H-1’), 5.07-5.04 (m, 5H, H-3’ and 2 x OCH2Ph), 4.49-4.40 (m, 
2H, αH-Met and αH-Phe), 4.33-4.18 (unresolved m, 4H, αH-Ala, αH-Lys, H-5’ and H-5’’), 4.12-4.08 
(m, 1H, H-4’) 3.57 (s, 3H, OCH3), 3.05-2.90 (m, 4H, εCH2-Lys and βCH2-Phe), 2.43 (t, J = 7.8 Hz, 
2H, γCH2-Met), 2.23-2.17 (m, 2H, H-2’ and H-2’’), 2.02 (s, 3H, SCH3), 1.95-1.75 (m, 2H, βCH2-
Met), 1.70 (s, 3H, CH3-Thy), 1.64-1.45 (m, 2H, βCH2-Lys), 1.41-1.34 (m, 2H, δCH2-Lys), 1.29-1.22 
(m, 2H, γCH2-Lys), 1.17 (d, J = 6.9 Hz, 3H, CH3-Ala); 13C NMR (75 MHz, DMSO-d6) δ = 172.2 
(CO-Ala), 171.7 (CO-Phe), 171.0 (CO-Lys), 170.6 (CO-Met), 163.6 (C-4), 161.0 (CHO), 155.2 
(OCONH), 150.4 (C-2), 136.9 (1C of Phe), 135.9 (d, 3JC,P = 6.9 Hz, 1C of OCH2Ph), 135.4 (C-6), 
129.0 (Ar-C), 128.5 (Ar-C), 128.4 (Ar-C), 128.2 (Ar-C), 127.8 (Ar-C), 126.5 (Ar-C),  110.0 (C-5), 
83.9 (C-1’), 82.2 (d, 3JC,P = 7.4 Hz, C-4’), 73.6 (C-3’), 68.7 (2d, 2JC,P = 5.4 Hz, 2 x OCH2Ph), 67.0 (d, 
2JC,P = 4.9 Hz, C-5’), 53.5 (αC-Phe), 52.4 (αC-Lys), 51.8 (OCH3), 50.4 (αC-Met), 47.8 (αC-Ala), 40.2 
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(εC-Lys), 36.6 (βC-Phe), 36.0 (C-2’), 32.2 (βC-Met), 31.5 (βC-Lys), 29.3 (γC-Met), 29.0 (δC-Lys), 
22.6 (γC-Lys), 18.2 (CH3-Ala), 14.6 (-SCH3), 12.0 (CH3-Thy); 31P NMR (121 MHz, DMSO-d6) δ = -
0.9; HRMS for C50H64N7O15PS [M-H]-calcd.: 1064.3846, found: 1064.3867. 
5’-O-(Dibenzylphosphate)-3’-O-[N-For-L-Met-L-Lys(ε-carbamate)-L-Ala-L-Ala-L-Phe-OMe]-
2’-deoxythymidine (2.32): Compound 2.32 was prepared according to the general procedure starting 
from 2.24 (246.2 mg, 0.367 mmol), pentapeptide 2.10 (281 mg, 0.3882 mmol) and Et3N (0.22 mL, 
1.55 mmol) in dry CH2Cl2 (20 ml). The crude residue was purified by column chromatography on 
silica gel (gradient CH2Cl2/MeOH 99:1, v/v; 97:3, v/v; 92:6, v/v) to give conjugate 2.32 (380 mg, 
86%) as a colorless foam. 1H NMR (300 MHz, DMSO-d6) δ = 11.36 (br s, 1H, NH-Thy), 8.29 (d, J = 
8.6 Hz, 1H, NH-Met), 8.23 (d, J = 7.5 Hz, 1H, NH-Phe), 8.07 (d, J = 7.6 Hz, 1H, αNH-Lys), 8.02 (s, 
1H, CHO), 7.96 (d, J = 7.3 Hz, 1H, αNH-Ala), 7.86 (d, J = 7.6 Hz, 1H, αNH-Ala), 7.50 (s, 1H, H-6), 
7.36-7.32 (m, 11H, Ar-H of OBn and εNH-Lys), 7.29-7.19 (m, 5H, Ar-H of Phe), 6.19 (app t, J = 7.3 
Hz, 1H, H-1’), 5.07-5.04 (m, 5H, H-3’ and 2 x OCH2Ph), 4.49-4.40 (m, 2H, αH-Met and αH-Phe), 
4.29-4.19 (unresolved m, 5H, 2 x αH-Ala, αH-Lys H-5’ and H-5’’), 4.12-4.08 (m, 1H, H-4’), 3.57 (s, 
3H, OCH3), 3.05-2.89 (m, 4H, εCH2-Lys and βCH2-Phe), 2.43 (t, J = 7.9 Hz, 2H, γCH2-Met), 2.25-
2.17 (m, 2H, H-2’ and H-2’’), 2.03 (s, 3H, SCH3), 1.96-1.75 (m, 2H, βCH2-Met), 1.69 (s, 3H, CH3-
Thy), 1.67-1.46 (m, 2H, βCH2-Lys), 1.43-1.34 (m, 2H, δCH2-Lys), 1.31-1.22 (m, 2H, γCH2-Lys), 
1.20-1.13 (m, 6H, 2 x CH3-Ala); 13C NMR (75 MHz, DMSO-d6) δ = 172.1 (CO-AlaC-ter), 171.7 (CO-
Phe), 171.5 (CO-AlaN-ter), 171.1 (CO-Lys), 170.6 (CO-Met), 163.5 (C-4), 161.0 (CHO), 155.4 
(OCONH), 150.4 (C-2), 137.0 (1C of Phe), 135.9 (d, 3JC,P = 6.9 Hz, 1C of OCH2Ph), 135.4 (C-6), 
129.0 (Ar-C), 128.5 (Ar-C), 128.4 (Ar-C), 128.2 (Ar-C), 127.8 (Ar-C), 126.5 (Ar-C), 110.0 (C-5), 
83.9 (C-1’), 82.2 (d, 3JC,P = 7.3 Hz, C-4’), 73.6 (C-3’), 68.7 (2d, 2JC,P = 5.4 Hz, 2 x OCH2Ph), 67.0 (d, 
2JC,P = 5.3 Hz, C-5’), 53.5 (αC-Phe), 52.5 (αC-Lys), 51.8 (OCH3), 50.4 (αC-Met), 47.9 (αC-Ala), 47.7 
(αC-Ala), 40.2 (εC-Lys), 36.6 (βC-Phe), 36.0 (C-2’), 32.2 (βC-Met), 31.4 (βC-Lys), 29.3 (γC-Met), 
29.0 (δC-Lys), 22.7 (γC-Lys), 18.2 (CH3-Ala), 17.9 (CH3-Ala), 14.6 (-SCH3), 12.0 (CH3-Thy); 31P 
NMR (121 MHz, DMSO-d6) δ = -0.9; HRMS for C53H69N8O16PS [M-H]-calcd.: 1135.4217, found: 
1135.4203. 
General procedure for the synthesis of 3’-O-(peptide carbamate)-2’-deoxythymidine-5’-
monophosphate salts (2.19 and 2.33-2.40): To a stirring solution of 5’-O-(dibenzylphosphate)-3’-O-
(peptide carbamate)-2’deoxy-thymidine (1 eq.) in EtOH or MeOH was added 10% Pd/C Degussa 
(0.1-1.0 eq w/w) and the mixture was hydrogenated at atmospheric pressure using a balloon filled 
with H2 for 24 h. The catalyst was removed by filtration and the filtrate was concentrated under 
reduced pressure. The resulting crude residue was purified RP-HPLC (50 mmol TEAB in 98% H2O + 
2% ACN and 50 mmol TEAB in 50% H2O + 50% ACN). The collected eluate was lyophilized and 
freeze-dried repeatedly until constant mass to afford the desired 3’-O-(peptide carbamate)-2’-
deoxythymidine-5’-monophosphate triethylammonium salts. 
3’-O-[N-For-Gly-L-β-amino-Ala-(β-carbamate)-L-Phe-OMe]-2’-deoxythymidine-5’-
monophosphate triethylammonium salt (2.33): Compound 2.33 was obtained as a white solid (149 
mg, 81%), according to the general procedure starting from a stirring solution of 2.25 (180 mg, 
0.205mmol), Et3N (0.057 mL, 0.410 mmol) and 10% Pd/C Degussa (18 mg, 10% w/w) in MeOH (15 
mL). 1H NMR (500 MHz, D2O) δ = 8.16 (s, 1H, CHO), 7.79 (s, 1H, H-6), 7.31-7.19 (m, 5H, Ar-H of 
Phe), 6.32 (dd, J = 8.4, 6.6 Hz, 1H, H-1’), 5.22-5.21 (m, 1H, H-3’), 4.72-4.69 (m, 1H, αH-Phe), 4.48-
4.45 (m, 1H, αH-β-amino-Ala), 4.30-4.29 (m, 1H, H-4’), 4.05-4.03 (m, 2H, H-5’ and H-5’’), 3.91 (d, 
J = 3.4 Hz, 2H, CH2-Gly), 3.70 (s, 3H, OCH3), 3.44-3.24 (m, 2H, βCH2-β-amino-Ala), 3.22-2.95 (m, 
2H, βCH2-Phe), 2.39-2.36 (m, 2H, H-2’ and H-2’’), 1.88 (s, 3H, CH3-Thy); 13C NMR (125 MHz, 
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D2O) δ = 172.4 (CO-Phe), 170.3 (CO-β-amino-Ala), 170.1 (CO-Gly), 165.9 (C-4), 164.2 (CHO), 
156.9 (OCONH), 151.1 (C-2), 136.6 (C-6), 135.6 (1C of Ph), 128.6 (Ar-C), 128.0 (Ar-C), 126.5 (Ar-
C), 111.3 (C-5), 84.1 (C-1’), 83.0 (d, 3JC,P = 8.7 Hz, C-4’), 75.8 (C-3’), 64.3 (d, 2JC,P = 5.5 Hz, C-5’), 
53.4 (αC-Phe), 52.7 (αC-β-amino-Ala), 52.3 (OCH3), 40.6 (βC-β-amino-Ala), 40.3 (αC-Gly), 36.0 
(βC-Phe), 35.9 (C-2’), 11.0 (CH3-Thy); 31P NMR (202 MHz, D2O) δ = 0.3; HRMS for C27H35N6O14P 
[M-H]-calcd.: 697.1876, found: 697.1884. 
3’-O-[N-For-Gly-L-Lys-(ε-carbamate)-L-Phe-OMe]-2’-deoxythymidine-5’-monophosphate 
triethylammonium salt (2.19): Compound 2.19 was obtained as a white solid (255 mg, 83%), 
according to the general procedure starting from a stirring solution of 2.18 (300 mg, 0.326 mmol), 
Et3N (0.091 mL, 0.651 mmol) and 10% Pd/C Degussa (30 mg, 10% w/w) in MeOH (25 mL). 1H 
NMR (500 MHz, D2O) δ = 8.17 (s, 1H, CHO), 7.85 (s, 1H, H-6), 7.35-7.19 (m, 5H, Ar-H of Phe), 
6.32 (dd, J = 7.5, 6.1 Hz, 1H, H-1’), 5.26-5.23 (m, 1H, H-3’), 4.73-4.70 (m, 1H, αH-Phe), 4.31 (br s, 
1H, H-4’), 4.27-4.21 (m, 1H, αH-Lys), 4.04-4.00 (m, 2H, H-5’ and H-5’’), 3.96 (s, 2H, CH2-Gly), 
3.73 (s, 3H, OCH3), 3.12-3.10 (m, 2H, εCH2-Lys), 3.08-3.02 (m, 2H, βCH2-Phe), 2.45-2.40 (m, 2H, 
H-2’ and H-2’’), 1.93 (s, 3H, CH3-Thy), 1.69-1.58 (m, 2H, βCH2-Lys), 1.51-1.44 (m, 2H, δCH2-Lys), 
1.29-1.26 (m, 2H, γCH2-Lys merged with Et3N); 13C NMR (125 MHz, D2O) δ = 177.2 (CO-Phe), 
175.3 (CO-Lys), 172.7 (CO-Gly), 172.5 (C-4), 170.5 (CHO), 164.4 (OCONH), 157.3 (C-2), 137.2 (C-
6), 136.6 (1C of Ph), 129.1 (Ar-C), 128.2 (Ar-C), 126.5 (Ar-C), 111.8 (C-5), 84.6 (C-1’), 83.0 (d, 3JC,P 
= 7.5 Hz, C-4’), 75.8 (C-3’), 63.7 (d, 2JC,P = 4.0 Hz, C-5’), 55.7 (αC-Phe), 53.6 (αC-Lys), 53.5 
(OCH3), 43.3 (αC-Gly), 40.7 (εC-Lys), 37.5 (C-2’), 36.2 (βC-Phe), 30.3 (βC-Lys), 28.0 (δC-Lys), 
22.0 (γC-Lys), 12.1 (CH3-Thy); 31P NMR (202 MHz, D2O) δ = 3.8; HRMS for C30H41N6O14P [M-H]-
calcd.: 739.2345, found: 739.2336. 
3’-O-[N-For-L-Met-L-Lys(ε-carbamate)-L-Phe-OMe]-2’-deoxythymidine-5’-monophosphate 
triethylammonium salt (2.34): Compound 2.34 was obtained as a white solid (239 mg, 78%), 
according to the general procedure starting from a stirring solution of 2.26 (300 mg, 0.301 mmol), 
Et3N (0.084 mL, 0.603 mmol) and 10% Pd/C Degussa (240 mg, 80% w/w) in MeOH (25 mL). 1H 
NMR (600 MHz, D2O) δ = 11.29 (br s, 1H, NH-Thy), 8.43 (d, J = 7.1 Hz, 1H, NH-Lys), 8.35 (d, J = 
8.3 Hz, 1H, NH-Met), 8.01 (s, 1H, CHO), 7.90 (s, 1H, H-6), 7.34 (t, J = 5.5 Hz, εNH-Lys), 6.23 (dd, J 
= 9.0, 5.6 Hz, 1H, H-1’), 5.14-5.13 (m, 1H, H-3’), 4.49-4.45 (m, 1H, αH-Met), 4.21-4.17 (m, 1H, αH-
Lys), 4.05 (br s, 1H, H-4’), 3.86 (br s, 2H, H-5’ and H-5’’), 3.62 (s, 3H, OCH3), 2.99-2.96 (m, 2H, 
εCH2-Lys), 2.44 (t, J = 7.9 Hz, 2H, γCH2-Met), 2.30-2.13 (m, 2H, H-2’ and H-2’’), 2.04 (s, 3H, 
SCH3), 1.93-1.77 (m, 5H, βCH2-Met and CH3-Thy), 1.72-1.60 (m, 2H, βCH2-Lys), 1.41-1.37 (m, 2H, 
δCH2-Lys), 1.32-1.27 (m, 2H, γCH2-Lys); 13C NMR (150 MHz, D2O) δ = 172.8 (CO-Lys), 172.5 
(CO-Phe), 172.1 (CO-Met), 165.9 (C-4), 163.4 (CHO), 156.9 (OCONH), 151.1 (C-2), 136.5 (C-6), 
135.6 (1C of Phe), 128.5 (Ar-C), 128.0 (Ar-C), 126.5 (Ar-C), 111.3 (C-5), 84.2 (C-1’), 83.1 (d, 3JC,P = 
9.0 Hz, C-4’), 75.2 (C-3’), 64.4 (d, 2JC,P = 4.0 Hz, C-5’), 53.4 (αC-Phe), 52.9 (αC-Lys), 52.2 (OCH3), 
50.6 (αC-Met), 39.3 (εC-Lys), 36.1 (C-2’), 35.9 (βC-Phe), 30.0 (βC-Lys), 29.7 (βC-Met), 28.3 (γC-
Met), 27.5 (δC-Lys), 21.4 (γC-Lys), 13.4 (-SCH3), 11.0 (CH3-Thy); 31P NMR (202 MHz, D2O) δ = -
0.2; HRMS for C33H47N6O14PS [M-H]-calcd.: 813.2536, found: 813.2543.  
3’-O-[N-For-L-Met-L-Lys(ε-carbamate)-L-Ala-OMe]-2’-deoxythymidine-5’-monophosphate 
triethylammonium salt (2.35): Compound 2.35 was obtained as a white solid (148 mg, 76%), 
according to the general procedure starting from a stirring solution of 2.27 (190 mg, 0.206 mmol), 
Et3N (0.058 mL, 0.413 mmol) and 10% Pd/C Degussa (95 mg, 50% w/w) in MeOH (25 mL). 1H 
NMR (500 MHz, D2O) δ = 8.21 (s, 1H, CHO), 7.97 (s, 1H, H-6), 6.44 (dd, J = 8.6, 6.3 Hz, 1H, H-1’), 
5.35-5.34 (m, 1H, H-3’), 4.63-4.61 (m, 1H, αH-Met), 4.50-4.45 (q, J = 7.2 Hz, 1H, αH-Ala), 4.41-
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4.38 (m, 2H, H-4’ and αH-Lys), 4.11 (br s, 2H, H-5’ and H-5’’), 3.84 (s, 3H, OCH3), 3.24 (t, J = 6.4 
Hz, 2H, εCH2-Lys), 2.69-2.64 (m, 2H, γCH2-Met), 2.58-2.50 (m, 2H, H-2’ and H-2’’), 2.19 (s, 3H, 
SCH3), 2.18-2.07 (m, 2H, βCH2-Met), 2.02 (s, 3H, CH3-Thy), 1.94-1.80 (m, 2H, βCH2-Lys), 1.65-
1.59 (m, 2H, δCH2-Lys), 1.53-1.48 (m, 5H, γCH2-Lys and CH3-Ala),; 13C NMR (125 MHz, D2O) δ = 
174.3 (CO-Ala), 173.0 (CO-Lys), 172.5 (CO-Met), 166.1 (C-4), 163.5 (CHO), 157.0 (OCONH), 
151.3 (C-2), 136.9 (C-6), 111.4 (C-5), 84.2 (C-1’), 83.5 (d, 3JC,P = 9.2 Hz, C-4’), 75.5 (C-3’), 63.8 (d, 
2JC,P = 3.4 Hz, C-5’), 53.0 (αC-Lys), 52.2 (OCH3), 50.7 (αC-Met), 48.1 (αC-Ala), 39.4(εC-Lys), 36.0 
(C-2’), 29.9 (βC-Met and βC-Lys), 28.3 (γC-Met), 27.7 (δC-Lys), 21.4 (γC-Lys), 15.2 (CH3-Ala), 
13.5 (SCH3-Met), 11.1 (CH3-Thy); 31P NMR (202 MHz, D2O) δ = 2.0; HRMS for C27H43N6O14PS [M-
H]-calcd.: 737.2222, found: 737.2228. 
3’-O-[N-For-L-Met-L-Lys(ε-carbamate)-L-Lys(ε-NH2)-OMe]-2’-deoxythymidine-5’-
monophosphate triethylammonium hydrochloride salt (2.36): Compound 2.36 was prepared 
according to the general procedure starting from a stirring solution of 2.28 (300 mg, 0.270 mmol) and 
20% Pd(OH)2/C (150 mg, 50% w/w) in EtOH:H2O 10:1 (25 mL). After HPLC purification, the 
resulting triethylammonium salt was further acidified with HCl to stabilize the free amino group to 
afford 2.36 (173.5 mg, 58%) as a white solid. 1H NMR (600 MHz, D2O) δ = 8.11 (s, 1H, CHO), 7.78 
(s, 1H, H-6), 6.34 (dd, J = 8.6, 6.2 Hz, 1H, H-1’), 5.23-5.22 (m, 1H, H-3’), 4.49-4.47 (m, 1H, αH-
Met), 4.38-4.28 (m, 4H, 2 x αH-Lys and H-4’), 4.09 (br s, 1H, H-5’ and H-5’’), 3.73 (s, 3H, OCH3), 
3.13-3.10 (m, 2H, εCH2-Lys), 2.98-2.94 (m, 2H, εCH2-Lys), 2.57-2.50 (m, 2H, γCH2-Met), 2.43-2.36 
(m, 2H, H-2’ and H-2’’), 2.07 (s, 3H, SCH3), 2.05-1.98 (m, 2H, βCH2-Met), 1.89 (s, 3H, CH3-Thy), 
1.88-1.61 (m, 8H, 2 x βCH2-Lys and 2 x δCH2-Lys), 1.52-1.36 (m, 4H, 2 x γCH2-Lys); 13C NMR (150 
MHz, D2O) δ = 175.0 (CO-LysN-Ter), 173.7 (CO-LysC-Ter), 172.9 (CO-Met), 166.4 (C-4), 164.0 (CHO), 
157.3 (OCONH), 151.5 (C-2), 136.9 (C-6), 111.7 (C-5), 84.7 (C-1’), 83.5 (d, 3JC,P = 8.6 Hz, C-4’), 
75.5 (C-3’), 64.9 (d, 2JC,P = 4.0 Hz, C-5’), 53.5 (αC-LysN-Ter), 52.6 (OCH3), 52.2 (αC-LysC-Ter), 51.3 
(αC-Met), 39.7 (εC-Lys), 36.4 (C-2’), 30.4 (βC-LysN-Ter), 30.2 (βC-Met), 29.6 (βC-LysN-Ter), 28.7 (γC-
Met), 25.9 (2 x δC-Lys), 21.9 (2 x γC-Lys), 13.7 (SCH3), 11.4 (CH3-Thy); 31P NMR (202 MHz, D2O) 
δ = -0.2; HRMS for C52H68N7O16PS [M-H]-calcd.: 794.2801, found: 794.2811. 
3’-O-[N-For-L-Met-L-Lys(ε-carbamate)OMe]-2’-deoxythymidine-5’-monophosphate 
triethylammonium salt (2.38): Compound 2.38 was obtained as a white solid (217 mg, 79%), 
according to the general procedure starting from a stirring solution of 2.30 (240 mg, 0.316 mmol), 
Et3N (0.088 mL, 0.632 mmol) and 10% Pd/C Degussa (120 mg, 50% w/w) in MeOH (25 mL). 1H 
NMR (500 MHz, DMSO-d6) δ = 11.29 (br s, 1H, NH-Thy), 8.43 (d, J = 7.1 Hz, 1H, NH-Lys), 8.35 (d, 
J = 8.3 Hz, 1H, NH-Met), 8.01 (s, 1H, CHO), 7.90 (s, 1H, H-6), 7.34 (t, J = 5.5 Hz, εNH-Lys), 6.23 
(dd, J = 9.0, 5.6 Hz, 1H, H-1’), 5.14-5.13 (m, 1H, H-3’), 4.49-4.45 (m, 1H, αH-Met), 4.21-4.17 (m, 
1H, αH-Lys), 4.05 (br s, 1H, H-4’), 3.86 (br s, 2H, H-5’ and H-5’’), 3.62 (s, 3H, OCH3), 2.99-2.96 (m, 
2H, εCH2-Lys), 2.44 (t, J = 7.9 Hz, 2H, γCH2-Met), 2.30-2.13 (m, 2H, H-2’ and H-2’’), 2.04 (s, 3H, 
SCH3), 1.93-1.77 (m, 5H, βCH2-Met and CH3-Thy), 1.72-1.60 (m, 2H, βCH2-Lys), 1.41-1.37 (m, 2H, 
δCH2-Lys), 1.32-1.27 (m, 2H, γCH2-Lys); 13C NMR (125 MHz, DMSO-d6) δ = 172.5 (CO-Lys), 
171.1 (CO-Met), 163.8 (C-4), 161.0 (CHO), 155.4 (OCONH), 150.7 (C-2), 136.2 (C-6), 110.2 (C-5), 
83.8 (C-1’ and C-4’), 75.3 (C-3’), 64.3 (d, 2JC,P = 5.2 Hz, C-5’), 52.1 (αC-Lys), 51.9 (OCH3), 50.2 
(αC-Met), 39.6 (εC-Lys), 36.7 (C-2’), 32.3 (βC-Met), 30.3 (βC-Lys), 29.2 (γC-Met), 28.9 (δC-Lys), 
22.8 (γC-Lys), 14.7 (-SCH3), 12.1 (CH3-Thy); 31P NMR (202 MHz, DMSO-d6) δ = -0.3; HRMS for 
C24H38N5O13PS [M-H]-calcd.: 666.1851, found: 666.1854. 
3’-O-[N-For-L-Met-L-Lys(ε-carbamate)-L-Ala-L-Phe-OMe]-2’-deoxythymidine-5’-
monophosphate triethylammonium salt (2.39): Compound 2.39 was obtained as a white solid (232 
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mg, 81%), according to the general procedure starting from a stirring solution of 2.31 (280 mg, 0.263 
mmol), Et3N (0.073 mL, 0.525 mmol) and 10% Pd/C Degussa (224 mg, 80% w/w) in MeOH (30 mL). 
1H NMR (500 MHz, DMSO-d6) δ = 11.28 (br s, 1H, NH-Thy), 8.37 (d, J = 7.8 Hz, 1H, NH-Met), 
8.27 (d, J = 7.5 Hz, 1H, NH-Phe), 8.09 (d, J = 7.8 Hz, 1H, αNH-Lys), 8.02 (s, 1H, CHO), 7.95 (d, J = 
7.7 Hz, 1H, αNH-Ala), 7.89 (s, 2H, H-6), 7.31 (d, J = 5.4 Hz, 1H, εNH-Lys), 7.28-7.19 (m, 5H, Ar-H 
of Phe), 6.23 (dd, J = 8.7, 5.9 Hz, 1H, H-1’), 5.14-5.13 (m, 1H, H-3’), 4.47-4.40 (m, 2H, αH-Met and 
αH-Phe), 4.29-4.24 (m, 1H, αH-Ala), 4.21-4.17 (m, 1H, αH-Lys), 4.05 (br s, 1H, H-4’), 3.89-3.86 (m, 
2H, H-5’ and H-5’’), 3.57 (s, 3H, OCH3), 3.03-2.89 (m, 4H, εCH2-Lys and βCH2-Phe), 2.43 (t, J = 8.0 
Hz, 2H, γCH2-Met), 2.29-2.11 (m, 2H, H-2’ and H-2’’), 2.02 (s, 3H, SCH3), 1.93-1.73 (m, 5H, βCH2-
Met and CH3-Thy), 1.64-1.45 (m, 2H, βCH2-Lys), 1.40-1.34 (m, 2H, δCH2-Lys), 1.30-1.20 (m, 2H, 
γCH2-Lys), 1.20-1.16 (m, 3H, CH3-Ala); 13C NMR (125 MHz, DMSO-d6) δ = 172.3 (CO-Ala), 171.8 
(CO-Phe), 171.1 (CO-Lys), 170.7 (CO-Met), 163.8 (C-4), 161.1 (CHO), 155.4 (OCONH), 150.6 (C-
2), 137.1 (1C of Phe), 136.2 (C-6), 129.1 (Ar-C), 128.3 (Ar-C), 126.6 (Ar-C), 110.2 (C-5), 83.7 (C-1’ 
and C-4’), 75.2 (C-3’), 64.3 (d, 2JC,P = 5.0 Hz, C-5’), 53.6 (αC-Phe), 52.5 (αC-Lys), 51.9 (OCH3), 50.5 
(αC-Met), 47.9 (αC-Ala), 40.2 (εC-Lys), 36.7 (C-2’), 36.6 (βC-Phe), 32.1 (βC-Met), 31.5 (βC-Lys), 
29.4 (γC-Met), 29.1 (δC-Lys), 22.7 (γC-Lys), 18.2 (CH3-Ala), 14.6 (-SCH3), 12.1 (CH3-Thy); 31P 
NMR (202 MHz, DMSO-d6) δ = -0.3; HRMS for C36H52N7O15PS [M-H]-calcd.: 884.2907, found: 
884.2920. 
3’-O-[N-For-L-Met-L-Lys(ε-carbamate)-L-Ala-L-Ala-L-Phe-OMe]-2’-deoxythymidine-5’-
monophosphate triethylammonium salt (2.40): Compound 2.40 was obtained as a white solid (254 
mg, 78%), according to the general procedure starting from a stirring solution of 2.32 (320 mg, 0.281 
mmol), Et3N (0.078 mL, 0.563 mmol) and 10% Pd/C Degussa (256 mg, 80% w/w) in MeOH (30 mL). 
1H NMR (500 MHz, DMSO-d6) δ = 11.28 (br s, 1H, NH-Thy), 8.37 (d, J = 8.2 Hz, 1H, NH-Met), 
8.28 (d, J = 7.5 Hz, 1H, NH-Phe), 8.10 (d, J = 7.7 Hz, 1H, αNH-Lys), 8.02 (s, 1H, CHO), 7.99 (d, J = 
7.4 Hz, 1H, αNH-Ala), 7.89-7.86 (m, 2H, H-6 and αNH-Ala), 7.31 (d, J = 5.5 Hz, 1H, εNH-Lys), 
7.28-7.19 (m, 5H, Ar-H of Phe), 6.23 (dd, J = 8.8, 5.8 Hz, 1H, H-1’), 5.15-5.14 (m, 1H, H-3’), 4.47-
4.41 (m, 2H, αH-Met and αH-Phe), 4.30-4.25 (m, 1H, αH-AlaC-ter), 4.25-4.23 (m, 1H, αH-AlaN-ter), 
4.22-4.17 (m, 1H, αH-Lys), 4.05 (br s, 1H, H-4’), 3.89-3.86 (m, 2H, H-5’ and H-5’’), 3.57 (s, 3H, 
OCH3), 3.03-2.92 (m, 4H, εCH2-Lys and βCH2-Phe), 2.43 (t, J = 8.2 Hz, 2H, γCH2-Met), 2.30-2.12 
(m, 2H, H-2’ and H-2’’), 2.03 (s, 3H, SCH3), 1.94-1.74 (m, 5H, βCH2-Met and CH3-Thy), 1.68-1.47 
(m, 2H, βCH2-Lys), 1.40-1.35 (m, 2H, δCH2-Lys), 1.30-1.21 (m, 2H, γCH2-Lys), 1.20-1.16 (m, 6H, 2 
x CH3-Ala); 13C NMR (125 MHz, DMSO-d6) δ = 172.2 (CO-AlaC-ter), 171.7 (CO-Phe), 171.5 (CO-
AlaN-ter), 171.2 (CO-Lys), 170.7 (CO-Met), 163.8 (C-4), 161.0 (CHO), 155.3 (OCONH), 150.4 (C-2), 
137.0 (1C of Phe), 136.1 (C-6), 129.1 (Ar-C), 128.2 (Ar-C), 126.5 (Ar-C), 110.1 (C-5), 83.7 (C-1’ and 
C-4’), 75.2 (C-3’), 64.2 (d, 2JC,P = 4.6 Hz, C-5’), 53.6 (αC-Phe), 52.6 (αC-Lys), 51.8 (OCH3), 50.4 
(αC-Met), 48.0 (αC-AlaC-ter), 47.8 (αC-AlaN-ter), 40.2 (εC-Lys), 36.7 (C-2’), 36.6 (βC-Phe), 32.1 (βC-
Met), 31.4 (βC-Lys), 29.3 (γC-Met), 29.1 (δC-Lys), 22.7 (γC-Lys), 18.2 (CH3-Ala), 17.9 (CH3-Ala), 
14.6 (-SCH3), 12.0 (CH3-Thy); 31P NMR (202 MHz, DMSO-d6) δ = -0.3; HRMS for C39H57N8O16PS 
[M-H]-calcd.: 955.3278, found: 955.3293. 
3’-O-[H-L-Ala-L-Lys(ε-carbamate)-L-Ala-OMe]-2’-deoxythymidine-5’-monophosphate TFA 
salt (2.41): According to the general procedure, a stirring solution of 2.29 (400 mg, 0.476 mmol) and 
10% Pd/C Degussa (40 mg, 10% w/w) in MeOH (15 mL) was hydrogenated to give crude 3’-O-[N-
Boc-L-Ala-L-Lys-(ε-carbamate)-L-Ala-OMe]-2’-deoxythymidine-5’-monophosphate 2.37 (357 mg, 
quantitative) as a white solid, which was used in the next step without further purification. To a 
stirring solution of 2.37 (357 mg, 0.476 mmol) in H2O (3 mL) was added thioanisole (0.056 mL, 
0.476 mmol) followed by trifluoroacetic acid (1 mL) at 0 °C. The reaction mixture was stirred at r.t. 
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for 1.5 h and then the volatiles were removed in vacuo. The crude residue was coevaporated 3 times 
with toluene and purified by RP-Prep HPLC (0.05% TFA in 98% H2O + 2% ACN and 0.05% TFA in 
98% ACN + 2% H2O). The collected eluate was lyophilized and freeze-dried repeatedly until constant 
mass to afford 2.41 (258 mg, 71% over two steps) as a white solid. 1H NMR (500 MHz, D2O) δ = 
7.75 (s, 1H, H-6), 6.31 (dd, J = 8.7, 6.0 Hz, 1H, H-1’), 5.21-5.20 (m, 1H, H-3’), 4.35-4.30 (m, 1H, 
αH-AlaC-Ter), 4.29 (br s, 1H, H-4’), 4.25-4.22 (m, 1H, αH-Lys), 4.09-4.05 (m, 2H, H-5’ and H-5’’), 
4.05-4.02 (m, 1H, αH-AlaN-Ter), 3.70 (s, 3H, OCH3), 3.12-3.10 (m, 2H, εCH2-Lys), 2.40-2.34 (m, 2H, 
H-2’ and H-2’’), 1.87 (s, 3H, CH3-Thy), 1.76-1.70 (m, 1H, βCH2-Lys), 1.52-1.44 (m, 5H, δCH2-Lys 
and CH3-AlaN-Ter), 1.43-1.33 (m, 5H, γCH2-Lys and CH3-AlaC-Ter); 13C NMR (125 MHz, D2O) δ = 
174.2 (CO-AlaC-Ter), 173.1 (CO-Lys), 170.1 (CO-AlaN-Ter), 165.9 (C-4), 157.0 (OCONH), 151.2 (C-2), 
136.5 (C-6), 111.3 (C-5), 84.3 (C-1’), 83.1 (d, 3JC,P = 9.0 Hz, C-4’), 75.2 (C-3’), 64.5 (d, 2JC,P = 2.8 
Hz, C-5’), 53.1 (αC-Lys), 52.2 (OCH3), 48.2 (αC-AlaC-Ter), 48.1 (αC-AlaN-Ter), 39.3 (εC-Lys), 36.0 (C-
2’), 29.9 (βC-Lys), 27.8 (δC-Lys), 21.3 (γC-Lys), 15.9 (CH3-AlaN-Ter), 15.1 (CH3-AlaC-Ter), 11.0 (CH3-
Thy); 31P NMR (202 MHz, D2O) δ = -0.3; HRMS for C24H39N6O13P [M-H]-calcd.: 649.2240, found: 
649.2241. 
3’-O-[H-L-Ala-L-Lys(ε-carbamate)-L-Ala-OH]-2’-deoxythymidine-5’-monophosphate TFA 
salt (2.42): To a stirring solution of 2.41 (150 mg, 0.196 mmol) in THF:H2O:MeOH 1:1:1 (3 mL) was 
added LiOH (16.2 mg, 0.687 mmol) and the solution was stirred at r.t. for 3 h. The reaction mixture 
was neutralized with trifluoroacetic acid and the volatiles were removed under reduced pressure. The 
crude residue was purified by RP-Prep HPLC (0.05% TFA in 98% H2O + 2% ACN and 0.05% TFA 
in 98% ACN + 2% H2O) to afford 2.42 (109 mg, 74%) as a white solid. 1H NMR (600 MHz, D2O) δ = 
7.77 (s, 1H, H-6), 6.33 (dd, J = 8.9, 5.9 Hz, 1H, H-1’), 5.22-5.21 (m, 1H, H-3’), 4.32-4.29 (m, 2H, 
αH-AlaN-Ter and H-4’), 4.27-4.25 (m, 1H, αH-Lys), 4.09-4.08 (m, 2H, H-5’ and H-5’’), 4.07-4.05 (m, 
1H, αH-AlaC-Ter), 3.12-3.10 (m, 2H, εCH2-Lys), 2.42-2.36 (m, 2H, H-2’ and H-2’’), 1.88 (s, 3H, CH3-
Thy), 1.81-1.69 (m, 1H, βCH2-Lys), 1.53-1.46 (m, 5H, δCH2-Lys and CH3-AlaC-Ter), 1.44-1.36 (m, 
5H, γCH2-Lys and CH3-AlaN-Ter); 13C NMR (150 MHz, D2O) δ = 176.0 (CO-AlaC-Ter), 173.3 (CO-
Lys), 170.4 (CO-AlaN-Ter), 166.3 (C-4), 157.4 (OCONH), 151.5 (C-2), 136.9 (C-6), 111.7 (C-5), 84.7 
(C-1’), 83.5 (d, 3JC,P = 9.0 Hz, C-4’), 75.5 (C-3’), 64.9 (d, 2JC,P = 3.4 Hz, C-5’), 53.4 (αC-Lys), 48.5 
(αC-AlaC-Ter and αC-AlaN-Ter), 39.7 (εC-Lys), 36.4 (C-2’), 30.3 (βC-Lys), 28.1 (δC-Lys), 21.7 (γC-
Lys), 16.3 (CH3-AlaC-Ter), 15.7 (CH3-AlaN-Ter), 11.4 (CH3-Thy); 31P NMR (202 MHz, D2O) δ = -0.3; 
HRMS for C23H37N6O13P [M-H]-calcd.: 635.2083, found: 635.2093. 
5’-O-(4-Monomethoxytrityl)-xylo-2’-deoxythymidine (2.43): To a stirring solution of 2’-
deoxythymidine (2.50 g, 10.3 mmol) in pyridine (45 mL) were added Et3N (1.72 mL, 12.4 mmol), 
DMAP (0.13 g, 1.03 mmol) followed by 4-monomethoxytrityl chloride (3.66 g, 11.9 mmol) at r.t. and 
resulting mixture was stirred overnight at r.t. The reaction mixture was cooled and Et3N (1.72 mL, 
12.4 mmol) was added follwed by MsCl (0.88 mL, 11.4 mmol). After stirring for 2 h at r.t., the 
mixture was filtered, the solid was washed with ethyl acetate and the filtrate was concentrated in 
vacuo. The residue was dissolved in EtOH (45 mL) and then 1M NaOH (25 mL) was added. The 
mixture was refluxed for 1.5 h, then cooled to r.t. and neutralized with 1N HCl (10 mL). Ethanol was 
removed in vacuo and the residue was extracted with CH2Cl2 (3 x 70 mL). The collected organic 
fractions were washed with brine, dried over Na2SO4, concentrated under reduced pressure to leave a 
crude residue which was purified by column chromatography on silica gel (gradient Hexane/Ethyl 
acetate 2:1, v/v; 1:1, v/v; 1:2, v/v) to give 2.43 (2.54 g, 48%) as a pale yellow foam. 1H NMR (300 
MHz, CDCl3) δ = 9.85 (br s,1H, NH), 7.61 (s, 1H, H-6), 7.48-7.46 (m, 4H, Ar-H), 7.37-7.20 (m, 8H, 
Ar-H), 6.86-6.83 (m, 2H, Ar-H), 6.16 (dd, J = 7.8, 1.7 Hz, 1H, H-1’), 4.42-4.40 (m, 1H, H-3’), 4.06-
4.01 (m, 1H, H-4’), 3.78 (s, 3H, OCH3), 3.66-3.61 (m, 1H, H-5’), 3.61-3.46 (m, 1H, H-5’’), 2.56-
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2.479 (m, 1H, H-2’), 2.29-2.24 (m, 1H, H-2’’), 1.72 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ = 
164.4, 158.8, 151.0, 144.1, 144.0, 137.4, 135.1, 130.4, 128.4, 128.3, 128.1, 127.2, 113.4, 109.8, 87.2, 
85.6, 83.5, 62.2, 55.3, 41.4, 12.5; HRMS for C30H30N2O6 [M+Na]+calcd.: 537.1996, found: 537.1995. 
3’-O-phthalimido-2’-deoxythymidine (2.44): To a stirring suspension of 2.43 (1.85 g, 3.59 mmol), 
N-hydroxyphthalimide (0.79 g, 4.85 mmol) and PPh3 (1.25 g, 4.75 mmol) in toluene (35 mL), was 
added DIAD (0.98 g, 4.85 mmol) dropwise at 0°C. The reaction mixture was slowly warmed to r.t. 
and stirred for 2 h. After completion, the reaction mixture was concentrated in vacuo and the residue 
was dissolved in 80% AcOH (50 mL). After stirring for 3 h at r.t., the reaction mixture was 
concentrated in vacuo, coevaporating with toluene 3 times. The crude residue was purified by column 
chromatography on silica gel (gradient CH2Cl2/MeOH 99:1, v/v; 98:2, v/v; 97:3, v/v) to give 2.44 
(0.42 g, 28% over two steps) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ = 11.34 (br s,1H, 
NH), 7.89 (s, 4H, Ar-H), 7.72 (s, 1H, H-6), 6.39 (dd, J = 8.9, 5.6 Hz, 1H, H-1’), 5.20-5.14 (m, 1H, H-
3’), 4.97-4.95 (m, 1H, OH), 4.23-4.22 (m, 1H, H-4’), 3.62-3.59 (m, 2H, H-5’ and H-5’’), 2.46-2.26 
(m, 1H, H-2’ and H-2’’), 1.77 (s, 3H, CH3); 13C NMR (75 MHz, DMSO-d6) δ = 163.7 (C-4), 163.6 
(CO-Phthalimide), 150.5 (C-2), 135.9 (C-6), 134.9 (Ar-C), 128.6 (Ar-C), 123.4 (Ar-C), 109.7 (C-5), 
88.1 (C-1’), 83.7 (app. C-3’), 82.9 (app. C-4’), 61.4 (C-5’), 35.4 (C-2’), 12.3 (CH3); HRMS for 
C18H17N3O7 [M+Na]+calcd. 410.0959:, found: 410.0958. 
5’-O-(Dibenzylphosphate)-3’-O-phthalimido-2’-deoxythymidine (2.45): Following a similar 
procedure as used for the synthesis of 2.22, compound 2.45 was obtained starting from 2.44 (0.40 g, 
1.03 mmol), 0.45M tetrazole in ACN (11.47 mL, 5.16 mmol), dibenzyldiisopropyl phosphoramidite 
(0.78 mL, 2.27 mmol) in dry CH2Cl2 (5 mL) and 30% H2O2 (0.44 mL, 5.16 mmol). The crude residue 
was purified by column chromatography on silica gel (gradient CH2Cl2/MeOH 100:0, v/v; 99:1, v/v; 
98:2, v/v) to give 2.45 (0.62 g, 98%) as a colorless foam. 1H NMR (300 MHz, CDCl3) δ = 10.08 (br 
s,1H, NH), 7.82-7.73 (m, 4H, Ar-H), 7.37 (s, 1H, H-6), 7.31-7.30 (m, 10H, Ar-H), 6.49 (dd, J = 8.2, 
6.0 Hz, 1H, H-1’), 5.12-5.00 (m, 4H, OCH2Ph), 4.86-4.84 (m, 1H, H-3’), 4.53-4.52 (m, 1H, H-4’), 
4.26-4.25 (m, 2H, H-5’ and H-5’’), 2.69-2.63 (m, 1H, H-2’), 2.10-2.02 (m, 1H, H-2’’), 1.80 (s, 3H, 
CH3); 13C NMR (75 MHz, CDCl3) δ = 164.1 (C-4), 163.6 (CO-Phthalimide), 150.3 (C-2), 135.3 (C-6), 
135.2 (d, 3JC,P = 6.1 Hz, 1C of OCH2Ph), 134.7 (Ar-C), 128.6 (Ar-C), 128.5 (Ar-C), 128.4 (Ar-C), 
127.9 (Ar-C), 127.8 (Ar-C), 123.6 (Ar-C), 111.2 (C-5), 87.8 (C-1’), 84.9 (C-3’), 81.0 (d, 3JC,P = 8.3 
Hz, C-4’), 69.6 (app t, 2JC,P = 5.0 Hz, OCH2Ph), 67.0 (d, 2JC,P =5.4 Hz, C-5’), 36.4 (C-2’), 12.2 (CH3); 
31P NMR (121 MHz, CDCl3) δ = -0.8; HRMS for C31H30N3O12P [M+H]+calcd.: 648.1742, found: 
648.1728. 
5’-O-(Dibenzylphosphate)-3’-O-amino-2’-deoxythymidine (2.46): To a stirring solution of 2.45 
(0.57 g, 0.88 mmol) in EtOH (15 mL) was slowly added 4% methylamine in H2O (2.73 ml, 3.52 
mmol) at 0 °C. The mixture was stirred at r.t. for 0.5 h, filtered and washed with CH2Cl2. The filtrate 
was concentrated in vacuo and the crude residue was purified by column chromatography on silica gel 
(gradient CH2Cl2/MeOH 99:1, v/v; 98:2, v/v; 97:3, v/v) to give 2.46 (0.37 g, 81%) as a colorless 
foam. 1H NMR (300 MHz, CDCl3) δ = 9.91 (br s,1H, NH), 7.39 (s, 1H, H-6), 7.34 (s, 10H, Ar-H), 
6.28 (dd, J = 8.2, 5.8 Hz, 1H, H-1’), 5.46 (br s, 2H, ONH2), 5.12-4.99 (m, 4H, OCH2Ph), 4.22-4.19 
(m, 4H, H-3’, H-4’, H-5’ and H-5’’), 2.93-2.92 (m, 1H, H-2’), 2.40-2.34 (m, 1H, H-2’’), 1.81 (s, 3H, 
CH3); 13C NMR (75 MHz, CDCl3) δ = 164.1 (C-4), 150.6 (C-2), 135.4 (d, 3JC,P = 6.3 Hz, 1C of 
OCH2Ph), 135.2 (C-6), 128.8 (Ar-C), 128.6 (Ar-C), 128.0 (Ar-C), 111.3 (C-5), 84.8 (C-1’), 83.5 (C-
3’), 81.5 (d, 3JC,P = 8.1 Hz, C-4’), 69.7- 69.6 (2d, 2JC,P =5.2 Hz, 2 x OCH2Ph), 67.9 (d, 2JC,P =5.6 Hz, 
C-5’), 36.4 (C-2’), 12.2 (-CH3); 31P NMR (121 MHz, CDCl3) δ = -0.5; HRMS for C31H30N3O12P 
[M+Na]+calcd.: 540.1506, found: 540.1501. 
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5’-O-(Dibenzylphosphate)-3’-O-[N-For-L-Met-L-Glu(δ-carboxamide)-OMe]-2’-
deoxythymidine (2.47): To a stirring solution of 2.46 (120 mg , 0.232 mmol), dipeptide 2.2a (85.5 
mg, 0.267 mmol) and DMAP (1.10 mg, 0.009 mmol) in a mixture of dry DMF (1.0 ml) and dry 
CH2Cl2 (5 ml), was added DCC (77.0 mg, 0.371 mmol) at 0 ºC. The reaction mixture was slowly 
warmed to r.t. and stirred for 24 h. After removal of all the volatiles under reduced pressure, the 
residue was filtered and washed with CH2Cl2. The combined organic layers were concentrated under 
reduced pressure and the crude residue was purified by column chromatography on silica gel (gradient 
CH2Cl2/MeOH 99:2, v/v; 97:4, v/v; 94:7, v/v) to give 2.47 (120 mg, 63%) as a colorless foam. 1H 
NMR (300 MHz, CDCl3) δ = 10.65 (br s, 1H, NH), 10.34 (br s, 1H, NH), 8.20 (s, 1H, CHO), 7.80 (d, 
J = 7.9 Hz, 1H, NH-Met), 7.74 (d, J = 7.1 Hz, 1H, NH-Glu), 7.43 (s, 1H, H-6), 7.34-7.28 (m, 10H, 
Ar-H of OBn), 6.24 (dd, J = 8.2, 5.7 Hz, 1H, H-1’), 5.08-5.00 (m, 4H, 2 x OCH2Ph ), 4.74-4.70 (m, 
1H, αH-Glu), 4.63-4.62 (m, 1H, H-3’), 4.57-4.53 (m, 1H, αH-Met), 4.33 (br s, 1H, H-4’), 4.25-4.17 
(m, 2H, H-5’ and H-5’’), 3.70 (s, 3H, OCH3), 2.60-2.54 (m, 3H, H-2’ and γCH2-Met), 2.32-2.04 
(unresolved m, 7H, γCH2-Glu, βCH2-Met and SCH3), 2.00-1-91 (m, 2H, βCH2-Glu), 1.85-1.79 (m, 
4H, H-2’’ and CH3); 13C NMR (75 MHz, CDCl3) δ = 171.8 (CO2Me-Glu), 171.7 (CO-Met), 170.5 
(δCO-Glu), 164.1 (C-4), 162.4 (CHO), 151.0 (C-2), 135.2 (C-6), 135.1 (d, 3JC,P = 6.0 Hz, 1C of 
OCH2Ph), 128.8 (Ar-C), 128.6 (Ar-C), 128.0 (Ar-C), 111.7 (C-5), 84.9 (C-3’), 84.7 (C-1’), 81.0 (d, 
3JC,P = 6.7 Hz, C-4’), 69.8-69.6 (2d, 2JC,P = 5.3 Hz, 2 x -OCH2Ph), 67.6 (d, 2JC,P = 4.8 Hz, C-5’), 52.6 
(OCH3), 51.4 (αC-Met), 51.0 (αC-Glu), 36.0 (C-2’), 31.4 (βC-Met), 29.6 (γC-Met), 29.0 (γC-Glu), 
27.2 (βC-Glu), 15.1 (SCH3), 12.3 (CH3); 31P NMR (121 MHz, CDCl3) δ = -0.8; HRMS for 
C36H46N5O13PS [M-H]- calcd.: 818.2477, found: 818.2446. 
3’-O-[N-For-L-Met-L-Glu(δ-carboxamide)-OMe]-2’-deoxythymidine-5’-monophosphate 
triethylammonium salt (2.48): Compound 2.48 was obtained as a white solid (96 mg, 78%), 
according to the general procedure used for the synthesis of 2.19 and 2.33-2.40, starting from a 
stirring solution of 2.47 (120 mg, 0.146 mmol), Et3N (0.041 mL, 0.293 mmol) and 10% Pd/C Degussa 
(60 mg, 50% w/w) in MeOH (15 mL). 1H NMR (500 MHz, D2O) δ = 8.16 (s, 1H, CHO), 7.98 (s, 1H, 
H-6), 6.43 (dd, J = 9.1, 5.7 Hz, 1H, H-1’), 4.76-4.75 (m, 1H, H-3’), 4.60-4.57 (m, 1H, αH-Glu), 4.47-
4.45 (m, 1H, αH-Met), 4.38 (br s, 1H, H-4’), 3.97-3.96 (m, 2H, H-5’ and H-5’’), 3.77 (s, 3H, OCH3), 
2.64-2.59 (m, 2H, γCH2-Met), 2.53-2.49 (m, 1H, H-2’), 2.43-2.37 (m, 1H, H-2’’), 2.32-2.10 
(unresolved m, 7H, γCH2-Glu, βCH2-Met and SCH3), 2.06-2.01 (m, 2H, βCH2-Glu), 1.95 (s, 3H, 
CH3); 13C NMR (125 MHz, D2O) δ = 172.9 (αCO-Glu), 172.7 (CO-Met), 171.3 (δCO-Glu), 166.4 (C-
4), 163.7 (CHO), 151.4 (C-2), 137.3 (C-6), 111.4 (C-5), 85.7 (C-3’), 84.3 (C-1’), 82.1 (d, 3JC,P = 8.7 
Hz, C-4’), 63.7 (d, 2JC,P = 3.5 Hz, C-5’), 52.5 (OCH3), 51.5 (αC-Met), 50.8 (αC-Glu), 34.7 (C-2’), 30.0 
(βC-Met), 28.4 (γC-Met), 28.1 (γC-Glu), 25.3 (βC-Glu), 13.5 (SCH3), 11.2 (CH3); 31P NMR (202 
MHz, DMSO-d6) δ = 3.4; HRMS for C22H34N5O13PS [M-H]- calcd.: 638.1538, found: 638.1542. 
5’-O-(tert-Butyldiphenylsilyl)-2’deoxythymidine (2.49):[53] To a stirring solution of 2’-
deoxythymidine (2.54 g, 10.49 mmol) in dry DMF (20 mL) was added a solution of imidazole (1.57 
g, 23.08 mmol) and TBDPS-Cl (2.86 ml, 11.01 mmol) in dry DMF (15 mL) at r.t. After stirring for 4 
h at r.t., the reaction mixture was diluted with water (350 ml) and the aqueous layer was extracted 
with ethyl acetate (3 x 150 mL). The collected organic fractions were washed with brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude residue was purified by column 
chromatography on silica gel (gradient CH2Cl2/MeOH 99:1, v/v; 98:2, v/v; 95:5, v/v) to give 2.49 
(4.17 g, 83%) as a white solid. HRMS for C26H32N2O5Si [M+H]+calcd.: 481.2153, found: 481.2156. 
5’-O-(tert-Butyldiphenylsilyl)-3’-O-(methylthiomethyl)-2’-deoxythymidine (2.50):[41] To a 
stirring solution of 2.49 (4.08 g, 8.50 mmol) in DMSO (27.5 mL), acetic anhydride (19.4 ml) and 
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acetic acid (6.2 ml) were added. The reaction mixture was stirred at r.t. for 48 h and then concentrated 
under reduced pressure. The residue was neutralized with saturated aq. NaHCO3 (300ml) and 
extracted with ethyl acetate (3 x 180 mL). The collected organic fractions were washed with brine, 
dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was purified 
by column chromatography on silica gel (gradient Hexane/Ethyl acetate 4:1, v/v; 3:1, v/v; 2:1, v/v) to 
give 2.50 (3.3 g, 72%) as a white solid. 1H NMR (300 MHz, CDCl3) δ = 9.54 (br s,1H, NH), 7.70-
7.67 (m, 4H, Ar-H), 7.47-7.38 (m, 7H, H-6 and Ar-H), 6.35 (dd, J = 8.5, 5.7 Hz, 1H, H-1’), 4.66-4.56 
(m, 3H, H-3’ and OCH2S), 4.09-4.08 (m, 1H, H-4’), 4.00-3.82 (m, 2H, H-5’ and H-5’’), 2.49-2.43 (m, 
1H, H-2’), 2.16-2.04 (m, 4H, SCH3 and H-2’’), 1.66 (s, 3H, CH3), 1.10 (s, 9H, CH3-tBu); 13C NMR 
(75 MHz, CDCl3) δ = 164.1 (C-4), 150.6 (C-2), 135.6 (Ar-C), 135.4 (Ar-C), 135.2 (C-6), 130.2 (Ar-
C), 130.1 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 111.3 (C-5), 85.0 (C-1’), 84.8 (C-4’), 76.2 (C-3’), 73.7 
(OCH2S), 64.1 (C-5’), 37.9 (C-2’), 27.1 ((CH3)3), 19.4 (CMe3), 13.9 (SCH3), 12.2 (CH3); HRMS for 
C28H36N2O5SSi [M+Na]+calcd. 563.2006:, found: 563.2009. 
5’-O-(tert-Butyldiphenylsilyl)-3’-O-(phthalimidooxymethyl)-2’deoxy-thymidine (2.51): To a 
stirring solution of 2.50 (1.50 g, 2.77 mmol) in dry CH2Cl2 (20 mL) was added 1M solution of 
sulfuryl chloride in CH2Cl2 (3.32 mL, 3.32 mmol) at 0 °C. The reaction mixture was slowly warmed 
to r.t. over 2 h and then concentrated under reduced pressure to give a 3’-O-chloromethyluridine 
derivative as a sticky mass, which was used without further purification. In a separate round-bottom 
flask, N-hydroxyphthalimide (1.81 g, 11.08 mmol) was suspended in dry CH2Cl2 (30 mL) and to this 
DBU (1.45 mL, 9.69 mmol) was then added. After 10 min, the red coloured solution was added to the 
crude 3’-O-chloromethyluridine derivative and the reaction mixture was kept stirring at r.t. for 24 h. It 
was then diluted with CH2Cl2 (100 mL) and 1M aq. acetic acid (30 mL) was added under vigorous 
stirring. The aqueous layer was discarded and the organic layer was washed with saturated aq. 
NaHCO3 (2 x 50 ml) and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. 
The crude residue was purified by column chromatography on silica gel (gradient CH2Cl2/MeOH 
99:1, v/v; 98:2, v/v; 97:3, v/v) to give 2.51 (1.73 g, 95%) as a white solid. 1H NMR (300 MHz, 
CDCl3) δ = 9.35 (br s,1H, NH), 7.84-7.69 (m, 8H, Ar-H), 7.53 (s, 1H, H-6), 7.45-7.37 (m, 6H, Ar-H), 
6.34 (dd, J = 9.2, 5.1 Hz, 1H, H-1’), 5.16 (s, 2H, OCH2O), 5.11-5.09 (m, 3H, H-3’), 4.18 (br s, 1H, H-
4’), 4.14-4.00 (m, 2H, H-5’ and H-5’’), 2.56-2.50 (m, 1H, H-2’), 2.26-2.17 (m, 2H, H-2’’), 1.59 (s, 
3H, CH3), 1.14 (s, 9H, CH3-tBu); 13C NMR (75 MHz, CDCl3) δ = 164.0 (C-4), 163.5 (CO-
Phthalimide), 150.6 (C-2), 135.7 (Ar-C), 135.4 (Ar-C), 135.3 (C-6), 134.6 (Ar-C), 133.2 (Ar-C), 
132.4 (Ar-C), 130.2 (Ar-C), 130.1 (Ar-C), 129.0 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 123.7 (Ar-C), 
111.3 (C-5), 97.5 (OCH2O), 85.3 (C-1’), 84.7 (C-4’), 78.6 (C-3’), 64.6 (C-5’), 37.9 (C-2’), 27.1 
((CH3)3), 19.5 (CMe3), 12.1 (CH3); HRMS for C35H37N3O8Si [M+Na]+calcd.: 678.2242, found: 
678.2258. 
3’-O-(Phthalimidooxymethyl)-2’-deoxythymidine (2.52): To a stirring solution of 2.51 (1.73 g, 
2.64 mmol) in THF (25 mL (19.4 ml) was added triethylamine trihydrofluoride (1.72 ml, 10.55 mmol) 
at r.t. The reaction mixture was stirred at r.t. for 36 h and then concentrated under reduced pressure. 
The crude residue was purified by column chromatography on silica gel (gradient CH2Cl2/MeOH 
99:1, v/v; 98:2, v/v; 95:5, v/v) to give 2.52 (0.93 g, 84%) as a white solid. 1H NMR (300 MHz, 
DMSO-d6) δ = 11.30 (s, 1H, NH), 7.88 (s, 4H, Ar-H), 7.78 (d, J = 1.0 Hz, 1H, H-6), 6.12 (dd, J = 8.9, 
5.6 Hz, 1H, H-1’), 5.26-5.19 (m, 3H, OCH2O and 5’-OH ), 4.80-4.78 (m, 1H, H-3’), 4.03-4.02 (m, 
1H, H-4’), 3.78-3.63 (m, 2H, H-5’ and H-5’’), 2.38-2.32 (m, 1H, H-2’), 2.25-2.16 (m, 2H, H-2’’), 
1.79 (d, J = 0.9 Hz, 3H, CH3); 13C NMR (75 MHz, DMSO-d6) δ = 163.7 (C-4), 163.2 (CO-
Phthalimide), 150.4 (C-2), 135.9 (C-6), 134.9 (Ar-C), 128.5 (Ar-C), 123.4 (Ar-C), 109.5 (C-5), 97.8 
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(OCH2O), 84.9 (C-1’), 83.9 (C-4’), 78.7 (C-3’), 61.5 (C-5’), 36.6 (C-2’), 12.3 (CH3); HRMS for 
C19H19N3O8 [M+Na]+calcd.: 440.1064, found: 440.1071. 
5’-O-(Dibenzylphosphate)-3’-O-(phthalimidooxymethyl)-2’-deoxythymidine (2.53): Following 
a similar procedure as used for the synthesis of 2.22, compound 2.53 was obtained starting from 2.52 
(0.93 g, 2.23 mmol), 0.45M tetrazole in ACN (24.75 mL, 11.14 mmol), dibenzyldiisopropyl 
phosphoramidite (1.52 mL, 4.46 mmol) in dry CH2Cl2 (10 mL), and 30% H2O2 (0.96 mL, 11.14 
mmol). The crude residue was purified by column chromatography on silica gel (gradient 
CH2Cl2/MeOH 100:0, v/v; 99:1, v/v; 98:2, v/v) to give 2.53 (1.39 g, 92%) as a colorless foam. 1H 
NMR (300 MHz, CDCl3) δ = 9.5 (app d, 1H, NH), 7.84-7.74 (m, 4H, phthamido Ar-H), 7.37 (d, J = 
1.0 Hz, 1H, H-6), 7.38-7.33 (m, 10H, benzyl Ar-H), 6.49 (dd, J = 9.1, 5.3 Hz, 1H, H-1’), 5.11-5.04 
(m, 6H, OCH2Ph and OCH2O), 4.85-4.83 (m, 1H, H-3’), 4.53-4.52 (m, 1H, H-4’), 4.55-4.49 (m, 1H, 
H-5’), 4.30-4.24 (m, 1H, H-5’’), 4.20-4.19 (m, 1H, H-4’), 2.37-2.30 (m, 1H, H-2’), 1.90-1.80 (m, 4H, 
H-2’’ and CH3); 13C NMR (75 MHz, CDCl3) δ = 163.9 (C-4), 163.5 (CO-Phthalimide), 150.6 (C-2), 
135.6 (d, 3JC,P = 6.1 Hz, 1C of OCH2Ph), 135.2 (C-6), 134.7 (Ar-C), 128.9 (Ar-C), 128.8 (Ar-C), 
128.7 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 127.8 (Ar-C), 123.7 (Ar-C), 111.6 (C-5), 97.5 (OCH2O), 
84.7 (C-1’), 83.1 (d, 3JC,P = 8.3 Hz, C-4’), 78.3 (C-3’), 69.8-69.7 (2d, 2JC,P = 5.4 Hz, 2 x OCH2Ph), 
67.5 (d, 2JC,P =5.7 Hz, C-5’), 37.2 (C-2’), 12.4 (-CH3); 31P NMR (121 MHz, CDCl3) δ = -0.5; HRMS 
for C31H30N3O12P [M+Na]+calcd.: 570.1612, found: 570.1615. 
5’-O-(dibenzylphosphate)-3’-O-(aminooxymethyl)-2’-deoxythymidine (2.54): Following a 
similar procedure as used for the synthesis of 2.46, compound 2.54 was obtained starting from 2.53 
(1.3 g, 1.92 mmol), 4% methyl amine in H2O (5.96 ml, 3.52 mmol) and EtOH (30 mL). The crude 
residue was purified by column chromatography on silica gel (gradient CH2Cl2/MeOH 99:1, v/v; 98:2, 
v/v; 96:4, v/v) to give 2.54 (0.86 g, 82%) as a colorless foam. 1H NMR (300 MHz, CDCl3) δ = 9.75 
(br s, 1H, NH), 7.34-7.33 (m, 11H, H-6 and Ar-H), 6.25 (app t, J = 6.6 Hz, 1H, H-1’), 5.64 (br s, 2H, 
NH2), 5.12-4.99 (m, 4H, 2 x OCH2Ph), 4.78-4.72 (m, 2H, OCH2O), 4.31-4.26 (m, 1H, H-3’), 4.22-
4.12 (m, 3H, H-4’, H-5’ and H-5’’), 2.41-2.33 (m, 1H, H-2’), 2.03-1.98 (m, 1H, H-2’’), 1.81 (s, 3H, 
CH3); 13C NMR (75 MHz, CDCl3) δ = 164.0 (C-4), 150.5 (C-2), 135.4 (d, 3JC,P = 6.3 Hz, 1C of 
OCH2Ph), 135.3 (C-6), 128.9 (Ar-C), 128.7 (Ar-C), 128.1 (Ar-C), 111.2 (C-5), 98.3 (OCH2O), 84.8 
(C-1’), 82.9 (d, 3JC,P = 7.9 Hz, C-4’), 76.4 (C-3’), 69.8-69.7 (2d, 2JC,P = 5.5 Hz, 2 x OCH2Ph), 66.5 (d, 
2JC,P = 5.5 Hz, C-5’), 38.2 (C-2’), 12.4 (-CH3); 31P NMR (121 MHz, CDCl3) δ = -0.4; HRMS for 
C25H30N3O9P [M+H]+calcd.: 548.1792, found: 548.1812. 
5’-O-(Dibenzylphosphate)-3’-O-[N-For-L-Met-L-Glu-(methyloxy-δ-carboxamide)-OMe]-2’-
deoxythymidine (2.55): Following a similar procedure as used for the synthesis of 2.47, compound 
2.55 was obtained starting from 2.54 (200 mg , 0.365 mmol), dipeptide 2.2a (134.6 mg, 0.420 mmol), 
DCC (120.6 mg, 0.584 mmol) and DMAP (1.8 mg, 0.0146 mmol) in a mixture of dry DMF (2.0 ml) 
and dry CH2Cl2 (10 ml). The crude residue was purified by column chromatography on silica gel 
(gradient CH2Cl2/MeOH 99:1, v/v; 97:3, v/v; 94:6, v/v) to give 2.55 (211.0 mg, 68%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ = 10.52 (br s, 1H, NH), 10.20 (br s,1H, NH), 8.18 (s, 1H, CHO), 7.90 
(d, J = 7.0 Hz, 1H, NH-Met), 7.74 (d, J = 6.7 Hz, 1H, NH-Glu), 7.34-7.33 (m, 11H, H-6 and Ar-H of 
OBn), 6.24 (app t, J = 6.5 Hz, 1H, H-1’), 5.13-5.00 (m, 4H, 2 x OCH2Ph), 4.92-4.86 (m, 2H, 
OCH2O), 4.79-4.72 (m, 1H, H-3’), 4.54-4.52 (m, 1H, αH-Glu), 4.42 (br s, 1H, αH-Met), 4.34-4.30 (m, 
1H, H-5’), 4.22-4.16 (m, 2H, H-4’ and H-5’’), 3.71 (s, 3H, OCH3), 2.56 (t, J = 7.2 Hz, 2H, γCH2-
Met), 2.44-2.42 (m, 1H, H-2’), 2.35-2.15 (m, 3H, H-2’’ and γCH2-Glu), 2.14-1.85 (unresolved m, 7H, 
βCH2-Met, SCH3, βCH2-Glu), 1.79 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ = 171.9 (αCO-Glu), 
171.8 (CO-Met), 170.0 (δCO-Glu), 164.1 (C-4), 162.1 (CHO), 150.8 (C-2), 135.3 (C-6), 135.2 (1C of 
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OCH2Ph), 128.9 (Ar-C), 128.7 (Ar-C), 128.0 (Ar-C), 111.4 (C-5), 98.0 (OCH2O), 84.8 (C-1’), 82.9 
(d, 3JC,P = 6.8 Hz, C-4’), 77.1 (C-3’; merged with CDCl3), 68.9-69.8 (2d, 2JC,P = 5.6 Hz, 2 x OCH2Ph), 
66.7 (d, 2JC,P = 5.1 Hz, C-5’), 52.5 (OCH3), 51.8 (αC-Met), 51.1 (αC-Glu), 37.7 (C-2’), 31.7 (βC-Met), 
29.8 (γC-Met), 29.1 (γC-Glu), 27.3 (βC-Glu), 15.1 (SCH3), 12.3 (CH3); 31P NMR (121 MHz, CDCl3) 
δ = -0.6; HRMS for C37H48N5O14PS [M-H]- calcd.: 848.2583, found: 848.2560. 
5’-O-(Dibenzylphosphate)-3’-O-[N-For-L-Met-L-Glu-(methyloxy-δ-carboxamide)-NH2]-2’-
deoxythymidine (2.56): Following a similar procedure as used for the synthesis of 2.47, compound 
2.56 was obtained starting from 2.54 (200 mg , 0.365 mmol), dipeptide 2.2b (128.3 mg, 0.420 mmol), 
DCC (120.6 mg, 0.584 mmol) and DMAP (1.8 mg, 0.0146 mmol) in a mixture of dry DMF (2.0 ml) 
and dry CH2Cl2 (10 ml). The crude residue was purified by column chromatography on silica gel 
(gradient CH2Cl2/MeOH 99:1, v/v; 97:3, v/v; 92:8, v/v) to give 2.56 (186.0 mg, 61%) as a white solid. 
1H NMR (300 MHz, CD3OD) δ = 8.09 (s, 1H, CHO), 7.42 (s, 1H, H-6), 7.31(br s, 10H, Ar-H of 
OBn), 6.17 (app t, J = 6.9 Hz, 1H, H-1’), 5.06-5.03 (m, 4H, 2 x OCH2Ph ), 4.86 (s, 2H, OCH2O), 
4.52-4.48 (m, 2H, H-3’ and αH-Glu), 4.39-4.35 (m, 1H, αH-Met), 4.27-4.24 (m, 1H, H-4’ and H-5’), 
4.19-4.15 (m, 2H, H-5’’), 2.58-2.50 (m, 2H, γCH2-Met), 2.47-2.34 (m, 1H, H-2’), 2.23-2.07 (m, 3H, 
H-2’’ and γCH2-Glu), 2.04-1.84 (unresolved m, 7H, βCH2-Met, SCH3, βCH2-Glu), 1.71 (s, 3H, CH3); 
13C NMR (75 MHz, CD3OD) δ = 175.8 (αCO-Glu), 173.4 (CO-Met), 172.0 (δCO-Glu), 166.1 (C-4), 
164.0 (CHO), 152.2 (C-2), 137.3 (C-6), 137.0 (d, 3JC,P = 6.2 Hz, 1C of OCH2Ph), 129.9 (Ar-C), 129.7 
(Ar-C), 129.2 (Ar-C), 112.0 (C-5), 99.1 (OCH2O), 86.3 (C-1’), 84.3 (d, 3JC,P = 7.8 Hz, C-4’), 79.2 (C-
3’), 71.1-71.0 (2d, 2JC,P = 5.6 Hz, 2 x OCH2Ph), 68.7 (d, 2JC,P = 5.6 Hz, C-5’), 53.6 (αC-Met), 52.8 
(αC-Glu), 38.4 (C-2’), 32.6 (βC-Met), 30.9 (γC-Met), 29.9 (γC-Glu), 28.7 (βC-Glu), 15.3 (SCH3), 
12.5 (CH3); 31P NMR (121 MHz, CD3OD) δ = -1.1; HRMS for C36H47N6O13PS [M-H]- calcd.: 
833.2586, found: 833.2567. 
3’-O-[N-For-L-Met-L-Glu-(methyloxy-δ-carboxamide)-OMe]-2’-deoxythymidine-5’-
monophosphate triethylammonium salt (2.57): Compound 2.57 was obtained as a white solid (154 
mg, 75%), according to the general procedure used for the synthesis of 2.19 and 2.33-2.40, starting 
from a stirring solution of 2.55 (200 mg, 0.235 mmol), Et3N (0.065 mL, 0.471 mmol) and 10% Pd/C 
Degussa (100 mg, 50% w/w) in MeOH (20 mL). 1H NMR (500 MHz, DMSO-d6) δ = 12.51 (br s, 1H, 
NH), 11.24 (br s,1H, NH), 9.03 (d, J = 8.0 Hz, 1H, NH-Met), 8.94 (d, J = 6.4 Hz, 1H, NH-Glu), 8.04 
(s, 1H, CHO), 7.80 (s, 1H, H-6), 6.11 (app t, J = 5.8 Hz, 1H, H-1’), 4.88-4.77 (m, 2H, OCH2O), 4.67-
4.64 (m, 1H, H-3’), 4.49-4.45 (m, 1H, αH-Glu), 4.17-4.13 (m, 1H, αH-Met), 4.06-4.02 (m, 1H, H-5’), 
3.99 (br s, 1H, H-4’), 3.92-3.90 (m, 2H, H-5’’), 3.60 (s, 3H, OCH3), 2.46 (t, J = 7.9 Hz, 2H, γCH2-
Met), 2.34-2.29 (m, 1H, H-2’), 2.26-2.06 (m, 3H, H-2’’ and γCH2-Glu), 2.04 (s, 3H, SCH3), 2.03-1.86 
(m, 4H, βCH2-Glu and βCH2-Met), 1.81 (s, 3H, CH3); 13C NMR (125 MHz, DMSO-d6) δ = 172.1 
(αCO-Glu), 171.6 (CO-Met), 168.7 (δCO-Glu), 164.0 (C-4), 161.2 (CHO), 150.5 (C-2), 136.2 (C-6), 
109.8 (C-5), 96.2 (OCH2O), 83.6 (C-1’), 83.2 (d, 3JC,P = 5.8 Hz, C-4’), 74.1 (C-3’), 62.5 (d, 2JC,P = 4.8 
Hz, C-5’), 52.1 (αC-Met), 52.0 (OCH3), 50.7 (αC-Glu), 36.9 (C-2’), 32.4 (βC-Met), 29.5 (γC-Met), 
29.4 (γC-Glu), 27.0 (βC-Glu), 14.8 (SCH3), 12.3 (CH3); 31P NMR (202 MHz, DMSO-d6) δ = 0.0; 
HRMS for C23H36N5O14PS [M-H]- calcd.: 668.1644, found: 668.1656. 
3’-O-[N-For-L-Met-L-Glu-(methyloxy-δ-carboxamide)-NH2]-2’-deoxythymidine-5’-
monophosphate triethylammonium salt (2.58): Compound 2.58 was obtained as a white solid (135 
mg, 73%), according to the general procedure used for the synthesis of 2.19 and 2.33-2.40, starting 
from a stirring solution of 2.56 (180.0 mg, 0.216 mmol), Et3N (0.06 mL, 0.431 mmol) and 10% Pd/C 
Degussa (90.0 mg, 50% w/w) in a mixture of EtOH (18 mL) and H2O (2 mL). 1H NMR (600 MHz, 
DMSO-d6) δ = 12.26 (br s, 1H, NH), 11.28 (br s,1H, NH), 9.26 (d, J = 7.7 Hz, 1H, NH-Met), 8.37 (d, 
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J = 7.7 Hz, 1H, NH-Glu), 8.07 (s, 1H, CHO), 7.80 (s, 1H, H-6), 7.34 (s, 1H, CONH2-Glu), 7.04 (s, 
1H, CONH2-Glu), 6.13 (app t, J = 6.1 Hz, 1H, H-1’), 4.87-4.79 (m, 2H, OCH2O), 4.65-4.62 (m, 1H, 
H-3’), 4.40-4.36 (m, 1H, αH-Glu), 4.12-4.09 (m, 1H, αH-Met), 4.02-4.00 (m, 2H, H-4’ and H-5’), 
3.92-3.89 (m, 1H, H-5’’), 2.48 (t, J = 8.0 Hz, 2H, γCH2-Met), 2.33-2.29 (m, 1H, H-2’), 2.26-2.22 (m, 
1H, H-2’’), 2.13-2.00 (unresolved m, 5H, γCH2-Glu and SCH3), 1.98-1.82 (unresolved m, 7H, βCH2-
Glu, βCH2-Met and CH3); 13C NMR (150 MHz, DMSO-d6) δ = 173.2 (αCO-Glu), 171.2 (CO-Met), 
169.0 (δCO-Glu), 163.9 (C-4), 161.6 (CHO), 150.4 (C-2), 136.1 (C-6), 109.7 (C-5), 96.0 (OCH2O), 
83.6 (C-1’), 83.1 (d, 3JC,P = 6.0 Hz, C-4’), 74.3 (C-3’), 62.6 (d, 2JC,P = 4.1 Hz, C-5’), 52.5 (αC-Met), 
51.2 (αC-Glu), 36.7 (C-2’), 31.7 (βC-Met), 29.6 (γC-Met), 29.5 (γC-Glu), 28.2 (βC-Glu), 14.7 
(SCH3), 12.2 (CH3); 31P NMR (202 MHz, DMSO-d6) δ = 0.0; HRMS for C22H35N6O13PS [M-H]- 
calcd.: 653.1647, found: 653.1644. 
5’-O-(tert-Butyldiphenylsilyl)-3’-O-[N-For-Gly-L-Glu(γ-methyloxy-ester)-L-Ala-OMe]-2’-
deoxythymidine (2.59): Following a similar procedure as used for the synthesis of 2.51, compound 
2.59 was obtained in two steps starting from 2.50 (1.69 g, 3.12 mmol), 1M SO2Cl2 in CH2Cl2 (3.75 
mL, 3.75 mmol), followed by reaction with tripeptide 2.5a (1.24 g, 3.91 mmol) and DBU (0.61 mL, 
4.06 mmol) in dry CH2Cl2 (50 mL). The crude residue was purified by column chromatography on 
silica gel (gradient CH2Cl2/MeOH 99:1, v/v; 98:2, v/v; 96:4, v/v) to give 2.59 (1.87 g, 74%) as a 
colorless foam. 1H NMR (300 MHz, DMSO-d6) δ = 11.36 (s, 1H, NH-Thy), 8.43 (d, J = 6.7 Hz, 1H, 
NH-Ala), 8.21 (t, J = 5.5 Hz, 1H, NH-Gly), 8.11 (d, J = 8.3 Hz, 1H, NH-Glu), 8.05 (s, 1H, CHO), 
7.65-7.41 (m, 11H, H-6 and Ar-H of TBDPS), 6.14 (app t, J = 7.0 Hz, 1H, H-1’), 5.32 (dd, J = 19.9, 
6.6 Hz, 2H, OCH2O), 4.50-4.48 (m, 1H, H-3’), 4.40-4.32 (m, 1H, αH-Glu), 4.29-4.20 (m, 1H, αH-
Ala), 4.04-4.01 (m, 1H, H-4’), 3.93-3.82 (m, 2H, H-5’and H-5’’), 3.76 (d, J = 5.8 Hz, 2H, αCH2-Gly), 
3.57 (s, 3H, OCH3), 2.39 (t, J = 8.1 Hz, 2H, γCH2-Glu), 2.34-2.25 (m, 1H, H-2’and H-2’’), 1.98-1.74 
(m, 2H, βCH2-Glu), 1.51 (s, 3H, CH3-Thy), 1.28 (d, J = 7.3 Hz, 3H, CH3-Ala), 1.02 (s, 9H, tBu); 13C 
NMR (75 MHz, DMSO-d6) δ = 172.8 (CO-Ala), 172.0 (δCO-Glu), 170.7 (αCO-Glu), 168.2 (CO-
Gly), 163.5 (C-4), 161.4 (CHO), 150.3 (C-2), 135.4 (C-6), 135.1 (1C of Ph), 134.9 (1C of Ph), 132.7 
(Ar-C), 132.3 (Ar-C), 130.1 (Ar-C), 130.0 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 109.7 (C-5), 87.7 
(OCH2O), 83.9 (C-4’), 83.6 (C-1’), 79.1 (C-3’), 63.8 (C-5’), 51.7 (OCH3), 51.1 (αC-Glu), 47.6 (αC-
Ala), 40.5 (αC-Gly), 36.8 (C-2’), 29.7 (γC-Glu), 27.2 (βC-Glu), 26.6 (tBu), 18.8 (1C of tBu), 16.6 
(CH3-Ala), 11.8 (CH3-Thy); HRMS for C39H51N5O12Si [M-H]- calcd.: 808.3230, found: 808.3233. 
3’-O-[N-For-Gly-L-Glu(γ-methyloxy-ester)-L-Ala-OMe]-2’-deoxythymidine (2.60): Following 
a similar procedure as used for the synthesis of 2.52, compound 2.60 was obtained starting from 2.59 
(0.60 g, 0.74 mmol), Et3N·3HF (0.483 mL, 2.96 mmol) in THF (10 ml). The crude residue was 
purified by column chromatography on silica gel (gradient CH2Cl2/MeOH 99:1, v/v; 96:4, v/v; 92:8, 
v/v) to give 2.60 (0.34 g, 80%) as a colorless foam. 1H NMR (300 MHz, DMSO-d6) δ = 11.31 (s, 1H, 
NH-Thy), 8.44 (d, J = 6.7 Hz, 1H, NH-Ala), 8.21 (t, J = 5.0 Hz, 1H, NH-Gly), 8.10 (d, J = 8.0 Hz, 
1H, NH-Glu), 8.06 (s, 1H, CHO), 7.68 (s, 1H, H-6), 6.11 (app t, J = 7.0 Hz, 1H, H-1’), 5.31 (dd, J = 
11.6, 6.7 Hz, 2H, OCH2O), 4.39-4.35 (m, 2H, H-3’ and αH-Glu), 4.27-4.23 (m, 1H, αH-Ala), 3.93-
3.90 (m, 1H, H-4’), 3.77 (d, J = 6.8 Hz, 2H, αCH2-Gly), 3.61-3.58 (m, 5H, H-5’, H-5’’ and OCH3), 
2.40 (t, J = 8.0 Hz, 2H, γCH2-Glu), 2.25-2.19 (m, 1H, H-2’and H-2’’), 2.00-1.80 (m, 2H, βCH2-Glu), 
1.78 (s, 3H, CH3-Thy), 1.29 (d, J = 7.3 Hz, 3H, CH3-Ala); 13C NMR (75 MHz, DMSO-d6) δ = 172.8 
(CO-Ala), 172.0 (δCO-Glu), 170.7 (αCO-Glu), 168.3 (CO-Gly), 163.6 (C-4), 161.4 (CHO), 150.4 (C-
2), 135.9 (C-6), 109.5 (C-5), 87.6 (OCH2O), 84.7 (C-4’), 83.6 (C-1’), 79.3 (C-3’), 61.1 (C-5’), 51.8 
(OCH3), 51.1 (αC-Glu), 47.6 (αC-Ala), 40.5 (αC-Gly), 36.9 (C-2’), 29.8 (γC-Glu), 27.2 (βC-Glu), 
16.6 (CH3-Ala), 12.2 (CH3-Thy); HRMS for C23H33N5O12 [M-H]- calcd.: 570.2053, found: 570.2054. 
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5’-O-(Dibenzylphosphate)-3’-O-[N-For-Gly-L-Glu(γ-methyloxy-ester)-L-Ala-OMe]-2’-
deoxythymidine (2.61): Following a similar procedure as used for the synthesis of 2.22, compound 
2.61 (383 mg, 86%) was obtained starting from 2.60 (306 mg, 0.535 mmol) as a colorless foam. 1H 
NMR (300 MHz, DMSO-d6) δ = 11.33 (s, 1H, NH-Thy), 8.43 (d, J = 6.7 Hz, 1H, NH-Ala), 8.20 (t, J 
= 5.7 Hz, 1H, NH-Gly), 8.10 (d, J = 8.1 Hz, 1H, NH-Glu), 8.06 (s, 1H, CHO), 7.46 (d, J = 0.9 Hz, 1H, 
H-6), 7.36-7.35 (m, 10H, Ar-H of OBn), 6.12 (app t, J = 7.1 Hz, 1H, H-1’), 5.29 (dd, J = 15.7, 6.6 Hz, 
2H, OCH2O), 5.05 (d, J = 8.1 Hz, 4H, 2 x OCH2Ph), 4.37-4.29 (m, 2H, H-3’ and αH-Glu), 4.27-4.19 
(m, 3H, αH-Ala, H-5’and H-5’’), 4.10-4.07 (m, 1H, H-4’), 3.77 (d, J = 5.8 Hz, 2H, αCH2-Gly), 3.58 
(s, 3H, OCH3), 2.41 (t, J = 7.8 Hz, 2H, γCH2-Glu), 2.26-2.13 (m, 1H, H-2’and H-2’’), 1.99-1.74 (m, 
2H, βCH2-Glu), 1.51 (d, J = 0.9 Hz, 3H, CH3-Thy), 1.28 (d, J = 7.3 Hz, 3H, CH3-Ala); 13C NMR (75 
MHz, DMSO-d6) δ = 172.8 (CO-Ala), 171.9 (δCO-Glu), 170.7 (αCO-Glu), 168.3 (CO-Gly), 163.6 
(C-4), 161.4 (CHO), 150.3 (C-2), 135.9 (d, 3JC,P = 6.8 Hz, 1C of OCH2Ph), 135.7 (C-6), 128.5 (Ar-C), 
128.4 (Ar-C), 127.8 (Ar-C), 109.9 (C-5), 87.8 (OCH2O), 84.0 (C-1’), 82.0 (d, 3JC,P = 7.4 Hz, C-4’), 
78.8 (C-3’), 68.7 (d, 2JC,P = 5.4 Hz, 2 x OCH2Ph), 66.8 (d, 2JC,P = 4.8 Hz, C-5’), 51.8 (OCH3), 51.1 
(αC-Glu), 47.6 (αC-Ala), 40.5 (αC-Gly), 36.5 (C-2’), 29.7 (γC-Glu), 27.2 (βC-Glu), 16.6 (CH3-Ala), 
12.0 (CH3-Thy); 31P NMR (121 MHz, DMSO-d6) δ = -0.9; HRMS for C37H46N5O15P [M+H]+ calcd.: 
832.2800, found: 832.2803. 
3’-O-[N-For-Gly-L-Glu(γ-methyloxy-ester)-L-Ala-OMe]-2’-deoxythymidine5’-monophosphate 
triethylammonium salt (2.62): Compound 2.62 was obtained as a white solid (63.6 mg, 62%), 
according to the general procedure used for the synthesis of 2.19 and 2.33-2.40, starting from a 
stirring solution of 2.61 (100 mg, 0.120 mmol), NaHCO3 (20.2 mg, 0.240 mmol) and 20% Pd(OH)2/C 
(10.0 mg, 10% w/w) in EtOH/H2O 9:1 (10 mL). 1H NMR (500 MHz, D2O) δ = 8.14 (s, 1H, CHO), 
7.81 (s, 1H, H-6), 6.26 (app t, J = 7.2 Hz, 1H, H-1’), 5.38 (dd, J = 44.5, 6.9 Hz, 2H, OCH2O), 4.62-
4.61 (m, 1H, H-3’), 4.39-4.34 (m, 2H, αH-Glu and αH-Ala), 4.26-4.25 (m, 1H, H-4’), 3.98-3.94 (m, 
4H, αCH2-Gly and H-5’and H-5’’), 3.69 (s, 3H, OCH3), 2.56 (t, J = 7.4 Hz, 2H, γCH2-Glu), 2.46-2.34 
(m, 1H, H-2’and H-2’’), 2.17-1.95 (m, 2H, βCH2-Glu), 1.88 (d, J = 0.9 Hz, 3H, CH3-Thy), 1.38 (d, J 
= 7.3 Hz, 3H, CH3-Ala); 13C NMR (125 MHz, D2O) δ = 174.5 (CO-Ala), 174.0 (δCO-Glu), 172.8 
(αCO-Glu), 170.7 (CO-Gly), 166.4 (C-4), 164.6 (CHO), 151.5 (C-2), 137.4 (C-6), 111.5 (C-5), 88.3 
(OCH2O), 84.6 (C-1’), 83.9 (d, 3JC,P = 9.0 Hz, C-4’), 80.3 (C-3’), 64.0 (d, 2JC,P = 4.4 Hz, C-5’), 52.6 
(OCH3), 52.3 (αC-Glu), 48.5 (αC-Ala), 40.7 (αC-Gly), 36.8 (C-2’), 29.5 (γC-Glu), 25.6 (βC-Glu), 
15.5 (CH3-Ala), 11.4 (CH3-Thy); 31P NMR (202 MHz, D2O) δ = 1.8; HRMS for C23H34N5O15P 
[M+H]+ calcd.: 650.1716, found: 650.1718. 
5’-O-(Dibenzylphosphate)-3’-O-[N-For-L-Met-L-Lys(Boc)-L-Lys(Boc)-ester]-2’-
deoxythymidine (2.63): Following a similar procedure as used for the synthesis of 2.47, compound 
2.63 was obtained starting from 2.23 (250 mg, 0.498 mmol), tripeptide 2.4h (378.4 mg, 0.597 mmol), 
DCC (164.3 mg, 0.796 mmol) and DMAP (6.1 mg, 0.050 mmol) in a mixture of dry DMF (3 ml) and 
dry CH2Cl2 (15 ml). The crude residue was purified by column chromatography on silica gel (gradient 
CH2Cl2/MeOH 99:1, v/v; 97:2, v/v; 94:4, v/v) to give 2.63 (423 mg, 76%) as a colorless foam. 1H 
NMR (300 MHz, CDCl3) δ = 9.51 (br s,1H, NH), 9.31 (br s, 1H, NH), 8.22 (s, 1H, CHO), 7.41 (s, 1H, 
H-6), 7.35-7.34 (m, 10H, Ar-H of OBn), 6.33 (dd, J = 9.2, 5.4 Hz, 1H, H-1’), 5.18-5.12 (m, 1H, H-
3’), 5.10-4.95 (m, 4H, OCH2Ph), 4.89-4.77 (m, 1H, αH-Met), 4.73-4.34 (m, 2H, 2 x αH-Lys), 4.22-
4.10 (m, 3H, H-4’, H-5’ and H-5’’), 3.15-3.04 (m, 4H, 2 x εCH2-Lys), 2.56 (t, J = 6.7 Hz, 2H, γCH2-
Met), 2.35-2.22 (m, 1H, H-2’), 2.13-2.07 (m, 4H, H-2’’ and SCH3), 1.96-1.87 (m, 2H, βCH2-Met), 
1.82 (s, 3H, CH3-Thy), 1.77-1.64 (m, 4H, 2 x βCH2-Lys), 1.54-1.31 (m, 26H, 2 x δCH2-Lys, 2 x 
γCH2-Lys and 2 x CH3-tBu); 13C NMR (75 MHz, CDCl3) δ = 171.9 (CO-LysN-Ter), 171.7 (CO-Met), 
171.3 (CO-LysC-Ter), 163.7 (C-4), 161.9 (CHO), 156.4 (2 x OCONH), 150.9 (C-2), 135.5 (d, 3JC,P = 
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6.0 Hz, 1C of OCH2Ph), 135.1 (C-6), 129.1 (Ar-C), 128.9 (Ar-C), 128.2 (Ar-C), 112.1 (C-5), 84.5 (C-
1’), 82.6 (d, 3JC,P = 8.9 Hz, C-4’), 79.4 (2 x 1C of tBu), 75.7 (C-3’), 70.0 (app t, 2JC,P = 5.6 Hz, 2 x 
OCH2Ph), 67.3 (d, 2JC,P = 5.8 Hz, C-5’), 53.5 (2 x αC-Lys), 52.8 (αC-Met), 40.1 (2 x εC-Lys), 37.0 (C-
2’), 31.8 (βC-Met), 31.0 (2 x βC-Lys), 30.1 (γC-Met), 29.5 (2 x δC-Lys), 28.6 (2 x CH3-tBu), 22.9 (2 
x γC-Lys), 15.4 (SCH3), 12.5 (CH3-Thy); 31P NMR (121 MHz, CDCl3) δ = -0.7; HRMS for 
C52H76N7O16PS [M+H]+calcd.: 1118.4879, found: 1118.4878. 
3’-O-[N-For-L-Met-L-Lys-L-Lys-ester]-2’-deoxythymidine-5’-monophosphate TFA salt 
(2.65): Following a similar procedure as used for the synthesis of 2.41, compound 2.65 was obtained 
as a white solid in two steps (214 mg, 62%) starting from 2.63 (400 mg, 0.358 mmol) and 10% Pd/C 
Degussa (200 mg, 50% w/w) in EtOH:H2O 10:1 (30 mL), to give crude 3’-O-[N-For-Met-L-
Lys(Boc)-L-Lys(Boc)-ester]-2’-deoxythymidine-5’-monophosphate 2.64 (335.5 mg, quantitative) as a 
white solid, which was immediately deprotected in H2O (4.5 mL), thioanisole (0.056 mL, 0.476 
mmol) and trifluoroacetic acid (1.5 mL). 1H NMR (500 MHz, D2O) δ = 8.11 (s, 1H, CHO), 7.80 (s, 
1H, H-6), 6.38-6.33 (m, 1H, H-1’), 5.47-5.44 (m, 1H, H-3’), 4.52-4.48 (m, 1H, αH-Met), 4.46-4.33 
(m, 3H, 2 x αH-Lys and H-4’), 4.14-4.09 (m, 2H, H-5’ and H-5’’), 3.00-2.98 (m, 4H, 2 x εCH2-Lys), 
2.61-2.51 (m, 2H, γCH2-Met), 2.48-2.42 (m, 1H, H-2’ and H-2’’), 2.09 (m, 3H, SCH3), 2.05-1.97 (m, 
2H, βCH2-Met), 1.91 (s, 3H, CH3-Thy), 1.85-1.78 (m, 4H, 2 x βCH2-Lys), 1.72-1.66 (m, 4H, 2 x 
δCH2-Lys), 1.52-1.41 (m, 4H, 2 x γCH2-Lys); 13C NMR (125 MHz, D2O) δ = 173.3 (CO-LysN-Ter), 
172.7 (CO-Met), 171.7 (CO-LysC-Ter), 166.0 (C-4), 163.7 (CHO), 151.2 (C-2), 136.5 (C-6), 111.4 (C-
5), 84.2 (C-1’), 82.7 (d, 3JC,P = 8.9 Hz, C-4’), 76.1 (C-3’), 64.5 (d, 2JC,P = 4.8 Hz, C-5’), 52.9 (αC-Lys), 
52.0 (αC-Lys), 50.8 (αC-Met), 38.5 (2 x εC-Lys), 35.7 (C-2’), 29.8 (βC-Met), 28.8 (2 x βC-Lys), 28.4 
(γC-Met), 25.5 (2 x δC-Lys), 21.5 (2 x γC-Lys), 13.5 (SCH3), 11.0 (CH3-Thy); 31P NMR (202 MHz, 
D2O) δ = -0.2; HRMS for C28H48N7O12PS [M-H]-calcd.: 736.2746, found: 736.2742. 
3’,5’-O-Di(tert-Butyldimethylsilyl)-2’deoxy-thymidine (2.66):[51] To a stirring solution of 
thymidine (2.00 g, 8.26 mmol) in dry DMF was added imidazole (3.37 g, 49.5 mmol) followed by 
TBDMSCl (3.73 g, 24.8 mmol) and the solution was stirred overnight at r.t. The reaction mixture was 
then diluted with CH2Cl2, washed with water and dried over Na2SO4, filtered and evaporated in vacuo. 
The remaining crude residue was purified by column chromatography on silica gel (gradient 
Hexane/EtOAc 90:10, v/v; 80:20, v/v; 70:30, v/v) to give 2.66 (3.03 g, 78%) as a white foam. 1H 
NMR (300 MHz, CDCl3) δ =9.23 (br s, 1H, NH), 7.45 (s, 1 H, H-6), 6.34-4.30 (m, 1H, H-1’), 4.39-
4.37 (m, 1H, H-3’), 3.91-3.83 (m, 2H, H-5’ and H-4’), 3.76-3.71 (m, 1H, H-5’’), 2.27-2.20 (m, 1H, H-
2’), 2.02-1.96 (m, 1H, H-2’’), 1.89 (s, 3H, CH3-Thy), 0.91 (s, 9H, C(CH3)3), 0.97 (s, 9H, C(CH3)3), 
0.09 (s, 6H, CH3), 0.06 (s, 6H, CH3); 13C NMR (75 MHz, CDCl3) δ = 163.6 (C-4), 150.1 (C-2), 135.1 
(C-6), 110.5 (C-5), 87.5 (C-4’), 84.5 (C-1’), 71.9 (C-3’), 62.6 (C-5’), 41.5 (C-2’), 25.6 (tBu), 25.4 
(tBu), 18.1 (1C of tBu), 17.7 (1C of tBu), 12.2 (CH3-Thy), -5.0 (CH3), -5.2 (CH3), -5.7 (CH3), -5.8 
(CH3); HRMS for C22H43N2O5Si2 [M+H]+calcd.: 471.2705, found: 471.2706. 
3’-O-(tert-Butyldimethylsilyl)-2’deoxy-thymidine (2.67):[51] Compound 2.66 (2.39 g, 5.08 mmol) 
was dissolved in CH2Cl2 (28 mL) and the solution was cooled to 0 °C. A cooled TFA:H2O (8:1, 2.8 
mL) mixture was then added dropwise and the reaction mixture was stirred for 4 h at 0 °C. The 
solution was then diluted with cooled CH2Cl2, washed with ice-cold water and brine, dried over 
Na2SO4, filtered and evaporated in vacuo. The remaining crude residue was purified by column 
chromatography on silica gel (gradient CH2Cl2/MeOH 99:1, v/v; 95:5, v/v) to give 2.67 (1.07 g, 59%) 
as a white foam. 1H NMR (300 MHz, CDCl3) δ = 9.40 (br s, 1H, NH), 7.38 (d, J = 1.08 Hz, 1H, H-6), 
6.13 (t, J = 6.7 Hz, 1H, H-1’), 4.48-4.43 (m, 1H, H-3’), 3.89-3.86 (m, 2H, H-5’ and H-5’’), 3.73-3.72 
(m, 1H, H-4’), 3.07 (br s, 1H, OH), 2.29-2.27 (m, 1H, H-2’), 2.22-2.18 (m, 1H, H-2’’), 1.85 (s, 3H, 
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CH3-Thy), 0.85 (s, 9H, C(CH3)3), 0.05 (s, 6H, CH3); 13C NMR (75 MHz, CDCl3) δ = 164.1 (C-4), 
150.4 (C-2), 137.0 (C-6), 110.8 (C-5), 87.5 (C-4’), 86.5 (C-1’), 71.5 (C-3’), 61.8 (C-5’), 40.5 (C-2’), 
25.6 (tBu), 17.9 (1C of tBu), 12.4 (CH3-Thy), -4.8 (CH3), -4.9 (CH3); HRMS for C16H29N2O5Si 
[M+H]+calcd.: 357.1840, found: 357.1841. 
5’-O-(Dibenzylphosphate)-3’-O-(tert-butyldimethylsilyl)-2’-deoxythymidine (2.68): Following a 
similar procedure as used for the synthesis of 2.22, compound 2.68 was obtained starting from 2.67 
(0.47 g, 1.32 mmol), 0.45M tetrazole in ACN (15 mL, 6.57 mmol), dibenzyldiisopropyl 
phosphoramidite (0.95 mL, 2.87 mmol) in dry CH2Cl2 (10 mL), and 35% H2O2 (0.57 mL, 7.01 mmol). 
The crude residue was purified by column chromatography on silica gel (gradient Hexane/EtOAc 
90:10, v/v; 70:30, v/v; 50:50, v/v) to give 2.68 (0.75 g, 88%) as a colorless foam. 1H NMR (300 MHz, 
CDCl3) δ = 9.11 (br s,1H, NH), 7.33-7.32 (m, 11H, Ar-H and H-6), 6.29 (dd, J = 7.5, 6.1 Hz, 1H, H-
1’), 5.11-4.98 (m, 4H, OCH2Ph), 4.32-4.28 (m, 1H, H-3’), 4.15-4.09 (m, 2H, H-5’ and H-5’’), 3.95-
3.93 (m, 1H, H-4’), 2.15 (ddd, J = 13.4, 6.0, 3.1 Hz, 1H, H-2’), 1.93-1.84 (m, 1H, H-2’’), 1.82 (d, J = 
0.9 Hz, 3H, CH3-Thy), 0.86 (s, 9H, C(CH3)3), 0.04 (s, 3H, CH3), 0.03 (s, 3H, CH3); 13C NMR (75 
MHz, CDCl3) δ = 163.5 (C-4), 150.0 (C-2), 135.2 (1C of OCH2Ph), 135.0 (C-6), 128.5 (Ar-C), 128.4 
(Ar-C), 127.7 (Ar-C), 110.9 (C-5), 85.0 (d, 3JC,P = 8.0 Hz, C-4’), 84.5 (C-1’), 71.5 (C-3’), 69.4 (2 x d, 
2JC,P = 5.4 Hz, OCH2), 66.2 (d, 2JC,P =5.8 Hz, C-5’), 40.4 (C-2’), 25.3 (tBu), 17.6 (1C of tBu), 12.0 
(CH3-Thy), -5.0 (CH3), -5.2 (CH3); 31P NMR (121 MHz, CDCl3) δ = -0.5; HRMS for C30H42N2O8PSi 
[M+H]+calcd.: 617.2442, found: 617.2447. 
5’-O-(Dibenzylphosphate)-2’-deoxythymidine (2.23): Method (a). To a solution of 2.68 (570 mg, 
0.92 mmol) in THF (10 mL) cooled at 0 ºC was added TBAF (1M in THF, 0.92 mL, 0.92 mmol). The 
reaction mixture was stirred for 45 min at 0 ºC and for 15 min at r.t. The mixture was partially 
evaporated and then purified by column chromatography on silica gel (gradient CH2Cl2/MeOH 99:1, 
v/v; 98:2, v/v; 96:4, v/v) to give 2.23 (227 mg, 49%) as a colorless foam. Method (b). To a solution 
of 2.68 (0.80 g, 1.30 mmol) in THF (10 mL) was added Et3N·3HF (0.53 mL, 3.24 mmol) and the 
solution was stirred at r.t. for 24 h. After removal of all the volatiles, the resulting residue was 
redissolved in CH2Cl2 and washed with 10% NaHCO3 solution. The organic layer was then dried over 
Na2SO4, filtered and evaporated under reduced pressure. The crude residue was purified by column 
chromatography on silica gel (gradient CH2Cl2/MeOH 99:1, v/v; 98:2, v/v; 96:4, v/v) to give 2.23 
(0.58 g, 89%) as a colorless foam. 
5’-O-(Dibenzylphosphate)-3’-O-[N-For-Gly-L-Glu(δ-ester)-L-Phe-OMe]-2’-deoxythymidine 
(2.69): Following a similar procedure as used for the synthesis of 2.47, compound 2.69 was obtained 
starting from 23 (230 mg, 0.458 mmol), tripeptide 2.5b (200.0 mg, 0.508 mmol), DCC (110.0 mg, 
0.533 mmol) and DMAP (1.1 mg, 0.090 mmol) in a mixture of dry DMF (4 ml) and dry CH2Cl2 (4 
ml). The crude residue was purified by column chromatography on silica gel (gradient CH2Cl2/MeOH 
99:1, v/v; 95:5, v/v; 93:7, v/v) to give 2.69 (230 mg, 57%) as a white foam. 1H NMR (300 MHz, 
MeOD) δ = 8.18 (s, 1H, CHO), 7.46 (s, 1H, H-6), 7.36 (br s, 10H, Ar-H of OBn), 7.29-7.19 (m, 5H, 
Ar-H of Phe), 6.25 (dd, J = 8.6, 5.7 Hz, 1H, H-1’), 5.21-5.20 (m, 1H, H-3’), 5.13-5.09 (m, 4H, 
OCH2Ph), 4.68 (dd, J = 8.5, 5.7 Hz, 1H, αCH-Phe), 4.68 (dd, J = 8.3, 5.7 Hz, 1H, αCH-Glu), 4.28-
4.26 (m, 2H, H-5’ and H-5’’), 4.19-4.18 (m, 1H, H-4’), 3.93 (br s, 2H, CH2-Gly), 3.68 (s, 3H, OCH3), 
3.16 (dd, J= 13.7, 5.6 Hz, 1H, βCH2-Phe), 3.00 (dd, J= 13.9, 8.6 Hz, 1H, βCH2-Phe), 2.43 (t, J = 7.1 
Hz, 2H, γCH2-Glu), 2.37-2.33 (m, 1H, H-2’), 2.15-2.06 (m, 2H, H-2’’ and βCH2-Glu), 1.96-1.86 (m, 
1H, βCH2-Glu), 1.77 (s, 3H, CH3-Thy); 13C NMR (75 MHz, MeOD) δ = 172.0 (δCO-Glu), 171.5, 
171.4, 169.1, 164.4 (C-4), 162.6 (CHO), 150.5 (C-2), 135.4 (C-6), 135.3 (d, 3JC,P = 6.1 Hz, 1C of 
OCH2Ph), 128.6 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 127.8 (Ar-C), 127.5 (Ar-C), 126.2 (Ar-C), 110.4 
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(C-5), 84.5 (C-1’), 82.2 (d, 3JC,P = 7.8 Hz, C-4’), 74.1 (C-3’), 69.4 (d, 2JC,P = 5.7 Hz, 2 x OCH2Ph), 
66.9 (d, 2JC,P = 5.8 Hz, C-5’), 53.5 (αC-Phe), 51.6 (αC-Glu), 51.1 (OCH3), 40.3 (αC-Gly), 36.5 (βC-
Phe), 36.0 (C-2’), 29.0 (γC-Glu), 26.4 (βC-Glu), 10.8 (CH3-Thy); 31P NMR (121 MHz, MeOD) δ = -
1.1; HRMS for C42H49N5O14P [M+H]+calcd.: 878.3008, found: 878.3006. 
3’-O-[N-For-L-Gly-L-Glu(δ-ester)-L-Phe-OMe]-2’-deoxythymidine-5’-monophosphate 
triethylammonium salt (2.70): Compound 2.70 was obtained as a white solid (160 mg, 66%), 
according to the general procedure used for the synthesis of 2.19 and 2.33-2.40, starting from a 
stirring solution of 2.69 (190 mg, 0.216 mmol) and 10% Pd/C Degussa (120 mg, 50% w/w) in THF 
(20 mL). 1H NMR (300 MHz, D2O) δ = 8.15 (s, 1H, CHO), 7.70 (s, 1H, H-6), 7.34-7.20 (m, 5H, Ar-H 
of Phe), 6.36 (dd, J = 9.1, 5.5 Hz, 1H, H-1’), 5.35 (d, J = 5.2 Hz, 1H, H-3’), 4.68 (dd, J = 9.5, 5.5 Hz, 
1H, αCH-Phe), 4.29-4.24 (m, 2H, αCH-Glu and H-4’), 4.93-3.92 (m, 4H, αCH2-Gly, H-5’ and H-5’’), 
3.70 (s, 3H, OCH3), 3.25-3.18 (m, 1H, βCH2-Phe), 2.99-2.91 (m, 1H, βCH2-Phe), 2.42-2.88 (m, 4H, 
γCH2-Glu, H-2’ and H-2’’), 1.98-1.82 (m, 2H, βCH2-Glu), 1.86 (s, 3H, CH3-Thy); 13C NMR (151 
MHz, D2O) δ = 173.6, 172.1, 170.4, 169.1, 164.4 (CHO), 163.8 (C-4), 153.6 (C-2), 137.4 (1C of Ph), 
137.1 (C-6), 129.0 (Ar-C), 128.3 (Ar-C), 126.5 (Ar-C), 111.5 (C-5), 85.6 (d, 3JC,P = 8.0 Hz, C-4’), 
84.5 (C-1’), 71.0 (C-3’), 63.4 (d, 2JC,P = 4.06 Hz, C-5’), 53.7 (αC-Phe), 55.8 (αC-Glu), 53.5 (OCH3), 
41.6 (αC-Gly), 38.0 (βC-Phe), 37.4 (C-2’), 28.6 (γC-Glu), 26.7 (βC-Glu), 11.7 (CH3-Thy); 31P NMR 
(121 MHz, D2O) δ = -3.7; HRMS for C28H35N5O14P [M-H]- calcd.: 696.1923, found: 696.1926. 
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Chapter 3 
 
Synthesis of novel 5’-linked peptide nucleotide conjugates (PNCs) for 
nucleotides delivery in bacterial cells 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
The rational design and synthesis of novel peptide nucleotide conjugates (PNCs), assembled 
from α-substituted glycine dipeptides and TMP, are described. The two composing structural 
units are connected by various phosphoester linkers between the α-carbon of a C-terminal 
glycine residue and the 5’-hydroxyl group of thymidine. The resulting conjugates are of 
interest in the development of a nucleotide delivery system in prokaryotes and as potential 
artificial substrates for DNA polymerases. The performance of all dipeptide-TMP conjugates 
as pyrophosphate mimics and the influence of the different linkers in the DNA 
polymerization reaction were evaluated by in vitro chain elongation assay, using both 
thermophilic and mesophylic microbial DNA polymerases. 
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3.1. INTRODUCTION 
In Chapter 2 we have already discussed the relevance of peptide transport systems[1] for potential 
nucleotide delivery in bacterial cells, detailing the design of peptide-nucleotide conjugates (PNCs), 
which were prepared by covalently binding, through various linkers, the side chain functionalities of 
oligopeptides (di- to penta-) to the 3’-position of thymidine monophosphate. 
Throughout our search for a suitable peptidic-based system for cargo delivery in bacterial cells, 
we came across a report by Gilvarg et al., which described glycine-containing peptides comprising a 
nucleophilic moiety or a toxophoric agent (mostly uncharged small molecules) attached to the α-
carbon of the C-terminal glycine residue.[2] Such peptide-conjugates were found not only to be 
accepted by peptide transporters, but also to undergo hydrolysis in the presence of intracellular 
peptidases, thus liberating the attached cargo inside the bacterial cells (Fig 3-1).[3] Inspired by this 
model, we envisioned that this type of peptide delivery system could also be functional for nucleotide 
delivery. In order to test this hypothesis, we chose to synthesize 5’-thymidylate (TMP) nucleotide 
conjugates with various α-substituted glycine dipeptides as initial synthetic targets, for evaluation 
within our well-established nutritional selection system, using auxotrophic E. coli mutants lacking 
thymidylate synthase (Fig 3-2). These peptide 5’-nucleotide conjugates (PNCs) were thought to be 
embedded with the potential to liberate TMP intracellularly based on their variable metabolic 
(in)stability, depending on the different phosphate, phosphoramidate, phosphorothioate and thioethyl-
phosphate ester functionalities used to connect the α-substituted glycine dipeptide (L-Ala-Gly) to the 
5’-position of thymidine. 
 
 
 
 
 
 
 
 
 
Fig 3-1: Structures of α-substituted glycine peptide-conjugates and their mode of breakdown after 
peptidase cleavage. 
 
α-Substituted glycines are highly reactive compounds, but their stabilization can be accomplished 
by masking the lone pair of the glycyl nitrogen through N-acylation.[4] Due to their inherent chemical 
instability, however, the synthesis of the corresponding PNCs cannot be accomplished by standard 
methods. Generally, the α-substituent in α-substituted glycines acts as a good leaving group, therefore 
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the synthesis of α-substituted phosphoester glycines is more challenging due to the likely increase of 
nucleophilicity at the α-carbon.  
Although a number of reports illustrate the synthesis of carba(cyclic) and simple hetero-atomic 
(aromatic)[2, 3, 5] α-substituted glycines, careful literature investigation revealed the lack of synthetic 
methods for the introduction of a phosphoester group at the α-carbon of glycines. Herein, we report 
the first syntheses of PNCs of α-substituted glycines with different phospho-ester groups, such as 
phosphate, phosphoramidate, phosphorothioate and thioethyl-phosphate. 
 
3.2. RESULTS and DISCUSSION 
Phosphorus-containing α-substituted glycines pose a greater synthetic challenge when compared 
to uncharged hetero-atomic α-substituted glycines. Synthetic routes have to be carefully designed and 
executed, resorting to suitable orthogonal protection-deprotection methods, to yield labile 
phosphoester moieties. Our retrosynthetic analysis for the proposed phospho-ester target compounds 
is shown in Fig. 3-3. It becomes apparent that those conjugates can be obtained by nucleophilic 
substitution either at the α-position of glycine (route 1), or at the phosphorus group itself (route 2).  
 
Fig 3-2: Structures of α-substituted glycine peptide-nucleotide conjugates with different phosphoester 
linkages. 
 
. 
Figure 3-3. Retrosynthetic analysis of planned PNCs. 
 
Among the various options available for the formation of a phosphodiester linkage, the approach 
based on the use of a dialkylphosphoramidite followed by in situ oxidation was selected in our initial 
efforts to access phosphate derivative 3.1. α-Hydroxy glycine derivative 3.5 was synthesized as a 
diastereomeric mixture in good yield, after coupling Z-L-Ala-NH2 with benzyl glyoxalate according to 
an improved protocol, including the addition of a catalytic amount of p-TSA to increase the reaction 
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rate.[2] In order to access the target molecule 3.1, we first attempted to make bis(alkyl)-N,N-
diisopropyl phosphoramidite 3.6, but as the reaction met with failure, we turned to an alternative 
strategy by converting 3-O-benzyl thymidine[6] 3.8 into the pro-moiety 3.9,[7] followed by 
phosphoramidite coupling with 3.5 and in situ oxidation. Although phosphoramidite 3.9 could be 
successfully isolated, the subsequent coupling with 3.5 in the presence of 1-H tetrazole and oxidation 
with H2O2 did not produce compound 3.7, but 3’-O-benzyl-(benzyloxy)-TMP was obtained instead. 
Despite various coupling agents with different pKa, like 4,5-dicyanoimidazole, 2-ethylthio tetrazole 
and 2-benzylthio tetrazole were screened in the phosphoramidite coupling with the α-OH of 3.5, none 
of those conditions were found to be beneficial. 
 
Scheme 3-1. Route towards the synthesis of 5’-O-(L-alanyl-D,L-2-aminoglycine)-TMP. Reagents and 
conditions: (a) benzyl glyoxalate, p-TSA, CH2Cl2, 168 h; (b) Benzyloxy-bis(N,N-
diisopropylphosphoramino) phosphine, 0.45 M 1H-tetrazole in CH3CN, CH2Cl2, 0 °C to r.t., 4 h. 
 
 
Scheme 3-2. Route towards the synthesis of 5’-O-(L-alanyl-D,L-2-aminoglycine)-TMP. Reagents and 
conditions: (a) POCl3, trimethyl phosphate, -20 °C to r.t., 8 h; (b) Base, CH2Cl2, 0 °C to r.t., 16 h. 
 
As the phosphoramidite approach was not successful to provide phosphate derivative 3.1, we 
decided to use a method based on a more reactive chlorophosphate intermediate, as described in 
Scheme 2. First, 3’-O-benzyl thymidine 3.8 was converted to its active form 5’-O-dichlorophospho-
3’-O-benzyl-thymidine 3.10 using POCl3 in trimethyl phosphate, which was then treated in situ with 
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3.5 in the presence of N-methyl imidazole. Surprisingly, the reaction did not afford the desired 
product, but resulted in the formation of 3-O-benzyl-TMP along with other uncharacterized by-
products. Since bases with high pKb are known to form acyliminio glycine intermediates,[8] a number 
of weaker bases such as Et3N, DIPEA and pyridine were employed to increase the basicity of the α-
OH of glycine, but yielded almost the same results. This may be due to the lower nucleophilicity of 
the α-OH group, a sterical hindrance at the α-position, or the instability of the mono-chlorophosphate 
intermediate during quenching of the reaction. 
 
Scheme 3-3. Synthesis of 5’-O-(L-alanyl-D,L-2-aminoglycine methyl ester)-TMP. Reagents and 
conditions: (a) Ac2O, pyridine, 0 °C, 8 h; (b) TMP triethylammonium salt, Et3N, DMF, 40 °C, 24 h; 
(c) 10% Pd/C (Degussa-type), EtOH:H2O 5:1, r.t., 4 h. 
 
Those unsatisfactory results led us to switch to Route 1 in the retrosynthetic analysis for the 
synthesis of 3.1. Thus, the α-hydroxy glycine derivative 3.5 was activated at the α-position for 
nucleophilic substitution by conversion to its α-acetoxy derivative 3.12, which was then reacted with 
the triethylammonium salt of TMP (Scheme 3-3). Although at first a single product was thought to 
have formed on the basis of mass spectroscopic analysis of the crude residue, results from RP-HPLC 
purification revealed a mixture of products with the same mass. After in-deepth 2D NMR analysis of 
the separated products, it could be concluded that the desired phosphodiester derivative 3.13 was 
obtained as a minor product (8%) along with thymidylate N3-peptide adduct 3.14 as major product 
(40%). A 3’-TMP-peptide adduct and different dimers were also produced in traces in the reaction. 
This result can be rationalized on the basis of the hard-soft acid base (HSAB) principle, according to 
which a α-carbon, being a soft center, prefers a soft donor like the electrons from the N3 atom rather 
than the oxygen atom of the phosphate group. Despite attempts to optimize the reaction yield, longer 
times and higher temperatures only led to the formation of more undesired side-products. As the 3’-
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TMP-peptide adduct and compound 3.13 have very similar Rf, it was difficult to separate the two 
regio-isomers even by preparative-HPLC, thus the compounds were eventually separated in the next 
step. Finally, removal of all protecting groups of 3.13 by reductive hydrogenation using 10% Pd/C, 
Degussa-type, as previously optimized in our group, and preparative HPLC purification yielded the 
desired PNC 3.1 in moderate yield (42%). During the conversion of 3.13 to 3.1, the formation of TMP 
as an impurity was observed, whilst the same reaction conditions applied to 3.14 gave 3.15 in 
excellent yield (92%). 
The synthesis of phosphoramidate analogue 3.2 could theoretically be accessed either via Route 1 
or 2 as shown in the retrosynthetic analysis (Fig 3-3). As earlier witnessed in Route 1, a potential 
competition for nucleophilicity might arise between the N3-atom of thymine and the N-atom of 
thymidine-5’-O-phosphoramidate, therefore the more selective approach Route 2 was employed. The 
synthesis of α-amino glycine derivative 3.17 from its corresponding hydroxyl derivative 3.5 was 
performed via azide intermediated conversion (Scheme 3-4). Azide 3.16 was prepared from 3.5 in 
good yield using the DPPA/DBU method[9] and it was then converted to its amino form 3.17 by 
classical azide reduction in the presence of PPh3. The phosphoramidate coupling was carried out 
under standard DCC coupling conditions[10] to obtain a diastereomeric mixture of compounds 3.18a 
and 3.18b in good yield. Our initial efforts to separate the isomers 3.18a-b after the final 
debenzylation step turned out to be problematic, however the protected diastereomers could be 
successfully separated by preparative RP-HPLC yielding two pure 3.18a and 3.18b in an approximate 
1:1 ratio. Finally, the protecting groups were removed by catalytic hydrogenation as described earlier 
to afford the corresponding isomers of desired phosphoramidates 3.2a and 3.2b in moderate yields.  
 
 
Scheme 3-4. Synthesis of 5’-O-(L-alanyl-D/L-2-aminoglycine methyl ester)-TMP 3.2a and 3.2b. 
Reagents and conditions: (a) DPPA, DBU, dry toluene, 0 °C to r.t., 16 h; (b) PPh3, THF, reflux, 2 h; 
(c) TMP triethylammonium salt, Et3N, DCC, tBuOH:H2O 4:1, 85 °C, 2.5 h; (d) 10% Pd/C (Degussa-
type), EtOH:H2O 5:1, r.t., 4 h. 
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Scheme 3-5. Synthesis of thymidine-5’-(L-alanyl-D,L-2-aminoglycine methyl ester) phosphoramidate. 
Reagents and conditions: (a) Pb(OAc)4, dry EtOAc, mol. sieves 4 Å, reflux, 2 h; (b) 4-
methoxybenzylamine, DIPEA, dry DMF, 40 °C, 24 h; (c) 10% Pd/C, EtOH, r.t., 5 h (d) TMP 
triethylammonium salt, DCC, Et3N, tBuOH:H2O 4:1, 85 °C, 2.5 h; (e) TFA, thioanisole, CH2Cl2, 0 °C 
to r.t., 4 h. 
 
Since it can be anticipated that the free α-carboxylic group of glycine might play a role in the 
formation of TMP as a side product during the hydrogenolysis of 3.13, 3.18a and 3.18b, we were 
interested to synthesize phosphoramidate analogue 3.23, where the carboxylic group of glycine is 
protected as a methyl ester. A suitable choice of orthogonal protecting groups was crucial for the 
synthesis of phosphoramidate 3.23 (Scheme 3-5), whilst the main synthetic strategy resembled that 
employed for 3.2a-b. Unlike benzyl-protected α-acetoxy glycine derivative 3.12 which was 
synthesized in a convergent manner, for the synthesis of α-actoxy derivative 3.19 a more practical 
degradative approach was used, starting from N-Boc-L-Ala-L-Ser-OMe in the presence of Pb(OAc)4,[8] 
as the protecting groups were well tolerated during the reaction. The acetoxy derivative 3.19 was then 
converted to the protected amino derivative 3.20 by nucleophilic substitution with 4-methoxybenzyl 
amine. Subsequent deprotection by Pd/C catalyzed hydrogenation yielded the desired amine 3.21 in 
excellent yield (96%). Phosphoramidate 3.22 was obtained in good yield using the standard protocol 
and removal of the Boc group with TFA in the presence of the radical scavenger thioanisole produced 
the desired methyl ester derivative 3.23. As for compounds 3.18a-b, a late stage effort was made to 
separate the diastereomers of 3.22 and 3.23 by preparative RP-HPLC, but was not effective in this 
case. 
Although both retro-synthetic routes are feasible for the synthesis of thioethyl phosphate 
derivative 3.4, the instability of the thioethyl-TMP synthon can be considered potentially problematic. 
As described in the literature, this unit can be readily synthesized[11] but as soon as it is formed from 
its precursor, it immediately decomposes with formation of TMP and thiirane via nucleophilic attack 
of the naked thiol group.[12] According to Route 2, thioethanol derivative 3.24 derived from the 
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corresponding acetoxy derivative 3.12 and 2-mercaptoethanol by selective S-alkylation in good yield 
(70%) (Scheme 3-6). The phosphoramidite approach could in theory be utilized for the synthesis of 
3.25, nonetheless selective oxidation of PIII to PV in the presence of a sulfur atom pose a real 
challenge.[13] Therefore by alternatively adopting the POCl3 method, intermediate 3.10 was obtained 
from the corresponding 3’-O-benzyl thymidine, and it was then treaded in situ with 3.24 in the 
presence of N-methyl imidazole. Quenching followed by preparative RP-HPLC purification furnished 
3.25 as a diastereomeric mixture, in 66% yield over two steps. For the conversion of 3.25 to 3.4, 
removal of the Cbz and benzyl groups by hydrogenation was performed using a range of palladium 
derivatives, including 10% Pd/C, 10% Pd/C (Degussa), 20% Pd(OH)2/C, Pd-black and Pd(OAc)2. The 
use of an excess of catalyst was necessary in view of catalyst poisoning occurring in the presence of 
sulfur atoms. However, all catalysts failed to provide 3.4, either producing undesired over-reduced 
side products under harsher conditions or starting material under milder conditions.  
 
 
Scheme 3-6. Route towards the synthesis of 5’-O-(L-alanyl-D,L-2-mercaptoethanolglycine) TMP. 
Reagents and conditions: (a) 2-mercaptoethanol, Et3N, dry DMF, 0 °C to r.t.,16 h; (b) POCl3, 
trimethyl phosphate, -20 °C to r.t., 8 h (c) N-methyl imidazole, CH2Cl2, 0 °C to r.t.,16 h. 
 
It was therefore decided to turn to an alternative protecting group approach for the synthesis of 
3.4 (Scheme 7). Thioethanol derivative 3.26 was isolated in good yield (77%) from its acetoxy 
derivative 3.12. Analogously to the synthesis of 3.25, the corresponding phospho-diester derivative 
3.29 was obtained in low yield (12%) over two steps. It was found that the low conversion rates of 
3.27 into intermediate 3.28 is the main cause for the formation of complex by-products in the next 
base-promoted step, due to the presence of unreacted starting material. Other methods were explored 
in order to improve the yield of 3.28, including the use of POCl3 with different bases and solvents,[14] 
but unfortunately none led to improved conversions, and the formation of dimers was detected even 
under controlled conditions. Finally, the removal of the Boc group was achieved via the 
TFA/Thioanisole method, followed by the simultaneous hydrolysis of glycine-ester and the 3’-
benzoyl group with LiOH, affording 3.4 in good yield (72%) over two steps. 
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Scheme 3-7. Synthesis of 5’-O-(L-alanyl-D,L-2-mercaptoethanolglycine) TMP. Reagents and 
conditions: (a) 2-mercaptoethanol, Et3N, dry DMF, 0 °C to r.t.,16 h; (b) POCl3, trimethyl phosphate, -
20 °C to r.t., 8 h (c) N-methyl imidazole, CH2Cl2, 0 °C to r.t.,16 h; (d) TFA, CH2Cl2, thioanisole, 0 °C 
to r.t., 4 h; (e) LiOH, MeOH:H2O 1:1, 0 °C to r.t., 3 h. 
 
As separation of diastereomers by preparative RP-HPLC represents a limitation with regard to the 
quantities of products that can be purified, we tried to perform this step at the latest stage of the 
synthetic pathway for all the conjugates. Moreover effective separation could be achieved only in 
some cases. Therefore it was thought that the enzymatic separation of starting diastereomeric peptides 
could offer a solution to obtain large quantities of pure final compounds. Accordingly, the 
diastereomeric mixture of N-Boc-L-Val-D,L-benzyloxy-Gly-OMe was successfully resolved by 
enzyme catalyzed ester hydrolysis using subtilin Carlsberg (Scheme 3-8).[8] Conversely, similar 
conditions applied to N-Boc-L-Ala-D,L-benzyloxy-Gly-OMe resulted in a lousy separation, may be 
due to poor substrate specificity. 
 
 
Scheme 3-8. Route towards the enzymatic separation of diastereomers. Reagents and conditions: (a) 
DABCO, dry THF, BnOH, -78 °C to r.t., 24 h; (b) Subtilisin Carlsberg, 1M NaOH, DMF/H2O 1:1, pH 
= 7.2, 55 °C. 
 
For our last targets, phosphorothioate derivatives 3.38a and 3.38b, the initially followed retro-
synthetic Route 2 was replaced by the alternative approach described in Scheme 3-9, as it was not 
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possible to isolate the N-Boc-L-alanyl-D,L-2-thioglycine methyl ester synthon in pure form, likely due 
to the instability of the free thiol group. The synthesis of thymidine-5’-O-phosphorothioate 3.36 is 
reported in the literature via a solid-phase methodology.[15] Despite being effective for small amounts, 
on scale-up this protocol was not reproducible. Thus, monothiophosphorylation with PSCl3[16] was 
next explored to access 3.36 in one step from thymidine, but the reaction rates were found to be 
sluggish and the process non-selective in the presence of an excess of reagent. However, the 
protection of 3’-OH of thymidine and the use of an improved oxathiaphospholane approach adapted 
from the literature were, could overcome the low conversions.[17] As depicted in Scheme 3-9, 
compound 3.34 was obtained from N,N-diisopropyl phosphoramidous dichloride and 2-mercapto 
ethanol in the presence of DIPEA, and, without purification, was reacted with 3’-O-benzoyl 
thymidine and S-ethylthio tetrazole. In situ sulfurization with elemental S8 afforded 3.35 in excellent 
yield (93%) over three steps. Opening of the oxathiaphospholane ring of 3.35 with 3-
hydroxypropionitrile and simultaneous removal of 2-cyanoethyl and 3’-benzoyl groups using 25% 
aqueous ammonia in a sealed tube produced 3.36 in good yield. Compound 3.37 was obtained in just 
4 h as a diastereomeric mixture following selective S-alkylation over N3-alkylation, by reacting 
compound 3.36 with compound 3.19. Ultimately Boc cleavage and preparative RP-HPLC purification 
allowed the isolation of diastereomers 3.38a and 3.38b. When the two diastereomers were separately 
subjected to ester hydrolysis with LiOH , TMP was mainly isolated. 
 
 
Scheme 3-9. Synthesis of thymidine-5’-O-(L-alanyl-D,L-2-aminoglycine methyl ester)-
phosphorothioate. Reagents and conditions: (a) 2-mercapto ethanol, DIPEA, diethyl ether, -20 °C to 
r.t., 2.5 h, (b) (i) 3'-O-benzoyl thymidine, S-ethylthio tetrazole, CH2Cl2, 0 °C to r.t., 3 h; (ii) S8, r.t., 
overnight; (c) 3-hydroxy propionitrile, DBU, r.t., 8 h; (d) 25% NH3, 55 °C, sealed tube, 16 h; (e) 
Compound 3.19, Et3N, DMF, 37 °C, 4 h; (f) TFA, thioanisole, CH2Cl2, 0 °C to r.t., 3 h. 
 
The in cellulo mode of breakdown of α-substituted glycine peptide-conjugates after peptidase 
cleavage was postulated by Gilverg et. al.[2] In this context, the formation of TMP as side-product 
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during the synthesis of compounds 3.1-3.3 could be explained with the anchimeric assistance of the α-
carboxylic group of glycine to the phosphorus atom leading to the formation of a 5-membered ring 
intermediate. This phenomenon has previously been noticed at different rates in the presence of 
phosphate, phosphoramidate and phosphorothiate moieties.[18] By masking the free α-carboxyl group 
of glycine as methyl ester it was possible to resolve the meta-stability of the corresponding 
compounds. 
 
3.3. CHAIN ELONGATION EXPERIMENTS (performed by Lia Margamuljana) 
As dipeptides are comparable in terms of size to the pyrophosphate group,[19] it was envisioned 
that L-Ala-Gly could also act as a alternative leaving group in the enzyme catalyzed DNA 
polymerization reaction. In this study, the activities of different thermophilic and mesophilic 
microbial DNA polymerases were compared, comprising Therminator, Vent (exo-) and the Klenow 
fragment (exo-) of E. coli DNA Polymerase I. In order to investigate the strand elongation capacity of 
all the final analogues exhibiting α-substituted glycines connected through various phospho-linkers 
(3.1, 3.2a, 3.2b, 3.23, 3.4 and 3.38a-b), a polyacrylamide gel-based template-dependent incorporation 
assay of multiple nucleotides was carried out, using a tagged 5’-radiolabelled γ-33P or a fluorescent 
DNA primer (P1) annealed in turn to T1-3 templates (Table 3-1).  
 
Table 3-1. Overview of primer and templates sequences used in the incorporation experiments. 
Primer  P1:     5’ /5Cy5/CAGGAAACAGCTATGAC 3’ 
Template T1:  3’ GTCCTTTGTCGATACTGAAAAA 5’ 
Template T3:    3’ GTCCTTTGTCGATACTGATTTT 5’ 
 
Amongst all the compounds screened as potential triphosphate mimics, phosphoramidate 
analogues 3.2a and 3.2b exhibited interesting incorporation efficiencies with all tested polymerases 
(Fig. 3-4A). Compound 3.1 showed poor incorporation efficiency and exclusively with Therminator 
polymerase. On the basis of these observations, it can be deduced that the free carboxylic group along 
with an appropriate chain length are both crucial factors for incorporation. Vent (exo-) showed poorer 
efficiency than Therminator and the Klenow fragment, producing only 4% (P + 4) strand formation 
for 3.2a, and 11% (P + 3) for 3.2b at 1mM concentration after 60 min. Therminator gave 76% full 
length product (P + 5) and up to 4% (P + 4) strand formation for 3.2a and 3.2b respectively. The 
Klenow fragment showed the best incorporation efficiency, leading to the formation of 27% full 
length product (P + 5) and up to 11% of (P + 4) strand at 1mM concentration after only 15 min. 
Notably, 3.2a exhibited better substrate properties than its diastereomer 3.2b, probably because of 
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different binding efficacy in the enzyme pocket which might be clarified with the aid of a modeling 
study.  
 
 
 
Figure 3-4. (A) Chain elongation efficiencies of compounds 3.2a and 3.2b by Vent (exo-) (0.01 U.µl-
1), Therminator (0.01 U.µl-1) and Klenow fragment (0.05 U.µl-1) polymerases, at 1mM conc. after 
60 min. (B) Chain elongation profile of control TTP and compounds 3.2a and 3.2b as substrates into 
the P1:T1 complex by Klenow polymerase (0.05 U.µl-1). 
 
Table 3-2 Steady–state kinetics of single nucleotide incorporation into P1T3 by Klenow fragment 
(0.005 U.µl-1). 
Substrate Vmax [nM.min-1] Km [µM] 
Vmax / Km 
[x 10-3 min-1] 
TTP 30.59 ± 0.74 0.088 ± 0.006 347.61 
Compound 2a 30.48 ± 1.04 87.21 ± 9.21 0.3495 
 
As the best incorporation results were obtained with phosphoramidate 3.2a and Klenow fragment 
(exo-) polymerase, the kinetic parameters of 3.2a were compared with its natural substrate counterpart 
TTP, based on the Single Complete Hot model. Steady-state kinetic analysis (Table 3-2) indicates a 
comparable Vmax value, but a Km which is 991-fold higher, with a final Vmax/Km ratio for compound 
3.2a 994-fold lower than the natural substrate. This result is falls within the range of kinetic values 
previously reported for other leaving groups in our lab.[10] 
 
3.4. MODELING STUDY OF 3.2a AND 3.2b BOUND TO E. coli KLENOW FRAGMENT 
(DNA polymerase) (performed by Prof. Mathy Froeyen) 
Based on a homology model of E. coli Klenow fragment of DNA polymerase I (details can be 
found in the experimental section and supplementary information), both diastereomers 3.2a and 3.2b 
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were able to bind in the enzyme-binding site for the accommodation of triphosphates. The molecular 
mechanics energy of the complex enzyme-DNA duplex-3.2a is slightly lower than that of the similar 
complex with 3.2b. The better energetic profile for the 3.2a molecule complex can be attributed to the 
extra ionic interaction of the carbonyl group with one Mg2+ ion in the 3.2a-complex. In the 3.2b-
complex, the Mg2+ ion interacts with an uncharged carbonyl group of the peptide bond, which is 
supposed to be weaker. Additionally, 3.2a forms also a hydrogen bond between this C=O and the 
residue I386 backbone nitrogen and possibly a stabilizing cationic-pi-interaction of the charged NH3+ 
to the F439 electron rich aromatic ring. This modeling study clearly indicates that a stronger binding 
affinity to the enzymatic site might be the key factor for the better incorporation efficiency observed 
for 3.2a over 3.2b. The determination of the absolute configuration (R/S) of each diastereomer is 
based on incorporation efficiency and modeling study. 
 
 
 
Figure 3-5. Compounds TTP (Fig 3-5A), 3.2a (Fig 3-5B) and 3.2b (Fig 3-5C) in the E. coli Klenow 
fragment pocket. The primer strand is shown as a cameo pink ribbon, whilst the template strand is in 
cyan. Hydrogen bond distances between the bases are indicated in Å. The ligation of the 2Mg2+ ions 
to the complex is also visualized by dashes and distances in Å. The figures were generated using 
chimera. 
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3.5. CONCLUSION 
A novel series of 5’-modified derivatives of TMP with the dipeptide L-Ala-Gly were successfully 
prepared, by nucleophilic substitution either at the α-position of glycine or at the phosphorous-group 
of TMP. Different phosphoester linkers such as phosphate, phosphoramidate, phosphorothioate and 
thioethyl-phosphate were used to connect those PNCs. In a template-based multiple incorporation 
assay, analogues 3.2a and 3.2b featuring a phosphoramidate linker and the Klenow fragment 
(exonuclease-free) of DNA polymerase I were found to be the best substrate and the most effective 
polymerase respectively, giving the best strand elongation rates. A free carboxylic group at the C-
terminal of the dipeptidic chain was necessary for binding in the active site of the enzyme, and is also 
accountable for the destabilization of the conjugates resulting from hydrolytic cleavage through 
anchimeric assistance. The further exploration of such dipeptides as leaving groups for DNA 
polymerization can be a valuable tool for synthetic biology, drug delivery, polymerase chain reaction 
(PCR) and as potential prodrugs for antiviral therapy. 
 
3.6. EXPERIMENTAL SECTION 
General Information 
For all reactions, analytical grade solvents were used. TMP-disodium salt was transformed into its 
triethylammonium salt, first by treatment with Amberlite IRA-120B ion exchange resin (H+ form) and 
then with triethylamine. All moisture-sensitive reactions were carried out using oven-dried glassware 
(135 ºC) under a nitrogen or argon atmosphere. Reaction temperatures are reported as bath 
temperatures. Pre-coated aluminum sheets (254 nm) were used for TLC. Compounds were visualized 
with UV light (λ = 254 nm). Products were purified by flash chromatography on ICN silica gel 63-
200, 60 Å. All final compounds were purified by preparative RP-HPLC (XbridgeTM Prep C18 5µm 
OBD 19 x 150 mm column) using a gradient of H2O and CH3CN, or both containing 50 mmol TEAB 
as eluent buffer. 1H, 13C and 31P NMR spectra were recorded on Bruker Avance 300 MHz, 500 MHz 
or 600 MHz spectrometers. Final compounds were characterized using 2D NMR (H-COSY, HSQC, 
HMBC, TOCSY and NOESY) techniques. For sake of clarity, NMR signals of protons and carbons 
for sugar and base moieties are indicated with and without a prime, respectively. Chemical shifts were 
referenced to residual solvent signals at δ H/C 7.26/77.00 (CDCl3), 3.31/49.10 (CD3OD), 1.94/118.7 
(CD3CN) and 2.50/39.50 (DMSO-d6) relative to TMS as internal standard wherever applied. Coupling 
constants are expressed in hertz (Hz) and were directly obtained from the spectra. Splitting patterns 
are designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad) and apparent 
(app). High-resolution mass spectra (HRMS) were obtained on a quadruple orthogonal acceleration 
time-of-flight mass spectrometer (Synapt G2 HDMS, Waters, Milford, MA). Samples were infused at 
3 µL/min and spectra were obtained in positive (or negative) ionization mode with a resolution of 
15000 (FWHM) using leucine enkephalin as lock mass. 
 
N-Carbobenzyloxy-L-alanyl-D,L-2-hydroxyglycine benzyl ester (3.5). 
To a stirred suspension of N-carbobenzoxy-L-alanine amide (2.0 g, 9.0 mmol) in CH2Cl2 (40 mL) 
were added benzyl glyoxalate (1.85 g, 11.25 mmol) and a catalytic amount of p-toluene sulfonic acid 
(0.03 g, 0.18 mmol). The reaction mixture was then stirred at room temperature for 7 days and 
monitored by TLC. Upon completion, the reaction mixture was concentrated under reduced pressure 
and the resulting crude residue was purified by column chromatography on silica gel (gradient 
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EtOAc/Hexane, 1:4, v/v; 2:3, v/v; 3:2, v/v) to give 3.5 (2.44 g, 70%) as a white solid. 1H NMR (300 
MHz, DMSO-d6) δ = 8.79 and 8.77 (2 x d, J = 8.5 Hz, 1H, NH-Gly), 7.44 (d, J = 7.9 Hz, 1H, NH-
Ala), 7.37-7.33 (m, 10H, 2 x OBn), 6.74-6.65 (m, 1H, αH-Gly), 5.53 (br s, 1H, αOH-Gly), 5.16-5.14 
(m, 2H, CH2-CO2Bn), 5.02 (s, 2H, CH2-Cbz), 4.17-4.07 (m, 1H, αH-Ala), 1.19 (app t, J = 7.7 Hz, 3H, 
CH3-Ala); 13C NMR (75 MHz, DMSO-d6) δ = 172.5 and 172.5 (CO-Ala), 169.6 and 169.6 (CO-Gly), 
155.6 (NHCONH), 137.0 and 137.0 (1C of OCH2Ph), 135.7 and 135.7 (1C of OCH2Ph), 128.4 and 
128.4 (Ar-C), 128.2 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.8 and 127.8 (Ar-C), 127.7 and 127.7 
(Ar-C), 71.4 and 71.4 (αC-Gly), 66.1 and 66.1 (CH2-CO2Bn), 65.4 and 65.4 (CH2-Cbz), 49.9 and 49.8 
(αC-Ala), 18.1 and 18.0 (CH3-Ala); HRMS for C20H22N2O6 [M-H]- calcd.: 385.1405, found: 385.1402. 
 
3’-O-Benzyl-5’-O-(O-benzyl-N,N-diisopropyl phosphoramidite)thymidine (3.9). 
To a stirred solution of compound 3.8 (300 mg, 0.903 mmol) in anhydrous CH2Cl2 (18 mL) was 
added a solution of benzyloxy-bis(N,N-diisopropylamino)phosphine (1.68 mL, 0.92 mmol, 0.549 M in 
anhydrous CH2Cl2) followed by a solution of 1H-tetrazole (2.04 mL, 0.92 mmol, 0.45 M in anhydrous 
AcCN) at 0 °C. The reaction mixture was stirred at room temperature for 4 h. It was then quenched 
with saturated aq. NaHCO3 and extracted with CH2Cl2. The organic layer was dried over Na2SO4 and 
concentrated under reduced pressure. The crude residue was purified by flash chromatography on 
silica gel (gradient Et3N/EtOAc/Hexane, 0.2:20:79.8, v/v/v; 0.2:40:59.8, v/v/v; 0.2:80:19.8, v/v/v). 
The fraction containing the phosphoramidite were combined and concentrated to afford compound 3.9 
(497 mg, 72% over two steps) as a white solid. 1H NMR (300 MHz, CDCl3) δ = 7.67 and 7.56 (2 x s, 
1H, H-6), 7.36-7.24 (m, 10H, 2 x OBn), 6.43-6.34 (m, 1H, H-1’), 4.80-4.63 (m, 2H, CH2P-OBn), 
4.58-4.34 (m, 2H, H-5’ and H-5’’), 4.27 and 4.23 (2 x s, 2H, CH2-3’-OBn), 3.79-3.78 (m, 1H, H-3’), 
3,64-3.60 (m, 3H, H-4’ and 2 x H-iPr), 2.54-2.38 (m, 1H, H-2’), 2.01-1.95 (m, 1H, H-2’’), 1.86 and 
1.80 (2 x s, 3H, CH3-Thy), 1.23-1.15 (m, 12H, CH3, 4 x iPr); 31P NMR (121 MHz, CDCl3) δ = 148.6 
and 148.1; HRMS for C30H40N3O6P [M+H]+ calcd.: 570.2727, found: 570.2732. 
 
N-Carbobenzyloxy-L-alanyl-D,L-2-acetoxyglycine benzyl ester (3.12). 
Pyridine (21.6 mL) was added dropwise to a stirred suspension of compound 3.5 (2.4 g, 6.21 mmol) 
in acetic anhydride (30 mL) at 0 °C. The reaction mixture was stirred at the same temperature for 8 h 
and monitored by TLC. Upon completion, the mixture was concentrated under reduced pressure (bath 
temp. ~15 °C). The residue was diluted with EtOAc (150 mL) and washed with H2O (2 x 50 mL), 1N 
HCl (2 x 50 mL), 5% NaHCO3 (2 x 50 mL) and finally with brine (100 mL). The organic layer was 
dried over Na2SO4, filtered and concentrated in vacuo. The resulting crude residue was triturated with 
cold Et2O to give 3.12 (2.02 g, 76%) as a white solid. 1H NMR (300 MHz, CDCl3) δ = 7.59, 7.54 (2 x 
d, J = 8.5 Hz, 1H, NH-Gly), 7.35-7.26 (m, 10H, 2 x OBn), 6.43, 6.39 (2 x d, J = 8.9 Hz, 1H, αH-Gly), 
5.31 (app t, 1H, NH-Ala), 5.20 (s, 2H, CH2-CO2Bn), 5.09 (s, 2H, CH2-Cbz), 4.35-4.30 (m, 1H, αH-
Ala), 2.05 (s, 3H, CH3-OAc), 1.38 and 1.36 (2 x d, J = 7.0 Hz, 3H, CH3-Ala); 13C NMR (75 MHz, 
CDCl3) δ = 172.4 and 172.4 (CO-Ala), 170.3 and 170.3 (CO-OAc), 166.4 (CO-Gly), 156.0 
(OCONH), 136.1 (1C of OCH2Ph), 134.8 (1C of OCH2Ph), 128.8 (Ar-C), 128.7 (Ar-C), 128.4 (Ar-C), 
128.2 (Ar-C), 72.3 and 72.3 (αC-Gly), 68.3 (CH2-CO2Bn), 67.4 and 67.4 (CH2-Cbz), 50.5 (αC-Ala), 
20.7 (CH3-OAc), 18.5 and 18.2 (CH3-Ala); HRMS for C22H24N2O7 [M+Na]+ calcd.: 451.1476, found: 
451.1474. 
 
5’-O-(N-Carbobenzyloxy-L-alanyl-D,L-2-aminoglycine benzyl ester)-TMP (3.13) and 3-N-(N-
carbobenzyloxy-L-alanyl-D,L-2-aminoglycine benzyl ester)-TMP triethylammonium salt (3.14).  
To a stirred solution of TMP-triethylammonium salt (344 mg, 0.809 mmol) and compound 3.12 (476 
mg, 1.496 mmol) in dry DMF (6 mL) was added Et3N (0.45 mL, 3.234 mmol). The reaction mixture 
was heated at 40 °C for 24 h. It was then allowed to cool to room temperature, the volatiles were 
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removed under reduced pressure, and the resulting residue was dissolved in water and lyophilized. 
The crude product was purified by preparative RP-HPLC (98% H2O + 2% CH3CN and 98% CH3CN + 
2% H2O). The collected eluates were freeze-dried repeatedly until constant mass to afford compound 
3.13 (49.6 mg, 8%) as minor product and compound 3.14 (270 mg, 40%) as major product, both as 
white solids. Data for 3.13: 1H NMR (600 MHz, CD3OD) δ = 7.77 and 7.76 (2 x s, 1H, H-6), 7.36-
7.26 (m, 10H, 2 x OBn), 6.32-6.29 (m, 1H, H-1’), 6.06 and 6.01 (2 x d, J = 10.0 Hz, 1H, αH-Gly), 
5.22-5.15 (m, 2H, CH2-CO2Bn), 5.09-5.03 (m, 2H, CH2-Cbz), 4.49-4.46 (m, 1H, H-3’), 4.19-4.16 (m, 
1H, αH-Ala), 4.07-4.02 (m, 2H, H-5’ and H-5’’), 3.99-3.97 (m, 1H, H-4’), 2.22-2.14 (m, 2H, H-2’ and 
H-2’’), 1.90 and 1.89 (2 x s, 3H, CH3-Thy), 1.30-1.27 (m, 3H, CH3-Ala, merged with Et3N); 13C NMR 
(125 MHz, CD3OD) δ = 175.1 and 175.0 (CO-Ala), 169.2 (CO-Gly), 166.6 and 166.5 (C-4), 158.2 
and 158.1 (OCONH), 152.5 (C-2), 138.1 (C-6 and 1C OBn), 136.9 (1C OBn), 129.6 (Ar-C), 129.5 
(Ar-C), 129.4 (Ar-C), 129.3 (Ar-C), 129.0 (Ar-C), 128.9 (Ar-C), 112.0 (C-5), 87.5 and 87.4 (d, 3JC,P = 
9.4 Hz, C-4’), 86.2 and 86.1 (C-1’), 75.3 (d, 2JC,P = 12.2 Hz, αC-Gly), 72.9 and 72.8 (C-3’), 68.5 
(CH2-CO2Bn), 67.7 (CH2-Cbz), 66.6 and 66.5 (d, 2JC,P = 5.4 Hz, C-5’), 51.8 (αC-Ala), 40.9 (C-2’), 
18.4 and 18.2 (CH3-Ala), 12.6 (CH3-Thy); 31P NMR (202 MHz, CD3OD) δ = -2.1 and -2.2; HRMS for 
C30H35N4O13P [M-H]- calcd.: 689.1865, found: 689.1879. 
Data for 3.14: 1H NMR (500 MHz, CD3OD) δ = 7.93 (s, 1H, H-6), 7.37-7.29 (m, 11H, αH-Gly and 2 
x OBn), 6.34-6.30 (m, 1H, H-1’), 5.28-5.08 (m, 2H, CH2-CO2Bn), 5.06-5.04 (m, 2H, CH2-Cbz), 4.50 
(br s, 1H, H-3’), 4.26-4.19 (m, 1H, αH-Ala), 4.08-4.04 (m, 3H, H-4’, H-5’ and H-5’’), 2.26-2.19 (m, 
2H, H-2’ and H-2’’), 1.95 (s, 3H, CH3-Thy), 1.34 and 1.32 (2 x d, J = 7.1 Hz, 3H, CH3-Ala, merged 
with Et3N); 13C NMR (125 MHz, CD3OD) δ = 175.4 and 175.3 (CO-Ala), 168.3 and 168.2 (CO-Gly), 
164.3 (C-4), 158.3 and 158.2 (OCONH), 151.7 (C-2), 138.1 and 138.0 (1C OBn), 137.5 and 137.4 (C-
6), 136.7 (1C OBn), 129.6 (Ar C), 129.5 (Ar C), 129.4 (Ar C), 129.2 (Ar C), 129.1 (Ar C), 129.0 (Ar 
C), 128.9 (Ar C), 128.8 (Ar C), 111.3 and 111.2 (C-5), 87.9 and 87.8 (d, 3JC,P = 8.8 Hz, C-4’), 87.1 
and 87.0 (C-1’), 72.7 and 72.6 (C-3’), 68.9 (CH2-CO2Bn), 67.8 and 67.7 (CH2-Cbz), 65.9 (d, 2JC,P = 
4.8 Hz, C-5’), 58.2 and 58.1 (αC-Gly), 52.0 and 51.6 (αC-Ala), 41.1 and 41.0 (C-2’), 18.0 and 17.9 
(CH3-Ala), 13.0 (CH3-Thy); 31P NMR (202 MHz, CD3OD) δ = 0.7; HRMS for C30H35N4O13P [M-H]- 
calcd.: 689.1865, found: 689.1862. 
 
5’-O-(L-Alanyl-D,L-2-aminoglycine)-TMP (3.1). 
To a stirred solution of 3.13 (30 mg, 0.0434 mmol, 1 eq.) in EtOH/H2O (5:1, 5 mL), was added 10% 
Pd/C, Degussa-type (6 mg, 0.2 eq w/w) and evacuation was then carried out with hydrogen 
atmosphere replacements (3x). The reaction mixture was stirred at room temperature for 4 h under an 
atmospheric pressure of hydrogen. Upon completion, the catalyst was removed by filtration through a 
cellulose filter (0.45 µm) and ethanol was removed under reduced pressure (bath temp. ~ 10 °C). The 
residue was lyophilized to obtain a crude product which was purified by preparative RP-HPLC (98% 
H2O + 2% CH3CN and 98% CH3CN + 2% H2O as eluent). The collected eluates were freeze-dried 
repeatedly until constant mass to afford compound 3.1 as a white solid (8.5 mg, 42%). 1H NMR (300 
MHz, D2O) δ = 7.73 and 7.70 (2 x s, 1H, H-6), 6.37-6.30 (m, 1H, H-1’), 5.73 (d, J = 9.0 Hz, 1H, αH-
Gly), 4.60-4.54 (m, 1H, H-3’), 4.18-4.02 (m, 4H, H-4’, αH-Ala, H-5’ and H-5’’), 2.37-2.33 (m, 2H, 
H-2’ and H-2’’), 1.91 (s, 3H, CH3-Thy), 1.53 (d, J = 7.1 Hz, 3H, CH3-Ala); 13C NMR (125 MHz, 
D2O) δ = 172.8 (CO-Gly), 169.9 and 169.8 (CO-Ala), 166.4 (C-4), 151.5 (C-2), 137.1 and 137.0 (C-
6), 111.5 and 111.5 (C-5), 85.1 and 85.0 (d, 3JC,P = 9.2 Hz, C-4’), 84.7 and 84.6 (C-1’), 74.8 (C-3’), 
70.9 and 70.8 (αC-Gly), 64.9 and 64.8 (d, 2JC,P = 5.2 Hz, C-5’), 48.8 and 48.7 (αC-Ala), 38.4 and 38.3 
(C-2’), 15.9 and 15.8 (CH3-Ala), 11.4 (CH3-Thy); 31P NMR (121 MHz, D2O) δ = -2.0; HRMS for 
C15H23N4O11P [M-H]- calcd.: 465.1028, found: 465.1029. 
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3-N-(L-Alanyl-D,L-2-aminoglycine)-TMP triethylammonium salt (3.15). 
Following a similar procedure as the one used for the synthesis of 3.1, compound 3.15 was obtained 
as a white solid (179.1 mg, 92%), starting from 3.14 (260 mg, 0.343 mmol), 10% Pd/C, Degussa-type 
(52 mg, 0.2 eq w/w) in a 5:1 EtOH:H2O mixture (15 mL). 1H NMR (500 MHz, D2O) δ = 7.76 and 
7.74 (2 x s, 1H, H-6), 6.90 and 6.86 (2 x s, 1H, αH-Gly), 6.32 (app t, J = 6.8 Hz, 1H, H-1’), 4.55-4.52 
(m, 1H, H-3’), 4.21-4.16 (m, 1H, αH-Ala), 4.15-4.14 (m, 1H, H-4’), 4.11-4.01 (m, 2H, H-5’ and H-
5’’), 2.36-2.33 (m, 2H, H-2’ and H-2’’), 1.91 (s, 3H, CH3-Thy), 1.58 and 1.41 (2 x d, J = 7.1 Hz, 3H, 
CH3-Ala); 13C NMR (150 MHz, D2O) δ = 171.0 and 170.9 (CO-Gly), 170.5 and 170.4 (CO-Ala), 
164.1 (C-4), 150.7 (C-2), 135.9 (C-6), 110.6 (C-5), 85.6 (C-1’), 85.3 (d, 3JC,P = 9.3 Hz, C-4’), 70.7 (C-
3’), 64.4 (C-5’), 58.3 and 58.2 (αC-Gly), 48.7 and 48.6 (αC-Ala), 38.6 (C-2’), 16.1 and 16.0 (CH3-
Ala), 11.9 (CH3-Thy); 31P NMR (202 MHz, D2O) δ = 0.04; HRMS for C15H23N4O11P [M-H]- calcd.: 
465.1028, found: 465.1025. 
 
N-Carbobenzyloxy-L-alanyl-D,L-2-azidoglycine benzyl ester (3.16).  
DPPA (1.56 mL, 7.26 mmol) was added dropwise to a stirred suspension of compound 3.5 (2.0 g, 
5.18 mmol) and DBU (1.08 mL, 7.26 mmol) in dry toluene (50 mL) at 0 °C. The reaction mixture was 
then slowly warmed to room temperature and the stirring was continued for 16 h. The resulting 
mixture was concentrated under reduced pressure (bath temp. ~15 °C). The residue was diluted with 
EtOAc (150 mL) and washed with brine (50 mL) and 5% HCl (2 x 50 mL). The organic layer was 
dried over Na2SO4, filtered and concentrated in vacuo and the resulting crude residue was purified by 
column chromatography on silica gel (gradient EtOAc/Hexane, 1:9, v/v; 1:4, v/v; 2:3, v/v) to give 
3.16 (1.51 g, 71%) as a colorless foam. 1H NMR (300 MHz, CDCl3) δ = 7.81-7.77 (2 x d, J = 7.1 Hz, 
1H, NH-Gly), 7.34-7.30 (m, 10H, 2 x OBn), 5.79 and 5.78 (2 x d, J = 8.2 Hz, 1H, αH-Gly), 5.65 (d, J 
= 6.3 Hz, 1H, NH-Ala), 5.21 and 5.20 (2 x s, 2H, CH2-CO2Bn), 5.08 and 5.07 (2 x s, 2H, CH2-Cbz), 
4.43-4.38 (m, 1H, αH-Ala), 1.36 (app t, J = 6.3 Hz, 3H, CH3-Ala); 13C NMR (75 MHz, CDCl3) δ = 
173.3 (CO-Ala), 166.4 (CO-Gly), 156.1 (OCONH), 136.2 (1C of OCH2Ph), 134.4 (1C of OCH2Ph), 
128.9 (Ar-C), 128.7 (Ar-C), 128.6 (Ar-C), 128.5 (Ar-C), 128.3 (Ar-C), 128.1 (Ar-C), 68.5 (αC-Gly), 
67.3 (CH2-CO2Bn), 64.7 and 64.6 (CH2-Cbz), 50.4 (αC-Ala), 18.6, 18.3 (CH3-Ala); HRMS for 
C20H21N5O5 [M+Na]+ calcd.: 434.1435, found: 434.1432. 
 
N-Carbobenzyloxy-L-alanyl-D,L-2-aminoglycine benzyl ester (3.17).  
Triphenylphospine (0.92 g, 3.50 mmol) was added to a stirred solution of 3.16 (1.2 g, 2.92 mmol) and 
water (0.26 mL, 14.6 mmol) in THF (15 mL). The reaction mixture was refluxed for 2 h, then cooled 
to room temperature and concentrated under reduced pressure. Water (100 mL) was added to the 
residue and the solution was extracted with CH2Cl2 (3 x 100 mL). The organic layer was dried over 
Na2SO4, filtered and concentrated in vacuo and the resulting crude residue was purified by column 
chromatography on silica gel (gradient MeOH/CH2Cl2, 1:99, v/v; 1:49, v/v; 1:19, v/v) to give 3.17 
(0.79 g, 70%) as a colorless foam. 1H NMR (300 MHz, CDCl3) δ = 7.77 and 7.73 (2 x d, J = 8.3 Hz, 
1H, NH-Gly), 7.31-7.29 (m, 10H, 2 x OBn), 5.74 (app t, J = 9.0 Hz, 1H, NH-Ala), 5.17- 5.07 (m, 3H, 
αH-Gly and CH2-CO2Bn), 5.06 and 5.04 (2 x s, 2H, CH2-Cbz), 4.30-4.20 (m, 1H, αH-Ala), 2.84 (br s, 
2H, αNH2-Gly), 1.31 and 1.30 (2 x d, J = 7.0 Hz, 3H, CH3-Ala); 13C NMR (75 MHz, CDCl3) δ = 
172.7 (CO-Ala), 170.5 (CO-Gly), 156.0 (OCONH), 136.3 (1C of OCH2Ph), 135.1 (1C of OCH2Ph), 
128.6 (Ar-C), 128.5 (Ar-C), 128.3 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 67.6 (αC-Gly), 67.0 (CH2-
CO2Bn), 60.3 and 60.2 (CH2-Cbz), 50.5 (αC-Ala), 18.5 (CH3-Ala); HRMS for C20H23N3O5 [M+Na]+ 
calcd.: 408.1530, found: 408.1523. 
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Thymidine-5’-O-(N-carbobenzyloxy-L-alanyl-R-2-aminoglycine benzyl ester) phosphoramidate 
(3.18a) and thymidine-5’-O-(N-carbobenzyloxy-L-alanyl-S-2-aminoglycine benzyl ester) 
phosphoramidate (3.18b).  
o a stirred suspension of TMP-triehtylammonium salt (400 mg, 0.737 mmol) and compound 3.17 (640 
mg, 1.659 mmol) in a 4:1 tBuOH/H2O mixture (15 mL), triethylamine (0.1 mL, 0.737 mmol) was 
added to facilitate dissolution, followed by DCC (532 mg, 2.579 mmol). The reaction mixture was 
heated at 85 ºC for 2.5 h. The reaction progress was monitored by TLC (CH2Cl2:MeOH:H2O 17:7:1). 
Upon completion, the mixture was cooled to room temperature and the solvent was removed by rotary 
evaporation. The resulting residue was resuspended in water and lyophilized to give a crude material 
which was purified by column chromatography on silica gel using the following gradient 
(CH2Cl2:MeOH:H2O 19:1:0, v/v/v;  9:1:0, v/v/v; 17:7:1, v/v/v) to provide the desired nucleoside 
phosphoramidates as salts. Semi-preparative RP-HPLC (98% H2O + 2% CH3CN and 98% CH3CN + 
2% H2O as eluent) was employed for further separation, to obtain the pure diastereomers as a ~1:1 
ratio, as white powders (131 mg of compound 3.18a, 129 mg of compound 3.18b, overall yield 3.18a 
+ 3.18b 260 mg, 51%). The isolated products were freeze-dried repeatedly until constant mass. Data 
for 3.18a: 1H NMR (500 MHz, CD3CN + D2O, 50 ºC) δ = 7.55 (s, 1H, H-6), 7.32-7.28 (m, 10H, 2 x 
OBn), 6.14 (app t, J = 6.8 Hz, 1H, H-1’), 5.21 and 5.16 (2 x d, J = 10.9 Hz, 1H, αH-Gly), 5.14- 4.99 
(m, 4H, CH2-CO2Bn and CH2-Cbz), 4.38-4.36 (m, 1H, H-3’), 4.11-4.06 (m, 1H, αH-Ala), 3.93-3.91 
(m, 1H, H-4’), 3.87-3.82 (m, 2H, H-5’ and H-5’’), 2.17-2.13 (m, 2H, H-2’ and H-2’’), 1.80 and 1.79 
(2 x s, 3H, CH3-Thy), 1.20 (app t, J = 7.0 Hz, 3H, CH3-Ala); 13C NMR (150 MHz, CD3CN + D2O, 10 
ºC) δ = 174.6 (CO-Ala), 171.3 (CO-Gly), 166.3 (C-4), 157.5 (OCONH), 151.5 (C-2), 137.9 (C-6), 
137.5 (1C of OCH2Ph), 136.2 (1C of OCH2Ph), 129.5 (Ar-C), 129.4 (Ar-C), 129.2 (Ar-C), 129.0 (Ar-
C), 128.7 (Ar-C), 111.9 (C-5), 86.4 (d, 3JC,P = 8.9 Hz, C-4’), 84.8 (C-1’), 71.7 (C-3’), 68.3 (CH2-
CO2Bn), 67.4 (CH2-Cbz), 64.9 (d, 2JC,P = 3.9 Hz, C-5’), 61.1 (d, 2JC,P = 9.8 Hz, αC-Gly), 51.1 (αC-
Ala), 39.8 (C-2’), 18.1 (CH3-Ala), 12.6 (CH3-Thy); 31P NMR (202 MHz, CD3CN + D2O, 50 ºC) δ = 
4.4; [α]20589 = -0.147° (c = 1, CH3OH); HRMS for C30H36N5O12P [M-H]- calcd.: 688.2025, found: 
688.2040. 
Data for 3.18b: 1H NMR (300 MHz, CD3CN + D2O, 25 ºC) δ = 7.54 (s, 1H, H-6), 7.32-7.27 (m, 10H, 
2 x OBn), 6.14 (app t, J = 6.8 Hz, 1H, H-1’), 5.21 and 5.16 (2 x d, J = 10.9 Hz, 1H, αH-Gly), 5.11-
4.93 (m, 4H, CH2-CO2Bn and CH2-Cbz), 4.37-4.32 (m, 1H, H-3’), 4.11-4.01 (m, 1H, αH-Ala), 3.95-
3.90 (m, 1H, H-4’), 3.89-3.85 (m, 2H, H-5’ and H-5’’), 2.17-2.11 (m, 2H, H-2’ and H-2’’), 1.79 and 
1.77 (2 x s, 3H, CH3-Thy), 1.19 (app t, J = 7.0 Hz, 3H, CH3-Ala); 13C NMR (150 MHz, CD3CN + 
D2O, 10 ºC) δ = 174.7 (CO-Ala), 171.3 (CO-Gly), 166.3 (C-4), 157.5 (OCONH), 152.0 (C-2), 137.9 
(C-6), 137.5 (1C of OCH2Ph), 136.3 (1C of OCH2Ph), 129.5 (Ar-C), 129.4 (Ar-C), 129.0 (Ar-C), 
128.7 (Ar-C), 112.0 (C-5), 86.3 (d, 3JC,P = 8.7 Hz, C-4’), 85.5 (C-1’), 71.6 (C-3’), 68.4 (CH2-CO2Bn), 
67.4 (CH2-Cbz), 64.9 (d, 2JC,P = 5.1 Hz, C-5’), 61.1 (d, 2JC,P = 9.1 Hz, αC-Gly), 51.1 (αC-Ala), 39.7 
(C-2’), 18.1 (CH3-Ala), 12.6 (CH3-Thy); 31P NMR (121 MHz, CD3CN + D2O, 25 ºC) δ = 3.2; [α]20589 
= -0.052° (c = 1, CH3OH); HRMS for C30H36N5O12P [M-H]- calcd.: 688.2025, found: 688.2019. 
 
Thymidine-5’-O-(L-alanyl-R-2-aminoglycine) phosphoramidate (3.2a). 
Following a similar procedure as the one used for the synthesis of 3.1, compound 3.2a was obtained 
as a white solid (45.5 mg, 54%), starting from 3.18a (125 mg, 0.136 mmol, 1 eq.), 10% Pd/C, 
Degussa-type (25 mg, 0.2 eq w/w) in a 5:1 EtOH/H2O mixture (10 mL). 1H NMR (300 MHz, D2O) δ 
= 7.63 (d, J = 1.1 Hz, 1H, H-6), 6.14 (app t, J = 6.8 Hz, 1H, H-1’), 5.23 (d, J = 11.3 Hz, 1H, αH-Gly), 
4.50-4.45 (m, 1H, H-3’), 4.06-4.02 (m, 1H, H-4’), 4.00-3.88 (m, 3H, αH-Ala, H-5’ and H-5’’), 2.31-
2.26 (m, 2H, H-2’ and H-2’’), 1.82 (d, J = 1.1 Hz, 3H, CH3-Thy), 1.44 (d, J = 7.1 Hz, 3H, CH3-Ala); 
13C NMR (150 MHz, D2O) δ = 172.0 (d, 3JC,P = 9.1 Hz, CO-Gly), 169.9 (CO-Ala), 166.3 (C-4), 151.5 
(C-2), 137.3 (C-6), 111.5 (C-5), 85.2 (d, 3JC,P = 9.0 Hz, C-4’), 84.8 (C-1’), 70.8 (C-3’), 64.2 (d, 2JC,P = 
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4.6 Hz, C-5’), 61.1 (d, 2JC,P = 6.5 Hz, αC-Gly), 48.7 (αC-Ala), 38.4 (C-2’), 16.0 (CH3-Ala), 11.5 (CH3-
Thy); 31P NMR (121 MHz, D2O) δ = 4.4; HRMS for C15H24N5O10P [M-H]- calcd.: 464.1188, found: 
464.1185. 
 
Thymidine-5’-O-(L-alanyl-S-2-aminoglycine) phosphoramidate (3.2b). 
Following a similar procedure as the one used for the synthesis of 3.1, compound 3.2b was obtained 
as a white solid (43.0 mg, 51%), starting from 3.18b (125 mg, 0.136 mmol, 1 eq.), 10% Pd/C, 
Degussa-type (25 mg, 0.2 eq w/w) in a 5:1 EtOH/H2O mixture (10 mL). 1H NMR (300 MHz, D2O) δ 
= 7.68 (s, 1H, H-6), 6.25 (app t, J = 6.9 Hz, 1H, H-1’), 5.24 and 5.19 (2 x d, J = 11.0 Hz, 1H, αH-
Gly), 4.52-4.47 (m, 1H, H-3’), 4.11-4.07 (m, 1H, H-4’), 4.06-3.90 (m, 3H, αH-Ala, H-5’ and H-5’’), 
2.34-2.29 (m, 2H, H-2’ and H-2’’), 1.86 (s, 3H, CH3-Thy), 1.47 and 1.46 (2 x d, J = 7.0 Hz, 3H, CH3-
Ala); 13C NMR (150 MHz, D2O) δ = 172.2 (d, 3JC,P = 9.2 Hz, CO-Gly), 169.9 (CO-Ala), 166.4 (C-4), 
151.6 (C-2), 137.3 (C-6), 111.5 (C-5), 85.3 (d, 3JC,P = 8.4 Hz, C-4’), 84.9 (C-1’), 71.0 (C-3’), 64.3 (d, 
2JC,P = 4.7 Hz, C-5’), 61.1 (d, 2JC,P = 9.1 Hz, αC-Gly), 48.7 (αC-Ala), 38.5 (C-2’), 16.0 (CH3-Ala), 
11.5 (CH3-Thy); 31P NMR (121 MHz, D2O) δ = 4.2; HRMS for C15H24N5O10P [M-H]- calcd.: 
464.1188, found: 464.1187. 
 
N-Boc-L-Alanyl-D,L-2-acetoxyglycine methyl ester (3.19). 
To a stirred solution of Boc-L-Ala-L-Ser-OMe (3.9 g, 13.43 mmol) in dry ethyl acetate (220 mL) were 
added molecular sieves 4 Å (5 g) followed by Pb(OAc)4 (17.89 g, 40.30 mmol) under an inert 
atmosphere. The reaction mixture was heated at reflux for 2 h, and cooled to room temperature. The 
solid was filtered off through a pad of Celite and the organic layer was stirred with 10% aq. citric acid 
until the organic layer became nearly colourless. The organic layer was separated, washed with 10% 
aq. citric acid, water and brine. It was then dried over Na2SO4, filtered and concentrated to give a 
crude diastereomeric mixture of 3.19 (4.27 g, quant.) as a colourless foam, which was used in the next 
step without any further purification. 1H NMR (300 MHz, CDCl3) δ = 7.70-7.52 (m, 1H, NH-Gly), 
6.40 and 6.38 (2 x d, J = 9.1 Hz, 1H, αH-Gly), 5.31 (app t, J = 6.9 Hz, 1H, NH-Ala), 4.27-4.13 (m, 
1H, αH-Ala), 3.81 and 3.80 (2 x s, 3H, OCH3-Gly), 2.11 (s, 3H, CH3-OAc), 1.45 (s, 9H, tBu), 1.38 
and 1.37 (2 x d, J = 7.1 Hz, 3H, CH3-Ala); 13C NMR (75 MHz, CDCl3) δ = 172.8 (CO-Ala), 170.3 and 
170.2 (CO-Gly), 167.2 and 167.1 (CO-OAc), 155.6 (OCONH), 88.7 (1C-tBu), 72.3 and 72.2 (αC-
Gly), 53.4 and 53.3 (OCH3-Gly), 50.3 and 50.1 (αC-Ala), 28.4 (tBu), 20.7 (CH3-OAc), 17.8 and 17.6 
(CH3-Ala); HRMS for C13H22N2O7 [M+Na]+ calcd.: 341.1319, found: 341.1318. 
 
N-Boc-L-Alanyl-D,L-2-p-anisylaminoglycine methyl ester (3.20). 
DIPEA (3.01 mL, 17.28 mmol) was added to a stirred solution of 3.19 (2.2 g, 6.91 mmol) and 4-
methoxybenzylamine (1.0 mL, 7.60 mmol) in dry DMF (20 mL) at room temperature. The reaction 
mixture was heated at 40 °C for 24 h and was then concentrated under reduced pressure. Water (200 
mL) was added to the residue and extracted with ethyl acetate (3 x 120 mL). The combined organic 
layers were washed with brine, dried over Na2SO4, filtered and concentrated and the resulting crude 
was purified by column chromatography on silica gel (gradient EtOAc/Hexane, 2:3, v/v; 3:2, v/v; 4:1, 
v/v) to give a diastereomeric mixture of 3.20 (2.07 g, 76%) as a colorless foam. 1H NMR (300 MHz, 
CDCl3) δ = 7.22 (d, J = 8.5 Hz, 1H, o-H PMB), 7.04- 6.93 (m, 1H, NH-Gly), 6.84 (d, J = 8.5 Hz, 1H, 
m-H PMB), 5.27 (d, J = 7.8 Hz, 1H, αH-Gly), 5.08-4.99 (m, 1H, NH-Ala), 4.20-4.18 (m, 1H, αH-
Ala), 3.78 (s, 3H, OCH3-PMB), 3.73-3.70 (m, 5H, OCH3-Gly and CH2-PMB), 2.37 (br s, 1H, NH-
PMB), 1.46 and 1.45 (2 x s, 9H, tBu), 1.37 (app t, J = 7.0 Hz, 3H, CH3-Ala); 13C NMR (75 MHz, 
CDCl3) δ = 173.1 (CO-Ala), 170.6 and 170.5 (CO-Gly), 159.0 (Ar-C), 155.6 (OCONH), 131.3 and 
131.2 (1C of PMB), 129.7 (Ar-C), 129.3 (Ar-C), 114.3 (Ar-C), 113.9 (Ar-C), 80.4 (1C-tBu), 64.4 and 
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64.3 (αC-Gly), 55.4 (OCH3-PMB), 52.9 (OCH3-Gly), 50.3 (αC-Ala), 48.5 (CH2-PMB), 28.4 (tBu), 
18.3 and 18.1 (CH3-Ala); HRMS for C19H29N3O6 [M-H]- calcd.: 394.1983, found: 394.1973. 
 
N-Boc-L-Alanyl-D,L-2-aminoglycine methyl ester (3.21). 
To a stirring solution of 3.20 (1.8 g, 2.44 mmol) in EtOH (80 mL) was added 10% Pd/C (0.18 g, 0.1 
eq w/w) and the mixture was hydrogenated at atmospheric pressure using a balloon filled with H2 for 
5 h at room temperature. The catalyst was then removed by filtration through a pad of Celite and the 
filtrate was concentrated under reduced pressure. The resulting crude residue was purified by column 
chromatography on silica gel (gradient MeOH/CH2Cl2, 1:99, v/v; 1:49, v/v; 1:24, v/v) to give a 
diastereomeric mixture of 3.21 (1.2 g, 96%) as a colorless foam. 1H NMR (300 MHz, CDCl3) δ = 7.41 
(br s, 1H, NH-Gly), 5.28-5.24 (m, 2H, αH-Gly and NH-Ala), 4.20-4.18 (m, 1H, αH-Ala), 3.79 (s, 3H, 
OCH3-Gly), 2.24 (br s, 1H, αNH2-Gly), 1.45 (s, 9H, tBu), 1.36 (d, J = 7.1 Hz, 3H, CH3-Ala); 13C 
NMR (75 MHz, CDCl3) δ = 173.1 and 173.0 (CO-Ala), 171.2 and 171.1 (CO-Gly), 155.5 (OCONH), 
80.3 (1C-tBu), 60.2 and 60.1 (αC-Gly), 53.0 (OCH3-Gly), 50.1 (αC-Ala), 28.3 (tBu), 18.3 and 18.2 
(CH3-Ala); HRMS for C19H29N3O6 [M+Na]+ calcd.: 298.1377, found: 298.1390. 
 
Thymidine-5’-O-(N-Boc-L-alanyl-D,L-2-aminoglycine methyl ester) phosphoramidate 
triethylammonium salt (3.22). 
Following a similar procedure as the one used for the synthesis of 3.18a-b, the triethylammonium salt 
of compound 3.22 was obtained as a diastereomeric mixture (538 mg, 74%, white solid), starting from 
TMP-triehtylammonium salt (560 mg, 1.07 mmol), compound 3.21 (647 mg, 2.35 mmol), 
triethylamine (163 µL, 1.17 mmol) and DCC (881 mg, 4.27 mmol) in a 4:1 tBuOH/H2O mixture (15 
mL). 1H NMR (500 MHz, CD3OD) δ = 7.68 (d, J = 1.1 Hz, 1H, H-6), 6.35-6.31 (m, 1H, H-1’), 5.30 
and 5.22 (2 x d, J = 11.1 Hz, 1H, αH-Gly) 4.48-4.45 (m, 1H, H-3’), 4.10-4.05 (m, 1H, αH-Ala), 4.02-
4.00 (m, 1H, H-4’), 3.99-3.95 (m, 2H, H-5’ and H-5’’), 3.71 and 3.69 (2 x s, 3H, OCH3-Gly), 2.29-
2.17 (m, 2H, H-2’ and H-2’’), 1.94 (d, J = 1.1 Hz, 3H, CH3-Thy), 1.44 and 1.43 (2 x s, 9H, tBu), 1.29 
(app t, J = 7.1 Hz, 3H, CH3-Ala, merged with Et3N); 13C NMR (125 MHz, CD3OD) δ = 175.2 (CO-
Ala), 172.1 and 172.0 (CO-Gly), 166.5 (C-4), 157.5 (OCONH), 152.5 (C-2), 138.3 (C-6), 111.9 (C-5), 
87.6 (app t, 3JC,P = 9.5 Hz, C-4’), 86.2 and 86.0 (C-1’), 80.6 (1C-tBu), 73.0 and 72.9 (C-3’), 65.7 (app 
t, 2JC,P = 6.9 Hz, C-5’), 61.7 (αC-Gly), 53.1 and 53.0 (OCH3-Gly), 51.3 (αC-Ala), 40.8 (C-2’), 28.7 
(tBu), 18.4 (CH3-Ala), 12.7 (CH3-Thy); 31P NMR (202 MHz, CD3OD) δ = 3.4; HRMS for 
C21H34N5O12P [M-H]- calcd.: 578.1869, found: 578.1873. 
 
Thymidine-5’-(L-alanyl-D,L-2-aminoglycine methyl ester) phosphoramidate TFA salt (3.23). To 
a stirred solution of 3.22 (220 mg, 0.323 mmol) and thioanisole (42 µL, 0.356 mmol) in CH2Cl2 (4.5 
mL), was added TFA (1.5 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h and then at 
room temperature for 3 h. After completion of the reaction, all the volatiles were removed under 
reduced pressure and coevaporated three times with toluene to remove residual TFA. The residue was 
redissolved in H2O and lyophilized (2x) to obtain a crude residue which was purified by preparative 
RP-HPLC (98% H2O + 2% CH3CN and 98% CH3CN + 2% H2O). The collected eluates were freeze-
dried repeatedly until constant mass to obtain a diastereomeric mixture of 3.23 (158 mg, 85%, white 
solid). 1H NMR (600 MHz, D2O) δ = 7.72 (s, 1H, H-6), 6.29 (app t, J = 7.0 Hz, 1H, H-1’), 5.64 (d, J = 
9.5 Hz, 1H, αH-Gly), 4.54-4.52 (m, 1H, H-3’), 4.18-4.15 (m, 1H, αH-Ala), 4.14-4.12 (m, 1H, H-4’), 
4.07-4.03 (m, 2H, H-5’ and H-5’’), 3.84 (s, 3H, OCH3-Gly), 2.32-2.30 (m, 2H, H-2’ and H-2’’), 1.86 
(s, 3H, CH3-Thy), 1.53 and 1.52 (2 x d, J = 7.2 Hz, 3H, CH3-Ala); 13C NMR (150 MHz, D2O) δ = 
171.6 and 171.4 (CO-Ala), 166.3 (CO-Gly), 166.2 (C-4), 151.5 (C-2), 137.1 (C-6), 111.4 (C-5), 85.2 
(app t, 3JC,P = 9.0 Hz, C-4’), 84.8 (C-1’), 70.9 (C-3’), 64.7 (d, 2JC,P = 4.5 Hz, C-5’), 56.8 (d, 2JC,P = 7.5 
Hz, αC-Gly), 54.1 (OCH3-Gly), 48.5 (αC-Ala), 38.6 (C-2’), 15.9 and 15.8 (CH3-Ala), 11.4 (CH3-Thy); 
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31P NMR (202 MHz, D2O) δ = -0.1; HRMS for C16H26N5O10P [M-H]- calcd.: 478.1344, found: 
478.1346. 
 
N-Carbobenzyloxy-L-alanyl-D,L-2-mercaptoethanolglycine benzyl ester (3.24). 
Et3N (0.55 mL, 3.92 mmol) was added dropwise to a stirred solution of 3.12 (1.4 g, 3.27 mmol) and 
2-mercaptoethanol (0.25 mL, 3.59 mmol) in dry DMF (12 mL) at 0 °C. The reaction mixture was then 
slowly warmed to room temperature and the stirring was continued for 16 h. The resulting mixture 
was concentrated under reduced pressure. Water (100 mL) was added to the residue and extracted 
with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated and the resulting crude was purified by column chromatography on 
silica gel (gradient EtOAc/Hexane, 1:4, v/v; 2:3, v/v; 3:2, v/v) to give a diastereomeric mixture of 
3.24 (1.2 g, 70%) as a colorless foam. 1H NMR (300 MHz, DMSO-d6) δ = 8.83 and 8.79 (2 x d, J = 
8.2 Hz, 1H, NH-Gly), 7.47 (d, J = 7.3 Hz, 1H, NH-Ala), 7.39-7.32 (m, 10H, 2 x OBn), 5.46 and 5.44 
(2 x d, J = 10.0 Hz, 1H, αH-Gly ), 5.19- 5.16 (m, 2H, CH2-CO2Bn), 5.00 (s, 2H, CH2-Cbz), 4.96-4.93 
(m, 1H, OH), 4.19-4.12 (m, 1H, αH-Ala), 3.54-3.48 (m, 2H, OCH2CH2S), 2.72-2.65 (m, 2H, 
OCH2CH2S), 1.19 (app t, J = 7.8 Hz, 3H, CH3-Ala); 13C NMR (75 MHz, DMSO-d6) δ = 172.7 and 
172.6 (CO-Ala), 168.5 and 168.4 (CO-Gly), 155.7 and 155.6 (OCONH), 137.0 (1C of OCH2Ph), 
135.6 and 135.5 (1C of OCH2Ph), 128.5 (Ar-C), 128.4 (Ar-C), 128.2 (Ar-C), 127.9 (Ar-C), 127.7 (Ar-
C), 66.8 and 66.7 (CH2-CO2Bn), 65.5 (CH2-Cbz), 60.4 and 60.3 (OCH2CH2S), 53.2 and 53.1 (αC-
Gly), 49.9 and 49.8 (αC-Ala), 32.7 and 32.6 (OCH2CH2S), 18.1 and 18.0 (CH3-Ala); HRMS for 
C22H26N2O6S [M-H]- calcd.: 445.1439, found: 445.1443. 
 
3’-O-Benzyl-5’-O-(N-carbobenzyloxy-L-alanyl-D,L-2-mercaptoethanolglycine benzyl ester) TMP 
triethylammonium salt (3.25).  
POCl3 (169 µL, 3.92 mmol) was added dropwise to a stirred solution of 3.8 (0.5 g, 1.50 mmol) in dry 
trimethyl phosphate (5 mL) at -20 °C. The reaction mixture was then slowly warmed to room 
temperature and the stirring was continued for 8 h until reaction completion (monitored by TLC). The 
solution was again cooled to 0 °C and a mixture of compound 3.24 (0.672 g, 1.50 mmol) and N-
methyl imidazole (0.36 mL, 4.51 mmol) dissolved in dry CH2Cl2 (14 mL) was then added. The 
resulting mixture was stirred at room temperature for 16 h. It was then quenched with water at 0 °C 
and the volatiles were removed under reduced pressure, water was added to the residue which was 
then lyophilized (3x). The resulting crude residue was purified first by column chromatography on 
silica gel (gradient MeOH/CH2Cl2, 1:99, v/v; 3:97, v/v; 8:92, v/v), then by preparative RP-HPLC (25 
mmol TEAB in 98% H2O + 2% CH3CN and 25 mmol TEAB in 98% CH3CN + 2% H2O as eluent). 
The collected eluates were freeze-dried repeatedly until constant mass, to obtain a diastereomeric 
mixture of 3.25 (935 mg, 66%) as a white solid. 1H NMR (300 MHz, CD3OD) δ = 7.76 (s, 1H, H-6), 
7.35-7.25 (m, 15H, 3 x OBn), 6.45 (dd, J = 8.7, 5.8 Hz, 1H, H-1’), 5.51 (d, J = 13.4 Hz, 1H, αH-Gly), 
5.24- 5.13 (m, 2H, CH2-CO2Bn), 5.06 (s, 2H, CH2-Cbz), 4.57-4.55 (m, 2H, CH2-3’OBn), 4.34-4.31 
(m, 1H, αH-Ala), 4.25-4.18 (m, 1H, H-3’ and H-4’), 4.07-4.01 (m, 2H, H-5’ and H-5’’), 4.00-3.90 (m, 
2H, OCH2CH2S), 2.93-2.78 (m, 2H, OCH2CH2S), 2.40-2.17 (m, 2H, H-2’ and H-2’’), 1.91 (s, 3H, 
CH3-Thy), 1.34 and 1.32 (2 x d, J = 7.2 Hz, 3H, CH3-Ala); 13C NMR (75 MHz, CD3OD) δ = 175.2 
(CO-Ala), 169.7 and 169.6 (CO-Gly), 166.4 and 166.3 (C-4), 158.1 (OCONH), 152.5 and 152.4 (C-
2), 139.4 (1C Ar-C), 138.2 (1C Ar-C), 137.9 (C-6), 136.8 (1C Ar-C), 129.6 (Ar-C), 129.5 (Ar-C), 
129.4 (Ar-C), 129.3 (Ar-C), 129.2 (Ar-C), 129.0 (Ar-C), 128.9 (Ar-C), 128.8 (Ar-C), 128.7 (Ar-C), 
112.1 and 112.0 (C-5), 86.2 and 86.1 (C-1’), 85.1 (d, 3JC,P = 8.7 Hz, C-4’), 81.1 and 81.0 (C-3’), 72.2 
and 72.1 (CH2-3’OBn), 68.6 and 68.5 (CH2-CO2Bn), 67.6 (CH2-Cbz), 66.9 (d, 2JC,P = 5.5 Hz, C-5’), 
65.8 and 65.7 (d, 2JC,P = 5.4 Hz, OCH2CH2S), 54.8 and 54.7 (αC-Gly), 52.0 and 51.9 (αC-Ala), 38.1 
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(C-2’), 32.1 and 32.0 (OCH2CH2S), 18.3 and 18.2 (CH3-Ala), 12.7 (s, CH3-Thy); 31P NMR (121 MHz, 
CD3OD) δ = -0.5; HRMS for C39H45N4O13PS [M-H]- calcd.: 839.2368, found: 839.2376. 
 
N-Boc-L-Alanyl-D,L-2-mercaptoethanolglycine methyl ester (3.26). 
Following a similar procedure as the one used for the synthesis of 3.24, a diastereomeric mixture of 
compound 3.26 was obtained as a colorless foam (3.5 g, 77%), starting from 3.19 (4.28 g, 13.43 
mmol), 2-mercaptoethanol (1.04 mL, 14.77 mmol) and Et3N (2.24 mL, 16.12 mmol) in dry DMF (12 
mL). 1H NMR (300 MHz, CDCl3) δ = 7.63 (br s, 1H, NH-Gly), 5.56- 5.50 (m, 1H, αH-Gly), 5.10 and 
5.06 (2 x d, J = 7.0 Hz, 1H, NH-Ala), 4.28-4.13 (m, 1H, αH-Ala), 3.92-3.77 (m, 5H, OCH2CH2S and 
OCH3-Gly), 2.90-2.85 (m, 2H, OCH2CH2S), 1.46 and 1.45 (2 x s, tBu), 1.38 and 1.37 (2 x d, J = 7.0 
Hz, 3H, CH3-Ala); 13C NMR (75 MHz, CDCl3) δ = 172.5 (CO-Ala), 169.8 and 169.6 (CO-Gly), 155.6 
(OCONH), 80.7 (1C-tBu), 62.1 (OCH2CH2S), 53.2 (OCH3-Gly), 52.9 (αC-Gly), 50.4 (αC-Ala), 34.2 
and 34.1 (OCH2CH2S), 28.4 (tBu), 18.0 and 17.9 (CH3-Ala); HRMS for C13H24N2O6S [M+Na]+ calcd.: 
359.1247, found: 359.1240. 
 
3’-O-Benzoyl-5’-O-(N-Boc-L-alanyl-D,L-2-mercaptoethanolglycine methyl ester)TMP (3.29).  
Following a similar procedure as the one used for the synthesis of 3.25, a diastereomeric mixture of 
compound 3.29 was obtained as a white solid (101.5 mg, 12%), starting from 3.27 (394 mg, 1.138 
mmol), POCl3 (128 µL, 1.366 mmol) in dry trimethyl phosphate (4 mL) and compound 3.26 (383 mg, 
1.138 mmol), N-methyl imidazole (272 µL, 1.366 mmol) in dry CH2Cl2 (10 mL). The resulting crude 
residue was purified first by column chromatography on silica gel (gradient MeOH/CH2Cl2, 1:99, v/v; 
3:97, v/v; 8:92, v/v), then by preparative RP-HPLC (98% H2O + 2% CH3CN and 98% CH3CN + 2% 
H2O as eluent). The collected eluates were freeze-dried repeatedly until constant mass. 1H NMR (300 
MHz, CD3OD) δ = 8.06 (d, J = 7.5 Hz, 2H, oH-OBz), 7.78 (s, 1H, H-6), 7.64 (t, J = 7.4 Hz, 1H, pH-
OBz), 7.64 (t, J = 7.6 Hz, 2H, mH-OBz), 6.45 (app t, J = 7.5 Hz, 1H, H-1’), 5.67-5.62 (m, 1H, H-3’), 
5.59-5-56 (m, 1H, αH-Gly), 4.67-4.37 (m, 1H, H-4’), 4.35-4.23 (m, 2H, H-5’ and H-5’’), 4.18-4.04 
(m, 3H, OCH2CH2S and αH-Ala), 3.74 (s, 3H, OCH3-Gly), 3.02-2.92 (m, 2H, OCH2CH2S), 2.58-2.50 
(m, 2H, H-2’ and H-2’’), 1.95 (s, 3H, CH3-Thy), 1.42 (s, 9H, tBu), 1.30 and 1.29 (2 x d, J = 7.0 Hz, 
3H, CH3-Ala); 13C NMR (150 MHz, D2O) δ = 175.5 and 175.4 (CO-Ala), 170.4 and 170.3 (CO-Gly), 
167.3 (CO-OBz), 166.4 and 166.3 (C-4), 157.6 (OCONH), 152.6 and 152.5 (C-2), 137.8 (C-6), 134.6 
and 134.5 (1C Ar-C), 131.0 (Ar-C), 130.9 (Ar-C), 130.7 (Ar-C), 130.6 (Ar-C), 129.7 (Ar-C), 129.6 
(Ar-C), 112.4 and 112.3 (C-5), 86.1 and 86.0 (C-1’), 85.1 (d, 3JC,P = 7.9 Hz, C-4’), 80.6 (1C-tBu), 77.6 
and 77.4 (C-3’), 66.9 (d, 2JC,P = 3.0 Hz, C-5’), 66.1 (d, 2JC,P = 6.2 Hz, OCH2CH2S), 54.7 and 54.6 (αC-
Gly), 53.4 and 53.3 (OCH3-Gly), 51.5 (αC-Ala), 38.3 and 38.2 (C-2’), 31.9 (OCH2CH2S), 28.7 (tBu), 
18.2 and 18.1 (CH3-Ala), 12.7 and 12.6 (CH3-Thy); 31P NMR (202 MHz, D2O) δ = -0.5; HRMS for 
C30H41N4O14PS [M-H]- calcd.: 743.2005, found: 743.2014. 
 
5’-O-(L-Alanyl-D,L-2-mercaptoethanolglycine) TMP (3.4). 
Following a similar procedure as the one used for the synthesis of 3.23, the TFA salt of the crude 
diastereomeric amine 3.30 was obtained as a sticky mass (~100 mg, quant.), starting from compound 
3.29 (100 mg, 0.134 mmol), thioanisole (16 µL, 0.134 mmol) and TFA (0.5 mL) in CH2Cl2 (1.5 mL). 
HRMS for C25H33N4O12PS [M-H]- calcd.: 643.1480, found: 643.1472. 
The so obtained residue 3.30 was treated without further purification with LiOH (19.4 mg, 0.809 
mmol) in a 1:1 MeOH:H2O mixture (2 mL) at 0 °C and then the solution was stirred at room 
temperature for 3 h. After completion of the reaction, the mixture was neutralized with 5% acetic acid 
and evaporated to dryness in vacuo. The crude residue was purified by preparative RP-HPLC (98% 
H2O + 2% CH3CN and 98% CH3CN + 2% H2O). The collected eluates were freeze-dried repeatedly 
until constant mass to afford a diastereomeric mixture of compound 3.4 (51 mg, 72% over two steps) 
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as a white solid. 1H NMR (500 MHz, D2O) δ = 7.60 (s, 1H, H-6), 6.39 (app t, J = 6.9 Hz, 1H, H-1’), 
5.22 (d, J = 20.5 Hz, 1H, αH-Gly), 4.56-4.53 (m, 1H, H-3’), 4.12-4.10 (m, 1H, H-4’), 4.07-4.03 (m, 
2H, H-5’ and H-5’’), 4.00-3.94 (m, 2H, OCH2CH2S), 3.51-3.46 (m, 1H, αH-Ala), 2.83-2.79 (m, 2H, 
OCH2CH2S), 2.31-2.26 (m, 2H, H-2’ and H-2’’), 1.85 (s, 3H, CH3-Thy), 1.21 and 1.19 (2 x d, J = 7.0 
Hz, 3H, CH3-Ala); 13C NMR (125 MHz, D2O) δ = 177.0 (CO-Gly), 173.0 (CO-Ala), 165.5 (C-4), 
156.7 (C-2), 135.9 and 135.8 (C-6), 111.3 (C-5), 84.4 (d, 3JC,P = 8.4 Hz, C-4’), 84.3 (C-1’), 70.5 and 
70.4 (C-3’), 64.5 (d, 2JC,P = 5.1 Hz, C-5’), 64.1 (d, 2JC,P = 5.5 Hz, OCH2CH2S), 55.6 (αC-Gly), 49.2 
(αC-Ala), 38.2 (C-2’), 29.6 (d, 3JC,P = 7.8 Hz, OCH2CH2S), 19.1 (CH3-Ala), 12.0 and 11.9 (CH3-Thy); 
31P NMR (202 MHz, D2O) δ = -0.3; HRMS for C17H27N4O11PS [M-H]- calcd.: 525.1062, found: 
525.1058. 
 
N-Boc-L-Alanyl-D,L-2-O-benzylglycine methyl ester (3.31). 
To a stirred solution of 3.19 (1.59 g, 5.0 mmol) in dry THF (100 mL), a solution of DABCO (1.35 g, 
12.0 mmol) in dry THF (15 mL) was added at -78 °C. After stirring at the same temperature for 10 
min, benzyl alcohol (0.62 mL, 6 mmol) was added and the solution was stirred for additional 6 h at -
78 °C. The reaction mixture was slowly warmed to room temperature and the stirring was continued 
for 24 h. The reaction was cooled to 0 °C, quenched with 10% aq. citric acid (100 mL) and all the 
volatiles were removed in vacuo. The residue was extracted with ethyl acetate (3 x 150 mL) and the 
combined organic layers were washed with 10% aq. citric acid, saturated aq. NaHCO3, water, brine, 
then dried over Na2SO4, filtered and concentrated in vacuo. The resulting crude product was purified 
by column chromatography on silica gel (gradient Acetone/Petroleum ether, 1:99, v/v; 1:19, v/v; 1:9, 
v/v) to give a diastereomeric mixture of 3.31 (0.82 g, 45%) as a colorless oil. 1H NMR (300 MHz, 
Acetone-d6) δ = 8.01 (d, J = 8.6 Hz, NH-Gly), 7.39-7.28 (m, Ar-H OBn), 6.26 (br s, 1H, NH-Ala), 
5.69 and 5.67 (2 x d, J = 9.3 Hz, 1H, αH-Gly), 4.71-4.56 (m, 2H, CH2-OBn), 4.24-4.19 (m, 1H, αH-
Ala), 3.74 and 3.73 (2 x s, 3H, OCH3-Gly), 1.42 and 1.41 (2 x s, 9H, tBu), 1.36 and 1.35 (2 x d, J = 
7.2 Hz, 3H, CH3-Ala); 13C NMR (75 MHz, Acetone-d6) δ = 174.5 (CO-Ala), 168.9 and 168.8 (CO-
Gly), 156.4 (OCONH), 138.7 and 138.6 (1C of OBn), 129.1 (Ar-C), 129.0 (Ar-C), 128.9 (Ar-C), 
128.8 (Ar-C), 128.5 (Ar-C), 79.5 (1C-tBu), 77.7 and 77.6 (αC-Gly), 70.7 and 70.6 (CH2-OBn), 52.8 
(OCH3-Gly), 51.2 (αC-Ala), 28.5 (tBu), 18.2 and 18.0 (CH3-Ala); HRMS for C18H26N2O6 [M+H]+ 
calcd.: 367.1863, found: 367.1860. 
 
N-Boc-L-Alanyl-L-2-O-benzylglycine (3.32). 
To a stirred solution of the diastereomeric mixture 3.31 (400 mg, 1.092 mmol) in a 1:1 DMF/H2O 
mixture (16 mL) was added at 55 °C subtilisin Carlsberg (20 mg). 1M NaOH (0.61 mL) was then 
added dropwise by maintaining the pH of the reaction at 7.2 and monitoring by a pH-meter. Upon 
completion, the volatiles were removed in vacuo. The residue was dissolved in 5% NaHCO3 and 
extracted with ethyl acetate (3 x 50 mL) and the combined organic layers were washed with 5% 
NaHCO3, 10% aq. citric acid, water, brine, then dried over Na2SO4, filtered and concentrated in vacuo 
to give the diastereomeric mixture (320 mg, recovered). The aqueous layer was acidified with 10% 
citric acid and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed 
with 10% aq. citric acid, water, brine, then dried over Na2SO4, filtered and concentrated in vacuo to 
get the pure diastereomer (L,L) 3.32 (54 mg, 14%) as a white solid. 1H NMR (300 MHz, CD3CN) δ = 
7.56 (d, J = 8.6 Hz, NH-Gly), 7.36-7.30 (m, Ar-H OBn), 5.67 (br s, 1H, NH-Ala), 5.55-5.50 (m, 1H, 
αH-Gly), 4.67-4.53 (m, 2H, CH2-OBn), 4.10-4.02 (m, 1H, αH-Ala), 1.41 (s, 9H, tBu), 1.28 (d, J = 7.2 
Hz, 3H, CH3-Ala); 13C NMR (75 MHz, CD3CN) δ = 175.1 (CO-Gly), 169.2 (CO-Ala), 156.6 
(OCONH), 138.4 (1C of OBn), 129.3 (Ar-C), 129.1 (Ar-C), 128.8 (Ar-C), 80.2 (1C-tBu), 77.6 (αC-
Gly), 70.8 (CH2-OBn), 51.4 (αC-Ala), 28.5 (tBu), 17.9 (CH3-Ala); HRMS for C17H24N2O6 [M+H]+ 
calcd.: 351.1561, found: 351.1563. 
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2-N,N-Diisopropylamino-1,3,2-oxathiaphospholane (3.34). 
To a stirred solution of N,N-diisopropyl phosphoramidous dichloride (293 µL, 1.588 mmol) and 2-
mercapto ethanol (112 µL, 1.588 mmol) in dry diethyl ether (8 mL) was slowly added DIPEA (664 
µL, 3.811 mmol) at -20 °C. The reaction mixture was then stirred at the same temperature for 30 min 
and slowly warmed to room temperature over 2 h. The so formed white precipitate was filtered off 
under an inert atmosphere and the filtrate was concentrated (bath temp. ~15 °C) and dried in vacuo to 
get crude 3.34 (301 mg, quant.) as a colorless oil. The product was checked for purity using 31P NMR 
and was immediately used in the next step without any further purification. 
 
3’-O-Benzoyl-5’-(2-thio-1,3,2-oxathiaphospholane)-thymidine (3.35). 
To a stirred suspension of crude 3.34 (301 mg, 1.588 mmol) and 3.27 (500 mg, 1.444 mmol) in dry 
CH2Cl2 (18 mL) was slowly added a solution of S-ethylthiotetrazole (273 mg, 2.094 mmol) in dry 
CH2Cl2 (5 mL) at 0 °C. The reaction mixture was then stirred at room temperature for 3 h. When the 
solution became homogeneous, dry elemental sulfur (153 mg) was added and the stirring was 
continued overnight. The mixture was filtered and the filtrate was concentrated under reduced 
pressure. The resulting crude residue was purified by column chromatography on silica gel (gradient 
MeOH/CHCl3, 0:100, v/v; 0.5:95.5, v/v; 1:99, v/v) to give 3.35 (650 mg, 93%) as a pale yellow foam. 
1H NMR (300 MHz, CDCl3) δ = 9.09 (br s, 1H, NH-Thy), 8.07 (d, J = 1.0 Hz, 1H, H-6), 8.05-7.46 
(m, 5H, OBz), 6.53-6.46 (m, 1H, H-1’), 4.58-4.54 (m, 1H, H-3’), 4.64-4.44 (m, 4H, H-5’, H-5’’ and 
OCH2CH2S), 4.42-4.39 (m, 1H, H-4’), 3.61-3.52 (m, 2H, OCH2CH2S), 2.67-2.60 (m, 1H, H-2’), 2.36-
2.23 (m, 1H, H-2’’), 2.01 (d, J = 1.0 Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ = 166.3 (CO-OBz), 
164.0 (C-4), 150.6 (C-2), 135.4 and 135.3 (C-6), 133.9 (1C-OBz), 129.9 (Ar-C), 128.7 (Ar-C), 112.1 
and 112.0 (C-5), 85.1 and 85.0 (C-1’), 83.2 (d, 3JC,P = 8.7 Hz, C-4’), 75.5 and 75.4 (C-3’), 70.9 (d, 
3JC,P = 11.3 Hz, OCH2CH2S), 68.1 (d, 2JC,P = 6.6 Hz, C-5’), 37.7 and 37.6 (C-2’), 37.1 (d, 3JC,P = 16.3 
Hz, OCH2CH2S), 12.7 and 12.6 (CH3-Thy); 31P NMR (121 MHz, CDCl3) δ = 104.3 and 104.1; HRMS 
for C19H21N2O6PS2 [M+Na]+ calcd.: 507.0420, found: 507.0421. 
 
Thymidine-5’-O-phosphorothioate triethylammonium salt (3.36).  
To a stirred solution of 3.35 (650 mg, 1.342 mmol) and 3-hydroxypropionitrile (0.46 mL, 6.708 
mmol) in dry CH2Cl2 (18 mL) was added dropwise DBU (0.22 mL, 1.476 mmol). The reaction 
mixture was stirred at room temperature for 8 h. It was then concentrated under reduced pressure and 
the crude residue was purified by flash chromatography on silica gel (gradient MeOH/CHCl3, 1:49, 
v/v; 1:9, v/v; 1:4, v/v). The fractions containing the phosphorothioate monoester [31P NMR (121 
MHz, CD3OD) δ = 56.6, HRMS for C20H22N3O8PS [M-H]- calcd.: 494.0792, found: 494.0789] were 
combined, concentrated in vacuo and the resulting residue was treated with 25% NH3 in a sealed tube 
at 55 °C for 16 h.  Ammonia was removed in vacuo, the residue was diluted with water and 
lyophilized. The crude product was purified by preparative RP-HPLC (50 mmol  TEAB in 98% H2O 
+ 2% CH3CN and 50 mmol  TEAB in 50% CH3CN + 50% H2O). The collected eluates were freeze-
dried repeatedly until constant mass to afford compound 3.36 (497 mg, 72% over two steps) as a 
white solid. 1H NMR (300 MHz, D2O) δ = 7.80 (d, J = 1.0 Hz, 1H, H-6), 6.34 (app t, J = 7.0 Hz, 1H, 
H-1’), 4.60-4.56 (m, 1H, H-3’), 4.20-4.18 (m, 1H, H-4’), 4.12-4.08 (m, 2H, H-5’ and H-5’’), 2.36-
2.32 (m, 2H, H-2’ and H-2’’), 1.92 (d, J = 1.0 Hz, 3H, CH3); 13C NMR (75 MHz, D2O) δ = 166.2 (C-
4), 151.4 (C-2), 137.1 (C-6), 111.4 (C-5), 85.2 (d, 3JC,P = 9.4 Hz, C-4’), 84.7 (C-1’), 71.0 (C-3’), 64.5 
(d, 2JC,P = 5.1 Hz, C-5’), 38.4 (C-2’), 11.3 (CH3-Thy); 31P NMR (121 MHz, D2O) δ = 50.2; HRMS for 
C10H15N2O7PS [M-H]- calcd.: 337.0265, found: 337.0262. 
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Thymidine-5’-O-(N-Boc-L-alanyl-D,L-2-aminoglycine methyl ester)-phosphorothioate (3.37). To 
a stirred solution of compound 3.19 (344 mg, 0.809 mmol) and compound 3.36 (309 mg, 0.970 mmol) 
in dry DMF (6 mL) was added Et3N (0.45 mL, 3.234 mmol). The reaction mixture was heated at 37 
°C for 4 h. After cooling, DMF was removed under reduced pressure and the resulting residue was 
dissolved in water and lyophilized. The crude product was purified by preparative RP-HPLC (98% 
H2O + 2% CH3CN and 98% CH3CN + 2% H2O). The collected eluates were freeze-dried repeatedly 
until constant mass to afford a diastereomeric mixture of compound 3.37 (329 mg, 68%) as a white 
solid. 1H NMR (500 MHz, CD3OD) δ = 7.74 (s, 1H, H-6), 6.35 (q, J = 6.9 Hz, 1H, H-1’), 5.76-5.69 
(m, 1H, αH-Gly), 4.50-4.46 (m, 1H, H-3’), 4.16-4.08 (m, 4H, H-4’, αH-Ala, H-5’ and H-5’’), 3.79 
and 3.78 (2 x s, 3H, OCH3-Gly), 2.29-2.25 (m, 2H, H-2’ and H-2’’), 1.96 and 1.94 (2 x s, 3H, CH3-
Thy), 1.47 and 1.46 (2 x s, 9H, tBu), 1.35 and 1.34 (2d, J = 7.1 Hz, 3H, CH3-Ala; merged with Et3N); 
13C NMR (125 MHz, CD3OD) δ = 175.4 and 175.3 (CO-Ala), 170.8 and 170.7 (CO-Gly), 166.4 (C-4), 
157.6 (OCONH), 152.4 (C-2), 138.0 (C-6), 112.0 and 111.9 (C-5), 87.0 (d, 3JC,P = 7.6 Hz, C-4’), 86.2 
(C-1’), 80.8 and 80.8 (1C-tBu), 72.7 and 72.6 (C-3’), 67.0 (C-5’), 55.0 and 54.9 (αC-Gly), 53.6 
(OCH3-Gly), 51.7 and 51.6 (αC-Ala), 40.8 and 40.7 (C-2’), 28.7 (tBu), 18.2 and 18.0 (CH3-Ala), 12.7 
and 12.6 (CH3-Thy); 31P NMR (202 MHz, CD3OD) δ = 13.1; HRMS for C21H33N4O12PS [M-H]- 
calcd.: 595.1480, found: 595.1486. 
 
Thymidine-5’-O-(L-alanyl-(-)-2-aminoglycine methyl ester)-phosphorothioate (3.38a) and 
thymidine-5’-O-(L-alanyl-(+)-2-aminoglycine methyl ester)-phosphorothioate (3.38b).  
A similar synthetic protocol as the one used for the synthesis of 3.23 was employed for the synthesis 
of 3.38a-b, starting from compound 3.37 (160 mg, 0.2293 mmol), thioanisole (33 µL, 0.356 mmol) 
and TFA (1.5 mL) in CH2Cl2 (4.5 mL). Semi-preparative RP-HPLC (98% H2O + 2% CH3CN and 
98% CH3CN + 2% H2O as eluent) was employed for further separation to obtain the TFA salts of pure 
diastereomers as a ~1:1 ratio (isomer 3.38a 59.6 mg, isomer 3.38b 60 mg), as white powders (overall 
yield 3.38a+3.38b 119.6 mg, 84%). The isolated products were freeze-dried repeatedly until constant 
mass. Data for 3.38a: 1H NMR (300 MHz, D2O) δ = 7.71 (d, J = 1.0 Hz, 1H, H-6), 6.35 (app t, J = 7.0 
Hz, 1H, H-1’), 5.60 (d, J = 15.7 Hz, 1H, αH-Gly) 4.61-4.56 (m, 1H, H-3’), 4.20-4.18 (m, 1H, H-4’), 
4.16-4.09 (m, 3H, αH-Ala, H-5’ and H-5’’), 3.81 (s, 3H, OCH3-Gly), 2.42-2.37 (m, 2H, H-2’ and H-
2’’), 1.94 (d, J = 1.0 Hz, 3H, CH3-Thy), 1.55 (d, J = 7.1 Hz, 3H, CH3-Ala); 13C NMR (125 MHz, D2O) 
δ = 170.1 (d, 3JC,P = 6.2 Hz, CO-Gly), 169.7 (CO-Ala), 166.3 (C-4), 151.5 (C-2), 137.2 (C-6), 111.5 
(C-5), 84.9 (d, 3JC,P = 9.2 Hz, C-4’), 84.8 (C-1’), 70.8 (C-3’), 65.4 (d, 2JC,P = 5.6 Hz, C-5’), 53.6 (αC-
Gly and OCH3-Gly), 48.7 (αC-Ala), 38.4 (C-2’), 15.9 (CH3-Ala), 11.5 (CH3-Thy); 31P NMR (202 
MHz, D2O) δ = 15.1; [α]20589 = -0.518° (c = 1, CH3OH); HRMS for C16H25N4O10PS [M-H]- calcd.: 
495.0956, found: 495.0956. Data for 3.38b: 1H NMR (500 MHz, D2O) δ = 7.69 (s, 1H, H-6), 6.36 
(app t, J = 7.0 Hz, 1H, H-1’), 5.64 (d, J = 14.5 Hz, 1H, αH-Gly) 4.57-4.54 (m, 1H, H-3’), 4.19-4.16 
(m, 1H, H-4’), 4.15-4.04 (m, 3H, αH-Ala, H-5’ and H-5’’), 3.75 (s, 3H, OCH3-Gly), 2.42-2.35 (m, 
2H, H-2’ and H-2’’), 1.88 (s, 3H, CH3-Thy), 1.53 (d, J = 7.1 Hz, 3H, CH3-Ala); 13C NMR (125 MHz, 
D2O) δ = 169.8 (d, 3JC,P = 6.8 Hz, CO-Gly), 169.7 (CO-Ala), 166.2 (C-4), 151.5 (C-2), 137.3 (C-6), 
111.4 (C-5), 84.9 (d, 3JC,P = 8.9 Hz, C-4’), 84.8 (C-1’), 70.6 (C-3’), 65.4 (d, 2JC,P = 5.3 Hz, C-5’), 53.6 
(OCH3-Gly), 53.3 (d, 2JC,P = 3.0 Hz, αC-Gly), 48.8 (αC-Ala), 38.1 (C-2’), 16.0 (CH3-Ala), 11.5 (CH3-
Thy); 31P NMR (202 MHz, D2O) δ = 15.1; [α]20589 = +0.730° (c = 1, CH3OH); HRMS for 
C16H25N4O10PS [M-H]- calcd.: 495.0956, found: 495.0959. 
 
General Protocol for the DNA polymerase reaction.  
The primer P1 was purchased from IDT, whilst all the templates T1-5 were acquired from Eurogentec. 
Primer oligonucleotides were labeled with 5’-[γ-33P]-ATP (Perkin Elmer) using T4 polynucleotide 
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kinase (New England Biolabs) according to the manufacturer’s procedure. The labeled primers were 
additionally purified using Illustra MicroSpin G-25 Column (GE Healthcare) and then annealed with 
the corresponding template oligonucleotides in a 1:2 molar ratio, by heating the mixture at 75 °C for 5 
min, with subsequent slow cooling to room temperature. The DNA polymerisation mixtures contained 
125 nM primer-template complex, 1X reaction buffer (supplied with the enzyme), different 
concentrations of building blocks (125 µM, 500 µM and 1 mM) and 0.01 U.µl-1 Therminator, 0.01 
U.µl-1 Vent (-exo) or 0.05 U.µl-1 Klenow (-exo) polymerases (New England Biolabs). The reaction 
was performed either at 37 °C (mesophilic polymerase) or at 75 °C (thermophilic polymerases) and 
aliquots were acquired after 15, 30 and 60 min. In the control reaction, 50 µM of the corresponding 
natural triphosphate TTP was used. All the polymerase reactions were quenched by addition of a 
double volume of gel loading buffer (90% formamide, 50mM EDTA, 0.05% bromophenol blue and 
0.05% xylene cyanol). Samples were heated either at 75 °C (mesophilic polymerase) or at 90 °C 
(thermophilic polymerases) for 5 min prior to separation on a 0.4mm 20% denaturing polyacrylamide 
gel. The bands were then visualized utilizing phosphorimaging (Perkin Elmer).  
Steady-state kinetics of single nucleotide incorporation. 
Primer 5’ /5Cy5/CAGGAAACAGCTATGAC 3’ (IDT) was annealed with template  3’ 
GTCCTTTGTCGATACTGATTTT 5’ (IDT) in a 1:2 molar ratio by heating the mixture at 75 °C for 5 
min, with subsequent slow cooling to room temperature. A series of reactions with different enzyme 
concentrations and different time points were carried out to achieve the optimum conditions satisfying 
the ‘single completed hit’ principle.[20] The final DNA polymerisation mixtures each contained 125 
nM primer-template complex, 1X Ex TaqTM reaction buffer (Takara), 2.5 mM MgSO4, building 
blocks (for modified building blocks the concentration ranged between 15 µM and 2 mM, whilst for 
natural nucleoside triphosphates the concentration ranged between 10 nM and 2 µM) and 0.005 U.µl-1 
Klenow fragment (New England Biolabs). The reactions were executed at 37 °C and aliquots were 
acquired after 30 seconds. All polymerase reactions were quenched by adding a double volume of gel 
loading buffer (90 % formamide, 50 mM EDTA and 0.05% bromophenol blue) and heated at 90 °C 
for 5 min. The samples were allowed to run on a 1 mm 15% denaturing polyacrylamide gel and gel 
bands were visualized using Ettan DIGE Imager (GE Healthcare). The gel bands were then measured 
using ImageQuant TL 1D version 7.0 (GE Healthcare) and the kinetics parameters (Vmax and Km) were 
determined by fitting the data to a non-linear Michaelis–Menten regression utilizing GraphPad Prism 
Software version 5.0. 
 
Molecular modeling study.  
Although a structure of the Klenow fragment of E. coli DNA Polymerase I exists in the pdb 
(2KZM), no ternary complex (enzyme, DNA, triphosphate substrate) was found. Therefore a 
homology model of the Klenow fragment was created based on the crystal structure of a ternary 
complex of DNA Polymerase I from Thermos aquaticus (3KTQ). For this model building the I-
tasser server was employed. In a second step, DNA, triphosphate and Mg2+ ions (copied from 
3KTQ) were added to the homology model via a DALI superposition. The triphosphate cytosine 
base was changed into a thymine (residue TTP) and the complementary base in the template 
strand was replaced by an adenine. Steric hindrance was removed by vacuum energy 
minimization using the Amber molecular mechanics suite, while partly restraining the movement 
of the triphosphate ligand, Mg2+ ions and DNA double strand. 3D models of molecules 3.2a and 
3.2b were superimposed onto the triphosphate using an in house developed flexible superposition 
program. Both models were then energy minimized in the same way as the structure with the 
triphosphate substrate. Finally all structures were analysed in the chimera modelling software.[21]  
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Table 3-2. Overview of interactions between TTP, 3.2a, 3.2b molecules and the polymerase. 
TTP 3.2a 3.2b  
- -16435 kcal/mol -16287 kcal/mol 
Final potential 
energy after 
minimization 
R432.NH1 /  O1A first 
phosphate 
R432.NH1 / O1A 
oxygen on 1st 
phosphate 
R432.NH1 / O1A 
oxygen on 1st 
phosphate 
ionic 
MG902 /O2A oxygen 
on 1st phosphate 
MG902 / O1A oxygen 
on 1st phosphate 
- ionic 
 
MG902 / O2A oxygen 
on 1st phosphate 
MG902 / O2A oxygen 
on 1st phosphate 
ionic 
MG901 / O2A oxygen 
on 1st phosphate 
MG901 / O2A oxygen 
on 1st phosphate 
MG901 / O2A oxygen 
on 1st phosphate 
ionic 
K435.NZ / O1B 
oxygen on 2nd 
phosphate 
- 
K435.NZ / carboxyl 
group 
ionic 
MG901 /  O2B oxygen 
on 2nd phosphate 
- - Ionic 
- 
MG901 /carboxyl 
group 
- Ionic 
- 
I386.N / C=O of 
peptide bond 
- Hydrogen bond 
- - 
MG901 / C=O of 
peptide bond 
Ionic hydrogen bond 
MG901 / O1G oxygen 
on 3rd phosphate 
- - ionic 
- 
F439 / terminal 
-NH3+ 
- cation - pi 
Q526.NE2 / O2 on 
base 
Q526.NE2 / O2 of base 
Q526.NE2 + Y443.OH 
/ O2 of base 
Hydrogen bonds 
R345.NH2 / O4’ in 
sugar ring 
R345.NH2 / O4’ in 
sugar ring 
R345.NH2 / O4’ Hydrogen bonds 
Watson-Crick base pair Watson-Crick base pair Watson-Crick base pair hydrogen bonds 
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Chapter 4 
 
Sulfonate derived phosphoramidates as active intermediates in the 
enzymatic primer-extension of DNA and nucleotide delivery in bacteria. 
 
 
 
 
This article is based on an article published by S. De, E. Groaz, L. Margamuljana, M. Abramov, 
P. Marlière and P. Herdewijn, Org. Biomol. Chem 2015, 13, 3950-3962.  
 
 
ABSTRACT 
Novel unnatural 5’-phosphoramidate nucleosides, have been designed to be evaluated both 
for delivery of nucleotides and as substrates of DNA polymerases. The mimics feature 
metabolites such as taurine and a broad range of aliphatic sulfonates coupled through a P-N 
bond to the 5′-phosphate position of deoxynucleotides, to allow binding interactions in the 
enzyme active site. The utility of all of the analogues as pyrophosphate mimics was 
demonstrated in in vitro studies for the chain elongation of DNA, using both thermophilic 
and mesophylic microbial polymerases. 
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4.1. INTRODUCTION 
In biological systems, phosphate esters and anhydrides are amongst the prevailing molecular 
fragments being released by metabolic transformations requiring good leaving groups, such as 
elimination and nucleophilic substitution reactions.1 For instance, DNA polymerization, the 
polynucleotide synthesis reaction, is an enzymatically-catalysed process, in which a free 3′-
hydroxyl nucleophilic group of a primer, base-paired to a DNA template, attacks the α-phosphate 
group of a nucleoside triphosphate with displacement and ensuing hydrolysis of pyrophosphate.2 
This biochemical mechanism might have emerged during evolution as a result of either functional 
selection or synthetic accessibility.  
Our group has an ongoing program devoted to the diversification of nucleic acid metabolism 
by means of the systematic variation of both structural and enzymatic elements inherent to the 
genetic propagation of natural biopolymers.3 One important goal is the identification of novel 
components that, although not favored by natural selection, may nevertheless exist in nature and 
follow biochemical pathways orthogonal to natural ones. This may provide an opportunity to 
implement and propagate in vivo a third type of information carrier molecule (XNA), whilst 
succeeding in the establishment of both genetic and energetic enclaves.  
In the search for non-phosphate synthetic alternatives to pyrophosphate we have already 
demonstrated the leaving group properties of L-aspartic acid and other unnatural amino acids, in 
the DNA polymerase-catalyzed synthesis of DNA.4 This selection of substrates was partly 
motivated by the structural and electronic properties necessary to consent accommodation and 
recognition within the enzyme catalytic site, but most importantly by their significance as non-
toxic intermediates of metabolic steps in living cells.  
In an extension of the substrate scope of the DNA polymerization reaction, we became 
interested in 5’-phosphoramidate deoxyribonucleoside analogues conserving the anionic residues 
for key binding interactions with polymerases in the form of aliphatic sulfonate-based 
functionalities.5 The design of such unnatural mimics of triphosphates is defined by the 
abundance of simple organic molecules such as taurine (2-aminoethanesulfonic acid) and L-
cysteic acid in natural environments and nutrients and their contribution as sources of mineral 
sulfur to microbial growth.6 Organic sulfonates are ionized at physiological pH with very low pKa 
values, thus their cellular uptake cannot occur by passive diffusion, but are rather taken up across 
bacterial membranes by complex transport systems and actively degraded by the action of 
oxygenolytic enzymes over desulfonation pathways. Typically, this process releases sulfite as 
degradative intermediate, which then enters the sulphur assimilation cycle. This is one of the 
essential conditions that a good leaving group candidate must fulfil in order for nucleotide 
incorporation to be irreversible.  
It is well documented in the literature that under conditions of inorganic sulfate and cysteine 
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starvation, various gene clusters are expressed in E. coli, allowing the alternative utilization of 
aliphatic sulfonates.7 Two operons, tauABCD8 and ssuEADCB,9 have been identified which 
encode for distinct ABC-type permeases, thus promoting uptake of taurine and other 
alkanesulfonates respectively, while the TauD gene expresses for the protein alpha-ketoglutarate-
dependent dioxygenase responsible for the liberation of sulphite from taurine.10 Therefore, given 
our interest in developing an uptake system for nucleotides in bacterial cells, the synthesis of 
these molecules was also deemed important in view of their potential use as substrates for cellular 
delivery within a sulfur-based nutritional selection system. 
 
Figure 4-1. Overview of sulfonate-containing phosphoramidate analogues of thymidine. 
 
Herein, we report novel straightforward syntheses of taurine, L-cysteic acid and a wide range of 
relevant sulfono-modified phosphoramidate nucleotide analogues (examples of TMP derivatives 
are shown in Figure 4-1), as well as an account of the efficiency with which various mesophilic 
and thermophilic microbial polymerases accept them as substrates. 
Along with the biochemical relevance, the knowledge of the extent to which molecular diversity 
can be manipulated but still accepted within the polymerase active site will provide fundamental 
parameters in the selection and design of new synthetic genetic variants. 
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4.2. RESULTS AND DISCUSSION 
In an early communication, we established a synthetic approach to sulfonate-containing 
phosphoramidates Tau-dAMP 4.12 and L-Cys-dAMP 4.13, which centred upon an EDC-mediated 
coupling reaction between deoxyadenosine monophosphate (dAMP) and the relevant 
aminoalkylsulfonate motifs.11 However, protection of both sulfonic and carboxylic acids as ethyl 
ester groups was necessary to prevent formation of undesired side-products (Scheme 4-1).  
In addition, it was anticipated that in order to accomplish the synthesis of higher 
functionalized substrates, multiple selective protection and deprotection steps of acidic groups 
would be cumbersome, and most likely produce the novel phosphoramidate products in 
inadequate yields.  
Surprisingly, the replacement in our existing method of EDC by DCC in tBuOH-H2O as 
coupling agent proved to be an alternative satisfactory procedure, even so in the presence of 
unprotected sulfonic acid functionalities. The resulting adenosine 5’-sulfono-phosphoramidates 
4.12 and 4.13 were obtained in a single step with increased yields, provided that an excess of 
Et3N (5 eq.) was added to the reaction mixture in order to mask the charges of the sulfonic acid 
groups. Similarly, sulfono-phosphoramidates 4.1, 4.4 and 4.5 were isolated in good yields (72-
77%) from thymidine monophosphate (TMP) and either taurine, N-methyl taurine or homo-
taurine as starting materials (Scheme 4-2). This methodology was also applied to the preparation 
of L-Cys-dTMP 4.2 and D-Cys-dTMP 4.3 in the presence of both free sulfonic and carboxylic 
acids, albeit with reduced coupling efficiencies (25-30% yields) (Scheme 4-2). 
 
 
Scheme 4-1. Early route towards sulfono-phosphoramidates via ester protection of sulfonic acid. 
 
The same DCC-mediated protocol was also valuable to generate bis-sulfonate 
phosphoramidate 4.6 after coupling between the triethylammonium salt of TMP and the 
secondary amine N,N-di-2-aminoethanesulfonate 4.14, afforded in turn from the Michael addition 
of taurine to sodium vinyl sulfonate (Scheme 4-3).  
In order to provide further evidence to the geometry accepted by the active site,12 we decided 
to prepare dipeptide-like phosphoramidate thymidine analogues bearing various amino acids 
interconnecting the taurine unit with the amidate bond, as shown in Scheme 4-4. Peptidic bonds 
can be degraded in vivo by hydrolase enzymes releasing amino acid and taurine. 
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Scheme 4-2. Synthesis of sulfono-phosphoramidate analogues of thimydine 4.1-4.5 and 
adenosine 4.12 and 4.13. (a) TMP or dAMP (Na or Et3N salt), DCC, Et3N, tBuOH: H2O (4:1), 90 
°C, 4-6 h. 
 
 
Scheme 4-3. Synthesis of thymidine phosphoramidate analogue 4.6. (a) NaHCO3, H2O, reflux, 72 
h; (b) TMP, DCC, Et3N, tBuOH: H2O (4:1), 90 °C, 5.5 h. 
 
The first pyrophosphate mimic of this series containing the neutral residue glycine, compound 
4.16a, was accessible through standard coupling conditions in the presence of DCC/NHS in a 
mixture of dioxane and water, followed by Boc-removal using IR-120B (H+) resin.13 When 
taurine was reacted with a non-neutral amino acid, the same two-steps sequence was found to be 
less rewarding, producing compound H-L-His-Tau-OH 4.16b in modest yield. All attempts to 
induce coupling of taurine to aspartic acid, however, met with failure producing only undesired 
side products (uncharacterized), with both methyl and benzyl featuring as protecting groups of 
the β-carboxyl functionality. Thus, compound H-L-Asp-Tau-OH 4.18, was alternatively obtained 
in two-steps starting from protected Z-L-Asp (OBn)-OH and taurine, followed by hydrogenolysis. 
The final modified nucleosides were prepared under standard DCC coupling conditions, as 
outlined in Scheme 4-4.  
As the reaction between TMP and 4.18 led to the isolation of phosphoramidate 4.9 in low 
yield, which we believe to be due to the presence of a free carboxylic acid group in compound 
4.18, we opted for a different route for this latter substrate. The 5’-phosphate group was thus pre-
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activated by conversion into a better phosphoraimidazolide leaving group, which allows for 
enhanced nucleophilic attack of amines even under mild conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4-4. Synthesis of taurine-amino acid phosphoramidate nucleoside analogues 4.7-4.9. (a) 
(i) NHS, DCC, THF, 0 °C to r.t., 2 h, (ii) Taurine Na-Salt, Dioxane-H2O (1:1), r.t., 14 h; (b) IR-
120B resin (H+ form); (c) TMP-Na salt, DCC, Et3N, tBuOH:H2O (4:1), 90 °C, 4.5 h; (d) 10% 
Pd/C, H2, EtOH-H2O (5:1), r.t., 16 h; (e) Et3N, DMF, 35 °C, 168 h. 
 
N-Acetic acid-2-aminoethane sulfonic acid and N-propionic acid-2-aminoethane sulfonic can 
mimic respectively iminodiacetic acid (IDA) and iminodipropionic acid (IDP), previously 
reported by our group as very good pyrophosphate mimics for DNA polymerization.14, 15 
Therefore, a series of 2’-deoxynucleoside-5’-O-[N-(alkyl acid)-2-aminoethane sulfonic acid] 
phosphoramidates was prepared according to a three-step synthetic methodology (Scheme 4-5), 
starting from taurine without the need for protection of the sulfonic acid group. The formation of 
N-(ethyl acetate)-2-aminoethane sulfonic acid 4.19, following the nucleophilic diplacement of the 
bromo atom in ethylbromoacetate by taurine, occurred only upon heating, whilst N-(ethyl 
acetate)-2-aminoethane sulfonic acid 4.20 resulted from the Michael addition of taurine to ethyl 
acrylate at ambient temperature over seven days.  
As it might be speculated that DCC-mediated phosphoramidate coupling of secondary amines 
would prove less effective than that of primary amines, we thought it necessary to employ 
protected carboxylic ester derivatives in order to improve the reaction outcome in terms of 
isolated yields. Accordingly, reactions of TMP or dAMP thiethylammonium salts with secondary 
amine 4.20 were both reasonably efficient to yield respectively compound 4.25 and dAMP-
analogue 4.26. However, to our surprise, the secondary amine N-(ethyl acetate)-2-aminoethane 
sulfonic acid 4.19 failed to react under this condition. Thus, for the synthesis of compounds 4.21-
4.24 bearing all four nucleobases, we adopted the phosphoraimidazolide- based protocol 
described above, which delivered the T, A and C analogues 4.21, 4.22, and 4.24 in moderate 
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yields (38-52%) and G analogue 4.23 in modest yield (22%). Ultimately, the deprotection of the 
ethyl ester group was carried out by treatment with a dilute solution of sodium hydroxide (0.4 M), 
and subsequent HPLC purification furnished the pure unprotected analogues 4.10-4.11 and 4.27-
4.30 for incorporation studies. 
 
Scheme 4-5. Synthesis of sulfono-phosphoramidate nucleoside analogues 4.10-4.11 and 4.27-
4.30. (a) Ethylbromo acetate, NaHCO3, Dioxane/H2O, 70 °C, 24 h; (b) Ethyl acrylate, NaHCO3, 
EtOH-H2O (1:1), r.t., 168 h; (c) dTMP-Et3N salt, DCC, Et3N, tBuOH-H2O (4:1), 90 °C, 6 h; (d) 
Nucleoside-Imidazolide Na-Salt, Et3N, DMF, 35 °C, 168 h; (e) 0.4 M NaOH in MeOH:H2O (4:1 
v/v), r.t., 3 h. 
 
Next, Tau-dTDP β-phosphoramidate 4.33 was prepared according to the DCC-mediated 
phosphoramidate coupling between taurine and the triethylammonium salt of thymidine 
diphosphate 4.32. Compound 4.32 was derived in turn from 5’-O-tosyl derivative 4.31,16 upon 
treatment with tris(tetra-n-butylammonium) hydrogen pyrophosphate, acting as a nucleophile to 
displace the tosyl group as reported by Davisson et. al (Scheme 4-6).17  
 
Scheme 4-6. Synthesis of taurine diphosphoramidate analogue 4.33 of thymidine. (a) Tris (tetra-
n-butylammonium) hydrogen pyrophosphate, CH3CN, r.t., 24 h; (b) Taurine, DCC, Et3N,  
tBuOH:H2O (4:1), 85 °C, 4.5 h. 
 
Finally, the synthesis of Tau-dTTP γ-phosphoramidate 4.35 was accomplished through initial 
conversion of dTTP-Et3N salt 4.34 to thymidine-5’-trimetaphosphates by dehydration with 
DCC,18 followed by ring opening of thymidine-5’-trimetaphosphate with an excess of taurine 
(Scheme 4-7).  
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Scheme 4-7. Synthesis of taurine triphosphoramidate analogue 4.35 of thymidine. (a) DCC, 
DMF, r.t., 3.5 h; (b) Taurine, MeOH/DMF, r.t., 6 h. 
 
4.3. CHAIN ELONGATION EXPERIMENTS (performed by Lia Margamuljana)  
The individual competency of chemically-modified sulfono-phosphoramidate nucleosides 
4.1-4.11, 4.27-4.30, 4.32-4.33 and 4.35 to perform as active intermediates in the DNA 
polymerization reaction was assessed by comparing the activities of different bacterial DNA 
polymerases, including Therminator, Vent (exo-) and the Klenow fragment (exo-) of E. coli DNA 
Polymerase I. The last two mutants lacking 3´→ 5´proofreading activity were included in the 
study as preferred for affording high yield primer extension reactions in the presence of poor 
substrates, by suppressing simultaneous synthesis and editing. 
Multiple nucleotides incorporation efficiencies in primer extension were estimated by means 
of a polyacrylamide gel-based template dependent assay, using a 5’-radiolabelled γ-33P DNA 
primer annealed in turn to T1-5 templates (Table 4-1). For each enzyme, reactions were also 
carried out with natural deoxynucleoside triphosphates (dNTP) as positive controls.  
 
Table 4-1. Overview of primer and templates sequences used in the incorporation experiments. 
 
Primer      P1: 5’ /5Cy5/CAGGAAACAGCTATGAC 3’ 
Template T1:  3’ GTCCTTTGTCGATACTGAAAAA 5’ 
Template T2:  3’ GTCCTTTGTCGATACTGTTTTTTT 5’ 
Template T3:  3’ GTCCTTTGTCGATACTGGGGGG 5’ 
Template T4:  3’ GTCCTTTGTCGATACTGCCCCC 5’ 
Template T5:  3’ GTCCTTTGTCGATACTGCAAAA 5’ 
 
The first set of compounds to be examined as potential triphosphate mimics, were adenine 
sulfonate-phosphoramidates 4.12-4.13 and thymidine analogues 4.1-4.5. Preliminary results of 
single nucleotide incorporation experiments for analogues Tau-dAMP 4.12 and L-Cys-dAMP 
4.13 had shown modest incorporation efficiencies into a growing DNA chain, as catalyzed by 
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HIV-1 reverse transcriptase11 or family C E. coli Pol III.19 However, it is recognized that 
phylogenetically distinct classes of enzymes might show different substrate-specificities, despite 
sharing similar polymerization domains and mechanism. As evidence of a dynamic effect 
triggered by multiple incorporations on the progression of the reaction emerged in the course of 
previous studies,19 all compounds were directly subjected to elongation tests. 
  
While Vent (exo-) was not able to accept adenine analogues Tau-dAMP 4.12 and L-Cys-
dAMP 4.13 or thymidine analogues Tau-dTMP 4.1, L-Cys-dTMP 4.2 and D-Cys-dTMP 4.3, 6% 
and 14% formation of the P + 1 strand was observed at 1mM (60 min) with Klenow (exo-) for 
cysteic acid-containing thymidine phophoramidates 4.2 and 4.3, and incorporation efficiencies 
with the same polymerase were relatively higher for adenine analogues 4.12 and 4.13, showing 
5% (P + 2) and 6% (P + 4) respectively. However, the thermostable polymerase Therminator 
could use all those compounds as substrates, in line with the significant propensity of this 
replicative enzyme to accept modified nucleotides substrates. We have observed 75% (P + 1) and 
6% (P + 2) for 4.1, 68% (P + 1) and 6% (P + 2) for compound 4.2, 70% (P + 1) and 16% (P + 2) 
for compound 4.3, 18% (P+1) for compound 4.12 and complete conversion to (P + 1) strand, 58% 
of (P + 2), 28% of (P + 3), 9% of  (P + 4) and up to 2% of (P + 5) strand for compound 4.13. 
 
Within the series of analogues containing thymine as nucleobase, N-methyl taurine derivative 
N-Me-Tau-dTMP 4.4 showed to be incorporated into the primer template duplex more efficiently 
than compounds bearing taurine, D- or L-cysteic acid, with 14% conversion up to (P + 2) strand 
using Vent (60 min, 1mM) and 17% conversion up to (P + 3) using Therminator (60 min, 1mM), 
whilst homotaurine-dTMP 4.5 showed only 6% and 20% conversion to (P + 1) strand with Vent 
and Therminator (60 min, 1mM) respectively. The leaving group properties of bis-taurine in 
derivative 4.6 was comparable to that of N-methyl taurine, showing formation of 15 % of (P + 2) 
and 2% of (P + 3) strand with Vent and 21 % of (P + 2) and 3% of (P + 3) strand with 
Therminator at 60 min (1mM). 
 
The acceptance of taurine-amino acid containing derivatives Tau-Gly-dTMP 7, Tau-His-
dTMP 4.8 and Tau-Asp-dTMP 4.9 in primer extension reactions by Vent (exo-) and Therminator 
polymerases was disappointing, with the exception of aspartate analogue 4.9 which showed 17% 
P + 1 and 2% P + 2 after 60 min (1mM) with Therminator. Since the individual aminoacids 
composing those structural units are proved to be good leaving groups, it can be concluded that 
the increased linear size of those compounds does not allow accommodation in the enzymatic 
pocket, and the results obtained for aspartate analogue 4.9 might be due to induction from the β-
carboxylic functionality.  
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Figure 4-2. Chain elongation efficiency of compounds 4.1-4.11, 4.27-4.30, 4.32-4.33 and 4.35 by 
Vent (exo-) polymerase (0.01 U.µl-1), at 1mM conc. after 60 min. 
 
 
 
 
 
Figure 4-3. Chain elongation efficiency of compounds 4.1-4.13, 4.27-4.30, 4.32-4.33 and 4.35 by 
Therminator polymerase (0.01 U.µl-1), at 1mM conc. after 60 min. 
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Figure 4-4. Chain elongation efficiency of compounds 4.1-4.3, 4.10, 4.12-4.13, 4.27-4.30 and 
4.35 by Klenow fragment polymerase (exo-) (0.05 U.µl-1), at 1mM conc. after 60 min. 
 
The next analogues to be studied were the phosphoramidates derived from taurine-N-acetic 
acid and taurine-N-propionic acid. Previously, we observed a preference for incorporation for 
purines over pyrimidines with various polymerases with the order A ≥ T = G > C, so we initially 
wished to compare with a comparable efficiency, taurine-N-acetic acid adenine nucleoside 4.27 
was a better substrate for thermophilic polymerases than taurine-N-propionic acid adenine 
analogue 4.30. In particular, for the thymidine analogue 4.10, only 3%, 1% and up to 10% 
formation of P + 2 strand in 60 min at 1mM was observed with Vent, Klenow and Therminator 
respectively, whereas the incorporation properties of adenine analogue 4.27 were better than the 
thymidine analogue, showing up to 3% P + 3 strand with Vent, 15% of P + 2 with Therminator 
and 1% of P + 4 strand with Klenow. In view of these observations, it was considered important 
to additionally explore the influence of the other nucleobase moieties on the incorporation 
efficiency. To this end, we synthesized and investigated deoxynucleoside monophosphate 
analogues of G and C nucleobases 4.28 and 4.29, modified at the 5’-position with the selected 
taurine-N-acetic acid as leaving group using Vent (exo-), Therminator and Klenow as 
polymerases. As anticipated, the cytidine analogue 4.29 showed the lowest efficiency, giving rise 
to the formation of 8% of P + 1 with Vent and Klenow and 10 % of (P + 1) only with 
Therminator. Surprisingly, guanidine analogue 4.28 was added into a growing DNA chain more 
efficiently than any other nucleotide, with a final base ranking order G > A ≥ T > C for this set of 
derivatives, showing formation of 87% of (P + 4) and up to 5% of full length (P + 5) strand with 
Vent, up to 93% of (P + 4) with Klenow and 71% of (P + 4) and 4% of (P + 5) strand with 
Therminator (Figure 5). The rationale behind the base-specificity of DNA polymerases is 
uncertain. In a distinct literature report, it has been shown that kinetics of incorporation could be 
affected by the diversification of the 3’-flanking neighbouring base on the template and between 
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pairing of dCTP or dTTP opposite to O6-methylguanine.20  
Ultimately, the elongation ability of diphosphate analogue tau-dTDP 4.33 was excellent, 
giving up to 41% full-length chain (P + 5) formation at 1 mM in 60 min with Vent and 9 % full 
length chain (P + 5) formation even at 0.125 mM in 15 min with Therminator. These findings 
were thought to be due to the presence of the diphosphate group, thus as additional evidence we 
compared compound 4.33 with natural 5’-thymidine diphosphate 4.32 (dTDP). Enzymatic results 
pointed to a slightly reduced incorporation efficiency for tau-dTDP in comparison to dTDP. 
Unsurprisingly, the last compound to be evaluated, Tau-dTTP 4.35, was found to be as efficient 
as the natural substrate dTTP using both Therminator and Klenow although less efficient in the 
presence of Vent (exo-), showing only 22% formation of P + 5 strand at 1mM concentration. 
 
 
 
Figure 4-5. Profile of chain elongation of the control dGTP and compound 4.28 as substrate into 
the P1:T4 by three different DNA polymerase; Klenow (0.05 U.µl-1), Vent (0.01 U.µl-1) and 
Therminator (0.01 U.µl-1).  
 
Table 4-2 Steady–state kinetics of single nucleotide incorporation into P1T5 by Klenow fragment 
(0.001 U.µl-1) 
Substrate Vmax [nM.min-1] Km [µM] 
Vmax / Km 
[x 10-3 min-1] 
dGTP 58.10 ± 3.23 0.089 ± 0.015 652.80 
Compound 4.28 62.55 ± 3.30 67.34 ± 11.00 0.93 
 
As the best results were seen with modified guanidine substrate 4.28 and Klenow fragment 
(exo-), incorporation and subsequent extension of compound 4.28 into primed-template P1:T5 
were quantitatively determined, based on the Single Complete Hit model, in comparison to its 
natural nucleoside triphosphate (dGTP). The steady-state kinetic analysis, the results of which are 
15#30#60###15#30#60###15#30#60###15#30#60#
control# 125µM# 500µM# 1mM#
Klenow#
control# 125µM# 500µM# 1mM#
Vent#
15#30#60###15#30#60###15#30#60###15#30#60# 15#30#60###15#30#60###15#30#60###15#30#60#
control# 125µM# 500µM# 1mM#
Therminator#
P+6#
P+5#
P+3#
P+4#
P+2#
P+1#
P##
P+5#
P+3#
P+4#
P+2#
P+1#
P##
P+3#
P+4#
P+2#
P+1#
P##
Min#!#
Chapter 4  Sulfonate-Nucleotide Conjugates 
 118 
summarized in Table 4-2, indicates a Vmax value for compound 4.28 1.07 fold higher than that of 
natural dGTP, but a Km value 758 fold higher, with a Vmax/Km ratio of compound 4.28 702-fold 
lower than the natural substrate. Although the relevant nucleobase (adenine) and DNA enzyme 
(HIV-1 RT) previously employed in the analysis of bio-isosteres iminodiacetic acid (IDA) and 
iminodipropionic acid (IDP) were different, we can nevertheless conclude that the leaving group 
properties of taurine-N-acetic acid is comparable to IDA (IDA-dAMP resulted 940-fold lower 
than the natural substrate) and slightly lower than IDP (IDP-dAMP was 83-fold lower than the 
natural substrate). 
 
4.4. CONCLUSION 
A novel series of modified deoxyribonucleosides bearing sulfonate or both carboxylate and 
sulfonate functional groups, connected through a phosphoramidate linker to the 5’-position were 
successfully prepared. Following multiple incorporation screening of various microbial 
polymerases (as reviewed in Figures 4.2, 4.3 and 4.4), the A family Klenow fragment 
exonuclease-free polymerase mutant was found to be the most effective polymerase, giving the 
best elongation rates, while B family thermostable Therminator was confirmed as possessing the 
broader substrate-specificity. The development of new leaving groups for DNA polymerization 
can be a valuable tool for synthetic biology, for which the mesophylic Klenow polymerase from 
E. coli was tested and should aid the search for novel reagents able to perform DNA synthesis at 
high temperature for polymerase chain reaction (PCR) for which thermostable DNA polymerases 
were tested. 
 
4.5. EXPERIMENTAL SECTION 
General information 
For all reactions, analytical grade solvents were used. All moisture-sensitive reactions were 
carried out under an argon or a nitrogen atmosphere in oven-dried glassware (135 ºC). Reaction 
temperatures are reported as bath temperatures. If not mentioned, all amino acids used were L-
isomer.  Precoated aluminum sheets (254 nm) were used for TLC. Compounds were visualized 
with UV light (λ = 254 nm). Products were purified by flash chromatography on ICN silica gel 
63-200, 60 Å. All final compounds were purified by preparative RP-HPLC (XbridgeTM Prep C18 
5µm OBD 19 x 150 mm column) or Ion-exchange resin (Source 15 Q). All the elution methods 
use MeCN/H2O gradients for RP-HPLC or TEAB-H2O gradient for Ion-exchange. 1H, 13C and 31P 
NMR spectra were recorded on Bruker Avance 300 MHz, 500 MHz or 600 MHz spectrometers. 
For all final compounds, 1H and 13C resonance assignments were made using 2D NMR 
correlation experiments (COSY, gHSQC and gHMBC). For sake of clarity, NMR signals of 
protons and carbons for sugar and base moieties are indicated with and without a prime, 
respectively. Chemical shifts were referenced to residual solvent signals at δ H/C 7.26/77.00 
(CDCl3), 3.31/49.10 (CD3OD) and 2.50/39.50 (DMSO-d6) relative to TMS as internal standard. 
Coupling constants are expressed in hertz (Hz). Splitting patterns are reported as s (singlet), d 
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(doublet), t (triplet), q (quartet), m (multiplet), br (broad) and app (apparent). High-resolution 
mass spectra were acquired on a quadruple orthogonal acceleration time-of-flight mass 
spectrometer (Synapt G2 HDMS, Waters, Milford, MA). Samples were infused at 3 µL/min and 
spectra were obtained in positive or negative ionization mode with a resolution of 15000 
(FWHM), using leucine enkephalin as lock mass. 
 
General procedure for phosphoramidates synthesis (A) 
The relevant 2’-deoxynucleoside-5’-monophosphate (1 eq.) and amino derivative (3-5 eq.) were 
suspended in a 4:1 tBuOH/H2O mixture (~20 mL/mmol). Triethylamine (5-10 eq.) was then added 
to the suspension to facilitate dissolution, followed by DCC (2-5 eq.). The reaction mixture was 
heated at 90 ºC for 3-6 h. The reaction progress was monitored by TLC (iPrOH:H2O:Et3N/NH3 
10:2:2). Upon completion, the reaction mixture was cooled to room temperature and the solvent 
was removed by rotary evaporation. The residue was resuspended in water (100 ml), washed with 
diethyl ether (3 x 100 ml) and the aqueous phase was lyophilized. The resulting crude material 
was purified by column chromatography on silica gel using the following gradient IPA:H2O:NH3 
20:1:1, v/v/v;  15:1:1, v/v/v; 10:1:1, v/v/v (Et3N was used instead of NH3 for carboxylic ester 
containing compounds, to avoid amide formation), to provide the desired nucleoside 
phosphoramidates as salts. Semi-preparative RP-HPLC (50 mmol TEAB in H2O + 2% ACN and 
50 mmol TEAB in 50% H2O + 50% ACN ) was employed for further purification to obtain the 
pure products (except for compounds 4.1, 4.2, 4.3 and 4.8). The residues were lyophilized and 
freeze-dried repeatedly until constant mass. 
 
Thymidine-5’-taurine phosphoramidate ammonium salt (4.1)  
The ammonium salt of compound 4.1 was obtained as a white solid (0.27 g, 72%) following the 
general procedure (A), starting from 2’-deoxythymidine-5’-monophosphate (TMP) disodium-salt 
(0.3 g, 0.82 mmol), taurine (0.31 g, 2.46 mmol), triethylamine (0.57 mL, 4.09 mmol), DCC 
(0.51g, 2.46 mmol) in a 4:1 tBuOH/H2O mixture (15 mL) at 90 ºC for 3 h. 1H NMR (300 MHz, 
D2O) δ = 7.69 (d, J = 1.0 Hz, 1H, H-6), 6.27 (app t, J = 7.1 Hz, 1H, H-1’), 4.51-4.49 (m, 1H, H-
3’), 4.09-4.07 (m, 1H, H-4’), 3.94-3.91 (m, 2H, H-5’ and H-5’’), 3.17-3.10 (m, 2H, -
CH2αCH2SO3H), 2.97 (t, J = 6.6 Hz, 2H, -CH2CH2βSO3H), 2.33-2.27 (m, 2H, H-2’ and H-2’’), 
1.85 (d, J = 1.0 Hz, 3H, CH3-Thy); 13C NMR (75 MHz, D2O) δ = 166.2 (C-4), 151.4 (C-2), 137.1 
(C-6), 111.4 (C-5), 85.3 (d, 3JC,P = 8.9 Hz, C-4’), 84.7 (C-1’), 70.9 (C-3’), 63.8 (d, 2JC,P = 4.9 Hz, 
C-5’), 52.0 (d, 3JC,P = 6.3 Hz, -CH2CβH2SO3H), 38.4 (C-2’), 36.7 (-CαH2CH2SO3H), 11.3 (CH3-
Thy);  31P NMR (121 MHz, D2O) δ = 8.0; HRMS for C12H20N3O10PS [M-H]- calcd.: 428.0534, 
found: 428.0531. 
 
Thymidine-5’-(L-cysteic acid) phosphoramidate ammonium salt (4.2) 
 The ammonium salt of compound 4.2 was obtained as an off-white solid (0.086 g, 30%) 
following the general procedure (A), starting from TMP disodium-salt (0.2 g, 0.55 mmol), L-
cysteic acid (0.31 g, 1.64 mmol), triethylamine (0.76 mL, 5.46 mmol), DCC (0.34g, 1.64 mmol) 
in a 4:1 tBuOH/H2O mixture (14 mL) at 90 ºC for 3 h. 1H NMR (300 MHz, D2O) δ = 7.72 (d, J = 
1.0 Hz, 1H, H-6), 6.27 (app t, J = 7.0 Hz, 1H, H-1’), 4.51-4.49 (m, 1H, H-3’), 4.09-4.07 (m, 1H, 
H-4’), 3.96-3.92 (m, 2H, H-5’ and H-5’’), 3.87-3.83 (m, 1H, CHCO2H), 3.16 (d, J = 5.8 Hz, 2H, 
CH2SO3H), 2.31-2.25 (m, 2H, H-2’ and H-2’’), 1.86 (d, J = 1.0 Hz, 3H, CH3-Thy); 13C NMR (75 
MHz, D2O) δ = 178.6 (CO2H), 166.3 (C-4), 151.5 (C-2), 137.1 (C-6), 111.5 (C-5), 85.5 (d, 3JC,P = 
9.3 Hz, C-4’), 84.6 (C-1’), 70.9 (C-3’), 63.7 (d, 2JC,P = 4.8 Hz, C-5’), 54.5 (d, 3JC,P = 6.6 Hz, -
CH2SO3H), 53.8 (d, 2JC,P = 6.1 Hz, CHCO2H), 38.2 (C-2’), 11.3 (CH3-Thy);  31P NMR (121 MHz, 
D2O) δ = 6.1; HRMS for C13H20N3O12PS [M-H]- calcd.: 472.0432, found: 472.0436. 
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Thymidine-5’-(D-cysteic acid) phosphoramidate ammonium salt (4.3) 
 The ammonium salt of compound 4.3 was obtained as an off-white solid (0.072 g, 25%) 
following the general procedure (A), starting from TMP disodium-salt (0.2 g, 0.55 mmol), D-
cysteic acid (0.31 g, 1.64 mmol), triethylamine (0.76 mL, 5.46 mmol), DCC (0.34g, 1.64 mmol) 
in a 4:1 tBuOH/H2O mixture (14 mL) at 90 ºC for 3 h. 1H NMR (300 MHz, D2O) δ = 7.69 (d, J = 
1.0 Hz, 1H, H-6), 6.26 (app t, J = 7.1 Hz, 1H, H-1’), 4.52-4.49 (m, 1H, H-3’), 4.09-4.07 (m, 1H, 
H-4’), 3.96-3.92 (m, 2H, H-5’ and H-5’’), 3.86-3.82 (m, 1H, CHCO2H), 3.16 (d, J = 5.8 Hz, 2H, 
CH2SO3H), 2.31-2.25 (m, 2H, H-2’ and H-2’’), 1.86 (d, J = 1.0 Hz, 3H, CH3-Thy); 13C NMR (75 
MHz, D2O) δ = 178.0 (d, 3JC,P = 5.1 Hz, CO2H), 166.3 (C-4), 151.5 (C-2), 137.2 (C-6), 111.4 (C-
5), 85.4 (d, 3JC,P = 9.3 Hz, C-4’), 84.7 (C-1’), 71.0 (C-3’), 63.9 (d, 2JC,P = 5.1 Hz, C-5’), 54.5 (d, 
3JC,P = 6.6 Hz, CH2SO3H), 53.5 (d, 2JC,P = 6.6 Hz, CHCO2H), 38.2 (C-2’), 11.3 (CH3-Thy);  31P 
NMR (121 MHz, D2O) δ = 6.1; HRMS for HRMS for C13H20N3O12PS [M-H]- calcd.: 472.0432, 
found: 472.0430. 
 
2’-Deoxyadenine-5’-taurine phosphoramidate ammonium salt (4.12)11  
 The ammonium salt of compound 4.12  was obtained as a white solid (0.45 g, 71%) following 
the general procedure (A), starting from dAMP (0.441 mg, 1.333 mmol), taurine (0.5 g, 4.00 
mmol), triethylamine (1.48 mL, 10.66 mmol), DCC (0.82 g, 4.00 mmol) in a 4:1 tBuOH/H2O 
mixture (40 mL) at 90 ºC for 3 h. Spectral data are in accordance with literature report. Ref. 11 
 
2’-Deoxyadenine-5’-(L-cysteic acid) phosphoramidate ammonium salt (4.13)11  
 The ammonium salt of compound 4.13 was obtained as a white solid (0.23 g, 32%) following the 
general procedure (A), starting from dAMP (441.5 mg, 1.333 mmol), L-cysteic acid (338 mg, 
1.999 mmol), triethylamine (1.48 mL, 10.66 mmol), DCC (0.82 g, 4.00 mmol) in a 4:1 
tBuOH/H2O mixture (40 mL) at 90 ºC for 3 h. Spectral data are in accordance with literature 
report. Ref. 11 
 
Thymidine-5’-O-(N-methyltaurine) phosphoramidate triethylammonium salt (4.4) 
 The triethylammonium salt of compound 4.4 was obtained as a white solid (0.39 g, 74%) 
following the general procedure (A), starting from TMP-triethylammonium salt (0.43 g, 0.82 
mmol), N-methyltaurine (0.57 g, 4.09 mmol), triethylamine (0.91 mL, 6.55 mmol) and DCC (1.01 
g, 4.91 mmol) in a 4:1 tBuOH/H2O mixture (12 mL) at 90 ºC for 5.5 h.1H NMR (500 MHz, D2O) 
δ = 7.73 (s, 1H, H-6), 6.20 (app t, J = 7.0 Hz, 1H, H-1’), 4.53-4.52 (m, 1H, H-3’), 4.12-4.11 (m, 
1H, H-4’), 3.94-3.91 (m, 2H, H-5’ and H-5’’), 3.33-3.27 (m, 2H, CH2αCH2SO3H), 3.08 (t, J = 7.0 
Hz, 2H, CH2CH2βSO3H), 2.58 (d, 3JH,P = 9.5 Hz , 3H, N-CH3), 2.34-2.31 (m, 2H, H-2’ and H-2’’), 
1.89 (s, 3H, CH3-Thy); 13C NMR (125 MHz, D2O) δ = 166.0 (C-4), 151.1 (C-2), 136.7 (C-6), 
111.1 (C-5), 84.9 (d, 3JC,P = 9.1 Hz, C-4’), 84.3 (C-1’), 70.6 (C-3’), 63.5 (d, 2JC,P = 5.3 Hz, C-5’), 
48.8 (d, 3JC,P = 2.9 Hz, CH2CβH2SO3H), 44.5 (d, 2JC,P = 4.3 Hz, CαH2CH2SO3H), 38.0 (C-2’), 33.0 
(d, 2JC,P = 3.5 Hz, N-CH3), 11.1 (CH3-Thy);  31P NMR (202 MHz, D2O) δ = 8.9; HRMS for 
C13H22N3O10PS [M-H]- calcd.: 442.0691, found: 442.0689. 
 
Thymidine-5’-(3-aminopropanesulfonic acid) phosphoramidate triethylammonium salt (4.5) 
 The triethylammonium salt of compound 4.5 was obtained as a white solid (0.272 g , 77%) 
following the general procedure (A), starting from TMP-disodium salt (0.2 g, 0.55 mmol), 3-
aminoethanesulfonic acid (0.23 g, 1.64 mmol), triethylamine (0.46 mL, 3.28 mmol) and DCC 
(0.45 g, 2.18 mmol) at 90 ºC for 4 h.1H NMR (500 MHz, D2O) δ = 7.76 (s, 1H, H-6), 6.32 (app t, 
J = 7.0 Hz, 1H, H-1’), 4.55-4.53 (m, 1H, H-3’), 4.13 (br s, 1H, H-4’), 3.99-3.92 (m, 2H, H-5’ and 
H-5’’), 22.91-2.86 (m, 4H, -CH2αCH2CH2SO3H and -CH2CH2CH2γSO3H), 2.39-2.28 (m, 2H, H-2’ 
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and H-2’’), 1.89 (s, 3H, CH3-Thy), 1.87-1.81 (m, 2H, -CH2CH2βCH2SO3H); 13C NMR (125 MHz, 
D2O) δ = 166.4 (C-4), 151.5 (C-2), 136.9 (C-6), 111.1 (C-5), 85.0 (d, 3JC,P = 9.1 Hz, C-4’), 84.3 
(C-1’), 70.7 (C-3’), 63.4 (d, 2JC,P = 4.9 Hz, C-5’), 48.2 (-CH2CH2CγH2SO3H), 39.4 (-
CαH2CH2CH2SO3H), 38.1 (C-2’), 26.0 (d, 3JC,P = 6.8 Hz, -CH2CβH2CH2SO3H), 11.2 (CH3-Thy);  
31P NMR (202 MHz, D2O) δ = 8.5 ; HRMS for C13H22N3O10PS [M-H]- calcd.: 442.0690, found: 
442.0668. 
 
N,N-2-Diaminoethanesulfonate-disodium salt (4.14) 
 To a stirred solution of 2-aminoethane sulfonic acid (2.0 g, 16.0 mmol) and NaHCO3 (1.34 g, 
16.0 mmol) in water, was added an aqueous solution (25%) of sodium vinylsulfonate (6.72 mL, 
15.2 mmol). The resulting mixture was heated to reflux for 3 d. The reaction mixture was then 
cooled and the solvent was removed by distillation under vacuum. The remaining solid was 
purified by column chromatography on silica gel (gradient: IPA:H2O 50:1, v/v; 20:1, v/v;  10:1, 
v/v) to provide compound 4.14 (3.58 g, 85%) as a fluffy white solid. 1H NMR (300 MHz, D2O) δ 
= 3.56 (t, J = 6.6 Hz, 2H, CH2αCH2SO3H), 3.32 (t, J = 6.6 Hz, 2H, CH2CH2βSO3H); 13C NMR (75 
MHz, D2O) δ = 46.2 (CH2CβH2SO3H), 43.3 (CαH2CH2SO3H); HRMS for C4H11NO6S2 [M-H]- 
calcd.: 231.9955, found: 231.9954. 
 
Thymidine-5’-(N,N-2-diaminoethanesulfonate) phosphoramidate triethylammonium salt 
(4.6) 
 The triethylammonium salt of compound 4.6 (0.243 g, 53%) was obtained as a white solid 
following the general procedure (A), starting from TMP-triethylammonium salt (0.286 g, 0.55 
mmol), compound 4.14 (0.76 g, 2.73 mmol), triethylamine (0.91 mL, 6.55 mmol) and DCC (0.68 
g, 3.28 mmol) in a 4:1 tBuOH/H2O mixture (9 mL) at 90 ºC for 5.5 h. 1H NMR (500 MHz, D2O) δ 
= 7.80 (s, 1H, H-6), 6.37 (app t, J = 7.0 Hz, 1H, H-1’), 4.61-4.58 (m, 1H, H-3’), 4.18 (br s, 1H, 
H-4’), 4.05-3.99 (m, 2H, H-5’ and H-5’’), 3.43-3.36 (m, 4H, CH2αCH2SO3H), 3.17 (t, J = 8.0 Hz, 
4H, CH2CH2βSO3H), 2.40-2.37 (m, 2H, H-2’ and H-2’’), 1.96 (s, 3H, CH3-Thy); 13C NMR (125 
MHz, D2O) δ = 166.0 (C-4), 151.2 (C-2), 136.7 (C-6), 111.3 (C-5), 84.9 (d, 3JC,P = 9.3 Hz, C-4’), 
84.4 (C-1’), 70.6 (C-3’), 63.5 (d, 2JC,P = 5.4 Hz, C-5’), 49.5 (CH2CβH2SO3H), 41.7 (d, 2JC,P = 4.9 
Hz, CαH2CH2SO3H), 38.1 (C-2’), 11.2 (CH3-Thy);  31P NMR (202 MHz, D2O) δ = 7.4 ; HRMS for 
C14H24N3O13PS2 [M-H]- calcd.: 536.0415, found: 536.0418. 
General procedure for taurine-amino acid synthons synthesis 
 DCC (1.1 eq.) was added to a solution of N-Boc-protected amino acid (1 eq.) and N-hydroxy 
succinimide (1.04 eq.) in dry THF (~4 mL/mmol) at 0 ºC, and the mixture was stirred for an 
additional 0.5 h at same temperature, then for 1.5 h at room temperature. The resulting DCU was 
filtered off, and the filtrate was concentrated in vacuo to afford the activated ester. The crude 
residue was then dissolved in dioxane (3 mL/mmol), and to this solution was added a solution of 
taurine sodium salt (1 eq.) in water (2 mL/mmol) at room temperature. The reaction mixture was 
stirred at room temperature for 14 h, followed by evaporation of the organic phase in vacuo. The 
aqueous layer was washed with ethyl acetate (3 x) and was then loaded on a column packed with 
IR-120B (H+ form) resin. The aqueous eluent was evaporated to dryness in vacuo to give a 
crystalline powder, which was recrystallized from ethanol-water to give pure H2N-aminoacid-
Taurine-OH as a white crystalline solid. 
 
H-Gly-Tau-OH (4.16a) 
 Compound 4.16a was obtained as a white solid (0.95 g, 91%) according to the general procedure, 
starting from DCC (1.29 g, 6.27 mmol), Boc-Gly-OH 4.15a (1.0 g, 5.70 mmol), N-hydroxy 
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succinimide (0.68 g, 5.93 mmol) in THF (20 mL) and taurine sodium salt (0.84 g, 5.70 mmol) in 
dioxane-water (1:1, 30 mL). 1H NMR (300 MHz, D2O) δ = 3.82 (s, 2H, CH2-Gly), 3.67 (t, J = 6.0 
Hz, 2H, CH2αCH2SO3H), 3.13 (t, J = 6.8 Hz, 2H, CH2CH2βSO3H); 13C NMR (75 MHz, D2O) δ = 
166.5 (CO-Gly), 49.1 (CH2CβH2SO3H), 40.1 (CH2-Gly), 34.8 (CαH2CH2SO3H); HRMS for 
C4H10N2O4S [M-H]- calcd.: 181.0288, found: 181.0290. 
 
H-His-Tau-OH (4.16b) 
 Compound 4.16b was obtained as a white solid (1.55 g, 52%) according to the general 
procedure, starting from DCC (2.58 g, 12.54 mmol), Boc-His-OH 4.15b (2.92 g, 11.40 mmol), N-
hydroxy succinimide (1.36 g, 11.86 mmol) in THF (44 mL) and taurine sodium salt (1.68 g, 11.40 
mmol) in dioxane-water (1:1, 60 mL). 1H NMR (300 MHz, D2O) δ = 8.05 (s, 1H, His Ar-H), 7.17 
(s, 1H, His Ar-H), 4.13 (t, J = 6.9 Hz, 1H, His-CH), 3.62-3.54 (m, 2H, CH2αCH2SO3H), 3.18 (d, J 
= 6.9 Hz, 2H, His-CH2), 3.08-2.98 (m, 2H, CH2CH2βSO3H); 13C NMR (75 MHz, D2O) δ = 169.6 
(CO-His), 135.4 (Ar C-His), 129.6 (Ar C-His), 116.9 (Ar C-His), 52.9 (αC-His), 49.0 
(CH2CβH2SO3H), 34.8 (CαH2CH2SO3H), 28.0 (βC-His); HRMS for C8H14N4O4S [M-H]- calcd.: 
261.0663, found: 261.0663. 
 
Thymidine-5’-N-(Gly-Tau-OH)-phosphoramidate ammonium salt (4.7) 
 The ammonium salt of compound 4.7 was obtained as a white solid (0.29 g , 68%) following the 
general procedure (A), starting from TMP-disodium salt (0.3 g, 0.82 mmol), H-Gly-Tau-OH (0.49 
g, 2.70 mmol), triethylamine (0.57 mL, 4.09 mmol) and DCC (0.78 g, 3.78 mmol) in a 4:1 
tBuOH/H2O mixture (8 mL) at 90 ºC for 4.5 h. 1H NMR (500 MHz, DMSO-d6) δ = 8.19 (t, J = 5.4 
Hz, 1H, NH-Gly), 7.82 (d, J = 1.0 Hz, 1H, H-6), 6.20 (dd, J = 7.8, 6.0 Hz, 1H, H-1’), 4.27-4.25 
(m, 1H, H-3’), 3.86-3.65 (m, 1H, H-4’), 3.76-3.74 (m, 2H, H-5’ and H-5’’), 3.68 (br s, 1H, 3’-
OH), 3.41-3.37 (m, 2H, CH2αCH2SO3H), 3.21 (d, J = 6.3 Hz, 2H, CH2-Gly), 3.62 (t, J = 6.3 Hz, 
2H, CH2CH2βSO3H), 2.14-2.00 (m, 2H, H-2’ and H-2’’), 1.80 (d, J = 1 Hz, 3H, CH3-Thy); 13C 
NMR (125 MHz, DMSO-d6) δ = 171.7 (d, 3JC,P = 5.1 Hz, CO-Gly), 163.9 (C-4), 150.6 (C-2), 
136.4 (C-6), 109.9 (C-5), 86.2 (d, 3JC,P = 7.8 Hz, C-4’), 83.8 (C-1’), 71.2 (C-3’), 63.9 (d, 2JC,P = 
4.9 Hz, C-5’), 50.3 (CH2CβH2SO3H), 45.8 (CH2-Gly), 39.2 (C-2’), 35.1 (CαH2CH2SO3H), 12.2 
(CH3-Thy);  31P NMR (202 MHz, DMSO-d6) δ = 5.1 ; HRMS for C14H23N4O11PS [M-H]- calcd.: 
485.0749, found: 485.0750. 
 
Thymidine-5’-(N-His-Tau-OH)-phosphoramidate triethylammonium salt (4.8) 
 The triethylammonium salt of compound 4.8 was obtained  as white solid (0.26 g, 41%) 
following the general procedure (A), starting from TMP-disodium salt (0.3 g, 0.82 mmol), H-His-
Tau-OH (0.97 g, 3.68 mmol), triethylamine (0.57 mL, 4.09 mmol) and DCC (0.85 g, 4.09 mmol) 
in a 4:1 tBuOH/H2O mixture (10 mL) at 90 ºC for 4.5 h. 1H NMR (500 MHz, D2O) δ = 7.61 (d, J 
=1 Hz, 1H, H-6), 7.59 (d, J = 0.5 Hz, 1H, imidazole), 6.88 (s, 1H, imidazole), 6.32 (app t, J = 6.5 
Hz, 1H, H-1’), 4.43-4.41 (m, 1H, H-3’), 4.04 (br s, 1H, H-4’), 3.81-3.75 (m, 3H, H-5’, H-5’’ and 
αCH-His), 3.54-3.47 (m, 2H, CH2αCH2SO3H), 2.93-2.91 (m, 2H, βCH2-His), 2.90-2.88 (m, 2H, 
CH2CH2βSO3H), 2.28-2.18 (m, 2H, H-2’ and H-2’’), 1.84 (d, J = 1Hz, 3H, CH3); 13C NMR (125 
MHz, D2O) δ = 177.0 (CO-His), 173.9 (C-4), 157.0 (C-2), 137.9 (C-6), 136.9 (Ar C-His), 113.0 
(C-5), 86.4 (d, 3JC,P =9.3 Hz, C-4’), 86.1 (C-1’), 72.5 (C-3’), 65.2 (d, 2JC,P = 4.2 Hz, C-5’), 57.1 
(αCH-His), 50.6 (CH2CβH2SO3H), 40.0 (C-2’), 35.9 (CαH2CH2SO3H), 32.2 (βCH2-His), 13.5 
(CH3); 31P NMR (202 MHz, D2O) δ = 5.3; HRMS for C18H27N6O11PS [M-H]- calcd.: 565.1123, 
found: 565.1126. 
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N-Cbz-Asp(OBn)-Tau-OH (4.17) 
 Compound 4.17 was prepared according to a modification of the general procedure for taurine-
amino acid synthon synthesis (ion-exchange chromatography was not required) starting from N-
Cbz-Asp(OBn)-OH (2.5 g, 6.99 mmol), N-hydroxy succinimide (0.84 g, 7.27 mmol), DCC (1.59 
g, 7.70 mmol) in THF (30 mL), and taurine (0.92 g, 7.35 mmol) and NaHCO3 (1.17 g, 13.99 
mmol) in dioxane-water (1:1, 60 mL). The crude product was resuspended in water, cooled in an 
ice-bath and acidified to pH = 5 with the addition of 1N HCl. The aqueous layer was then 
lyophilized and the crude residue was purified by column chromatography on silica gel (gradient: 
IPA:H2O 100:0, v/v; 30:1, v/v;  20:1, v/v) to give compound 4.17 (2.89 g, 89%) as a white solid. 
1H NMR (300 MHz, DMSO-d6) δ = 8.06 (t, J = 5.2 Hz, 1H, NH-Tau), 7.67 (d, J = 8.3 Hz, 1H, 
NH-Asp), 7.37-7.30 (m, 10H, 2 x ArH of OBn), 5.08 and 5.02 (2 s, 2H, 2 x OCH2Ph), 4.40-4.33 
(m, 1H, αCH-Asp), 3.37-3.33 (m, 2H, CH2αCH2SO3H), 2.87-2.60 (m, 2H, βCH2-Asp), 2.56 (t, J = 
7.3 Hz, 2H, CH2CH2βSO3H); 13C NMR (75 MHz, DMSO-d6) δ = 170.2 (βCO-Asp), 169.8 (αCO-
Asp), 155.8 (OCONH), 136.9 (1C of OCH2Ph), 136.1 (1C of OCH2Ph), 128.4 (Ar-C), 128.3 (Ar-
C), 127.9 (Ar-C), 127.8 (Ar-C), 127.7 (Ar-C), 65.6 (2 x OCH2Ph), 51.5 (αC-Asp), 50.1 
(CH2CβH2SO3H), 36.4 (βC-Asp), 35.7 (CαH2CH2SO3H); HRMS for C21H24N2O8S [M-H]- calcd.: 
463.1180, found: 463.1181. 
 
H-Asp-Tau-OH (4.18) 
 To a stirring solution of 4.17 (2.89 g, 2.44 mmol) in EtOH:H2O (5:1, 80 mL) was added 10% 
Pd/C (0.5 g, 15% w/w) and the mixture was hydrogenated at atmospheric pressure using a balloon 
filled with H2 for 16 h. The catalyst was then removed by filtration over a pad of Celite and the 
filtrate was concentrated under reduced pressure to give compound 4.18 as a white solid (1.49 g, 
quan.). The resulting solid was analysed for purity and used in the next step without any further 
purification. 1H NMR (300 MHz, D2O) δ = 4.22-4.18 (m, 1H, αCH-Asp), 3.66-3.60 (m, 2H, 
CH2αCH2SO3H), 3.11 (t, J = 6.7 Hz, 2H, CH2CH2βSO3H), 2.84-2.64 (m, 2H, βCH2-Asp); 13C 
NMR (75 MHz, D2O) δ = 177.7 (CO2H), 170.9 (αCO-Asp), 52.5 (αC-Asp), 51.1 (CH2CβH2SO3H), 
38.5 (βC-Asp), 37.0 (CαH2CH2SO3H); HRMS for C6H12N2O6S [M-H]- calcd.: 239.0343, found: 
239.0339. 
General procedure for phosphoramidites synthesis starting from 2’-deoxynucleoside-5’-
phosphorimidazolide sodium salts (B) 
To a stirred solution of 2’-deoxynucleoside-5’-phosphorimidazolide sodium salt (1 eq.) and 
amino-acid (2.5-3.0 eq.) in DMF, Et3N (5-10 eq.) was added and the mixture was stirred 
vigorously until total dissolution. The reaction was stirred at 35 °C for 7 days and then quenched 
by addition of water. The solvent was removed under reduced pressure and the resulting crude 
material was purified by column chromatography on silica gel (gradient: IPA/H2O/Et3N  
20:1.5:0.5, v/v/v;  15:1.5:0.5, v/v/v; 10:1.5:0.5, v/v/v) to provide the corresponding 
phosphoramidate as a trietylammonium salt which was further purified by RP-HPLC (50 mmol 
TEAB in 98% H2O + 2% ACN and 50 mmol TEAB in 50% H2O + 50% ACN) to give the pure 
product as a white solid. The isolated product was freeze-dried repeatedly until constant mass. 
 
Thymidine-5’-(Asp-Tau-OH) phosphoramidate triethylammonium salt (4.9) 
 The triethylammonium salt of compound 4.9 was obtained as a white solid (0.17 g, 53%) 
following the general procedure (B), starting from thymidine 5’-phosphorimidazolide-sodium salt 
(0.15 g, 0.38 mmol), compound 4.18 (0.229 g, 0.951 mmol) and Et3N (0.41 mL, 3.04 mmol) in 
DMF (4 mL). 1H NMR (500 MHz, D2O) δ = 7.81 (s, 1H, H-6), 6.39 (app t, J = 7.0 Hz, 1H, H-1’), 
4.58-4.57 (m, 1H, H-3’), 4.20 (br s, 1H, H-4’), 4.03-4.01 (m, 2H, H-5’, H-5’’), 3.84-3.79 (m, 1H, 
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αCH-Asp), 3.64-3.60 (m, 2H, CH2αCH2SO3H), 3.13 (t, J = 7.0 Hz, 2H, CH2CH2βSO3H), 2.71 (dd, 
J = 16.0, 5.4 Hz, 1H, βCH’-Asp), 2.60 (dd, J = 15.7, 5.1 Hz, 1H, βCH’’-Asp), 2.40-2.37 (m, 2H, 
H-2’ and H-2’’), 1.95 (s, 3H, CH3-Thy); 13C NMR (125 MHz, D2O) δ = 177.7 (CO2H), 175.6 (d, 
3JC,P = 6.6 Hz, αCO-Asp), 166.0 (C-4), 151.2 (C-2), 136.8 (C-6), 111.1 (C-5), 85.1 (d, 3JC,P = 9.2 
Hz, C-4’), 84.4 (C-1’), 70.8 (C-3’), 63.6 (d, 2JC,P = 4.6 Hz, C-5’), 52.6 (αCH-Asp), 49.0 
(CH2CβH2SO3H), 39.9 (d, 3JC,P = 3.5 Hz, βCH2-Asp), 38.1 (C-2’), 34.5 (CαH2CH2SO3H), 11.1 
(CH3-Thy); 31P NMR (202 MHz, D2O) δ = 5.8; HRMS for C16H25N4O13PS [M-H]- calcd.: 
543.0803, found: 543.0813. 
 
N-(Ethyl acetate)-2-aminoethanesulfonic acid (4.19) 
 To a stirred solution of 2-aminoethane sulfonic acid (4.0 g, 31.96 mmol) in a 1:1 dioxane/H2O 
mixture (80 mL), NaHCO3 (2.68 g, 31.96 mmol) was added, followed by ethyl bromo acetate 
(3.75 mL, 35.16 mmol). The reaction mixture was then heated at 70 ºC for 24 h. The organic 
layer was removed under reduced pressure and the remaining aqueous layer was washed with 
ethyl acetate (2 x 100 mL) and neutralized with 1N HCl. The aqueous layer was then 
concentrated under reduced pressure and the residue was purified by column chromatography on 
silica gel (gradient: DCM/MeOH 9:1, v/v; 8:2, v/v; 7.5:2.5, v/v) to afford compound 4.19 (3.24 g, 
48%) as a white solid. 1H NMR (300 MHz, D2O) δ = 4.32 (q, J = 7.1 Hz , 2H, CO2CH2CH3), 4.05 
(s, 2H, CH2CO2Et), 3.54 (t, J = 6.8 Hz, 2H, CH2αCH2SO3H), 3.33 (t, J = 6.8 Hz, 2H, 
CH2CH2βSO3H), 1.31 (t, J = 7.1 Hz, 3H, CO2CH2CH3); 13C NMR (75 MHz, D2O) δ = 167.8, 64.1, 
48.3, 47.1, 43.9, 13.8; HRMS for C6H13NO5S [M-H]- calcd.: 210.04416, found: 210.0439. 
 
N-(Ethyl propionate)-2-aminoethanesulfonic acid (4.20) 
 To a stirred solution of 2-aminoethane sulfonic acid (4.0 g, 31.96 mmol) in a 1:1 EtOH/H2O 
mixture (80 mL), NaHCO3 (2.68 g, 31.96 mmol) was added, followed by ethyl acrylate (3.75 mL, 
35.16 mmol). The reaction mixture was then stirred at room temperature for 7 days. Ethanol was 
removed under reduced pressure and the aqueous layer was washed with ethyl acetate (2 x 100 
mL) and neutralized with 1N HCl. The aqueous layer was then concentrated under reduced 
pressure and the residue was purified by column chromatography on silica gel (gradient: 
DCM/MeOH 9:1, v/v; 8:2, v/v; 7:3, v/v) to afford compound 4.20 (4.17 g, 58%) as a white solid. 
1H NMR (300 MHz, D2O) δ = 4.15 (q, J = 7.1 Hz , 2H, CO2CH2CH3), 3.45 (t, J = 6.6 Hz, 2H, 
CH2αCH2SO3H), 3.35 (t, J = 6.5 Hz, 2H, CH2αCH2CO2Et), 3.23 (t, J = 6.6 Hz, 2H, 
CH2CH2βSO3H), 2.80 (t, J = 6.5 Hz, 2H, CH2CH2βCO2Et), 1.20 (t, J = 7.1 Hz, 3H, CO2CH2CH3); 
13C NMR (75 MHz, D2O) δ = 172.1, 62.1, 46.1, 43.1, 42.9, 29.9, 12.9; HRMS for C7H15NO5S [M-
H]- calcd.: 224.0598, found: 224.0598. 
 
Thymidine-5’-O-[N-(ethylacetate)-2-aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (4.21)  
 The triethylammonium salt of compound 4.21 was obtained as a white solid (123 mg, 52%) 
following the general procedure (B), starting from thymidine-5’-phosphorimidazolide sodium salt 
(130 mg, 0.33 mmol), compound 4.19 (195 mg, 0.92 mmol), triethylamine (0.28 mL, 1.98 mmol) 
and DMF (4 mL). 1H NMR (300 MHz, D2O) δ = 7.69 (s, 1H, H-6), 6.37 (t, J = 7.1 Hz, 1H, H-1’), 
4.58-4.54 (m, 1H, H-3’), 4.17-4.19 (m, 3H, H-4’ and OCH2CH3), 4.05-3.98 (m, 2H, H-5’ and H-
5’’), 3.85 (d, J = 10.6 Hz, 2H, CH2CO2Et), 3.48-3.37 (m, 2H, CH2αCH2SO3H), 3.18-3.10 (m, 2H, 
CH2CH2βSO3H) (merged with Et3N), 2.37-2.32 (m, 2H, H-2’ and H-2’’), 1.92 (s, 3H, CH3), 1.27-
1.22 (m, 3H, OCH2CH3) (merged with Et3N); 13C NMR (75 MHz, D2O) δ = 173.5 (d, 3JC,P = 2.4 
Hz, CO2Et), 171.0 (C-4), 155.1 (C-2), 136.5 (C-6), 111.5 (C-5), 85.0 (d, 3JC,P = 9.4 Hz, C-4’), 
84.6 (C-1’), 71.0 (C-3’), 63.9 (d, 2JC,P = 5.1 Hz, C-5’), 61.6 (OCH2CH3), 49.7 (CH2CβH2SO3H), 
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48.5 (d, 2JC,P = 5.5 Hz, CH2CO2Et), 43.4 (d, 2JC,P = 4.7 Hz, CαH2CH2SO3H), 38.5 (C-2’), 13.0 
(OCH2CH3), 11.9 (CH3); 31P NMR (121 MHz, D2O) δ = 7.1; HRMS for C16H26N3O12PS [M-H]- 
calcd.: 514.0902, found: 514.0902. 
 
2’-Deoxyadenosine-5’-O-[N-(ethylacetate)-2-aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (4.22) 
 The triethylammonium salt of compound 4.22 was obtained as a white solid (47 mg, 38%) 
following the general procedure (B), starting from 2’-deoxyadenosine-5’-phosphorimidazolide 
sodium salt (70 mg, 0.17 mmol), compound 4.19 (103 mg, 0.49 mmol), triethylamine (0.145 mL, 
1.04 mmol) and DMF (3 mL). 1H NMR (300 MHz, D2O) δ = 8.40 (s, 1H, H-8), 8.13 (s, 1H, H-2), 
6.40 (t, J = 6.7 Hz, 1H, H-1’), 4.72-4.68 (m, 1H, H-3’), 4.24-4.23 (m, 1H, H-4’), 4.05-3.95 (m, 
4H, H-5’,H-5’’ and OCH2CH3), 3.70 (d, J = 10.5 Hz, 2H, CH2CO2Et), 3.41-3.28 (m, 2H, 
CH2αCH2SO3H), 3.11-3.03 (m, 2H, CH2CH2βSO3H), 2.91-2.74 (m, 1H, H-2’), 2.64-2.53 (m, 1H, 
H-2’’), 1.13 (t, J = 7.1 Hz, 3H, OCH2CH3); 13C NMR (75 MHz, D2O) δ = 173.3 (d, 3JC,P = 2.8 Hz, 
CO2Et), 155.0 (C-6), 152.2 (C-2), 148.1 (C-4), 139.4 (C-8), 118.1 (C-5), 85.7 (d, 3JC,P = 9.3 Hz, 
C-4’), 83.3 (C-1’), 71.1 (C-3’), 63.8 (d, 2JC,P = 5.2 Hz, C-5’), 61.5 (OCH2CH3), 49.7 
(CH2CβH2SO3H), 48.4 (d, 2JC,P = 5.3 Hz, CH2CO2Et), 43.4 (d, 2JC,P = 4.6 Hz, CαH2CH2SO3H), 
38.6 (C-2’), 12.3 (OCH2CH3); 31P NMR (121 MHz, D2O) δ = 7.2; HRMS for C16H25N6O10PS [M-
H]- calcd.: 523.1017, found: 523.1019. 
 
2’-Deoxyguanosine-5’-O-[N-(ethyl acetate)-2-aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (4.23) 
 The triethylammonium salt of compound 4.23  was obtained as an off-white solid (58 mg, 22%) 
following the general procedure (B), starting from 2’-deoxyguanosine-5’-phosphorimidazolide 
sodium salt (150 mg, 0.36 mmol), compound 4.19 (212 mg, 1.00 mmol), triethylamine (0.30 mL, 
2.15 mmol) and DMF (4 mL). 1H NMR (300 MHz, D2O) δ = 7.99 (s, 1H, H-8), 6.26 (app t, J = 
7.0 Hz, 1H, H-1’), 4.65-4.63 (m, 1H, H-3’), 4.17-4.15 (m, 1H, H-4’), 4.04 (q, J = 7.0 Hz, 2H, 
OCH2CH3), 3.96-3.93 (m, 2H, H-5’ and H-5’’), 3.74 (d, J = 10.5 Hz, 2H, CH2CO2Et), 3.40-3.33 
(m, 2H, CH2αCH2SO3H), 3.01-2.96 (m, 2H, CH2CH2βSO3H), 2.83-2.71 (m, 1H, H-2’), 2.50-2.43 
(m, 1H, H-2’’), 1.13 (t, J = 7.4 Hz, 3H, OCH2CH3); 13C NMR (75 MHz, D2O) δ = 173.4 (d, 3JC,P 
= 2.9 Hz, CO2Et), 159.4 (C-6), 153.4 (C-2), 151.0 (C-4), 135.4 (C-8), 117.0 (C-5),  85.3 (d, 3JC,P 
= 9.3 Hz, C-4’), 82.6 (C-1’), 71.2 (C-3’), 64.0 (d, 2JC,P = 5.4 Hz, C-5’), 61.6 (OCH2CH3), 49.8 
(CH2CβH2SO3H), 48.5 (d, 2JC,P = 5.4 Hz, CH2CO2Et), 43.4 (d, 2JC,P = 4.6 Hz, CαH2CH2SO3H), 
38.4 (C-2’), 12.9 (OCH2CH3); 31P NMR (121 MHz, D2O) δ = 7.2; HRMS for C16H25N6O11PS [M-
H]- calcd.: 539.0967, found: 539.0969. 
 
2’-Deoxycytidine-5’-O-[N-(ethyl acetate)-2-aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (4.24) 
 The triethylammonium salt of compound 4.24 was obtained as a white solid (130 mg, 47%) 
following the general procedure (B), starting from 2’-deoxycytidine-5’-phosphorimidazolide 
sodium salt (150 mg, 0.39 mmol), compound 4.19 (234 mg, 1.11 mmol), triethylamine (0.33 mL, 
2.37 mmol) and DMF (4 mL).1H NMR (300 MHz, D2O) δ = 7.94 (d, J = 7.6 Hz, 1H, H-6), 6.29 
(app t, J = 6.8 Hz, 1H, H-1’), 6.08 (d, J = 7.5 Hz, 1H, H-5),  4.53-4.49 (m, 1H, H-3’), 4.17-4.10 
(m, 3H, H-4’ and OCH2CH3), 4.03-3.98 (m, 2H, H-5’ and H-5’’), 3.82 (d, J = 10.7 Hz, 2H, 
CH2CO2Et), 3.44-3.35 (m, 2H, CH2αCH2SO3H), 3.19-3.09 (unresolved m, 2H, CH2CH2βSO3H, 
merged with Et3N), 2.43-2.21 (m, 2H, H-2’ and H-2’’), 1.27-1.22 (unresolved m, 3H, OCH2CH3, 
merged with Et3N); 13C NMR (75 MHz, D2O) δ = 173.4 (d, 3JC,P = 2.5 Hz, CO2Et), 165.8 (C-4), 
157.1 (C-2), 141.2 (C-6), 96.1 (C-5), 85.6 (C-1’), 85.4 (d, 3JC,P = 9.3 Hz, C-4’), 70.7 (C-3’), 63.7 
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(d, 2JC,P = 5.2 Hz, C-5’), 61.6 (OCH2CH3), 49.7 (CH2CβH2SO3H), 48.6 (d, 2JC,P = 5.5 Hz, 
CH2CO2Et), 43.4 (d, 2JC,P = 4.7 Hz, CαH2CH2SO3H), 39.3 (C-2’), 13.0 (OCH2CH3); 31P NMR 
(121 MHz, D2O) δ = 7.2; HRMS for C15H25N4O11PS [M-H]- calcd.: 499.0905, found: 499.0898. 
 
Thymidine-5’-O-[N-(ethyl propionate)-2-aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (4.25) 
 The triethylammonium salt of compound 4.25 was obtained as a white solid (0.204 g, 51%) 
following the general procedure (A), starting from TMP-triethylammonium salt (0.286 g, 0.55 
mmol), compound 4.20 (0.553 g, 2.46 mmol), DCC (0.563 g, 2.73 mmol), triethylamine (0.38 
mL, 2.73 mmol) in a 4:1 tBuOH/H2O mixture (11 mL) at 90 °C for 6 h. 1H NMR (500 MHz, D2O) 
δ = 7.75 (s, 1H, H-6), 6.35 (app t, J = 7.1 Hz, 1H, H-1’), 4.58-4.56 (m, 1H, H-3’), 4.13-4.12 (m, 
1H, H-4’), 4.09-4.03 (m, 2H, OCH2CH3), 3.96-3.90 (m, 2H, H-5’ and H-5’’), 3.42-3.35 (m, 2H, 
CH2αCH2SO3H), 3.34-3.10 (m, 2H, CH2αCH2CO2Et), 3.12-3.07 (m, 2H, CH2CH2βSO3H), 2.63-
2.51 (m, 2H, CH2CH2βCO2Et), 2.41-2.30 (m, 2H, H-2’ and H-2’’), 1.90 (s, 3H, CH3), 1.19 (t, J = 
7.1 Hz, 3H, OCH2CH3); 13C NMR (125 MHz, D2O) δ = 174.2 (CO2Et), 165.9 (C-4), 151.2 (C-2), 
136.8 (C-6), 111.2 (C-5), 84.9 (d, 3JC,P = 9.4 Hz, C-4’), 84.2 (C-1’), 70.5 (C-3’), 63.3 (d, 2JC,P = 
5.0 Hz, C-5’), 61.1 (OCH2CH3), 49.5 (CH2CβH2SO3H), 41.7 (d, 2JC,P = 4.2 Hz, CαH2CH2SO3H), 
41.5 (d, 2JC,P = 4.2 Hz, CαH2CH2CO2Et), 37.9 (C-2’), 33.2 (CH2CβH2CO2Et), 12.6 (OCH2CH3), 
11.1 (CH3); 31P NMR (202 MHz, D2O) δ = 7.7; HRMS for C17H28N3O12PS [M-H]- calcd.: 
528.1058, found: 528.1058. 
 
2’-Deoxyadenosine-5’-O-[N-(ethyl propionate)-2-aminoethanesulfonic acid] 
phosphoramidate trietylammonium salt (4.26) 
 The triethylammonium salt of compound 4.26 was obtained as a white solid (237 mg, 53%) 
following the general procedure (A), starting from dAMP (200 mg, 0.60 mmol), compound 4.20 
(611.4 mg, 2.72 mmol), DCC (623.1 mg, 3.02 mmol), triethylamine (0.42 ml, 3.02 mmol) in a 4:1 
tBuOH/H2O mixture (12 mL) at 90 °C for 6 h. 1H NMR (300 MHz, D2O) δ = 8.42 (s, 1H, H-8), 
8.21 (s, 1H, H-2), 6.46 (app t, J = 6.6 Hz, 1H, H-1’), 4.74-4.69 (m, 1H, H-3’), 4.23-4.22 (m, 1H, 
H-4’), 3.98-3.94 (m, 2H, OCH2CH3), 3.93-3.89 (m, 2H, H-5’ and H-5’’), 3.32-3.23 (m, 2H, 
CH2αCH2SO3H), 3.18-3.12 (unresolved m, 2H, CH2αCH2CO2Et merged with Et3N), 3.06-2.99 (m, 
2H, CH2CH2βSO3H), 2.90-2.81 (m, 1H, H-2’), 2.64-2.55 (m, 1H, H-2’’), 2.42-2.27 (m, 2H, 
CH2CH2βCO2Et), 1.09 (t, J = 7.1 Hz, 3H, OCH2CH3); 13C NMR (75 MHz, D2O) δ = 174.2 
(CO2Et), 155.2 (C-6), 152.4 (C-2), 148.4 (C-4), 139.5 (C-8), 118.3 (C-5), 85.6 (d, 3JC,P = 9.3 Hz, 
C-4’), 83.4 (C-1’), 70.8 (C-3’), 63.5 (d, 2JC,P = 5.0 Hz, C-5’), 61.2 (OCH2CH3), 49.9 
(CH2CβH2SO3H), 42.1 (d, 2JC,P = 4.7 Hz, CαH2CH2SO3H), 41.9 (d, 2JC,P = 4.6 Hz, 
CαH2CH2CO2Et), 38.5 (C-2’), 33.5 (CH2CβH2CO2Et), 12.8 (OCH2CH3); 31P NMR (121 MHz, 
D2O) δ = 8.1; HRMS for C17H27N6O10PS [M-H]- calcd.: 537.1174, found: 537.1168. 
 
General deprotection procedure for 2’-deoxynucleoside-5’-O-[N-(alkyl acid)-2-
aminoethanesulfonic acid] phosphoramidate trietylammonium salts (4.10-4.11 and 4.27-4.30) 
synthesis (C) 
 A solution of 2’-deoxynucleoside-5’-O-[N-(ethyl alkylate)-2-aminoethane sulfonic acid] 
phosphoramidate trietylammonium salt (1 mmol) in a 0.4M NaOH solution in MeOH/H2O 
(4:1v/v, 15 mL) was stirred at room temperature for 3 h and then 1M TEAB buffer (8 mL) was 
added. All the volatiles were removed first by rotary evaporation (bath temp 10 °C) and then by 
lyophilization. The crude residue was purified by RP-HPLC (50 mmol TEAB in 98% H2O + 2% 
ACN and 50 mmol TEAB in 50% H2O + 50% ACN) to give pure 2’-deoxynucleoside-5’-O-[N,N-
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(alkyl acid)-2-aminoethane sulfonic acid] phos-phoramidate trietylammonium salt after the 
product was freeze-dried repeatedly to constant mass. 
 
Thymidine-5’-O-[N-(acetic acid)-2-aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (4.10) 
 The triethylammonium salt of compound 4.10 was obtained as a white solid (18.5 mg, 84%) 
following the general procedure (C), starting from compound 21 (20 mg, 0.028 mmol), 0.4M 
NaOH in MeOH/H2O (4:1v/v, 0.42 mL) and 1M TEAB (0.22 mL). 1H NMR (600 MHz, D2O) δ = 
7.78 (s, 1H, H-6), 6.37 (app t, J = 7.1 Hz, 1H, H-1’), 4.54-4.52 (m, 1H, H-3’), 4.14-4.13 (m, 1H, 
H-4’), 4.02-4.01 (m, 2H, H-5’ and H-5’’), 3.57 (d, J = 10.6 Hz, 2H, CH2CO2H), 3.39-3.35 (m, 
2H, CH2αCH2SO3H), 3.13-3.10 (m, 2H, CH2CH2βSO3H), 2.38-2.28 (m, 2H, H-2’ and H-2’’), 1.91 
(s, 3H, CH3); 13C NMR (150 MHz, D2O) δ = 178.6 (d, 3JC,P = 3.9 Hz, CO2H), 166.4 (C-4), 151.6 
(C-2), 137.1 (C-6), 111.6 (C-5), 85.5 (d, 3JC,P = 9.4 Hz, C-4’), 84.7 (C-1’), 71.1 (C-3’), 63.9 (d, 
2JC,P = 5.1 Hz, C-5’), 49.7 (d, 2JC,P = 4.0 Hz, CH2CO2H), 49.1 (CH2CβH2SO3H), 43.1 (d, 2JC,P = 
3.2 Hz, CαH2CH2SO3H), 38.4 (C-2’), 11.4 (-CH3); 31P NMR (202 MHz, D2O) δ = 7.8; HRMS for 
C16H26N3O12PS [M-H]- calcd.: 486.0589, found: 486.0591. 
 
2’-Deoxyadenosine-5’-O-[N-(acetic acid)-2-aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (4.27) 
 The triethylammonium salt of compound 4.27 was obtained as a white solid (41 mg, 81%) 
following the general procedure (C), starting from compound 4.22 (46 mg, 0.063 mmol), 0.4M 
NaOH in MeOH/H2O (4:1v/v, 1.0 mL) and 1M TEAB (0.5 mL). 1H NMR (500 MHz, D2O) δ = 
8.41 (s, 1H, H-8), 8.09 (s, 1H, H-2), 6.39 (t, J = 6.8 Hz, 1H, H-1’), 4.66-4.63 (m, 1H, H-3’), 4.21-
4.20 (m, 1H, H-4’), 4.01-3.92 (m, 2H, H-5’ and H-5’’), 3.50 (d, J = 9.0 Hz, 2H, CH2CO2H), 3.35-
3.30 (m, 2H, CH2αCH2SO3H), 3.03-3.00 (m, 2H, CH2CH2βSO3H), 2.80-2.75 (m, 1H, H-2’), 2.57-
2.52 (m, 1H, H-2’’); 13C NMR (125 MHz, D2O) δ = 178.2 (d, 3JC,P = 4.7 Hz, CO2H), 154.6 (C-6), 
151.7 (C-2), 147.8 (C-4), 139.1 (C-8), 117.7 (C-5), 85.4 (d, 3JC,P = 9.2 Hz, C-4’), 82.9 (C-1’), 
70.6 (C-3’), 63.3 (d, 2JC,P = 4.8 Hz, C-5’), 49.3 (d, 2JC,P = 3.7 Hz, CH2CO2H), 48.7 
(CH2CβH2SO3H), 42.7 (d, 2JC,P = 4.0 Hz, CαH2CH2SO3H), 38.3 (C-2’); 31P NMR (202 MHz, D2O) 
δ = 8.1; HRMS for C14H21N6O10PS [M-H]- calcd.: 495.0705, found: 495.0703. 
 
2’-Deoxyguanosine-5’-O-[N-(acetic acid)-2-aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (4.28) 
 The triethylammonium salt of compound 4.28 was obtained as an off-white solid (42 mg, 67%) 
following the general procedure (C), starting from compound 4.23 (58 mg, 0.078 mmol), 0.4M 
NaOH in MeOH/H2O (4:1v/v, 1.17 mL) and 1M TEAB (0.6 mL). 1H NMR (500 MHz, D2O) δ = 
7.78 (s, 1H, H-8), 6.25 (app t, J = 6.9 Hz, 1H, H-1’), 4.64-4.62 (m, 1H, H-3’), 4.18-4.16 (m, 1H, 
H-4’), 4.00-3.95 (m, 2H, H-5’ and H-5’’), 3.52 (d, J = 8.8 Hz, 2H, CH2CO2H), 3.37-3.31 (m, 2H, 
CH2αCH2SO3H), 3.07-3.04 (m, 2H, CH2CH2βSO3H), 2.80-2.75 (m, 1H, H-2’), 2.48-2.43 (m, 1H, 
H-2’’), 1.91 (s, 3H, CH3); 13C NMR (125 MHz, D2O) δ = 178.3 (d, 3JC,P = 4.8 Hz, CO2H), 158.3 
(C-6), 153.2 (C-2), 150.8 (C-4), 136.9 (C-8), 115.5 (C-5), 85.3 (d, 3JC,P = 9.0 Hz, C-4’), 82.9 (C-
1’), 70.8 (C-3’), 63.5 (d, 2JC,P = 4.9 Hz, C-5’), 49.3 (d, 2JC,P = 3.8 Hz, CH2CO2H), 48.7 
(CH2CβH2SO3H), 42.7 (d, 2JC,P = 4.4 Hz, CαH2CH2SO3H), 37.9 (C-2’); 31P NMR (202 MHz, D2O) 
δ = 8.1; HRMS for C14H21N6O11PS [M-H]- calcd.: 511.0654, found: 511.0651. 
 
2’-Deoxycytidine-5’-O-[N-(acetic acid)-2-aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (4.29) 
 The triethylammonium salt of compound 4.29 was obtained as a white solid (112 mg, 78%) 
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following the general procedure (C), starting from compound 4.24 (130 mg, 0.185 mmol), 0.4M 
NaOH in MeOH/H2O (4:1v/v, 2.77 mL) and 1M TEAB (1.4 mL). 1H NMR (500 MHz, D2O) δ = 
8.00 (d, J = 7.5 Hz, 1H, H-6), 6.37 (app t, J = 6.8 Hz, 1H, H-1’), 6.16 (d, J = 7.5 Hz, 1H, H-5), 
4.58-4.55 (m, 1H, H-3’), 4.21-4.20 (m, 1H, H-4’), 4.09-4.07 (m, 2H, H-5’ and H-5’’), 3.60 (dd, J 
= 8.9, 1.8 Hz, 2H, CH2CO2H), 3.46-3.40 (m, 2H, CH2αCH2SO3H), 3.19-3.15 (m, 2H, 
CH2CH2βSO3H), 2.46-2.41 (m, 1H, H-2’), 2.34-2.29 (m, 1H, H-2’’); 13C NMR (125 MHz, D2O) δ 
= 178.3 (d, 3JC,P = 4.9 Hz, CO2H), 165.5 (C-4), 157.0 (C-2), 140.9 (C-6), 96.0 (C-5), 85.3 (C-1’), 
85.2 (d, 3JC,P = 9.2 Hz, C-4’), 70.4 (C-3’), 63.3 (d, 2JC,P = 5.0 Hz, C-5’), 49.5 (d, 2JC,P = 3.5 Hz, 
CH2CO2H), 48.8 (CH2CβH2SO3H), 42.8 (d, 2JC,P = 4.3 Hz, CαH2CH2SO3H), 39.0 (C-2’); 31P NMR 
(202 MHz, D2O) δ = 8.1; HRMS for C13H21N4O11PS [M-H]- calcd.: 471.0592, found: 471.0594. 
 
Thymidine-5’-O-[N-(propionic acid)-2-aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (4.11) 
 The triethylammonium salt of compound 4.11 was obtained as a white solid (164 mg, 88%) 
following the general procedure (C), starting from compound 4.25 (170 mg, 0.23 mmol), 0.4M 
NaOH in MeOH/H2O (4:1v/v, 3.48 mL) and 1M TEAB (1.85 mL). 1H NMR (500 MHz, DMSO-
d6) δ = 7.78 (d, J = 1.2 Hz, 1H, H-6), 6.20 (dd, J =  7.9, 6.0 Hz, 1H, H-1’), 4.27-4.25 (m, 1H, H-
3’), 3.86-3.85 (m, 1H, H-4’), 3.74-3.72 (m, 2H, H-5’ and H-5’’), 3.17-3.13 (m, 2H, 
CH2αCH2SO3H), 3.10-3.05 (m, 2H, CH2αCH2CO2H), 2.60-2.57 (m, 2H, CH2CH2βSO3H), 2.41-
2.38 (m, 2H, CH2CH2βCO2H), 2.14-2.01 (m, 2H, H-2’ and H-2’’), 1.81 (d, J = 1.2 Hz, 3H, CH3); 
13C NMR (125 MHz, DMSO-d6) δ = 173.7 (CO2H), 163.9 (C-4), 150.6 (C-2), 136.2 (C-6), 109.9 
(C-5), 86.1 (d, 3JC,P = 7.6 Hz, C-4’), 83.8 (C-1’), 71.1 (C-3’), 64.0 (d, 2JC,P = 5.1 Hz, C-5’), 51.2 
(CH2CβH2SO3H), 44.0 (d, 2JC,P = 3.0 Hz, CαH2CH2SO3H), 43.0 (d, 2JC,P = 3.3 Hz, 
CαH2CH2CO2H), 39.6 (C-2’, merged with DMSO), 35.7 (CH2CβH2CO2H), 12.1 (CH3); 31P NMR 
(202 MHz, DMSO-d6) δ = 6.3; HRMS for C16H26N3O12PS [M-H]- calcd.: 500.0745, found: 
500.0746. 
 
2’-Deoxyadenosine-5’-O-[N-(propionic acid)-2-aminoethanesulfonic acid] phosphoramidate 
trietylammonium salt (4.30) 
 The triethylammonium salt of compound 4.30 was obtained as a white solid (142 mg, 86%) 
following the general procedure (C), starting from compound 4.26 (150 mg, 0.202 mmol), 0.4M 
NaOH in MeOH/H2O (4:1v/v, 3.04 mL) and 1M TEAB (1.50 mL). 1H NMR (500 MHz, D2O) δ = 
8.38 (s, 1H, H-8), 8.10 (s, 1H, H-2), 6.39 (app t, J = 6.6 Hz, 1H, H-1’), 4.69-4.67 (m, 1H, H-3’), 
4.20 (br s, 1H, H-4’), 3.91-3.89 (m, 2H, H-5’ and H-5’’), 3.30-3.24 (m, 2H, CH2αCH2SO3H), 
3.17-3.07 (m, 2H, CH2αCH2CO2H, merged with Et3N), 3.03-2.99 (m, 2H, CH2CH2βSO3H), 2.82-
2.76 (m, 1H, H-2’), 2.59-2.54 (m, 1H, H-2’’), 2.31-2.28 (t, 2H, J = 7.9 Hz, CH2CH2βCO2H); 13C 
NMR (125 MHz, D2O) δ = 180.2 (CO2H), 154.7 (C-6), 151.8 (C-2), 147.7 (C-4), 139.0 (C-8), 
117.8 (C-5), 85.3 (d, 3JC,P = 9.2 Hz, C-4’), 83.0 (C-1’), 70.4 (C-3’), 63.1 (d, 2JC,P = 5.1 Hz, C-5’), 
49.5 (CH2CβH2SO3H), 43.1 (d, 2JC,P = 4.2 Hz, CαH2CH2CO2H), 41.2 (d, 2JC,P = 4.6 Hz, 
CαH2CH2SO3H), 38.3 (C-2’), 36.8 (CH2CβH2CO2H); 31P NMR (202 MHz, D2O) δ = 8.3; HRMS 
for C15H23N6O10PS [M-H]- calcd.: 509.0861, found: 509.0853. 
 
Thymidine-5’-diphosphate triethylammonium salt (4.32) 
 To a stirred suspension of 5’-O-tosyl-thymidine 4.31 (0.20 g , 0.50 mmol) in dry acetonitrile (0.5 
mL) was added tris(terta-n-butylammonium) hydrogen phosphate (0.682 g, 0.75 mmol). The 
resulting solution was stirred at room temperature for 36 h. Upon reaction completion, the 
mixture was concentrated in vacuo, diluted with water (5 mL) and lyophilized. The crude product 
was purified by Source 15Q ion-exchance column chromatography from a gradient of 0-100% 
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1M TEAB solution. The product was freeze-dried repeatedly to constant mass, yielding 4.32 as a 
white triethylammonium salt solid (0.239 g, 67%). 1H NMR (300 MHz, D2O) δ = 7.75 (d, J = 1.0 
Hz, 1H, H-6), 6.35 (app t, J = 7.0 Hz, 1H, H-1’), 4.65-4.61 (m, 1H, H-3’), 4.18-4.14 (m, 3H, H-
4’, H-5’ and H-5’’), 2.39-2.34 (m, 2H, H-2’ and H-2’’), 1.92 (d, J = 1.0 Hz, 3H, CH3); 13C NMR 
(75 MHz, D2O) δ = 166.2 (C-4), 151.4 (C-2), 137.0 (C-6), 111.4 (C-5), 85.1 (d, 3JC,P = 9.1 Hz, C-
4’), 84.6 (C-1’), 70.7 (C-3’), 65.0 (d, 2JC,P = 5.5 Hz, C-5’), 38.2 (C-2’), 11.3 (CH3); 31P NMR 
(121 MHz, D2O) δ = -10.9 (d, JP,P = 20.0 Hz, β-P), -11.5 (d, JP,P = 20.0 Hz, α-P) HRMS for 
C10H16N2O11P2 [M-H]- calcd.: 401.0156, found: 401.0155. 
 
Thymidine-5’-[β-N-(2-aminoethanesulfonic acid)] diphosphoramidate triethylammonium 
salt (4.33) 
 The triethylammonium salt of compound 4.33 was obtained as a white solid (95 mg, 69%) 
following the general procedure (A), starting from compound 4.32 (0.12 g , 0.17 mmol), taurine 
(0.085 g, 0.68 mmol), triethylamine (0.12 mL, 0.85 mmol) and DCC (0.175 g, 0.85 mmol) in a 
4:1 tBuOH/H2O mixture (4 mL) at 85 ºC for 4.5 h.1H NMR (500 MHz, D2O) δ = 7.76 (s, 1H, H-
6), 6.32 (app t, J = 7.0 Hz, 1H, H-1’), 4.61-4.59 (m, 1H, H-3’), 4.15-4.14 (m, 1H, H-4’), 4.13-
4.12 (m, 2H, H-5’ and H-5’’), 3.28-3.23 (m, 2H, CH2αCH2SO3H), 3.07 (t, J = 7.0 Hz, 2H, 
CH2CH2βSO3H), 2.38-2.27 (m, 2H, H-2’ and H-2’’), 1.89 (s, 3H, CH3); 13C NMR (125 MHz, 
D2O) δ = 166.0 (C-4), 151.1 (C-2), 136.8 (C-6), 111.1 (C-5), 84.8 (d, 3JC,P = 10.0 Hz, C-4’), 84.2 
(C-1’), 70.4 (C-3’), 64.6 (d, 2JC,P = 5.0 Hz, C-5’), 51.8 (d, 3JC,P = 7.5 Hz, CH2CβH2SO3H), 37.9 
(C-2’), 36.6 (CαH2CH2SO3H), 11.1 (CH3); 31P NMR (202 MHz, D2O) δ = -2.6 (d, JP,P = 22.0 Hz, 
β-P), -11.7 (d, JP,P = 22.0 Hz, α-P); HRMS for C12H21N3O13P2S [M-H]- calcd.: 508.0197, found: 
508.0198. 
 
Thymidine-5’-[γ-N-(2-aminoethanesulfonic acid)] triphosphoramidate triethylammonium 
salt (4.35) 
 DCC (0.153 g, 0.744 mmol) was added to a stirred solution of dTTP triethylammonium salt 4.34 
(0.11 g, 0.124 mmol) in dry DMF (2 mL) under an argon atmosphere and stirred for 3.5 h at room 
temperature. The dTTP solution was then added dropwise to a solution of taurine (0.093 g, 0.744 
mmol) in a 1:1 miture of dry methanol and dry DMF (16 mL) and the reaction mixture was left to 
stir for 6 h at room temperture. The reaction was then diluted with water (50 mL) and the 
precipitate was filtered off. The clear solution was collected and lyophilized. The crude residue 
was redissolved in 0.01M TEAB buffer and purified by Source-15 Q ion-exchange resin column 
chromatography. The products adhering to the column were eluted with a linear buffer gradient of 
0 to 1 M TEAB. The desired product was isolated by using 0.6–0.8M TEAB and it was then 
further purified by HPLC to give compound 4.35 as a white triethylammonium salt solid (0.022 g, 
18%).1H NMR (500 MHz, D2O) δ = 7.64 (s, 1H, H-6), 6.35 (app t, J = 7.0 Hz, 1H, H-1’), 4.62-
4.60 (m, 1H, H-3’), 4.18-4.11 (m, 3H, H-4’, H-5’ and H-5’’), 3.29-3.24 (m, 2H, CH2αCH2SO3H), 
3.00-2.96 (m, 2H, CH2CH2βSO3H), 2.34-2.26 (m, 2H, H-2’ and H-2’’), 1.85 (s, 3H, CH3); 13C 
NMR (125 MHz, D2O) δ = 173.1 (C-4), 156.5 (C-2), 136.0 (C-6), 111.4 (C-5), 84.5 (d, 3JC,P = 9.8 
Hz, C-4’), 84.2 (C-1’), 70.3 (C-3’), 64.8 (d, 2JC,P = 5.5 Hz, C-5’), 51.9 (d, 3JC,P = 7.2 Hz, 
CH2CβH2SO3H), 42.1 (CαH2CH2SO3H), 37.9 (C-2’), 11.9 (CH3); 31P NMR (202 MHz, D2O) δ = -
2.7 (d, JP,P = 20.6 Hz, γ-P), -12.0 (d, JP,P = 19.8 Hz, α-P), -23.3 (app t, JP,P = 20.2 Hz, β-P); 
HRMS for C12H22N3O16P3S [M-H]- calcd.: 587.9861, found: 587.9866. 
 
General Protocol for DNA polymerase reaction 
 The primer P1 was purchased from IDT, whilst all the templates T1-5 were purchased from 
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Eurogentec. Primer oligonucleotides were labeled with 5’ [γ-33P]-ATP (Perkin Elmer) using T4 
polynucleotide kinase (New England Biolabs) according to the manufacturer’s protocol. The 
labeled primers were further purified using Illustra MicroSpin G-25 Column (GE Healthcare) and 
then annealed with the corresponding template oligonucleotides in a 1:2 molar ratio by heating 
the mixture at 75 °C for 5 min, followed by slow cooling to room temperature. The DNA 
polymerisation mixtures contained 125 nM primer-template complex, 1X reaction buffer 
(supplied with the enzyme), different concentrations of building blocks (125 µM, 500 µM and 1 
mM) and 0.01 U.µl-1 Therminator, 0.01 U.µl-1 Vent (-exo) or 0.05 U.µl-1 Klenow (-exo) 
polymerases (New England Biolabs). The reaction was performed either at 37 °C (mesophilic 
polymerase) or at 75 °C (thermophilic polymerases) and aliquots were taken after 15, 30 and 60 
min. In the control reaction, 50 µM of the corresponding natural deoxynucleoside triphosphate 
was used. All the polymerase reactions were quenched by addition of a double volume of gel 
loading buffer (90% formamide, 50mM EDTA, 0.05% bromophenol blue and 0.05% xylene 
cyanol). Samples were heated either at 75 °C (mesophilic polymerase) or at 90 °C (thermophilic 
polymerases) for 5 min prior to separation on a 0.4mm 20% denaturing polyacrylamide gel. The 
bands were then visualized using phosphorimaging (Perkin Elmer).  
 
 
Figure 4-6. Profile of chain elongation of the control dTTP, dCTP, and dATP  as substrate into 
the P1:T1, P1:T3 and P1:T2 respectively by two different DNA polymerase; Vent (0.01 U.µl-1) 
and Therminator (0.01 U.µl-1).  
 
Steady-state kinetics of single nucleotide incorporation 
 Primer 5’ /5Cy5/CAGGAAACAGCTATGAC 3’ was annealed with template 3’ 
GTCCTTTGTCGATACTGCAAAA 5’ in a 1:2 molar ratio by heating the mixture at 75 °C for 5 
min, followed by slow cooling to room temperature. A series of reactions with different enzyme 
concentrations and different time points were performed to obtain the optimum conditions 
satisfying the ‘single completed hit’ principle21. The final DNA polymerisation mixtures each 
contained 125 nM primer-template complex, 1X reaction buffer (supplied with the enzyme), 
building blocks (for modified building blocks the concentration ranged between 15 µM and 1 
mM, whilst for natural nucleoside triphosphates the concentration ranged between 25 nM and 2 
µM) and 0.001 U.µl-1 Klenow fragment (New England Biolabs). The reactions were performed at 
37 °C and aliquots were taken after 30 seconds. All polymerase reactions were quenched by 
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adding a double volume of gel loading buffer (90 % formamide, 50 mM EDTA and 0.05% 
bromophenol blue) and heated at 90 °C for 5 min. The samples were separated on a 1 mm 15% 
denaturing polyacrylamide gel and gel bands were visualized using Ettan DIGE Imager (GE 
Healthcare). The gel bands were then quantified using ImageQuant TL 1D version 7.0 (GE 
Healthcare) and the kinetics parameters (Vmax and Km) were determined by fitting the data to a 
non-linear Michaelis–Menten regression using GraphPad Prism Software version 5.0. 
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Chapter 5 
  
Synthesis of new biocarrier-nucleotide systems for cellular delivery in 
bacterial auxotrophic strains 
 
 
 
 
This chapter is based on an article published by S. De, E. Groaz, M. Maiti, V. Pezo, P. 
Marlière, and P. Herdewijn, Tetrahedron 2014, 70 (46), 8843–8851. 
 
 
 
 
ABSTRACT  
In search for a delivery approach for thymidine monophosphate (TMP) in bacterial cells, we 
have synthesized a series of conjugates of TMP with biotin having an oxymethyleneoxy ester, 
a carboxy ester and different carboxamide linkers between the carboxyl group of biotin and 
the 3’-OH group of TMP. The synthetic strategy starts from 5’-O-(dibenzylphosphate)-
thymidine having the linkers already connected at the 3’-position. Likewise, kanamycin A 
was linked at the 3’-position of TMP using a carbamoyl or thioethyl carbamoyl group.  
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5.1. INTRODUCTION 
Creating artificial genetic systems capable of supporting Darwinian evolution is of prominent 
importance to synthetic biology, not only to achieve expansion of the genetic alphabet but specially 
for the genetic reprogramming of engineered microorganisms.[1] The in vivo synthesis of xeno nucleic 
acids (XNAs), however, is thought to entail high intracellular consumption of unnatural nucleotide 
building blocks, which will thus need to be provided to the host cell, as most modified nucleosides are 
poorly phosphorylated by natural kinases. Nucleotides however suffer from low cell-penetrating 
ability and generally undergo fast enzymatic dephosphorylation before being taken up. Their bacterial 
uptake is further complicated by the complex multi-layered wall structure, which makes prokaryotic 
cells commonly more difficult to penetrate compared to eukaryotic membranes.  
Thus far, efforts have focused on overexpression of endogenous kinases to broad enzyme-
substrate specificity,[2] and more recently, on the transfection of Escherichia coli (E. coli) with a 
plasmid encoding an algal nucleotide triphosphate transporter to enhance triphosphates uptake.[3] 
Despite the groundbreaking value of this last approach, which resulted in the first in vivo replication 
of an unnatural DNA base pair, its universal applicability to all unnatural bases and types of backbone 
modifications is yet unpredictable. 
In the previous chapter, we discussed our interest in the development of a delivery tool for active 
uptake of nucleotides in bacterial cells based on a nutritional selection approach.[4] The general 
concept consists in linking the information system to an extracellular nutrient essential for the cell, 
thus taking advantage of natural transport pathways. A biocleavable covalent bond is designed to 
maintain the conjugate intact during cellular uptake, but allows facile release of the nucleotide 
intracellularly. Building on previous studies, thymidine monophosphate is selected as archetypal 
nucleotide system.[5] The relevant TMP conjugate is supplied within the nutrient medium to a 
bacterial strain deleted for the ThyA gene encoding for thymidilate synthase, which is known to 
unconditionally require thymine or thymidine for growth.  
Because of the novelty of our delivery approach, we decided to investigate a large diversity of 
biological carriers, such as peptides and vitamins. We describe here the synthesis of biotin−TMP 
conjugates. The appeal of this choice is due to the fact that biotin-negative mutants are also well-
established auxotrophs and can provide additional functional evidence.[6, 7] 
Expanding upon this idea, we also wish to prove the same concept using an inverse selection 
method. As in most cases, antimicrobial compounds penetrate prokaryotic cell membranes effectively 
through relatively non-specific transport systems, we describe here also the synthesis of conjugates of 
nucleotides with kanamycin A. Aminoglycosides (AGs) are clinically relevant drugs, which show 
broad-spectrum antibacterial activity against both gram-negative and gram-positive species, binding 
irreversibly to the prokaryotic ribosome and mainly interfering with peptide elongation at the 30S 
subunit.[8, 9] Although the detailed mechanism by which AGs penetrate into the bacterial cytoplasm 
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remains unclear, their uptake is known to be a multistep energy requiring process that can be 
accumulated against a concentration gradient.[10, 11] In this case, the observation of toxicity would 
ensure uptake and processing of the nucleotide by the cell. 
 
5.2. RESULTS AND DISCUSSION 
Our retrosynthetic analysis for the planned carrier−TMP target compounds is shown in Fig. 5-1. It 
becomes apparent that those conjugates can be accessed by either linking the carrier unit at the 3'-
position of thymidine followed by 5’-O-phosphorylation (route 5.1), or viceversa (route 5.2).  
 
 
Figure 5-1. Retrosynthetic analysis of carrier-TMP conjugates. 
 
Initially, we decided to follow route 5.1 (Fig. 5-1) by applying the same optimized conditions 
employed for the synthesis of peptide−TMP conjugates connected through an oxymethyleneoxy ester 
bond.[4] Coupling of biotin at the 3’-position of methylene thiomethyl thymidine derivative 5.1, 
obtained in turn from thymidine in 60% yield over two steps, and subsequent removal of the 5’-silyl 
group, proceeded efficiently giving compound 5.3 in good yield; however, further phosphorylation 
caused oxidation at the sulfur atom of biotin, during the conversion step from PIII to PV, giving 
undesired sulfoxide and sulfone by-products (Scheme 5-1A). Various mild conditions were attempted 
to attain selective phosphorus oxidation, including dilute solutions of I2,[12] m-chloroperbenzoic acid 
(MCPBA)[13] and (1S)-(+)-(10-camphorsulfonyl) oxaziridine[14] but none gave the desired product. 
Switching to the alternative disconnection, 5’-O-(dibenzylphosphate)-thymidine 5.5 was therefore 
prepared in four steps and subsequently subjected to coupling with biotin, leading to the formation of 
the desired compound 5.7 after deprotection (Scheme 5-1B). However, we found that the Pummerer 
rearrangement of compound 5.5 to 5.6 was less effective than in the previous route, probably due to 
side reaction of the electrophilic sulfur intermediate at the nucleophilic phosphate center. 
During the last step, formation of side products resulting from conjugate decomposition was 
observed, pointing at instability of this type of linker under hydrogenation conditions. 
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Scheme 5-1. Synthesis of 3'-O-methyleneacyloxy-TMP biotin conjugate 5.7. Reagents and 
conditions: (a) (i) SO2Cl2, DCM, 0 °C to rt, 2 h, (ii) biotin, DBU, DCM, rt, 24 h; (b) Et3N.3HF, 
THF, rt, 72 h; (c) DMSO, Ac2O, AcOH, rt, 48 h; (d) 10% Pd/C (Degussa), Et3N, MeOH, rt, 16 h. 
 
 
Figure 5-2. Proposed mechanism for the formation of 5.2 and 5.4 via α-halogenation of the 
corresponding thiomethyl derivative. 
 
 
Scheme 5-2. Synthesis of 3'-O-(carboxamide)-TMP biotin conjugate 5.10. Reagents and conditions: 
(a) biotin, DCC, DMAP, DCM/DMF, rt, 24 h; (b) 10% Pd/C (Degussa), MeOH, rt, 24 h. 
 
Different biotin−TMP analogues with carboxyamido-type linkers 5.10 (Scheme 5-2) and 5.13 
(Scheme 5-3) were prepared adopting previously optimized coupling and debenzylation 
procedures, which required access respectively to 3’-O-amino thymidylate 5.8 (obtained in four 
steps from thymidine) and 3’-O-aminoxymethyl thymidylate 5.11 (obtained in six steps from 
thymidine).[4] In general good to excellent isolated yields of products were obtained and linker 
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cleavage did not occur in the last step. 
 
 
Scheme 5-3. Synthesis of 3'-O-methyloxycarboxamide-TMP biotin conjugate 5.6. Reagents and 
conditions: (a) biotin, DCC, DMAP, DCM/DMF, rt, 24 h; (b) 10% Pd/C (Degussa), Et3N, MeOH, rt, 
24 h. 
 
The 3’-carboxy ester conjugate 5.15 was also prepared similarly, starting from 5.5 in 65% overall 
yield over two steps (Scheme 5-4). 
 
 
Scheme 5-4. Synthesis of 3'-ester-TMP biotin conjugate 5.15. Reagents and conditions: (a) 
biotin, DCC, DMAP, DCM/DMF, rt, 24 h; (b) 10% Pd/C (Degussa), MeOH, rt, 24 h. 
 
As route 5.2 (Figure 5-1) proved to be the most profitable for generating new biotin conjugates, 
we chose a similar strategy to connect TMP to kanamycin A by means of a 3’-carbamoyl linker, 
which gave access to conjugates 5.22 and 5.24 (Figure 5-3), and also led to a structural reassignment 
of the aminoglycosidic unit. 
As cationic amino functionalities of aminoglycosides are considered to be a crucial structural 
requirement for enhanced uptake,[15] we sought to retain all four amino groups of rings I−III in 
kanamycin A. To construct the relevant conjugates efficiently, we exploited the differences in 
chemical reactivity between the primary hydroxy and amino functionalities present in kanamycin A. 
We started by replacing the primary hydroxyl group at the 6''-position of 5.16 with a thioethanolamino 
group, which would serve for the formation of the desired carbamoyl linkage with TMP. The 
synthesis of compound 5.19 has been reported by Arya et al.,[16] however, we adopted here a shorter 
synthetic route by modifying a more recent procedure by Tor et. al.[17] (Scheme 5-5). To begin the 
synthesis, we first needed to selectively protect all four amino groups of kanamycin A. Among the 
several protecting strategies described in the literature, we opted for the classical Boc protection, 
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which gave compound 5.17 in excellent yield. Considering the good leaving group properties of 
triisopropylbenzenesulfonyl chloride (TIBS-Cl), compound 5.17 was selectively sulphonylated at the 
6''-primary hydroxyl group to its corresponding sulfonate 5.18, which upon further treatment with 2-
aminoethane thiol hydrochloride in the presence of cesium carbonate, gave compound 5.19.  
 
 
Figure 5-3. Structures of kanamycin A−TMP conjugates 5.22 and 5.24 and key HMBC correlations 
used for structure determination. Plain arrows ( ) indicate HMBC correlations with the carbamate 
(OCONH) linker (cf. Figure 5-4A/B) whilst dotted arrows ( ) show HMBC correlation used for 
other peak assignments. 
 
 
 
Scheme 5-5. Synthesis of kanamycin A cysteamine 5.19. Reagents and conditions: (a) Boc2O, Et3N, 
DMF/H2O, 50 ºC, 6 h; (b) TIBSCl, pyridine, rt, 16 h; (c) HCl.NH2CH2CH2SH, Cs2CO3, DMF, 25 ºC, 
16 h.  
 
The introduction of a carbamate linker at the 3’–position of nucleosides is possible starting from 
commercially available isocyanates such as phenyl isocyanates,[18] however this approach appears 
unsuitable for macromolecules containing unprotected polyhydroxyl and polyamino functionalities. 
Another commonly applied method to generate carbamates is the activation of the 3'-OH group with 
CDI,[19] but we felt that the strictly anhydrous conditions required by this protocol would not be 
compatible with the poor solubility of most aminoglycosides. A solution was found by choosing as 
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activating/leaving group 4-nitrophenyl carbonate,[20] which is electrophilic enough to react with amino 
functionalities, whilst still reasonably stable in aqueous media. Compound 5.20 was prepared in a 
series of straightforward steps, involving phosphorylation at the 5'-position of thymidine after 
selective protection−deprotection at the 3'- and 5'-position with a MMTr and benzoyl group 
respectively and final 3'-OH activation with 4-nitrophenyl chloroformate in a controlled way in the 
presence of pyridine/DCM. With both coupling units now available, we proceeded to react 3’-O-(4-
nitrophenylcarbonate)−TMP 5.20 with N-Boc kanamycin A cysteamine 5.19 (Scheme 5-6A). 
 
 
Scheme 5-6. Synthesis of 3'-carbamoyl kanamycin A−TMP conjugates 5.22 and 5.24. Reagents and 
conditions: (a) Et3N, 1,4-dioxane/water, 0 ºC to rt, 18 h; (b) 20% Pd(OH)2/C, H2, EtOH/H2O (8:2), rt, 
24 h; (c) TFA, thioanisole, H2O, rt, 5 h. 
 
An initial attempt to synthesize 5.21 using previously optimized conditions in the presence of 
triethylamine as base and DCM/DMF (1:1) as solvent, afforded the desired conjugate in poor yield. 
Replacement of the solvent system with a mixture of 1,4-dioxane/water (3:1), surprisingly resulted in 
an improved yield (90%) (Table 3-1). Removal of the dibenzyl phosphate protection of 5.21 was 
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achieved by catalytic hydrogenolysis using an excess of 20% Pd(OH)2/C to avoid potential catalyst 
poisoning due to the sulfide moiety. Without further purification, the N-Boc protected intermediate 
5.21 was converted to compound 5.22 upon treatment with aqueous TFA, in good yield and high 
purity after preparative RP-HPLC purification. 
As the convergent coupling of complex fragments is important to rapidly generate a variety of 
conjugates, we decided to further explore the versatility of this reaction process. Since a single 
aminomethyl group is present in kanamycin A, the regioselective formation of a mono-carbamate 
linker seemed feasible without prior protection of the other amino groups. The 6'-amino group of 
kanamycin A is known to be the most reactive following the series 6'-NH2 > 1-NH2 > 3-NH2 > 3''-
NH2).[21, 22] When the compound 5.20 was allowed to react directly with kanamycin A 5.16 utilising 
the general protocol for carbamate formation (Scheme 3-6B), intermediate 5.23 was obtained in good 
yield. Subsequent hydrogenolysis in the presence of 20% Pd(OH)2/C and preparative RP-HPLC 
purification yielded compound 5.24 in good yield and high purity. 
 
Table 5-1. Reaction circumstances for the synthesis of compounds 5.21 and 5.23 from 5.20. 
Entry Solvent Temp Time (h) Yield of 21a (%) Yield of 23 a (%) 
1 DCM : DMF (1:1) rt 60 48 - 
2 DMF rt 48 55 42 
3 Dioxane : H2O (3:1) 0 °C to rt 16 90 82 
a  Isolated yield 
 
 
Figure 5-4. A) Key HMBC correlation for compound 5.22; B) key HMBC correlation NMR spectrum 
of compound 5.24; C) and D) temperature-dependent NMR (1H and 31P) study of compound 5.22. All 
NMR spectra were recorded in D2O. 
 
Although the reactivity order of the various hydroxyl and amino groups of kanamycin A is well 
documented, we thought necessary to confirm the structures of the final analogues. The peak 
assignment for almost all proton and carbon signals of kanamycin A−TMP conjugates 5.22 and 5.24 
was unambiguously determined (Table 5-2), as well as the alignment of the carbamoyl linkage 
between the 9'' and 6' positions (Figure 5-4A and B), by means of two-dimensional NMR 
Compound 1 
C) 1H – 500 MHz D) 31P – 202 MHz 
50 °C  
25 °C  
5 °C  
50 °C  
25 °C  
5 °C  
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spectroscopy in D2O solution at 25 °C. The presence of a distinctive signal at 157.5 ppm in the 
carbonyl region of the carbon NMR spectrum, proton integration ratio along with HRMS mass 
spectrometry confirmed the formation of a single carbamate linkage at the expected positions. While 
performing the 1H and 31P NMR spectroscopic analysis of compound 3.22 (Figure 5-4C and D), the 
appearance of a minor conformation was observed at low temperature (5 °C), which disappeared 
when the temperature was raised (50 °C), indicating the presence of a single conformer. This 
phenomenon may arise due to the formation of rotamers, as the inherent flexibility around glycosidic 
bonds of kanamycin A−TMP conjugates allows them to easily adopt an array of conformations. [23] 
 
5.3. CONCLUSION 
In summary, we have accomplished the synthesis of a variety of biotin−TMP and kanamycin 
A−TMP conjugates in a straightforward manner starting from previously optimized 3’-modified TMP 
intermediates and featuring in turn an oxymethyleneoxy ester, a carboxy ester, a carboxamide, a 
carbamoyl and a thioethyl carbamoyl group. Particularly,	   kanamycin	   A-­‐dTMP	   conjugates	  connected	   through	   carbamate	   linker,	  were	   accomplished	   in	   a	   convergent	  manner	   considering	  the	  regioselectivity	  of	  the	  primary	  hydroxyl	  and	  amino	  functionality.	   
 
5.4. EXPERIMENTAL SECTION 
General information 
For all reactions, analytical grade solvents were used. Kanamycin A . H2SO4 was purchased from 
Sigma-Aldrich (containing kanamycin B as a 5% impurity). Kanamycin A. H2SO4 salt was 
transformed into its free amino form by treatment with Amberlite IRA-400 ion exchange resin. All 
moisture-sensitive reactions were carried out using oven-dried glassware (135 ºC) under a nitrogen or 
argon atmosphere. Reaction temperatures are reported as bath temperatures. Pre-coated aluminum 
sheets (254 nm) were used for TLC. Compounds were visualized with UV light (λ = 254 nm). 
Products were purified by flash chromatography on ICN silica gel 63-200, 60 Å. All final compounds 
were purified by preparative RP-HPLC using a gradient of H2O and MeCN, both contains either 50 
mmol TEAB or 0.1% TFA as eluent buffer as mentioned. 1H, 13C and 31P NMR spectra were recorded 
on 300, 500 or 600 MHz Bruker spectrometers. Final compounds were characterized using 2D NMR 
(H-COSY, HSQC, HMBC, TOCSY, NOESY) techniques. The 1H and 13C chemical shifts were 
referenced to residual solvent signals relative to TMS as internal standard wherever applied. Coupling 
constants J [Hz] were directly taken from the spectra. Splitting patterns are designated as s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet) and br (broad). High-resolution mass spectra were 
acquired on a quadrupole orthogonal acceleration time-of-flight mass spectrometer (Synapt G2 
HDMS, Waters, Milford, MA). Samples were infused at 3 µL/min and spectra were obtained in 
positive (or negative) ionization mode with a resolution of 15000 (FWHM) using leucine enkephalin 
as lock mass. 
 
5’-O-(tert-Butyl diphenyl silane)-3’-O-(biotinmethyloxyester)-thymidine (5.2)  
A 1M solution of SO2Cl2 in CH2Cl2 (2.07 mL, 2.07 mmol) was added to a stirred solution of 5.1 
(0.935 g, 0.107 mmol) in dry CH2Cl2 (20 mL) at 0 °C. The reaction mixture was allowed to warm 
slowly to room temperature over 2 h, then it was concentrated using a rotary evaporator (bath 
Chapter 5 Biotin- and Aminoglycoside-Nucleotide Conjugates 
 141 
temperature 10-15 °C) under reduced pressure to give a 3’-O-chloromethylthymidine derivative as a 
light yellowish foam, which was used without further purification. 
In a separate round-bottomed flask, biotin (0.634 g, 2.593 mmol) was suspended in dry CH2Cl2 
(20 mL), and DBU (0.38 mL, 2.51 mmol) was then added. After 15 min, the solution was added to the 
crude 3’-O-chloromethylthymidine derivative (redissolved in dry CH2Cl2, 20 mL), and the reaction 
mixture was kept stirring at room temperature for 24 h. The mixture was then diluted with CH2Cl2 
(100 mL), and 1M aq. acetic acid (4 mL) was added with vigorous stirring. The aqueous layer was 
discarded, and the organic layer was washed with saturated aq. NaHCO3 (2 x 50 mL) and brine, dried 
over Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by 
column chromatography on silica gel (gradient CH2Cl2/MeOH, 99:1, v/v; 98:2, v/v; 97:3, v/v) to give 
5.2 (0.91 g, 71%) as a colorless foam. 1H NMR (300 MHz, CDCl3) δ = 11.9 (s, 1H, NH-Thy), 7.68-
7.65 (m, 4H, Ar-H Ph), 7.51 (s, 1H, H-6), 7.46-7.37 (m, 6H, Ar-H Ph), 6.94 (s, 1H, NH Bio), 6.91 (s, 
1H, NH Bio), 6.27 (dd, J = 8.6, 5.2 Hz, 1H, H-1’), 5.71 (m, 1H, H-g Bio), 4.92 (m, 1H, H-f Bio), 
4.59-4.54 (m, 1H, H-3’), 4.38-4.35 (m, 2H, H-5’ and H-5’’), 4.12-4.10 (m, 1H, H-4’), 4.03-3.82 (m, 
2H, OCH2O), 3.21-3.14 (m, 1H, H-e Bio), 2.96-2.82 (m, 2H, H-h Bio and H-h’ Bio), 2.74-2.68 (m, 
1H, H-2’), 2.49-2.28 (m, 2H, H-a Bio), 2.14-2.05 (m, 1H, H-2’’), 1.83-1.65 (m, 4H, H-b and H-d 
Bio), 1.62 (s, 3H, CH3), 1.55-1.40 (m, 2H, H-c Bio), 1.11 (s, 9H, tBu); 13C NMR (75 MHz, CDCl3) δ = 
172.6 (OCO), 165.0 (C-4), 164.3 (NHCONH), 151.4 (C-2), 135.4 (Ar-C), 135.2 (Ar-C), 134.3 (C-6), 
132.6 (Ar-C), 132.2 (Ar-C), 130.1 (Ar-C), 130.0 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 111.2 (C-5), 
88.1 (OCH2O), 85.1 (C-1’), 84.5 (C-4’), 81.6 (C-3’), 64.0 (C-5’), 62.1 (C-f Bio), 60.3 (C-g Bio), 55.4 
(C-e Bio), 40.7 (C-h, h’ Bio), 38.9 (C-2’), 33.8 (C-a Bio), 28.0 (C-c Bio), 27.9 (C-d Bio), 26.9 (tBu), 
24.5 (C-b Bio), 19.2 (1C tBu), 12.1 (CH3-Thy); HRMS for C37H48N4O8SSi [M+H]+ calcd.: 737.3035, 
found: 737.3045. 
 
3’-O-(biotinmethyloxyester)-thymidine (5.3) 
Triethylamine trihydrofluoride (0.76 mL, 4.67 mmol) was added to a stirred solution of 5.2 (0.86 g, 
1.17 mmol) in THF (20 mL) in a falcon tube at room temperature. The reaction mixture was stirred at 
room temp. for 72 h, and then it was concentrated under reduced pressure. The crude residue was 
purified by column chromatography on silica gel (gradient CH2Cl2/MeOH, 99:1, v/v; 96:4, v/v; 93:7, 
v/v) to give 5.3 (0.49 g, 84%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ = 11.34 (s, 1H, NH-
Thy), 7.68 (s, 1H, H-6), 6.42 (s, 1H, NH Bio), 6.37 (s, 1H, NH Bio), 6.01 (app t, J = 7.0 Hz, 1H, H-
1’), 5.30 (dd, J = 20.2, 6.6 Hz, 2H, OCH2O), 5.13 (t, J = 5.1 Hz, 1H, 5’-OH), 4.39-4.36 (m, 1H, H-3’), 
4.33-4.28 (m, 1H, H-g Bio), 4.15-4.10 (m, 1H, H-f Bio), 3.93-3.90 (m, 1H, H-4’), 3.61-3.56 (m, 2H, 
H-5’ and H-5’’), 3.13-3.06 (m, 1H, H-e Bio), 2.82 (dd, J = 12.4, 5.1 Hz, 1H, H-h Bio), 2.57 (d, J = 
12.4 Hz, 1H, H-h’ Bio), 2.36 (t, J = 7.4 Hz, 1H, and H-a Bio), 2.27-2.18 (m, 2H, H-2’ and H-2’’), 
1.77 (s, 3H, CH3), 1.66-1.45 (m, 4H, H-b and H-d Bio), 1.42-1.29 (m, 2H, H-c Bio); 13C NMR (75 
MHz, DMSO-d6) δ = 172.4 (OCO), 163.6 (C-4), 162.7 (NHCONH), 150.5 (C-2), 135.9 (C-6), 109.5 
(C-5), 87.4 (OCH2O), 84.8 (C-1’), 83.6 (C-4’), 79.4 (C-3’), 61.1 (C-5’), 61.0 (C-f Bio), 59.2 (C-g 
Bio), 55.3 (C-e Bio), 40.2 (C-h, h’ Bio, merged with DMSO), 36.9 (C-2’), 33.3 (C-a Bio), 28.0 (C-c 
Bio), 27.9 (C-d Bio), 24.2 (C-b Bio), 12.2 (CH3-Thy); HRMS for C21H30N4O8S [M-H]- calcd.: 
497.1711, found: 497.1715. 
 
5’-O-(Dibenzylphosphate)-3’-O-(methylthiomethyl)-thymidine (5.6) 
Acetic anhydride (10.9 mL) and acetic acid (3.5 mL) were added to a stirred solution of 5.5 (2.40 g, 
4.78 mmol) in DMSO (15.5 mL). The reaction mixture was stirred at room temperature for 30 h, and 
then it was concentrated under reduced pressure. The residue was neutralized with saturated aq. 
NaHCO3 (230 mL), and the mixture was extracted with ethyl acetate (3 x 170 mL). The combined 
organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated under reduced 
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pressure. The crude residue was purified by column chromatography on silica gel (gradient 
hexane/EtOAc, 2:1, v/v; 1:1, v/v; 1:3, v/v) to give 5.6 (1.64 g, 61%) as a colorless foam. 1H NMR 
(300 MHz, CDCl3) δ = 8.22 (br s, 1H, NH), 7.37-7.35 (m, 11H, H-6 and Ar-H OBn), 6.26 (dd, J = 
8.2, 5.8 Hz, 1H, H-1’), 5.11-5.00 (m, 4H, 2 x OCH2Ph), 4.64-4.51 (m, 2H, OCH2S), 4.35-4.31 (m, 1H, 
H-3’), 4.17-4.09 (m, 3H, H-4’, H-5’ and H-5’’), 2.34-2.26 (m, 1H, H-2’), 2.11 (s, 3H, SCH3), 1.92-
1.81 (m, 4H, H-2’’ and CH3-Thy); 13C NMR (75 MHz, CDCl3) δ = 163.4 (C-4), 150.2 (C-2), 135.6 (d, 
3JC,P = 6.1 Hz, 1C of OCH2Ph), 135.3 (C-6), 129.0 (Ar-C), 128.9 (Ar-C), 128.2 (Ar-C), 111.5 (C-5), 
85.0 (C-1’), 82.8 (d, 3JC,P = 8.2 Hz, C-4’), 76.3 (C-3’), 74.1 (OCH2S), 69.9-69.8 (2 x d, 2JC,P = 3.5 Hz, 
2 x OCH2Ph), 67.0 (d, 2JC,P =5.7 Hz, C-5’), 37.5 (C-2’), 14.0 (SCH3), 12.5 (CH3-Thy); 31P NMR (121 
MHz, CDCl3) δ = -0.5; HRMS for C26H31N2O8PS [M-H]- calcd.: 561.1466, found: 561.1461. 
 
5’-O-(Dibenzylphosphate)-3’-O-(biotinmethyloxyester)-thymidine (5.4) 
Following a similar procedure as the one used for the synthesis of 5.2, compound 5.4 was obtained 
(41.0 mg, 51%) as a colorless foam, starting from 5.6 (60.0 mg, 0.107 mmol), a 1M solution of 
SO2Cl2 in CH2Cl2 (0.13 mL, 0.128 mmol) in dry CH2Cl2 (4 mL) and biotin (39.1 mg, 0.160 mmol), 
DBU (0.023 mL, 0.155 mmol) in dry CH2Cl2 (15 mL). The crude residue was purified by column 
chromatography on silica gel (gradient CH2Cl2/MeOH, 99:1, v/v; 97:3, v/v; 93:7, v/v). 1H NMR (300 
MHz, CDCl3) δ = 9.76 (s, 1H, NH-Thy), 7.35-7.37 (m, 11H, H-6 and Ar-H OBn), 6.81 (br s, 1H, NH 
Bio), 6.31 (app t, J = 6.6 Hz, 1H, H-1’), 6.18 (br s, 1H, NH Bio), 5.13-4.99 (m, 6H, OCH2O and 2 x 
OCH2Ph), 4.53-4.49 (m, 1H, H-3’), 4.38-4.35 (m, 1H, H-g Bio), 4.26-4.12 (m, 3H, H-f Bio, H-5’ and 
H-5’’), 4.05-4.03 (m, 1H, H-4’), 3.16-3.12 (m, 1H, H-e Bio), 2.89 (dd, J = 12.2, 7.2 Hz, 1H, H-h Bio), 
2.79 (d, J = 12.2 Hz, 1H, H-h’ Bio), 2.58-2.52 (m, 1H, H-2’), 2.40-2.27 (m, 3H, H-2’’ and H-a Bio), 
1.80 (s, 3H, CH3), 1.76-1.69 (m, 4H, H-b and H-d Bio), 1.52-1.43 (m, 2H, H-c Bio); 13C NMR (75 
MHz, CDCl3) δ = 172.7 (OCO), 164.7 (C-4), 164.2 (NHCONH), 150.7 (C-2), 135.5 (d, 3JC,P = 8.0 Hz, 
1C of OCH2Ph), 134.5 (C-6), 128.8 (Ar-C), 128.7 (Ar-C), 128.1 (Ar-C), 111.3 (C-5), 88.1 (OCH2O), 
84.8 (C-1’), 83.1 (d, 3JC,P = 8.1 Hz, C-4’), 81.3 (C-3’), 69.9-69.8 (2 x d, 2JC,P = 5.2 Hz, 2 x OCH2Ph), 
67.0 (d, 2JC,P = 5.9 Hz, C-5’), 62.3 (C-f Bio), 60.2 (C-g Bio), 55.6 (C-e Bio), 40.2 (C-h, h’ Bio), 38.6 
(C-2’), 33.9 (C-a Bio), 28.2 (C-c Bio), 28.0 (C-d Bio), 24.8 (C-b Bio), 12.5 (CH3-Thy); 31P NMR (121 
MHz, CDCl3) δ = -0.4; HRMS for C35H43N4O11PS [M+Na]+ calcd.: 781.2279, found: 781.2288. 
 
3’-O-(Biotinmethyloxyester)-thymidine monophosphate triethylammonium salt (5.7) 
10% Pd/C (Degussa, 15.0 mg, 50% w/w) was added to a degassed stirred solution of 5.4 (30.0 mg, 
0.039 mmol) and Et3N (0.011 mL, 0.079 mmol) in MeOH (10 mL), and the mixture was subjected to 
hydrogenation at atmospheric pressure using a balloon filled with H2 for 24 h. The catalyst was 
removed by filtration through a cellulose filter (0.45 µm) and the filtrate was concentrated under 
reduced pressure (bath temp 10-15 °C). The resulting crude residue was purified by RP-HPLC [TEAB 
(triethylammonium bicarbonate; 50 mmol) in H2O/MeCN, 98:2; and TEAB (50 mmol) in 
H2O/MeCN, 50:50]. The collected eluate was freeze-dried repeatedly until constant mass to obtain the 
triethylammonium salt of 5.7 (22.2 mg, 72%) as a white solid. 1H NMR (500 MHz, D2O) δ = 7.80 (s, 
1H, H-6), 6.28 (app t, J = 7.3 Hz, 1H, H-1’), 5.46-5.32 (m, 2H, OCH2O), 4.63-4.62 (m, 1H, H-3’), 
4.56-4.54 (m, 1H, H-g Bio), 4.38-4.36 (m, 1H, H-f Bio), 4.25 (br s, 1H, H-4’), 3.94-3.88 (m, 2H, H-5’ 
and H-5’’), 3.29-3.25 (m, 1H, H-e Bio), 2.92 (dd, J = 13.0, 5.0 Hz, 1H, H-h), 2.70 (d, 1H, J = 13.0 
Hz, H-h’ Bio), 2.45 (t, 2H, J = 7.2 Hz, H-a Bio), 2.42-2.40 (m, 1H, H-2’ and H-2’’), 1.88 (s, 3H, 
CH3), 1.73-1.52 (m, 4H, H-b and H-d Bio), 1.43-1.36 (m, 2H, H-c Bio) ; 13C NMR (125 MHz, D2O) δ 
= 175.5 (OCO), 168.3 (C-4), 164.8 (NHCONH), 152.9 (C-2), 137.0 (C-6), 111.4 (C-5), 88.1 
(OCH2O), 84.3 (C-1’), 83.8 (d, 3JC,P = 9.2 Hz, C-4’), 80.7 (C-3’), 63.3 (d, 2JC,P = 3.9  Hz, C-5’), 61.5 
(C-f Bio), 59.7 (C-g Bio), 54.8 (C-e Bio), 39.2 (C-h, h’ Bio), 36.6 (C-2’), 33.1 (C-a Bio), 27.4 (C-c), 
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27.1 (C-d Bio), 23.4 (C-b Bio), 11.5 (CH3-Thy); 31P NMR (202 MHz, D2O) δ = 3.4; HRMS for 
C21H31N4O11PS [M-H]- calcd.: 577.1375, found: 577.1375. 
 
5’-O-(Dibenzylphosphate)-3’-O-(biotincarboxamide)-thymidine (5.9) 
DCC (127.4 mg, 0.618 mmol) was added to a stirred solution of 5.8 (200.0 mg, 0.386 mmol), biotin 
(108.6 mg, 0.444 mmol), and DMAP (2.0 mg, 0.016 mmol) in a mixture of dry DMF (2.0 mL) and 
dry CH2Cl2 (10 mL) at 0 °C. The reaction mixture was allowed to warm slowly to room temperature 
and stirred for 24 h. All the volatiles were removed under reduced pressure and the resulting residue 
was purified by column chromatography on silica gel (gradient CH2Cl2/MeOH, 99:2, v/v; 97:4, v/v; 
94:7, v/v) to give 5.9 (201.0 mg, 70%) as a colourless foam. 1H NMR (300 MHz, CDCl3 + CD3OD) δ 
= 7.41 (d, J = 1.0 Hz, 1H, H-6), 7.39-7.34 (m, 10H, Ar-H OBn), 6.27 (dd, J = 8.9, 5.6 Hz, 1H, H-1’), 
5.12-5.00 (m, 4H, 2 x OCH2Ph), 4.55-4.48 (m, 2H, H-3’ and H-g Bio), 4.33-4.29 (m, 2H, H-4’ and H-
f Bio,), 4.23-4.22 (m, 2H, H-5’ and H-5’’), 3.21-3.15 (m, 1H, H-e Bio), 2.91 (dd, J = 12.8, 4.9 Hz, 
1H, H-h Bio), 2.73 (d, J = 12.8 Hz, 1H, H-h’ Bio), 2.54-2.48 (m, 1H, H-2’), 2.14 (t, J = 6.7 Hz, 3H, 
H-a Bio), 1.94-1.84 (m, 1H, H-2’’), 1.81 (d, J = 0.9 Hz, 3H, CH3), 1.75-1.61 (m, 4H, H-b and H-d 
Bio), 1.51-1.43 (m, 2H, H-c Bio) ; 13C NMR (75 MHz, CDCl3 + CD3OD) δ = 172.8 (ONHCO), 165.1 
(C-4), 164.9 (NHCONH), 151.3 (C-2), 136.0 (C-6), 135.6 (d, 3JC,P = 5.7 Hz, 1C of OCH2Ph), 129.4 
(Ar-C), 129.1 (Ar-C), 128.5 (Ar-C), 111.8 (C-5), 85.4 (C-3’), 85.3 (C-1’), 81.6 (d, 3JC,P = 8.3 Hz, C-
4’), 70.5-70.4 (d, 2JC,P = 5.6 Hz, 2 x OCH2Ph), 68.1 (d, 2JC,P = 5.8 Hz, C-5’), 62.4 (C-f Bio), 60.6 (C-g 
Bio), 55.9 (C-e Bio), 40.6 (C-h, h’ Bio), 36.4 (C-2’), 32.8 (C-a Bio), 28.7 (C-c Bio), 28.5 (C-d Bio), 
25.5 (C-b Bio), 12.4 (CH3-Thy); 31P NMR (121 MHz, CDCl3) δ = -1.0; HRMS for C34H42N5O10PS 
[M+Na]+ calcd.: 766.2282, found: 766.2302. 
 
3’-O-(Biotincarboxamide)-thymidine monophosphate triethylammonium salt (5.10) 
Following a similar procedure as the one used for the synthesis of 5.7, the triethylammonium salt of 
compound 5.10 was obtained as a white solid (169.0 mg, 82%), starting from 5.9 (200.0 mg, 0.269 
mmol), Et3N (0.075 mL, 0.538 mmol) and 10% Pd/C Degussa (100 mg, 50% w/w) in MeOH (20 mL). 
1H NMR (500 MHz, D2O) δ = 7.90 (s, 1H, H-6), 6.40 (dd, J = 9.1, 5.7 Hz, 1H, H-1’), 4.73-4.72 (m, 
1H, H-3’), 4.56-4.54 (m, 1H, H-g Bio), 4.38-4.35 (m, 1H, H-f Bio), 4.32 (br s, 1H, H-4’), 3.92-3.91 
(m, 2H, H-5’ and H-5’’), 3.32-3.28 (m, 1H, H-e Bio), 2.93 (dd, J = 13.0, 4.9 Hz, 1H, H-h), 2.69 (d, 
1H, J = 13.0 Hz, H-h’ Bio), 2.48-2.44 (m, 1H, H-2’),  2.40-2.34 (m, 1H, H-2’’), 2.15 (t, 2H, J = 7.0 
Hz, H-a Bio), 1.89 (s, 3H, CH3), 1.72-1.67 (m, 1H, H-b Bio), 1.65-1.60 (m, 2H, H-d Bio), 1.59-1.51 
(m, 1H, H-b’ Bio), 1.40-1.34 (m, 2H, H-c Bio) ; 13C NMR (125 MHz, D2O) δ = 172.8 (ONHCO), 
166.9 (C-4), 164.8 (NHCONH), 151.8 (C-2), 137.3 (C-6), 111.4 (C-5), 84.9 (C-3’), 84.3 (C-1’), 82.1 
(d, 3JC,P = 8.9 Hz, C-4’), 63.6 (d, 2JC,P = 3.9  Hz, C-5’), 61.4 (C-f Bio), 59.7 (C-g Bio), 54.7 (C-e Bio), 
39.2 (C-h, h’ Bio), 34.8 (C-2’), 31.8 (C-a Bio), 27.3 (C-c Bio), 27.0 (C-d Bio), 24.5 (C-b Bio), 11.3 
(CH3-Thy); 31P NMR (202 MHz, D2O) δ = 3.4; HRMS for C20H30N5O10PS [M-H]- calcd.: 562.1378, 
found: 562.1382. 
 
5’-O-(Dibenzylphosphate)-3’-O-(biotinmethyloxycarboxamide)-thymidine (5.12) 
Following a similar procedure as the one used for the synthesis of 5.9, compound 5.12 was obtained 
as a colorless foam (214.0 mg, 76%), starting from 5.11 (200 mg, 0.365 mmol), biotin (102.6 mg, 
0.420 mmol), DCC (120.6 mg, 0.584 mmol) and DMAP (1.8 mg, 0.0146 mmol) in a mixture of dry 
DMF (2.0 ml) and dry CH2Cl2 (10 ml). 1H NMR (300 MHz, DMSO-d6) δ = 11.34 (br s, 1H, NH), 
11.00 (br s, 1H, NH), 7.50 (s, 1H, H-6), 7.35-7.35 (m, 10H, Ar-H OBn), 6.41 (br s, 1H, NH Bio), 6.35 
(br s, 1H, NH Bio), 6.15 (dd, J = 8.2, 5.9 Hz, 1H, H-1’), 5.06 (d, J = 8.0 Hz, 4H, 2 x OCH2Ph), 4.87-
4.81 (m, 2H, OCH2O), 4.51-4.50 (m, 1H, H-3’), 4.33-4.29 (m, 3H, H-g Bio, H-f Bio and H-4’), 4.19-
4.10 (m, 2H, H-5’ and H-5’’), 3.10-3.04 (m, 1H, H-e Bio), 2.81 (dd, J = 12.6, 5.2 Hz, 1H, H-h Bio), 
Chapter 5 Biotin- and Aminoglycoside-Nucleotide Conjugates 
 144 
2.57 (d, J = 12.6 Hz, 1H, H-h’ Bio), 2.35-2.28 (m, 1H, H-2’), 2.17-2.08 (m, 1H, H-2’’), 2.00 (t, J = 
7.0 Hz, 3H, H-a Bio), 1.69 (s, 3H, CH3), 1.63-1.42 (m, 4H, H-b and H-d Bio), 1.36-1.27 (m, 2H, H-c 
Bio) ; 13C NMR (75 MHz, DMSO-d6) δ = 169.6 (ONHCO), 163.6 (C-4), 162.7 (NHCONH), 150.4 (C-
2), 135.9 (d, 3JC,P = 6.9 Hz, 1C of OCH2Ph), 135.6 (C-6), 128.5 (Ar-C), 128.4 (Ar-C), 127.8 (Ar-C), 
109.9 (C-5), 97.0 (OCH2O), 84.0 (C-1’), 82.3 (d, 3JC,P = 7.6 Hz, C-4’), 77.1 (C-3’), 68.7 (d, 2JC,P = 5.4 
Hz, 2 x OCH2Ph), 67.1 (d, 2JC,P = 5.0 Hz, C-5’), 61.0 (C-f Bio), 59.2 (C-g Bio), 55.3 (C-e Bio), 39.5 
(C-h, h’ Bio), 36.2 (C-2’), 32.0 (C-a Bio), 28.1 (C-c Bio), 28.0 (C-d Bio), 24.9 (C-b Bio), 12.0 (CH3-
Thy); 31P NMR (121 MHz, CDCl3) δ = -0.9; HRMS for C35H44N5O11PS [M+Na]+ calcd.: 796.2388, 
found: 796.2403. 
 
3’-O-(Biotinmethyloxycarboxamide)-thymidine monophosphate triethylammonium salt (5.13) 
Following a similar procedure as the one used for the synthesis of 5.7, the triethylammonium salt of 
compound 5.13 was obtained as a white solid (170.6 mg, 79%), starting from 5.12 (210 mg, 0.271 
mmol), Et3N (0.075 mL, 0.543 mmol) and 10% Pd/C Degussa (105 mg, 50% w/w) in MeOH (20 mL). 
1H NMR (500 MHz, D2O) δ = 7.85 (d, J = 1.1 Hz, 1H, H-6), 6.31 (app t, J = 7.3 Hz, 1H, H-1’), 4.98 
(s, 2H, OCH2O), 4.71-4.70 (m, 1H, H-3’), 4.57-4.54 (m, 1H, H-g Bio), 4.39-4.37 (m, 1H, H-f Bio), 
4.28-4.27 (m, 1H, H-4’), 3.97-3.90 (m, 2H, H-5’ and H-5’’), 3.31-3.27 (m, 1H, H-e Bio), 2.94 (dd, J = 
13.0, 5.0 Hz, 1H, H-h), 2.71 (d, 1H, J = 13.0 Hz, H-h’ Bio), 2.42-2.39 (m, 1H, H-2’ and H-2’’), 2.20 
(t, 2H, J = 7.0 Hz, H-a Bio), 1.89 (d, J = 1.1 Hz, 3H, CH3), 1.70-1.54 (m, 1H, H-b and H-d Bio), 1.39-
1.37 (m, 2H, H-c Bio) ; 13C NMR (125 MHz, D2O) δ = 172.9 (ONHCO), 166.2 (C-4), 164.8 
(NHCONH), 151.3 (C-2), 137.2 (C-6), 111.4 (C-5), 96.8 (OCH2O), 84.3 (C-1’), 83.8 (d, 3JC,P = 8.7 
Hz, C-4’), 78.4 (C-3’), 63.4 (d, 2JC,P = 3.7 Hz, C-5’), 61.5 (C-f Bio), 59.7 (C-g Bio), 54.8 (C-e Bio), 
39.2 (C-h, h’ Bio), 36.1 (C-2’), 31.5 (C-a Bio), 27.2 (C-c Bio), 27.1 (C-d Bio), 24.2 (C-b Bio), 11.2 
(CH3-Thy); 31P NMR (202 MHz, D2O) δ = 2.8; HRMS for C21H32N5O11PS [M-H]- calcd.: 592.1484, 
found: 592.1480. 
 
5’-O-(Dibenzylphosphate)-3’-O-(biotinester)-thymidine (5.14) 
Following a similar procedure as the one used for the synthesis of 5.9, compound 5.14 was obtained 
(370.0 mg, 74%) as a colorless foam, starting from 5.5 (345 mg, 0.686 mmol), biotin (201.0 mg, 
0.823 mmol), DCC (198.0 mg, 0.960 mmol) and DMAP (8.0 mg, 0.068 mmol) in a mixture of dry 
DMF (3 ml) and dry CH2Cl2 (15 ml). 1H NMR (300 MHz, CDCl3) δ = 10.95 (br s, 1H, NH Thy), 7.40 
(s, 1H, H-6), 7.34-7.33 (m, 10H, Ar-H OCH2Ph), 6.76 (br s, 1H, NH Bio), 6.50 (br s, 1H, NH Bio), 
6.26 (app t, J = 6.7 Hz, 1H, H-1’), 5.13-5.00 (m, 5H, H-3’ and OCH2Ph ), 4.51-4.50 (m, 1H, H-g Bio), 
4.30-4.22 (m, 1H, H-f Bio, H-5’ and H-5’’), 4.11 (br s, 1H, H-4’), 3.17-3.15 (m, 1H, H-e Bio), 2.91-
2.88 (m, 1H, H-h Bio), 2.78-2.74 (m, 1H, H-h’ Bio), 2.35-2.25 (m, 3H, H-a Bio and H-2’), 1.97-1.94 
(m, 1H, H-2’’), 1.81 (s, 3H, CH3), 1.69-1.60 (m, 4H, H-b and H-d Bio), 1.46-1.44 (m, 2H, H-c Bio) ; 
13C NMR (75 MHz, CDCl3) δ = 172.7 (OCO), 164.3 (C-4), 164.2 (NHCONH), 150.5 (C-2), 135.1 (d, 
3JC,P = 6.1 Hz, 1C of OCH2Ph), 134.7 (C-6), 128.5 (Ar-C), 128.3 (Ar-C), 127.7 (Ar-C), 111.2 (C-5), 
84.1 (C-1’), 82.4 (d, 3JC,P = 8.1 Hz, C-4’), 74.1 (C-3’), 69.4 (app t, 2JC,P = 4.7 Hz, 2 x OCH2Ph), 66.8 
(d, 2JC,P = 4.7 Hz, C-5’), 61.7 (C-f Bio), 60.0 (C-g Bio), 55.2 (C-e Bio), 40.2 (C-h, h’ Bio), 36.8 (C-
2’), 33.4 (C-a Bio), 28.0 (C-c Bio), 27.8 (C-d Bio), 24.3 (C-b Bio), 12.0 (CH3-Thy); 31P NMR (121 
MHz, CDCl3) δ = -0.7; HRMS for C34H41N4O10PS [M+H]+ calcd.: 729.2353, found: 729.2354. 
 
3’-O-(Biotinester)-thymidine monophosphate triethylammonium salt (5.15) 
Following a similar procedure as the one used for the synthesis of 5.7, the triethylammonium salt of 
compound 5.15 was obtained as a white solid (335.0 mg, 88%), starting from 5.14 (370.0 mg, 0.686 
mmol), Et3N (0.141 mL, 1.015 mmol) and 10% Pd/C (Degussa, 185.0 mg, 50% w/w) in MeOH (30 
ml). 1H NMR (600 MHz, DMSO-d6) δ = 11.34 (br s, 1H, NH Thy), 7.91 (s, 1H, H-6), 6.51 (br s, 1H, 
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NH Bio), 6.40 (br s, 1H, NH Bio), 6.23 (dd, J = 9.0, 5.8 Hz, 1H, H-1’), 5.28-5.27 (m, 1H, H-3’), 4.32-
4.30 (m, 1H, H-g Bio), 4.15-4.12 (m, 1H, H-f Bio), 4.07 (br s, 1H, H-4’), 3.90-3.83 (m, 2H, H-5’ and 
H-5’’), 3.13-3.10 (m, 1H, H-e Bio), 2.83-2.82 (m, 1H, H-h Bio merged with triethylamine), 2.58 (d, 
1H, J = 12.4 Hz, H-h’ Bio), 2.36 (t, 2H, J = 7.1 Hz, H-a Bio), 2.33-2.29 (m, 1H, H-2’), 2.21-2.17 (m, 
1H, H-2’’), 1.81 (s, 3H, CH3), 1.66-1.62 (m, 1H, H-b Bio), 1.61-1.55 (m, 2H, H-d Bio), 1.51-1.44 (m, 
1H, H-b’ Bio), 1.39-1.32 (m, 2H, H-c Bio); 13C NMR (150 MHz, DMSO-d6) δ = 172.6 (OCO), 163.9 
(C-4), 162.9 (NHCONH), 150.7 (C-2), 136.2 (C-6), 110.3 (C-5), 83.7 (C-1’), 83.5 (d, 3JC,P = 7.4 Hz, 
C-4’), 75.5 (C-3’), 64.2 (d, 2JC,P = 6.0 Hz, C-5’), 61.1 (C-f Bio), 59.3 (C-g Bio), 55.4 (C-e Bio), 39.6 
(C-h,h’ Bio merged with DMSO), 36.5 (C-2’), 33.4 (C-a Bio), 28.0 (C-c and C-d Bio), 24.5 (C-b Bio), 
12.2 (CH3-Thy); 31P NMR (202 MHz, DMSO-d6) δ = -0.1; HRMS for C20H29N4O10PS [M-H]- calcd.: 
547.1269, found: 547.1279. 
 
N-Boc kanamycin A (5.17) 
To a stirred solution of kanamycin A 5.16 (1.8 g, 3.71 mmol) in a mixture of DMF:H2O (4:1, 48 mL), 
was added di-tert-butyldicarbonate (5.12 mL, 22.29 mmol) and the solution was heated at 60 °C for 
5h and then cooled to room temperature. After removal of all the volatiles, the resulting residue was 
washed with hexane (2 x 100 ml) and then with water (3 x 100 mL), and finally dried in vacuo to 
afford 5.17 (2.99 g, 91%) as a white solid. Rf  = 0.4 (10% MeOH in DCM). 1H NMR (300 MHz, 
DMSO-d6) δ = 6.89 (br s, 1H), 6.58 (br s, 1H), 6.50 (d, J = 8.6 Hz, 1H), 6.34 (br s, 1H), 5.35 (d, J = 
3.8 Hz, 1H), 5.26 (s, 1H), 4.89 (m, 4H), 4.68 (d, J = 6.2 Hz, 1H), 4.19 (t, J = 5.4 Hz, 1H), 3.82 (m, 
1H), 3.61-3.35 (m, 9H), 3.30-3.17 (m, 6H), 3.07 (m, 1H), 1.80 (m, 1H), 1.40-1.35 (m, 37H); 13C NMR 
(75 MHz, DMSO-d6) δ = 156.3, 156.1, 155.3, 154.9, 101.1, 97.8, 84.0, 80.3, 77.8, 77.7, 77.2, 75.0, 
72.9, 72.7, 72.1, 70.5, 70.3, 70.1, 67.4, 60.3, 55.9, 50.0, 49.1, 41.4, 34.7, 28.3, 28.2, 28.1; HRMS 
[ESI+] for C38H68N4O19 [M+H]+calcd.: 885.4550, found: 885.4552. 
 
O-TIBS-N-Boc kanamycin A (5.18) 
To a stirred solution of 5.17 (2.48 g, 2.81 mmol) in dry pyridine (50 mL) was added 2,4,6-
triisopropylbenzenesulfonyl chloride (5.96 g, 19.67 mmol) and the solution was stirred at 25 °C for 
16h. The reaction mixture was neutralized by adding 1N HCl and diluted with water. The aqueous 
layer was extracted with ethyl acetate (3 x 400 mL). The collected organic fractions were washed with 
brine, dried over Na2SO4 and concentrated in vacuo. The crude residue was purified by column 
chromatography over silica gel (3% MeOH in DCM) to afford 5.18 (1.91 g, 59%) as a white solid. Rf  
= 0.48 (10% MeOH in DCM). 1H NMR (300 MHz, CD3OD) δ = 7.28 (s, 1H), 6.58 (br s, 1H), 5.35 (d, 
J = 3.8 Hz, 1H), 5.04 (m, 2H), 4.38 (m, 2H), 4.14 (m, 3H), 3.71-3.31 (m, 12H), 3.18 (t, J = 9.4 Hz, 
1H), 2.95 (m, 1H), 2.02 (m, 1H), 1.45-1.41 (m, 37H), 1.28-1.25 (m, 18H); 13C NMR (75 MHz, 
CD3OD) δ = 159.4, 159.2, 157.9, 157.7, 155.3, 152.3, 130.7, 124.9, 102.8, 99.8, 85.8, 80.9, 80.6, 80.4, 
80.2, 76.8, 74.5, 73.9, 72.3, 71.9, 71.7, 71.6, 69.2, 57.4, 52.2, 50.9, 41.9, 36.0, 35.5, 30.8, 28.9, 28.8, 
28.7, 25.2, 25.1, 23.9; HRMS [ESI+] for C53H90N4O21S [M+H]+calcd.: 1151.5890, found: 1151.5895. 
 
N-Boc kanamycin A cysteamine (5.19) 
To a stirred solution of 5.18 (0.9 g, 0.782 mmol) in DMF (30 mL) was added 2-mercaptoethylamine 
hydrochloride (0.67 g, 5.86 mmol) followed by cesium carbonate (2.55 g, 7.82 mmol) and the solution 
was stirred at 25 °C for 16h. DMF was partly removed in vacuo and then partitioned between water 
(150 ml) and ethyl acetate (300 ml). The aqueous layer was extracted with ethyl acetate (2 x 150 mL). 
The collected organic fractions were washed with brine, dried over Na2SO4 and concentrated in 
vacuo. The crude residue was purified by column chromatography over silica gel (5% MeOH in 
DCM) to afford 5.19 (0.45 g, 61%) as an off-white solid. Rf = 0.38 (10% MeOH in DCM). 1H NMR 
(300 MHz, CD3OD) δ = 5.13 (d, J = 3.5 Hz, 1H), 5.08 (d, J = 3.3 Hz, 1H), 4.17 (t, J = 6.7 Hz, 1H), 
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3.72-3.52 (m, 6H), 3.47-3.38 (m, 7H), 3.21 (m, 3H), 3.05 (m, 1H), 2.90-2.81 (m, 3H), 2.68 (dd, J = 
14.5, 6.8 Hz, 1H), 2.12 (m, 1H), 1.46-1.43 (m, 37H); 13C NMR (75 MHz, CD3OD) δ = 159.4, 159.2, 
158.1, 157.7, 102.6, 100.6, 85.2, 83.2, 80.6, 80.4, 80.2, 71.2, 74.5, 74.0, 73.8, 72.4, 72.1, 72.0, 71.8, 
57.0, 52.0, 50.8, 41.8, 40.0, 35.9, 34.7, 31.4, 30.4, 28.9, 28.8, 28.8, 28.7, 24.2; HRMS [ESI+] for 
C40H73N5O18S [M+H]+calcd.: 944.4744, found: 944.4733. 
 
5’-O-(Dibenzylphosphate)-3’-O-(N-Boc-kanamycin A cysteamine carbamate)-thymidine (5.21) 
To a stirred solution of compound 5.19 (353 mg, 0.374 mmol) in 1,4-dioxane/water (3:1, 8 mL) was 
added 5.20 (250 mg, 0.374 mmol) followed by triethylamine (0.052 mL, 0.374 mmol) at 0 °C and 
then the solution was stirred at room temperature for 16 h. After completion of the reaction, the 
mixture was evaporated to dryness in vacuo and the residue was purified by column chromatography 
(4% MeOH in DCM) to obtain compound 5.21 (495 mg, 90%) as a white solid. Rf  = 0.45 (10% 
MeOH in DCM). 1H NMR (500 MHz, CD3OD) δ = 7.47 (s, 1H), 7.36 (s, 10H), 6.25 (dd, J = 8.6, 5.8 
Hz, 1H), 5.14-5.07 (m, 6H), 5.05 (br s, 1H), 4.29 (m, 2H), 4.20 (m, 2H), 3.71-3.60 (m, 4H), 3.55-3.48 
(m, 4H), 3.42-3.32 (m, 6H), 3.19 (t, J = 9.3 Hz, 1H), 3.02 (dd, J = 13.9, 2.1 Hz, 1H), 2.75-2.62 (m, 
3H), 2.33 (dd, J = 14.2, 5.5 Hz, 1H), 2.07 (m, 1H), 1.76 (s, 3H), 1.44-1.42 (m, 37H); 13C NMR (125 
MHz, CD3OD) δ = 166.18, 159.5, 159.2, 158.0, 157.7, 152.3, 137.2, 137.1 (d, 3JC,P = 2.3 Hz), 137.0 
(d, 3JC,P = 2.3 Hz), 130.0, 129.8, 129.3, 112.2, 102.7, 100.2, 86.3, 84.4 (d, 3JC,P = 7.8 Hz), 80.6, 80.5, 
80.4, 80.2, 77.2, 76.0, 74.7, 74.1, 73.7, 72.5, 72.4, 72.3, 71.8, 71.2 (2 x d, 2JC,P = 5.8 Hz), 68.8 (d, 2JC,P 
= 6.1 Hz), 57.2, 50.9, 41.7, 38.2, 35.0, 33.9, 28.9, 28.9, 28.9, 28.8, 28.8, 12.6; 31P NMR (202 MHz, 
CD3OD) δ = -0.03; HRMS [ESI+] for C65H98N7O27PS [M+Na]+calcd.: 1494.5861, found: 1494.5873. 
 
3’-O-(kanamycin A cysteamine carbamate)-TMP (5.22) 
To a stirred solution of 5.21 (200 mg, 0.136 mmol, 1 eq.) in EtOH/H2O (8:2, 15 mL), was added 20% 
Pd(OH)2/C (160 mg, 0.8 eq w/w) and evacuation was then carried out with hydrogen atmosphere 
replacements (3x). The reaction mixture was stirred at room temperature for 24h under an 
atmospheric pressure of hydrogen. After completion of the reaction, the catalyst was removed by 
filtration through a cellulose filter (0.45 µm) and the filtrate was concentrated under reduced pressure 
to obtain crude 3’-O-(N-Boc-kanamycin A cysteamine carbamate)-TMP (~175 mg, quant.). The so 
obtained residue was treated without further purification with 90% aq. TFA (5 mL) at 0 °C and then 
the solution was stirred at room temperature for 5h. After completion of the reaction, the mixture was 
evaporated to dryness in vacuo. The residue was coevaporated three times with toluene to remove 
residual TFA and to give crude 3’-O-(kanamycin A cysteamine carbamate)-TMP. The crude residue 
was purified by preparative RP-HPLC (0.1% TFA in 98% H2O + 2% ACN and 0.1% TFA in 98% 
ACN + 2% H2O). The collected eluates were freeze-dried repeatedly until constant mass to afford 
compound 5.22 (86 mg, 71% over two steps) as trifluoroacetic salt. 31P NMR (202 MHz, D2O) δ = -
0.02; HRMS [ESI-] for C31H54N7O19PS [M-H]- calcd.: 890.2860, found: 890.2852. 
 
5’-O-(Dibenzylphosphate)-3’-O-(kanamycin A carbamate)-thymidine (5.23) 
Compound 5.23 was obtained according to the procedure for the preparation of compound 5.21 
starting from kanamycin A 5.16 (100 mg, 0.206 mmol), compound 5.20 (138 mg, 0.206 mmol) and 
triethylamine (29 µL, 0.206 mmol). The crude residue was purified by column chromatography 
(IPA:H2O:Et3N 10:2:1) to give 5.23 as a white solid (171 mg, 82%). Rf  = 0.45 (IPA:H2O:Et3N 6:2:2). 
1H NMR (300 MHz, D2O) δ = 7.16 (s, 1H), 7.09 (s, 10H), 6.1 (app t, J = 6.0 Hz, 1H), 5.21 (d, J = 5.5 
Hz, 1H), 5.01 (m, 2H), 4.84 (m, 4H), 4.19-3.89 (m, 4H), 3.81-3.08 (m, 14H), 2.99 (t, J = 10.4 Hz, 
1H), 2.82 (t, J = 11.3 Hz, 1H), 2.31 (m, 1H), 2.04-1.80 (m, 2H), 1.52 (s, 3H), 1.33-1.19 (m, 1H); 13C 
NMR (75 MHz, D2O) δ = 165.3, 156.8, 151.0, 135.7, 134.8 (d, 3JC,P = 5.3 Hz), 128.5, 128.3, 127.7, 
127.6, 127.1, 110.8, 99.9, 99.7, 86.8, 86.1, 84.6, 82.2, 74.2, 73.7, 72.4, 72.0, 71.5, 71.2, 70.6, 70.4, 
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69.6, 67.8, 67.0, 59.8, 54.2, 50.0, 48.9, 41.0, 36.2, 33.5, 11.5; 31P NMR (121 MHz, D2O) δ = -0.89; 
HRMS [ESI+] for C43H61N6O20P [M+H]+calcd.: 1013.3751, found: 1013.3745. 
 
3’-O-(kanamycin A carbamate)-TMP (5.24) 
Compound 5.24 was obtained as a white solid (86.7 mg, 88%) starting from compound 5.23 (120 mg, 
0.118 mmol) following the same hydrogenation procedure described for compound 5.22, using 20% 
Pd(OH)2/C (24 mg, 0.2 eq w/w). 31P NMR (202 MHz, D2O) δ = -0.02; HRMS [ESI-] for 
C29H49N6O20P [M-H]- calcd.: 831.2666, found: 831.2666. 
 
Table 5-2. 1H and 13C chemical shifts and peak assignments for compounds 5.22 and 5.24. 
5.22* (pH = 2.20)♯ 5.24* (pH = 2.66) ♯ 
 
No δH (J in Hz) δC δH (J in Hz) δC 
1 3.57, m 49.7 3.58, m 49.4 
2 2.52eq, m 
1.93ax, m 
27.5 2.54eq, m 
1.91ax, m 
27.5 
3 3.58, m 47.6 3.55, m 48.0 
4 3.91, m 78.6 3.84, app t (10) 79.4 
5 3.92, m 72.7 3.93, m 72.4 
6 3.75, app t (10) 83.9 3.75, m 83.5 
1' 5.56, d (3.7) 96.6 5.38, d (3.2) 97.2 
2' 3.67, dd (10, 3.7) 70.7 3.64, m 71.0 
3' 3.76, app t (9.4) 72.1 3.71, m 72.4 
4' 3.39, app t (9.7) 70.6 3.31, app t (9.4) 70.6 
5' 4.01, m 68.7 3.81, m 71.6 
6' 3.43(a), dd (14, 3.3) 
3.20(b), dd (14, 7.6) 
40.2 3.63(a), m 
3.24(b), dd (14, 5.7) 
41.1 
1'' 5.09, d (3.6) 100.5 5.13, d (2.6) 100.1 
2'' 3.96, dd (10.8, 3.5) 68.1 3.93, app t (10) 68.0 
3'' 3.46, app t (10.6) 54.7 3.69, app t (10) 65.4 
4'' 3.63, app t (10) 68.3 3.48, app t (10.6) 54.9 
5'' 4.01, m 72.0 3.92, m 73.0 
6'' 3.08(a), m 
2.77(b), m 
32.6 3.88(a), m 
3.76(b), m 
59.9 
8'' 2.77, m 32.2 - - 
9'' 3.34(a), m 
3.42(b), m 
39.9 - - 
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OCONH - 157.5 - 157.5 
2''' - 151.8 - 151.7 
4''' - 166.4 - 166.4 
 
 
 
 
 
 
 
6''' 7.74, s 137.0 7.74, s 137.1 
5-CH3 1.91, s 11.5 1.91, s 11.5 
1'''' 6.35, dd (8.5, 6) 85.0 6.33, app t (7) 85.0 
2'''' (a+b) 2.44, m 36.2 2.44, m 36.5 
3'''' 5.24, m 75.5 5.27, m 75.4 
4'''' 4.36, br s  83.7, d 
(3JC,P = 8 Hz) 
4.34, br s 83.4, d 
(3JC,P = 8 Hz) 
5'''' (a+b) 4.11, m 
65.1, d 
(2JC,P = 4 Hz) 
4.10, m 64.9, d 
(2JC,P = 4 Hz) 
* 1H (600 MHz) and 13C (150 MHz) chemical shift values (δ) are given in ppm; ♯ pH = pD - 0.4; eq = 
equatorial, ax = axial. 
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Chapter 6: NUTRITIONAL EVALUATION METHODOLOGIES 
  
6.1. Biological evaluation using auxotrophic bacterial strain 
(Performed in collaboration with Lia Margamuljana and Elisabetta Groaz from Rega 
Institute and with scientist from Genoscope, Institut de Génomique, Evry, France) 
  
In order to test the bacterial uptake of all synthetized peptide-dTMP conjugates (2.19, 2.33-
2.36, 2.38-2.42, 2.47-2.48, 2.57-2.58, 2.62, 2.65, 2.70 and 3.1, 3.2a, 3.2b, 3.15, 3.23, 3.38a, 3.38b, 
3.4), sulfono-dTMP phosphoramidate conjugates (4.1-4.11, 4.33 and 4.35), biotin-dTMP conjugates 
(5.7, 5.10, 5.13 and 5.15) and kanamycin Α-dTMP conjugates (5.22 and 5.24) as a source of TMP, 
an E. coli LN2666 thyA(-) strain[1] [a spontaneous streptomycin-resistant mutant of CB0129 (F- 
W1485 thiA, thyA, leu, deoB, rpsL)[2] was employed. (The strain was provided by Dr. Anirban Ghosh 
and Prof. Abram Aertsen, Centre for Food and Microbial Technology, Faculty of Bioscience 
Engineering, KU Leuven). Its genotype is E. coli LN2666 ΔphoA thyA(-). This strain is deleted for the 
thyA and phoA genes, which respectively encode for thymidylate synthase and alkaline phosphatase, 
in order to block all pathways that could lead to the formation or degradation of TMP inside the 
bacterial cells. All compounds were preventively analyzed (LC/MS or NMR) to exclude potential 
sample contamination, but no traces of thymine could be observed below detection limit. LB medium 
and LB agar were sterilized by autoclaving (120 °C, 30 min). Thymine (positive control), TMP 
(negative control) and all compounds were dissolved in Milli-Q water and sterilized through a 0.2µm 
sterile syringe filter (VWR). A single colony of the mutant strain was grown overnight at 37 °C in LB 
medium (3 mL). Cells were then harvested by centrifugation, washed and resuspended in fresh LB 
medium. The bacterial cells were then diluted 1:1000 in fresh LB medium before streaking on LB 
agar plates containing 20 µg/mL of each compound and grown overnight at 37 °C. Unfortunately, no 
colony formation was observed in the presence of compounds (peptide conjugates - 2.19, 2.33-2.36, 
2.38-2.42, 2.47-2.48, 2.57-2.58, 2.62, 2.65, 2.70 and 3.1, 3.2a, 3.2b, 3.15, 3.23, 3.38a, 3.38b, 3.4), 
(sulfonate conjugates - 4.1-4.11, 4.33, 4.35), (biotin conjugates - 5.7, 5.10, 5.13, 5.15 and kanamycin 
conjugates - 5.22, 5.24) or toxicity (kanamycin conjugates 5.22 and 5.24) were observed.  
 
On the basis of preliminary biological screening none of the conjugates showed functional 
activity in E.Coli mutants lacking thymine. However, this might be due to several reasons, for 
instance high concentrations necessary for considerable growth, which are currently under further 
study. As additional evidences, biotin-TMP conjugates and sulfonate-TMP conjugates are undergoing 
biological evaluation using biotin and sulfonate auxotrophic E. coli mutants respectively.  
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6.2.  Cell imaging with fluorescent microscopy (future work) 
 
6.2.1. Synthesis of sulfono-phosphoramidate analogues containing a fluorescent base: 
 
In parallel to the bacterial auxotrophic model, in order to gather additional evidences, we also 
planned to synthesize different biocarrier-nucleotide conjugates containing a fluorescent base, as 
uptake of these conjugates can be visualized and quantified using confocal microscopy through a live 
bacterial cell imaging. Although different fluorescent bases are available, pyrrolo-dC was selected for 
its non-toxic profile both for uptake and cell imaging purposes. Pyrrolo-dC mimics natural cytidine 
base (C) and its base pairing properties with guanidine (G) are not perturbed as it shows similar 
melting temperature (Tm) as natural C. Due to its small size it is also well accepted by most DNA and 
RNA polymerases and does not disturb the three dimensional structure of DNA. As the excitation and 
emission fluorescent spectra fall in the red zone (absorption band - 350 nm, emission band - 460 nm, 
ɸF = 0.2), visibility stands out from the noise of protein fluorescence and is significantly 
distinguishable from other natural nucleobases. 
As a proof of concept, we first planned to synthesize two derivatives of this fluorescent 
nucleotide by linking taurine (2-aminoethanesulfonic acid) and L-cysteic acid through a 
phosphoramidate linker at the 5’-phosphate of the nucleotide. The synthesis of these phosphoramidate 
conjugates (Tau-PydCMP and L-Cys-PydCMP) was performed following a similar protocol described 
in Chapter-4, starting from pyrrolo-dC-5’-monophosphate triethylammonium salt and the 
corresponding sulfono-amine in presence of DCC. The uptake study of these conjugates (6.2 and 6.3) 
in E. coli and their evaluation with confocal fluorescent microscopy are being performed in 
collaboration with Genoscope, Institut de Génomique, Evry, France. 
 
 
Pyrrolo-dC-5’-taurine phosphoramidate triethylammonium salt (6.2)  
Pyrrolo-dC-5’-monophosphate triethylammonium salt (32 mg, 0.058 mmol) and 2-
aminoethanesulfonic acid (21.9 mg, 0.175 mmol) were suspended in a 4:1 tBuOH/H2O mixture (2 
mL). Triethylamine (25 µL, 0.175 mmol) was then added to the suspension to facilitate 
dissolution, followed by DCC (48.2 mg, 0.234 mmol). The reaction mixture was heated at 90 ºC 
for 3 h. The reaction progress was monitored by TLC (iPrOH:H2O:Et3N 6:2:2). Upon completion, 
the reaction mixture was cooled to room temperature and the solvent was removed by rotary 
evaporation. The resulting crude material was purified by column chromatography on silica gel 
using the following gradient IPA:H2O:NH3 20:1:1, v/v/v;  15:1:1, v/v/v; 10:1:1, v/v/v, to provide 
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the desired nucleoside phosphoramidate as salt. Semi-preparative RP-HPLC (50 mmol TEAB in 
H2O + 2% ACN and 50 mmol TEAB in 50% H2O + 50% ACN ) was employed for further 
purification. The residue was lyophilized and freeze-dried repeatedly until constant mass to 
obtain the triethylammonium salt of compound 6.2 (27.2 mg, 71%) as a white solid. 1H NMR 
(300 MHz, D2O) δ = 8.52 (s, 1H, H-9), 6.33 (app t, J = 6.3 Hz, 1H, H-1’), 6.07 (d, J = 1.2 Hz, 
1H, H-7),  4.50-4.45 (m, 1H, H-3’), 4.19-4.18 (m, 1H, H-4’), 4.07-3.92 (m, 2H, H-5’ and H-5’’), 
3.15-3.05 (m, 2H, CH2αCH2SO3H), 2.97-2.90 (m, 2H, CH2CH2βSO3H, mergerd with Et3N), 2.57-
2.22 (m, 2H, H-2’ and H-2’’), 2.21 (s, 3H, CH3-Pyrrolo-dC); 13C NMR (75 MHz, D2O) δ = 157.4 
(C-4), 155.3 (C-2), 139.7 (C-6), 134.6 (C-9), 111.3 (C-8), 97.8 (C-7), 87.5 (C-1’), 85.8 (d, 3JC,P = 
8.9 Hz, C-4’), 70.2 (C-3’), 63.3 (d, 2JC,P = 5.0 Hz, C-5’), 52.0 (d, 3JC,P = 6.5 Hz, CH2CβH2SO3H), 
40.2 (C-2’), 36.7 (CαH2CH2SO3H), 12.4 (CH3-Pyrrolo-dC);  31P NMR (121 MHz, D2O) δ = 8.1; 
HRMS for C14H21N4O9PS [M-H]- calcd.: 451.0696, found: 451.0694. 
 
Pyrrolo-dC-5’-(L-cysteic acid) phosphoramidate triethylammonium salt (6.3) 
 The triethylammonium salt of compound 6.3 was obtained as an off-white solid (77.1 mg, 24%) 
following the same procedure as the one used for compound 6.2, starting from pyrrolo-dC-5’-
monophosphate triethylammonium salt (220 mg, 0.402 mmol), L-cysteic acid (204 mg, 1.205 
mmol), triethylamine (0.168 mL, 1.205 mmol), DCC (331.5 mg, 1.607 mmol) in a 4:1 
tBuOH/H2O mixture (10 mL) at 90 ºC for 3 h. 1H NMR (500 MHz, D2O) δ = 8.63 (s, 1H, H-9), 
6.40 (app t, J = 6.3 Hz, 1H, H-1’), 6.17 (s, 1H, H-7),  4.56-4.54 (m, 1H, H-3’), 4.23-4.22 (m, 1H, 
H-4’), 4.12-4.04 (m, 2H, H-5’ and H-5’’), 3.91-3.86 (m, 1H, CHCO2H), 3.23-3.19 (m, 2H, 
CH2SO3H), 2.58-2.30 (m, 2H, H-2’ and H-2’’), 2.28 (s, 3H, CH3-Pyrrolo-dC); 13C NMR (125 
MHz, D2O) δ = 178.3 (d, 3JC,P = 3.6 Hz, CO2H), 157.0 (C-4), 155.0 (C-2), 139.2 (C-6), 134.6 (C-
9), 111.2 (C-8), 97.8 (C-7), 87.0 (C-1’), 85.6 (d, 3JC,P = 8.6 Hz, C-4’), 69.7 (C-3’), 62.9 (d, 2JC,P = 
4.8 Hz, C-5’), 54.1 (d, 3JC,P = 6.9 Hz, CH2SO3H), 53.4 (CHCO2H), 39.7 (C-2’), 12.1 (CH3-
Pyrrolo-dC); 31P NMR (202 MHz, D2O) δ = 6.1; HRMS for C15H21N4O11PS [M-H]- calcd.: 
495.0592, found: 495.0596. 
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Chapter 7: General Discussion and Perspectives 
 
In the last two decades research efforts have been devoted to the development of xeno 
nucleic acids (XNAs) through modifications involving sugar backbone, base moiety or 
phosphodiester linkage. The role of non-natural nucleic acids has been rigorously studied for 
their potential application as therapeutics, in material sciences, molecular diagnostics, 
biotechnology and life sciences (antigene, antisense, siRNAs, cellular probes, aptamers, 
biosensors and XNAzymes). XNAs bearing base modifications, mimicking the canonical and 
non-canonical base pairing systems, have also been examined in the context of the genetic 
alphabet. Over the last few years, research aiming to achieve backbone modifications by 
replacing the (deoxy)ribose sugar, has clearly established that synthetic variants of natural 
polymers are also capable of storing genetic information. 
With the advent of solid phase synthesis of sequence-defined gene fragments and DNA-
oligomers, along with modern chemical biology methods like sequence assembling, PCR and 
recombinant technology, synthetic genes of interest have started to be evaluated in the 
reprogramming of living entities for a variety of applications in energetics, agriculture and 
bio-technology. However, risks of genetic pollution of the natural ecosystem are possible due 
to deliberate or unintended damage arising from genetic information exchanging (vertical or 
horizontal gene transfer) between synthetic genetic constructs and natural habitats, a major 
concern of biosafety in the society. To address such issues, the introduction of new 
technologies to avoid or limit genetic cross talk has been pursued, together with the design of 
artificial genetic constructs that could be safely used for beneficial purposes. 
Recently, it was hypothesized that the use of an artificial orthogonal system, a third type 
of self-reliant information system other than DNA and RNA, could serve the purpose of 
avoiding genetic cross-talk and pollution with the natural complements.[1] Modified nucleic 
acids or Xeno-nucleic acid (XNAs) were therefore designed and synthesized. In spite of the 
advancement in the chemical synthesis of nucleic acid oligomers, XNAs synthesis is often 
limited to <100 nucleotide. Additionally, enzymatic polymerization of XNAs with high 
fidelity remains a huge challenge due to the low selectivity of XNA building blocks in the 
active pocket of natural polymerase used for this purpose. The directed evolution of the 
active site of different enzymes using advanced techniques like phage display, CSR or CST is 
highly desired, for catalysing different XNA based biological functions with high selectivity, 
efficiency and fidelity. So far, Holliger and co-workers designed and fabricated engineered 
polymerases which can efficiently recognize, incorporate and transcribe sugar modified 
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XNAs (HNA, CeNA, ANA, FANA, TNA, and LNA) on a DNA based template and are also 
able to reverse-transcribe to DNA on XNA based templates. This represents a remarkable 
contribution to the field of XNA based directed enzyme evolution for in vitro assembling, 
replication and propagation of XNAs.[2] Very recently, the in vitro functional activity of 
XNAzymes that were devised on four XNA backbones (ANA, FANA, HNA and CeNA), 
mimicking RNA and DNA based enzymes was also successfully demonstrated.[3] Both of 
their achievements are a milestone for the establishment of alternative genetic polymers 
(XNAs) for their abilities to endure heredity and evolution. 
Because of the relatively simple genetic architecture of prokaryotes, the first in vivo 
invasion with XNA replicons was thought to be more likely to happen in bacteria. In order 
for the reprogrammed bacterial cells to reach their true evolutionary potential, the controlled 
in vivo propagation of XNA polymers is essential, and firstly requires the availability of XNA 
precursors in sufficient amount inside the bacterial cells. As XNA precursors do not occur in 
nature, their corresponding active intermediates of (XNA nucleotides) need to be supplied 
from outside the cells. Although most modified nucleosides can easily enter the bacterial cell, 
they are poorly recognized and phosphorylated to their monophosphate form by the host 
nucleoside kinases. On the other hand, modified nucleotides are charged and highly polar at 
physiological pH and their transport inside bacterial cells is restrained by the hydrophobic 
lipid bi-layer present in the bacterial cell wall. To solve this issue, so far efforts have involved 
over-expression of endogenous nucleoside kinases e.g. from Drosophila Melanogaster with 
broad substrate specificity in E. coli,[4] which can provide modified nucleoside 
monophosphates ensuing a nucleoside salvage pathway, and lately by algal nucleoside 
triphosphate transporters in bacterial cells which efficiently facilitates active transport of 
triphosphates of d5SICS and dNaM.[5] Selectivity and recognition of XNA-triphosphates by 
different algal triphosphate transporters represented a significant contribution towards the 
establishment of the first XNA-nucleotide uptake system and in vivo replication of XNA base 
pairs in bacterial cells, but broad substrate specificity for all type of XNA-triphosphates is 
still a huge concern of this approach. 
On the other hand, bacteria express different transmembrane transport proteins for the 
uptake of different nutrients against a concentration gradient, for their cellular survival such 
as amino acids, peptides, ions, sugars, vitamins like biotin and thiamine, sulfates and 
sulfonates, and other hydrophilic molecules, which otherwise would have a restricted entry 
through the rigid lipid bi-layer of the cell wall of bacteria. By exploiting such active transport 
systems it may be possible to deliver different cargo inside the bacterial cells, as it was 
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demonstrated utilizing peptide transport systems for delivery of different antimicrobial[6] and 
therapeutic[7] compounds with the enhanced efficacy compared to direct means. Likewise, the 
delivery of large peptides (up to 31-mer) was also promoted by biotinylation, which 
otherwise was not possible or limited to five to six-mer for non-biotinylated ones.[8] 
Interestingly, these types of natural delivery systems have never been explored for nucleotide 
delivery inside the bacterial cells. 
Therefore, this thesis is mainly aimed at the systematic exploration of different types of 
natural transporters and uptake systems in an attempt to facilitate the delivery of nucleotides 
inside bacterial cells, based on the synthesis and evaluation of a wide range of nucleotide-
conjugates through a nutritional selection approach. For this purpose, thymidine mono-
phosphate (TMP) was chosen as an exemplary nucleotide in a model study. Based on this 
hypothesis, an auxotrophic E.coli strain deleted for the ThyA gene encoding for thymidylate 
synthase was constructed. TMP-conjugates are then provided in extracellular medium to such 
strain which absolutely require thymine or thymidine for growth. The viability of this model 
can be visualized from the growth of thymidine auxotrophic E.coli strain in presence of 
TMP-conjugates, in a condition only when TMP-conjugate is taken up and TMP is released 
as nutrient inside the cells. Diverse conjugation strategies involving a covalent linker between 
either the 3’-hydroxyl or the 5’-phosphate position of TMP and selected delivery vehicles 
were designed such a way that linkers should be chemically or enzymatically cleavable and 
release the attached cargo, once internalized inside the cells. As additional evidence of this 
model, the synthesis of different conjugates containing a non-toxic fluorescent base 
mimicking the natural base and their evaluation under confocal fluorescent microscopy were 
also planned.  
 
 
Figure 7-1. Chemical structure of novel peptide-nucleotide conjugates (PNCs). 
Linker Peptide
OCONH
For-M-K-OMe,
For-G-K-F-OMe,
For-G-βA-F-OMe,
For-M-K-F-OMe,
For-M-K-A-OMe,
For-M-K-K-OMe,
For-M-K-A-F-OMe,
For-M-K-A-A-F-OMe,
A-K-A-OMe,
A-K-A
ONHCO For-M-E-OMe
OCH2ONHCO
For-M-E-OMe,
For-M-E-NH2
OCH2OCO For-G-E-A-OMe
OCO For-M-K-K,
For-G-E-F
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In Chapter 2, a series of peptide-TMP conjugates were designed and synthesized to 
evaluate their potential as delivery systems of nucleotides uptake in an auxotrophic E. coli 
strain. A variety of di- to penta-peptides was chosen as delivery vehicles mainly targeting 
different peptide permeases (Dpp, Tpp, Opp). As free N- and C-terminus and basic peptide 
residues are important for recognition by periplasmic binding proteins, whilst the protection 
of the N- and C-terminus could avoid extracellular degradation, peptidic sequences 
combining those features were accordingly designed. Different bioreversible linkages such as 
carbamate (OCONH), ester (OCO), oxyamide (ONHCO), oxymethyleneoxyamide 
(OCH2ONHCO), oxymethylene-oxyester (OCH2OCO) were introduced to allow conjugation 
of side chain functionalities of oligopeptides to the 3’-hydroxyl group of TMP, to tune 
metabolic stability. In this chapter we discussed different linear and convergent synthetic 
strategies in detail for the preparation of peptide-nucleotide conjugates (PNCs) along with 
orthogonal protection-deprotection chemistries starting from thymidine, as summarized in 
Fig. 7-1. Notably, the protection of carboxylic acid groups was not necessary with an 
incoming amino acid in the coupling step, during oligopeptide synthesized using NHS-DCC 
active ester method in solution phase. The construction of PNCs were accomplished either by 
conjugation of the peptide chain at the 3’-position of thymidine followed by phosphorylation 
at 5’-position or vice versa with respect to reactions order. Although attempts to synthesize 
PNCs with carbamoyl (OCONH) linker via the first approach was successful but it was not 
suitable for the synthesis of methionine containing peptides, where selective oxidation of PIII 
to PV was challenging in presence of sulfur. Such compounds could however be obtained 
following the second approach. The key steps for the preparation of PNCs with an oxyamide 
linker were the formation of 5’-protected xylo-thymidine followed by Mitsunobu inversion 
with a protected hydroxyl amino functionality. Very mild condition using diluted methyl 
amine (4%) was chosen for phthalimide deprotection to avoid side reactions of PNCs bearing 
delicate functionalities. Pummerer rearrangement and further functionalization of the 
thiomethyl group were the crucial steps for the synthesis of PNCs with 
oxymethyleneoxyamide, oxymethyleneoxyester linkers. Final deprotection of all conjugates 
was realized in high yield via hydrogenolysis, using either 10% Pd/C or 20% Pd(OH)2 
catalysts, to avoid over reduction of the thymine base. To our surprise, the thiomethyl 
functionality present in methionine-containing PNCs wad stable to such conditions. On the 
basis of a preliminary biological screening none of the conjugates showed colony growth in 
the presence of a thymidine auxotrophic E.coli strain, which may arise from different factors 
like requirement of higher concentrations or metabolic (in)stability of conjugates. With a 
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view to the development of a xenonucleotides delivery system in bacterial cells, the 
introduction of other types of residues may be explored in future, based on these peptide 
conjugation chemistries.   
 
 
Fig 7.2: Structures of α-substituted glycine peptide-nucleotide conjugates with different 
phospho-ester linkages. 
 
Aiming at targeting peptide delivery systems, α-substituted glycine containing peptides 
were successfully exploited to transport and liberate cargos such as antimicrobial agents or 
toxophoric agents inside bacterial cells following the metabolic action of intracellular 
peptidases. In Chapter 3 we described the design and synthesis of various α-substituted 
glycine PNCs with TMP. All the PNCs derived from glycine dipeptides were linked through 
the α-carbon of the C-terminal glycine residue to the 5’-hydroxyl of thymidine through 
various phosphoester linkers i.e. phosphate, phosphoramidate, phosphorothioate and 
thioethyl-phosphate. Synthesis of such conjugates were accomplished either by nucleophilic 
substitution at the α-position of glycine or at the phosphorous-group itself, as anticipated 
from retro-synthetic analysis. Following the second route for the synthesis of conjugate 3.1 
with a phosphate linkage, attempts were made using different phosphorous activation 
pathways like phosphoramidite or POCl3 based approaches, but met with failure presumably 
because of low nucleophilicity at the α-hydroxyl functionality of glycine. By inversing the 
reaction order and using the phosphate as nucleophile and OAc as leaving group, synthesis of 
3.1 was successful although low yields were obtained due to side products formation arising 
from competitive nucleophilic attack of the NH-group of the thymine base. The 
phosphoramidate analogues 3.2a,b were prepared following DCC-mediated coupling 
between TMP and an α-amino glycine derivative. The separation of diastereomers 3.2a and 
3.2b easily accomplished with preparative-HPLC in the pre-final step with protected amino 
acids. The synthesis of thioethyl-phosphate derivative 3.4 was realized in good yield by 
altering the protecting groups at the C-and N-terminal of peptide chain and at 3’-position of 
thymidine with orthogonal protecting groups like OMe, Boc and OBz respectively, due to the 
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problematic hydrogenolysis of the Cbz and OBn groups in the final step, arising from catalyst 
poising by the sulphur-atom present. The isolation and purification of thioester derivative 3.3 
were challenging, but methyl ester derivative 3.38a and 3.38b were synthesized and purified 
following a 1,3,2-oxathiaphospholane approach. Generally, the α-substituent in α-substituted 
glycines acts as a good leaving group, and in addition to that anchimeric assistance of free 
carboxylic groups from peptide makes the phosphorous-linker more vulnerable to hydrolytic 
cleavage. It was assumed that protection of the free carboxylic acid with an ester group would 
increase the stability of conjugates, as demonstrated by the synthesis and relative stability 
studies of methyl ester derivatives 3.23. The biological profile of all the conjugates was 
evaluated by in vitro DNA chain elongation experiments, catalysed by different thermophilic 
and mesophylic microbial DNA polymerases, comprising Therminator, Vent (exo-) and the 
Klenow fragment (exo-) of Pol I. Only compounds 3.2a and 3.2b showed good incorporation 
properties with the Klenow fragment indicating that a free carboxylic group is necessary for 
binding at the active site of the enzyme. The lower molecular mechanics energy of 3.2a over 
3.2b with this enzyme explains the better fidelity of 3.2a, as indicated from a homology 
model in a molecular modeling study. The absolute configurations of 3.2a and 3.2b were also 
determined based on the same model. Kinetic parameter showed that the Vmax/Km of 3.2a is 
only 994-fold lower than the natural substrate (TTP), comparable to previously explored 
alternative leaving groups in our lab. Although in the uptake assay with a thymidine 
auxotrophic E.coli strain none of these conjugates showed functional activity, in view of the 
good incorporation properties of phosphoramidates analogues, future efforts will focus on 
broadening the scope of substrates linked at the 5’-position of nucleotides with different 
linkers to establish an optimal stability for binding to periplasmic proteins along with 
improved physico-chemical properties in the DNA polymerisation reaction.  
 
 
Figure 7-3. Overview of sulfonate-containing phosphoramidate analogues of thymidine. 
 
In chapter 4, several novel modified phosphono-5’-phosphoramidate nucleosides have been 
synthesized featuring metabolites such as taurine and a broad range of aliphatic sulfonates 
(summarized in Fig.7-3) coupled through a P-N bond to the 5′-phosphate position of 
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deoxynucleotides. The design of different sulfono-groups in conjugates aimed both at 
exploitation of sulfonate transport systems for nucleotide uptake and at the development of 
alternative leaving groups capable of being processed by DNA polymerases for multiple 
nucleotide incorporations mimicking the pyrophosphate group. Synthesis of all the conjugates 
was achieved by different methods including phosphoramidate coupling like DCC mediated 
coupling and the imidazolide approach. Remarkably, in an improved protocol the protection of 
the sulfonic acid group was not necessary. Both thermophilic and mesophylic microbial 
polymerases Vent(exo-), Therminator and the Klenow fragment were used for in vitro template-
directed DNA polymerization studies. Amongst them, taurine-N-acetic acid-dTMP showed good 
substrate property, therefore such phosphoramidate derivatives with all four nucleobases were 
synthesized and evaluated to establish the influence of the base moiety on substrate properties. 
Results showed that the incorporation efficacy followed the order G > A ≥ T > C. Therminator 
polymerase exhibited the broader substrate-specificity but best incorporation results were 
obtained with most effective polymerase Klenow fragment (exo-) and taurine-N-acetic acid-
dGMP (4.28) as substrate. A kinetic study revealed that the Vmax/Km ratio of compound 4.28 was 
702-fold lower than the natural substrate dGTP, within the range of previously explored bio-
isosteric leaving groups (IDA, IDP and L-Asp). Unfortunately, none of this thymidine containing 
conjugates was able to sustain the growth of thymidine auxotrophic E. coli mutants. Therefore, it 
is important to investigate and broaden the substrate scope for this series of compounds to find 
structural similarities that can be relevant at the same time for the developments of substrates for 
DNA polymerases functional at room temperature, and for recognition by sulfonate transport 
systems through the modulation of physical parameters (e.g. polarisibility, solubility, binding 
constant, pKa, size and spatial arrangement). Apart from their interest in nucleotide delivery, 
phosphate group modified nucleotides discussed in Chapter 3 and 4 could be of use for other 
applications such as the polymerase chain reaction (PCR) for in vitro construction of DNA or 
RNA fragments or as pro-drugs for antiviral therapy. 
 
 
Fig 7-4: Structures of nucleotide conjugates of biotin and kanamycin with different linkages. 
 
In Chapter 5, a series of TMP conjugates of biotin and kanamycin A (Fig. 7-4) were 
designed and synthesized in the search for a nucleotide delivery system. Biotin-TMP 
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conjugates were linked through the carboxyl group of biotin to the 3’-OH group of TMP 
featuring an oxymethyleneoxy ester, a carboxy ester, a carbamate and 
oxymethyleneoxyamide linker, adopting previously optimized conjugation strategies such as 
coupling and debenzylation procedures used for PNCs (chapter 2). Similarly, kanamycin A-
TMP conjugates were constructed in a convergent manner with a carbamoyl or thioethyl 
carbamoyl group, exploiting the different chemical reactivity between the primary hydroxyl 
and amino groups amongst polyhydroxyl and polyamino functionalities present in the 
structure of kanamycin A. 2D and variable-temperature NMR spectroscopic analysis 
established the alignment of the carbamoyl linkage and the formation of rotamers, which may 
be arising from an inherent flexibility around glycosidic bonds for the kanamycin-TMP 
conjugates. On the basis of biological evaluation using the auxotrophic model, none of the 
biotin-TMP or the kanamycin A-TMP conjugates was able to sustain growth of a  thyA-, 
ΔphoA E. coli strain. However, based on these synthetic strategies of conjugation several 
other vitamin-TMP and polycationic-TMP conjugates could be synthesized and screened. 
 
In summary, through the systematic modification of synthetic TMP conjugates obtained 
by introduction of biocleavable linkers either at the 3’- or 5’-position of TMP through 
different metabolite hiring from microbial transport systems, in this thesis we have expanded 
the chemical scope of the potential vectors for the active uptake of nucleotides in bacterial 
cells. We have successfully demonstrated novel synthetic strategies to achieve chemical 
conjugation via linear and convergent methods together with orthogonal protection-
deprotection sequences. The 5’-modified nucleotide conjugates were designed in view of 
their intracellular metabolism as substrates for DNA polymerase and some of them showed 
moderate to good substrate properties. Unfortunately, it is apparent form preliminary 
biological data, that none of the vectors was successful for actively delivering TMP inside the 
bacterial cell. Although none of the conjugates was capable to produce growth of a thymidine 
auxotrophic LN2666 E.coli strain (thyA-, ΔphoA) (Chapter 6), this can be rationalized as 
due to numerous parameters e.g. (1) product concentration needed and type of culture media 
(2) mode of addition e.g. continuous or single shot (3) stability of conjugates in extracellular 
media (4) phosphatase activity other than phoA (5) binding constant with periplasmic binding 
protein (6) recognition and transportation through permeases (7) desired intracellular 
metabolism of conjugates releasing TMP or 5’-modified conjugates as substrate for E. coli 
DNA polymerase Pol I. 
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To gain supplementary proof in a nutritional model, peptide (methionine)-TMP, biotin-
TMP and sulfonate-TMP conjugates are currently undergoing biological evaluation using 
methionine, biotin and sulfonate auxotrophic E. coli mutants respectively. Fluorescent 
conjugates Tau-PydCMP and L-Cys-PydCMP are also being evaluated through live cell 
imaging techniques under confocal fluorescent microscopy. Recent preliminary data showed 
of sulfonate-TMP and biotin-TMP conjugates to be positive in sulphur-auxotrophic and 
biotin-auxotrophic strains respectively, but further investigations are needed to confirm 
whether this is caused by extracellular degradation, as bacteria require sulphur and biotin in 
lower concentrations than TMP for survival. 
 As nucleotides delivery in bacterial cells remains a challenging issue, we envisioned 
that future research should mainly emphasise on the following areas: 
1. To increase the chemical space between the conjugation partners with the variation 
and introduction of other types of unexplored bio-labile linkers and the use of delivery 
units based on other nutritional selection approaches e.g. sugars and vitamins etc. 
2. To perform stability studies of different conjugates with advanced techniques that can 
detect metabolites in low concentration e.g. HPLC or LCMS, in order to tune 
metabolic stability and unambiguously clarify biological data resulting from different 
auxotrophic models. 
3. To modify the 5’-phosphate group with neutral or hydrophobic moieties to increase 
the feasibility of passive diffusion with the aim of intracellular release of nucleoside 
mono phosphate or a metabolite that can be a substrate for DNA polymerases. 
Masking of the two anionic charges arising from naked 5’-phosphate groups is 
thought to influence the hydrophobic interactions with the lipid bi-layer and the 
susceptibility to the extracellular phosphatases degradation. 
4. To gain an understanding to the mode of transport of the various conjugates, the 
recognition and binding studies of different periplasmic binding proteins and 
permeases are very important, aided by in silico molecular modeling and different 
bio-physical assays. Besides, over-expression of a particular transporter during uptake 
study based on a type of conjugate will also shed a light on the amount of TMP 
needed for auxotrophic bacterial growth. 
5. To develop and establish double auxotrophic (e.g. thymidine and methionine, 
thymidine and biotin, thymidine and taurine) bacterial mutants along with the deletion 
of all genes encoding for enzymes with phosphatase activity, would be an ideal 
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auxotrophic model to establish nucleotide uptake even at low substrate concentration, 
in parallel to the use of non-toxic fluorescent bases. 
In short, it is once again significant to remember that delivery of nucleotides inside 
bacterial cells is essential for the construction and evolution of orthogonal genetic systems 
along with systematic exploration of nucleobases, sugar backbones, leaving groups and 
engineered polymerases to address important bio-safety issues. Moreover, the successful 
identification of a natural transport system able to deliver nucleoside mono-phosphate (NMP) 
inside the bacterial cells could be further exploited for delivery of different XNA-nucleotides 
and would aid the search for nucleotide-mimetic antibacterial drugs that are inefficient in vivo 
due to poor cell penetrating ability. As no nucleoside monophosphate transporter is known in 
the wild ecosystem to date, the only viable way up to now to actively transport nucleotides is 
by over-expressing algal nucleotide triphosphate (NTP) transporters that showed actively 
transport XNA-triphosphates in E. coli. However this approach was found to be substrate 
dependent with varied  specificity and rate of transportation, as demonstrated by Romesberg 
and co-workers recently.[5] Moreover over-expression of NTP-transporters and production of 
NTPs are not economic from a synthetic point of view. Our approach to nucleotide delivery is 
thought to be much simpler, as it relies on the exploitation of a delivery system already 
existing in bacteria.  
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